scnd_s1.htm

0001654954-22-007636.txt : 20220527 0001654954-22-007636.hdr.sgml : 20220527 20220527161022 ACCESSION NUMBER: 0001654954-22-007636 CONFORMED SUBMISSION TYPE: S-1 PUBLIC DOCUMENT COUNT: 87 FILED AS OF DATE: 20220527 DATE AS OF CHANGE: 20220527 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SCIENTIFIC INDUSTRIES INC CENTRAL INDEX KEY: 0000087802 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 042217279 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: S-1 SEC ACT: 1933 Act SEC FILE NUMBER: 333-265281 FILM NUMBER: 22977503 BUSINESS ADDRESS: STREET 1: 70 ORVILLE DR STREET 2: AIRPORT INTERNATIONAL PLZ CITY: BOHEMIA STATE: NY ZIP: 11716 BUSINESS PHONE: 6315674700 MAIL ADDRESS: STREET 1: 70 ORVILLE DR CITY: BOHEMIA STATE: NY ZIP: 11716 S-1 1 scnd_s1.htm FORM S-1 scnd_s1.htm

As filed with the Securities and Exchange Commission on ___________

Registration No. 333-

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form S-1

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

SCIENTIFIC INDUSTRIES, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware

3826

04-2217279

(State or other jurisdiction of

incorporation or organization)

(Primary Standard Industrial

Classification Code Number)

(I.R.S. Employer Identification No.)

80 Orville Drive, Suite 102

Bohemia, New York 11716

(631) 567-4700

(Address, including zip code, and telephone number, including area code, of principal executive offices)

Helena Santos

Chief Executive Officer

Scientific Industries, Inc.

80 Orville Drive, Suite 102

Bohemia, New York 11716

(631) 567-4700

(Address, including zip code, and telephone number, including area code, of agent for service)

Copies to:

John F.F. Watkins, Esq.

Reitler Kailas & Rosenblatt LLP

885 Third Avenue

New York, New York 10020

Telephone: (212) 209-3050

Approximate date of proposed sale to public: As soon as practicable on or after the effective date of this registration statement.

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box. ☒

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer	☐	Accelerated filer	☐

Non-accelerated Filer	☐ (Do not check if a smaller reporting company)	Smaller reporting company	☒

CALCULATION OF REGISTRATION FEE

Title of Each Class of

Securities to Be Registered

Amount

to Be

Registered

Proposed

Maximum

Offering Price

per Share (1)

Proposed

Maximum Aggregate

Offering Price

Amount of

Registration Fee

Shares of common stock, and shares of common stock issuable upon exercise of warrants, sold to selling stockholders in private placements

818,183

5.00

4,090,915

380

Total

818,183

5.00

4,090,915

380

(1)	Estimated solely for purposes of calculating the registration fee pursuant to Rule 457(c) under the Securities Act, based on average of bid and asked price per share of the common stock as reported on the Over-the-Counter Bulletin Board on May 23, 2022

The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act, as amended, or until this Registration Statement shall become effective on such date as the Commission, acting pursuant to such Section 8(a), may determine.

The information in this prospectus is not complete and may be changed. We may not sell these securities until the Securities and Exchange Commission declares our registration statement effective. This prospectus is not an offer to sell these securities and is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.

Subject to Completion, dated May 27, 2022

Preliminary Prospectus

Scientific Industries, Inc.

818,183 Shares

Common Stock

This prospectus relates to the resale or other disposition, from time to time, by the selling stockholders identified in this prospectus under the caption “Selling Stockholders,” of up to 818,183 shares of our common stock, par value $0.05 per share. We are not selling any shares of our common stock under this prospectus and will not receive any proceeds from the sale or other disposition of shares by the selling stockholders. The selling stockholders will bear all commissions and discounts, if any, attributable to the sale or other disposition of the shares. We will bear all costs, expenses and fees in connection with the registration of the shares.

The selling stockholders may sell or otherwise dispose of the shares of our common stock offered by this prospectus from time to time on terms to be determined at the time of sale through ordinary brokerage transactions or through any other means described in this prospectus under “Plan of Distribution.” The prices at which the selling stockholder may sell the shares will be determined by the prevailing market price for the shares or in negotiated transactions.

Our common stock trades on the Over-the-Counter Bulletin Board under the symbol “SCND.” The last reported sale price of our common stock on May 23, 2022 was $5.00 per share. You are urged to obtain current market quotations for the common stock.

The 818,183 shares of common stock covered by this prospectus were issued in a single private placement transaction completed on March 2, 2022. Additional information about the private placement is provided in the section entitled “Description of Private Placement” of this Prospectus.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

The date of this prospectus is ____, 2022

TABLE OF CONTENTS

		Page
PROSPECTUS SUMMARY		4

THE OFFERING		5

DESCRIPTION OF PRIVATE PLACEMENT		6

RISK FACTORS		6

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS		6

USE OF PROCEEDS		7

SELLING STOCKHOLDERS		7

PLAN OF DISTRIBUTION		14

MANAGEMENT'S DISCUSSION AND ANALYSIS		16

LEGAL MATTERS		20

EXPERTS		20

WHERE YOU CAN FIND ADDITIONAL INFORMATION		20

DOCUMENTS INCORPORATED BY REFERENCE		20

FINANCIAL STATEMENTS		22 - 68

Table of Contents

This prospectus is part of a registration statement that we have filed with the Securities and Exchange Commission (the “SEC”) pursuant to which the selling stockholders named herein may, from time to time, offer and sell or otherwise dispose of the shares of our common stock covered by this prospectus. You should not assume that the information contained in this prospectus is accurate on any date subsequent to the date set forth on the front cover of this prospectus or that any information we have incorporated by reference is correct on any date subsequent to the date of the document incorporated by reference, even though this prospectus is delivered or shares of common stock are sold or otherwise disposed of on a later date. It is important for you to read and consider all information contained in this prospectus, including the documents incorporated by reference therein, in making your investment decision. You should also read and consider the information in the documents to which we have referred you under the captions “Where You Can Find Additional Information” and “Documents Incorporated by Reference” in this prospectus.

We have not authorized any dealer, salesman or other person to give any information or to make any representation other than those contained or incorporated by reference in this prospectus. You must not rely upon any information or representation not contained or incorporated by reference in this prospectus. This prospectus does not constitute an offer to sell or the solicitation of an offer to buy any of our shares of common stock other than the shares of our common stock covered hereby, nor does this prospectus constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction.

Unless we have indicated otherwise, or the context otherwise requires, references in this prospectus to “Scientific,” the “Company,” “we,” “us” and “our” refer to Scientific Industries, Inc. and its subsidiaries.

PROSPECTUS SUMMARY

This summary description about us and our business highlights selected information contained elsewhere in this prospectus or incorporated by reference into this prospectus. It does not contain all the information you should consider before investing in our securities. Important information is incorporated by reference into this prospectus. To understand this offering fully, you should read carefully the entire prospectus, including “Risk Factors”, together with the additional information described under “Documents Incorporated By Reference”.

About Scientific Industries, Inc.

General.

Incorporated in 1954, Scientific Industries, Inc., a Delaware corporation (which along with its subsidiaries, the “Company”) is engaged in the design, manufacture, and marketing of standard benchtop laboratory equipment (“Benchtop Laboratory Equipment”), and through its wholly-owned subsidiary, Scientific Bioprocessing Holdings, Inc. (“SBHI”), the licensing, design, manufacture, and marketing of bioprocessing systems and products (“Bioprocessing Systems”). SBHI has two wholly-owned subsidiaries – Scientific Bioprocessing, Inc., a Delaware corporation (“SBI”) and aquila biolabs GmbH (“Aquila”), a German corporation. The Company’s products are used primarily for research purposes by universities, pharmaceutical companies, pharmacies, national laboratories, medical device manufacturers, and other industries performing laboratory-scale research. Until November 30, 2020, the Company was also engaged in the design, manufacture and marketing of customized catalyst research instruments through its wholly-owned subsidiary, Altamira Instruments, Inc, a Delaware corporation (“Altamira”). On November 30, 2020, the Company sold significantly all of Altamira’s assets and Altamira’s operations were discontinued.

Operating Segments.

The Company views its operations as two segments: the manufacture and marketing of standard Benchtop Laboratory Equipment which includes various types of equipment used for research and sample preparation in university, pharmacy and industrial laboratories sold primarily through laboratory equipment distributors and online; and the development, manufacture, and sublicensing of bioprocessing products.

Products.

Benchtop Laboratory Equipment. The Company’s Benchtop Laboratory Equipment products consist of mixers and shakers, rotators/rockers, refrigerated and shaking incubators, and magnetic stirrers sold under the “Genie ™” brand, and pharmacy and laboratory balances and scales, force gauges, and moisture analyzers under the “Torbal®” brand. Sales of the Company’s principal product, the Vortex-Genie® 2 Mixer, excluding accessories, represented approximately 47% and 39% of the Company’s total net revenues for each of the fiscal years ended June 30, 2021 (“fiscal 2021”) and June 30, 2020 (“fiscal 2020”) respectively, and 51% and 45% of the segment’s sales for fiscal 2021 and fiscal 2020, respectively.

Table of Contents

The Company’s vortex mixer is used to mix the contents of test tubes, beakers, and other various containers by placing such containers on a rotating cup or other attachments which cause the contents to be mixed at varying speeds. The Company’s additional mixers and shakers include a high-speed touch mixer, a mixer with an integral timer, a patented cell disruptor, microplate mixers, two vortex mixers incorporating digital control and display, a large capacity multi-vessel vortex mixer and a line of various orbital shakers.

The Company also offers various benchtop multi-purpose rotators and rockers, designed to rotate and rock a wide variety of containers, and a refrigerated incubator and incubated shakers, which are multi-functional benchtop environmental chambers designed to perform various shaking and stirring functions under controlled environmental conditions.

The Company’s line of magnetic stirrers includes a patented high/low programmable magnetic stirrer, a four-place high/low programmable magnetic stirrer, a large volume magnetic stirrer, and a four-place general purpose stirrer.

The Company’s Torbal brand line of products includes pharmacy, laboratory, and industrial digital scales, mechanical balances, moisture analyzers, mechanical and automated pill counters, and force gauges and test stands.

Bioprocessing Systems. The Company, through SBHI, sublicenses certain patents and technology it holds relating to bioprocessing products exclusively under a license with the University of Maryland, Baltimore County (“UMBC”), for which it receives royalties for patents that expired in August 2021 and will expire in December 2023. SBHI through its two wholly-owned subsidiaries, SBI and Aquila, is also engaged in the design, development, manufacture and marketing of bioprocessing products, principally products incorporating smart sensors and state of the art software analytics. Products offered for sale include the Cell Growth Quantifier (“CGQ”) for Biomass monitoring in shake flasks, the Liquid Injection System (“LIS”) for automated feeding in shake flasks, and a line of coaster systems and flow-through cells for pH and DO monitoring.

Private Placement

On March 2, 2022, the Company entered into a private placement transaction with the selling stockholders pursuant to which the selling stockholders acquired shares of common stock and warrants to purchase additional shares of common stock, for which the shares of common stock (including those issuable upon the exercise of warrants) are being registered hereunder. See “Description of Private Placement”.

Corporate Information

We were incorporated in Delaware on July 2, 1954. Our principal executive offices are located at 80 Orville Drive, Suite 102, Bohemia, New York 11716, and our telephone number is (631) 567-4700. Our website address is www.scientificindustries.com. Our website and the information contained on, or that can be accessed through, our website will not be deemed to be incorporated by reference in, and are not considered part of, this prospectus. You should not rely on our website or any such information in making your decision whether to purchase our common stock.

THE OFFERING

Shares of Common Stock to be Offered by the Selling Stockholders		818,183 shares

Use of Proceeds		All proceeds from the sale of the shares of common stock under this prospectus will be for the account of the selling stockholders. We will not receive any proceeds from the sale of the common stock by the selling stockholders pursuant to this prospectus. However, when applicable, we will receive proceeds in connection with the exercise price of the warrant to purchase shares of our common stock, unless any of such warrants are exercised via cashless exercise to the extent provided for in the applicable warrant. See “Use of Proceeds”.

Over the Counter Common Stock Symbol		SCND

Risk Factors		Investing in our common stock involves a high degree of risk. See “Risk Factors” below.

Table of Contents

RISK FACTORS

Investment in our common stock involves risks. Prior to making a decision about investing in our common stock, you should consider carefully the risk factors incorporated by reference in this prospectus, including the risk factors described in the section entitled “Risk Factors” contained in our most recent Annual Report on Form 10-K. Those risks and uncertainties are not the only risks and uncertainties we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations. If any of these risks actually occur, our business, results of operations and financial condition could suffer. In that event the trading price of our common stock could decline, and you may lose all or part of your investment.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This prospectus and any documents we incorporate by reference herein may contain “forward-looking statements” (within the meaning of Section 27A of the Securities Act and Section 21E of the Securities and Exchange Act of 1934, as amended, or the Exchange Act. All statements other than statements of historical facts contained in or incorporated by reference into this prospectus, including statements regarding the timing of our clinical trials, our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

The Company and its representatives may from time to time make written or oral forward-looking statements with respect to the Company’s annual or long-term goals, including statements contained in its filings with the Securities and Exchange Commission (“SEC”) and in its reports to stockholders.

The words or phrases "will likely result", “will be”, “will”, "are expected to", "will continue to", "is anticipated", "estimate", "project" or similar expressions identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties that could cause actual results to differ materially from historical earnings and those presently anticipated or projected. Readers are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date made.

These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. These forward-looking statements represent our current estimates and assumptions and, except as required by law, we undertake no obligation to update or review publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this prospectus. We anticipate that subsequent events and developments will cause our views to change. You should read this prospectus, the documents incorporated by reference herein, and the documents filed as exhibits to the registration statement of which this prospectus is a part completely and with the understanding that our actual future results may be materially different from what we expect. Our forward-looking statements do not reflect the potential impact of any future acquisitions, merger, dispositions, joint ventures or investments we may undertake. We qualify all of our forward-looking statements by these cautionary statements.

DESCRIPTION OF PRIVATE PLACEMENT

We have issued and sold shares of our common stock and warrants to purchase our common stock in a private placement pursuant to a Securities Purchase Agreement dated, March 2, 2022 (the “March 2022 Private Placement”).

The March 2022 Private Placement

Pursuant to the terms of the Securities Purchase Agreement dated March 2, 2022 (the “2022 Securities Purchase Agreement”), we sold to the investors an aggregate of 545,456 shares of our common stock (the “2022 Shares”) at a price of $5.50 per share and warrants (the “2022 Warrants”) to purchase an additional 272,727 shares of our common stock (the “2022 Warrant Shares”) at an exercise price of $5.50 per share. The 2022 Warrants were immediately exercisable as of their date of issuance and expire five years from their date of issuance. If at any time commencing 12 months from March 2, 2022, but before the expiration of the 2022 Warrants, the volume weighted average pricing of our common stock exceeds $11.00 (subject to adjustment for forward and reverse stock splits, recapitalizations, stock dividends and the like) for each of thirty consecutive trading days, then we may, at any time in our sole discretion, call for the exercise of the 2022 Warrants, in their entirety. The March 2022 Private Placement closed on March 2, 2022 (the “2022 Closing Date”).

Table of Contents

Registration Rights

We have filed the registration statement of which this prospectus is a part to fulfill certain of our contractual obligations under the Securities Purchase Agreement with respect to the registration for resale of the shares of our common stock and the shares of our common stock issuable upon the exercise of the warrants that we sold under the Securities Purchase Agreement.

We were required under the terms of the 2022 Securities Purchase Agreement to use reasonable efforts to prepare and file with the SEC, a registration statement covering the resale or other disposition of the 2022 Shares and the 2022 Warrant Shares on or prior to the date ninety (90) days after the 2022 Closing Date. We agreed to use our best efforts to have such registration statement declared to be declared effective under the Securities Act by the Commission on or before the date that is ninety (90) days of the filing (or, in the event of a “full review” by the Commission, the date that is one hundred twenty (120) days after the date of the filing. We agreed to bear the expenses incurred in complying with these registration rights provisions. The 2022 Securities Purchase Agreement also includes customary indemnification provisions regarding the registration rights.

This description of the Securities Purchase Agreement and Registration Rights Agreement is not complete and is qualified in its entirety by reference to each of these agreements which have been filed as an exhibit to the registration statement of which this prospectus is a part. See “Where You Can Find Additional Information” and “Documents Incorporated by Reference.” The representations, warranties and covenants made by us in the Securities Purchase Agreement and the Registration Rights Agreement were made solely for the benefit of the parties to such agreements, including, in some cases, for the purpose of allocating risk among the parties thereto, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were made as of an earlier date. Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs.

USE OF PROCEEDS

We will not receive any of the proceeds from the sale of the common stock by the selling stockholders named in this prospectus. All proceeds from the resale of the shares of our common stock offered by this prospectus will belong to the selling stockholders identified in this prospectus under “Selling Stockholders.”

We will, however, receive proceeds equal to the applicable exercise price of the warrants to purchase shares of our common stock, upon any exercise thereof, unless any of such warrants are exercised via cashless exercise to the extent provided for in the applicable warrant. We will use any such proceeds for ordinary course working capital needs. We have also agreed to bear all fees and expenses incident to our obligation to register shares of our common stock being offered by this prospectus.

MARKET FOR COMMON STOCK AND DIVIDEND POLICY

Our common stock is traded on the Over-the-Counter Bulletin Board under the symbol “SCND.” The last reported sale price of our common stock on May 23, 2022 was $5.00 per share. As of May 23, 2022, there were 290 stockholders of record of our common stock.

We have not declared or paid any cash dividends on our common stock since December 2018. We intend to retain any future earnings and do not expect to pay dividends in the foreseeable future.

SELLING STOCKHOLDERS

The common stock being offered by the selling stockholders are those previously issued and issuable to the selling stockholders upon exercise of the warrants to purchase shares of our common stock. For additional information regarding the issuances of those shares of common stock and warrants, see “Description of Private Placements”. We are registering the shares of common stock to permit the selling stockholders to offer the shares for resale or other disposition from time to time. In addition to the ownership of the shares of our common stock and warrants to purchase shares of our common stock that is the subject of this prospectus, certain of the selling stockholders have had material relationships with us within the past three years as disclosed in this prospectus and described below under “Relationships with Certain Selling Stockholders.”

Table of Contents

The table below sets forth information as of the date of this prospectus, to our knowledge, the selling stockholders and other information regarding the beneficial ownership (as determined under Section 13(d) of the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder) of the shares of common stock held by the selling stockholders. The second column lists the number of shares of common stock beneficially owned by the selling stockholders, as of May 23, 2022. The third column lists the maximum number of shares of common stock that may be sold or otherwise disposed of by the selling stockholders pursuant to the registration statement of which this prospectus forms a part. The selling stockholders may sell or otherwise dispose of some, all or none of their shares. Pursuant to Rules 13d-3 and 13d-5 of the Exchange Act, beneficial ownership includes any shares of our common stock as to which a stockholder has sole or shared voting power or investment power, and also any shares of our common stock which the stockholder has the right to acquire within 60 days. The percent of beneficial ownership for the selling stockholders is based on 7,003,599 shares of common stock outstanding as of the date of this prospectus

The shares of common stock being covered hereby may be sold or otherwise disposed of from time to time during the period the registration statement of which this prospectus is a part remains effective, by or for the account of the selling stockholders. After the date of effectiveness, the selling stockholders may have sold or transferred, in transactions covered by this prospectus or in transactions exempt from the registration requirements of the Securities Act, some or all of their common stock.

Unless otherwise noted below, the address of each selling stockholder listed on the table is c/o Scientific Industries, Inc., 80 Orville Drive, Suite 102, Bohemia, New York 11716.

	Shares Beneficially Owned as of this Prospectus		Shares Offered by this Prospectus	Shares Beneficially Owned After the Offering
Name of Selling Shareholder	Number	Percent		Number	Percent
21 April Fund L.P.	255,526¹	3.60%	18,684²	236,842³	3.34%
21 April Fund, LTD.	649,500⁴	9.00%	49,500⁵	600,000⁶	8.33%
A.G. Family, L.P.	305,023⁷	4.29%	68,181⁸	236,842⁹	3.34%
Ali El-Mohandes	54,546¹⁰	0.78%	54,546¹⁰	-	0.00%
Barry Butler	13,638¹¹	0.19%	13,638¹¹	-	0.00%
Benjamin F. Jackson	27,273¹²	0.39%	27,273¹²	-	0.00%
William J. Cassano	13,638¹³	0.19%	13,638¹³	-	0.00%
Bruce C. Conway	87,750¹⁴	1.25%	12,750¹⁵	75,000¹⁶	1.07%
Bruce Pettet	15,000¹⁷	0.21%	15,000¹⁷	-	0.00%
Daniel Grunes	24,706¹⁸	0.35%	2,250¹⁹	22,456²⁰	0.32%
David Frank	22,810²¹	0.32%	2,250²²	20,560²³	0.29%
Gary Cook Family Trust	27,273²⁴	0.39%	27,273²⁴	-	0.00%
Giuseppe Soldano	1,500²⁵	0.02%	1,500²⁵	-	0.00%
Harris Lydon	43,581²⁶	0.62%	12,003²⁷	31,578²⁸	0.45%
Helena Santos	184,695²⁹	2.58%	570³⁰	184,125³¹	2.57%
Henry Hazard Moore	9,237³²	0.13%	4,500³³	4,737³⁴	0.07%
James B. Polk	95,539³⁵	1.35%	1,500³⁶	94,039³⁷	1.33%
James A. Clancy	13,348³⁸	0.19%	5,454³⁹	7,894⁴⁰	0.11%
Jennifer Duncan’s Inheritors Trust	7,500⁴¹	0.11%	7,500⁴¹	-	0.00%
John A. Moore	226,583⁴²	3.16%	19,500⁴³	207,083⁴⁴	2.89%
Josiah T. Austin	71,644⁴⁵	1.02%	8,487⁴⁶	63,157⁴⁷	0.90%
Kikis Family Holdings LLC	13,635⁴⁸	0.19%	13,635⁴⁸	-	0.00%
Klaus Kretschmer	27,271⁴⁹	0.39%	27,271⁴⁹	-	0.00%
Konrad Herzog	25,456⁵⁰	0.36%	3,000⁵¹	22,456⁵²	0.32%
Lytton-Kambara Foundation	408,229⁵³	5.72%	109,092⁵⁴	299,137⁵⁵	4.21%
Magellan Partners I, LLC	54,546⁵⁶	0.78%	54,546⁵⁶	-	0.00%
Marcus Frampton	20,813⁵⁷	0.30%	10,500⁵⁸	10,313	0.15%
Michael Mullins	4,500⁵⁹	0.06%	4,500⁵⁹	-	0.00%

Table of Contents

	Shares Beneficially Owned as of this Prospectus		Shares Offered by this Prospectus	Shares Beneficially Owned After the Offering
Name of Selling Shareholder	Number	Percent		Number	Percent
Neal Polan	27,271⁶⁰	0.39%	27,271⁶⁰	-	0.00%
Robert Masters	15,000⁶¹	0.21%	15,000⁶¹	-	0.00%
Sandra F. Pessin	699,760⁶²	9.67%	68,181⁶³	631,579⁶⁴	8.75%
Shoup Revocable Trust 04/29/03	10,092⁶⁵	0.14%	10,092⁶⁵	-	0.00%
Starlight Investment Holdings Limited	122,008⁶⁶	1.73%	27,273⁶⁷	94,735⁶⁸	1.35%
TomSat Investment & Trading Co., Inc.	152,512⁶⁹	2.16%	34,092⁷⁰	118,420⁷¹	1.68%
VI LLC	6,819⁷²	0.10%	6,819⁷²	-	0.00%
Vogt Family Trust FBO William T. Vogt Jr.	8,181⁷³	0.12%	8,181⁷³	-	0.00%
Leedy Ying	5,460⁷⁴	0.08%	5,460⁷⁴	-	0.00%
YJP International Limited	27,273⁷⁵	0.39%	27,273⁷⁵	-	0.00%

____________________

1.	Includes 85,175 shares issuable upon exercise of warrants.
2.	Includes 6,228 shares issuable upon exercise of warrants.
3.	Includes 78,947 shares issuable upon exercise of warrants.
4.	Includes 216,500 shares issuable upon exercise of warrants.
5.	Includes 16,500 shares issuable upon exercise of warrants.
6.	Includes 200,000 shares issuable upon exercise of warrants.
7.	Includes 101,674 shares issuable upon exercise of warrants.
8.	Includes 22,727 shares issuable upon exercise of warrants.
9.	Includes 78,947 shares issuable upon exercise of warrants.
10.	Includes 18,182 shares issuable upon exercise of warrants.
11.	Includes 4,546 shares issuable upon exercise of warrants.
12.	Includes 9,091 shares issuable upon exercise of warrants.
13.	Includes 4,546 shares issuable upon exercise of warrants.
14.	Includes 29,250 shares issuable upon exercise of warrants.
15.	Includes 4,250 shares issuable upon exercise of warrants.
16.	Includes 25,000 shares issuable upon exercise of warrants.
17.	Includes 5,000 shares issuable upon exercise of warrants.
18.	Includes 2,013 shares issuable upon exercise of warrants, and options to purchase 18,667 shares of Common Stock.
19.	Includes 750 shares issuable upon exercise of warrants.
20.	Includes 1,263 shares issuable upon exercise of warrants, and options to purchase 18,667 shares of Common Stock.
21.	Includes 1,381 shares issuable upon exercise of warrants, and options to purchase 18,667 shares of Common Stock.
22.	Includes 750 shares issuable upon exercise of warrants.
23.	Includes 631 shares issuable upon exercise of warrants, and options to purchase 18,667 shares of Common Stock.
24.	Includes 9,091 shares issuable upon exercise of warrants.
25.	Includes 500 shares issuable upon exercise of warrants.
26.	Includes 14,527 shares issuable upon exercise of warrants.
27.	Includes 4,001 shares issuable upon exercise of warrants.
28.	Includes 10,526 shares issuable upon exercise of warrants.
29.	Includes 716 shares issuable upon exercise of warrants and options to purchase 161,295 shares of Common Stock.
30.	Includes 190 shares issuable upon exercise of warrants.
31.	Includes 526 shares issuable upon exercise of warrants, options to purchase 161,295 shares of Common Stock and 21,252 shares of Common Stock previously held by the stockholder.
32.	Includes 3,079 shares issuable upon exercise of warrants.
33.	Includes 1,500 shares issuable upon exercise of warrants.
34.	Includes 1,579 shares issuable upon exercise of warrants.

Table of Contents

35.	Includes 3,131 shares issuable upon exercise of warrants and options to purchase 86,146 shares of Common Stock.
36.	Includes 500 shares issuable upon exercise of warrants.
37.	Includes 2,631 shares issuable upon exercise of warrants and options to purchase 86,146 shares of Common Stock.
38.	Includes 4,449 shares issuable upon exercise of warrants.
39.	Includes 1,818 shares issuable upon exercise of warrants.
40.	Includes 2,631 shares issuable upon exercise of warrants.
41.	Includes 2,500 shares issuable upon exercise of warrants.
42.	Includes 17,026 shares issuable upon exercise of warrants, and options to purchase 153,305 shares of Common Stock.
43.	Includes 6,500 shares issuable upon exercise of warrants.
44.	Includes 10,526 shares issuable upon exercise of warrants, options to purchase 153,305 shares of Common Stock and 43,252 shares of Common Stock previously held by the stockholder.
45.	Includes 23,881 shares issuable upon exercise of warrants.
46.	Includes 2,829 shares issuable upon exercise of warrants.
47.	Includes 21,052 shares issuable upon exercise of warrants.
48.	Includes 4,545 shares issuable upon exercise of warrants.
49.	Includes 9,090 shares issuable upon exercise of warrants.
50.	Includes 2,263 shares issuable upon exercise of warrants, and options to purchase 18,667 shares of Common Stock.
51.	Includes 1,000 shares issuable upon exercise of warrants.
52.	Includes 1,263 shares issuable upon exercise of warrants, and options to purchase 18,667 shares of Common Stock.
53.	Includes 131,893 shares issuable upon exercise of warrants.
54.	Includes 36,364 shares issuable upon exercise of warrants.
55.	Includes 95,529 shares issuable upon exercise of warrants.
56.	Includes 18,182 shares issuable upon exercise of warrants.
57.	Includes 3,500 shares issuable upon exercise of warrants.
58.	Includes 3,500 shares issuable upon exercise of warrants.
59.	Includes 1,500 shares issuable upon exercise of warrants.
60.	Includes 9,090 shares issuable upon exercise of warrants.
61.	Includes 5,000 shares issuable upon exercise of warrants.
62.	Includes 233,253 shares issuable upon exercise of warrants.
63.	Includes 22,727 shares issuable upon exercise of warrants.
64.	Includes 210,526 shares issuable upon exercise of warrants.
65.	Includes 3,364 shares issuable upon exercise of warrants.
66.	Includes 40,669 shares issuable upon exercise of warrants.
67.	Includes 9,091 shares issuable upon exercise of warrants.
68.	Includes 31,578 shares issuable upon exercise of warrants.
69.	Includes 50,837 shares issuable upon exercise of warrants.
70.	Includes 11,364 shares issuable upon exercise of warrants.
71.	Includes 39,473 shares issuable upon exercise of warrants.
72.	Includes 2,273 shares issuable upon exercise of warrants.
73.	Includes 2,727 shares issuable upon exercise of warrants.
74.	Includes 1,820 shares issuable upon exercise of warrants.
75.	Includes 9,091 shares issuable upon exercise of warrants.

Relationship with Certain Selling Stockholders

Daniel Gruenes

Daniel Gruenes is the Vice President of Research and Development and Operations of the Company’s Bioprocessing Operations.

John A. Moore

John A. Moore was elected to the Company’s Board of Directors on January 23, 2019, and became the Chairman of the Board of Directors on January 29, 2020. Mr. Moore also served as a consultant to the Company from March 1, 2019 until June 30, 2020.

Table of Contents

James B. Polk

James B. Polk is Vice President of Sales for North, Central, and South America regions of the Company’s wholly-owned subsidiary, Scientific Bioprocessing, Inc.

Helena Santos

Helena Santos has been a Director of the Company and the President, Chief Executive Officer, Chief Financial Officer and Treasurer for the past three years.

DESCRIPTION OF COMMON STOCK

The following description of our common stock, together with the additional information we include in any applicable prospectus supplements, summarizes the material terms and provisions of our common stock that the selling stockholders may offer under this prospectus. It may not contain all the information that is important to you. For the complete terms of our common stock, please refer to our amended certificate of incorporation and our amended and restated bylaws, which are incorporated by reference into the registration statement which includes this prospectus. The Delaware General Corporation Law, or DGCL, may also affect the terms of our common stock. If we so indicate in a prospectus supplement, the terms of any security offered under that prospectus supplement may differ from the terms we describe below.

Our amended certificate of incorporation provides for one class of common stock. Our authorized capital stock consists of 20,000,000 shares of common stock. As of May 23, 2022, we had outstanding 7,003,599 shares of common stock, held by 290 stockholders of record. As of May 23, 2022, we also had outstanding options to acquire 1,221,977 shares of our common stock with a weighted average exercise price of $8.45 per share. In addition, as of May 23, 2022, there were warrants outstanding for the purchase of an aggregate of 3,420,510 shares of common stock with a weighted average exercise price of $8.98 per share. Further, as of May 23, 2022, 1,796,113 shares of our common stock are available for issuance pursuant to awards made under the Scientific Industries, Inc. 2022 Stock Option Plan, as amended.

Voting Rights

Under our amended certificate of incorporation, each share of our common stock entitles the holder to one vote with respect to each matter presented to our stockholders on which the holders of our common stock are entitled to vote. Our common stock votes as a single class on all matters relating to the election and removal of directors on our board of directors and as provided by law. Holders of our common stock do not have cumulative voting rights. Except in respect of matters relating to the election and removal of directors on our board of directors and as otherwise provided in our amended certificate of incorporation or required by law, all matters to be voted on by our stockholders must be approved by a majority of the shares present in person or by proxy at the meeting and entitled to vote on the subject matter. In the case of election of directors, all matters to be voted on by our stockholders must be approved by a plurality of the votes entitled to be cast by all shares of our common stock.

Dividends

The holders of our common stock will be entitled to share equally, identically and ratably in any dividends that our board of directors may determine to issue from time to time. We have not paid cash dividends on our common stock since December 14, 2018. We do not anticipate paying periodic cash dividends on our common stock for the foreseeable future. Any future determination about the payment of dividends will be made at the discretion of our board of directors and will depend upon our earnings, if any, capital requirements, operating and financial conditions and on such other factors as the board of directors deems relevant.

Liquidation Rights

In the event of any voluntary or involuntary liquidation, dissolution or winding up of our affairs, holders of our common stock would be entitled to share ratably in our assets that are legally available for distribution to stockholders after payment of our debts and other liabilities.

Other Rights

Our stockholders have no preemptive, conversion or other rights to subscribe for additional shares of our common stock. All outstanding shares of our common stock are, and all shares of our common stock offered by this prospectus will be, when sold, validly issued, fully paid and nonassessable. The rights, preferences and privileges of the holders of our common stock will be subject to, and may be adversely affected by, the rights of the holders of shares of any series of our preferred stock that we may designate and issue in the future.

Table of Contents

Listing

Our common stock is listed on the Over-the-Counter Bulletin Board under the symbol “SCND.”

Transfer Agent and Registrar

The transfer agent for our common stock is Continental Stock Transfer & Trust Company. Its address is 1 State Street, New York, New York 10004.

Certain Effects of Authorized but Unissued Stock

We have shares of common stock available for future issuance by action of the Board of Directors without stockholder approval. We may issue these additional shares for a variety of corporate purposes, including future public or private offerings to raise additional capital or to facilitate corporate acquisitions or for payment as a dividend on our capital stock.

Anti-Takeover Effects of Provisions of Our Charter Documents

Our amended certificate of incorporation provides for our board of directors to be divided into three classes with staggered three-year terms. Only one class of directors will be elected at each annual meeting of our stockholders, with the other classes continuing for the remainder of their respective three-year terms. Because our stockholders do not have cumulative voting rights, our stockholders holding a majority of the shares of our common stock outstanding will be able to elect all of our directors. Our amended certificate of incorporation and amended and restated bylaws provide that only our board of directors, president or secretary of the holders of 66 2/3 percent in interest of the stockholders entitled to vote may call a special meeting of stockholders.

Our amended certificate of incorporation also provides that a “Subject Transaction” with a “Related Party” requires the approval of the holders of 80% of the Company’s voting stock, unless (i) the Subject Transaction is approved by 2/3 of our Board of Directors and (ii) our stockholders receive at least $6.00 per share. A Subject Transaction is (i) a merger or consolidation of the Company, (ii) the sale, lease, exchange, transfer or other disposition of all or substantially all the assets of the Company, or (ii) the sale, lease, exchange, transfer or other disposition of any assets to the Company in exchange for voting securities, unless (i) the value of such assets is less than $1,000,000 (ii) the voting securities issued by the Company constitute less than 20% of the aggregate voting securities of the Company. A Related Person is a stockholder (or group of stockholders that are required under the Securities Exchange Act of 1934, as amended, to file a Form 13D or Form 13G) that is the beneficial owner of 5% or more of the voting securities of the Company.

These provisions may have the effect of deterring hostile takeovers or delaying changes in our control or management. These provisions are intended to enhance the likelihood of continued stability in the composition of our board of directors and its policies and to discourage certain types of transactions that may involve an actual or threatened acquisition of us. These provisions are designed to reduce our vulnerability to an unsolicited acquisition proposal. The provisions also are intended to discourage certain tactics that may be used in proxy fights. However, such provisions could have the effect of discouraging others from making tender offers for our shares and, as a consequence, they also may inhibit fluctuations in the market price of our common stock that could result from actual or rumored takeover attempts.

Anti-Takeover Effects of Provisions of Delaware Law

We are subject to Section 203 of the DGCL, which prohibits a Delaware corporation from engaging in any business combination with any interested stockholder for a period of three years after the date that such stockholder became an interested stockholder, with the following exceptions:

before such date, the board of directors of the corporation approved either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder;

upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction began, excluding for purposes of determining the voting stock outstanding (but not the outstanding voting stock owned by the interested stockholder) those shares owned (i) by persons who are directors and also officers and (ii) employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or

on or after such date, the business combination is approved by the board of directors and authorized at an annual or special meeting of the stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting stock that is not owned by the interested stockholder.

Table of Contents

In general, Section 203 defines business combination to include the following:

any merger or consolidation involving the corporation and the interested stockholder;

any sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the interested stockholder;

subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder;

any transaction involving the corporation that has the effect of increasing the proportionate share of the stock or any class or series of the corporation beneficially owned by the interested stockholder; or

the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits by or through the corporation.

In general, Section 203 defines an “interested stockholder” as an entity or person who, together with the person’s affiliates and associates, beneficially owns, or within three years prior to the time of determination of interested stockholder status did own, 15% or more of the outstanding voting stock of the corporation.

Limitation of Liability and Indemnification

We have adopted provisions in our amended certificate of incorporation that limit or eliminate the liability of our directors for monetary damages for breach of their fiduciary duties, except for liability that cannot be eliminated under the DGCL. Section 102(b)(7) of the DGCL, provides that a corporation may, in its original certificate of incorporation or an amendment thereto, eliminate or limit the personal liability of a director for violations of the director’s fiduciary duty, except (1) for any breach of the director’s duty of loyalty to the corporation or its stockholders, (2) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (3) pursuant to Section 174 of the DGCL, which provides for liability of directors for unlawful payments of dividends or unlawful stock purchases or redemptions or (4) for any transaction from which a director derived an improper personal benefit. Accordingly, our directors will not be personally liable for monetary damages for breach of their fiduciary duties as directors, except with respect to the following:

any breach of their duty of loyalty to us or our stockholders;

acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law;

unlawful payments of dividends or unlawful stock repurchases or redemptions as provided in Section 174 of the DGCL; or

any transaction from which the director derived an improper personal benefit.

This limitation of liability does not apply to liabilities arising under the federal securities laws and does not affect the availability of equitable remedies such as injunctive relief or rescission. If Delaware law is amended to authorize the further elimination or limiting of director liability, then the liability of our directors will be eliminated or limited to the fullest extent permitted by Delaware law as so amended.

Section 145 of the DGCL provides that a corporation may indemnify any person, including an officer or director, who is, or is threatened to be made, party to any threatened, pending or completed legal action, suit or proceeding, whether civil, criminal, administrative or investigative, other than an action by or in the right of such corporation, by reason of the fact that such person was an officer, director, employee or agent of such corporation or is or was serving at the request of such corporation as an officer, director, employee or agent of another corporation or enterprise. The indemnity may include expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding, provided such officer, director, employee or agent acted in good faith and in a manner he reasonably believed to be in, or not opposed to, the corporation’s best interest and, for criminal proceedings, had no reasonable cause to believe that his conduct was unlawful. A Delaware corporation may indemnify any officer or director in an action by or in the right of the corporation under the same conditions, except that no indemnification is permitted without judicial approval if the officer or director is adjudged to be liable to the corporation. Where an officer or director is successful on the merits or otherwise in the defense of any action referred to above, the corporation must indemnify him against the expenses that such officer or director actually and reasonably incurred.

Table of Contents

Our amended certificate of incorporation and our amended and restated bylaws provide that we shall indemnify our directors and executive officers and shall indemnify our other officers and employees and other agents to the fullest extent permitted by law. We believe that indemnification under our bylaws covers at least negligence and gross negligence on the part of indemnified parties. Our bylaws also permit us to secure insurance on behalf of any officer, director, employee or other agent for any liability arising out of his or her actions in this capacity, regardless of whether our bylaws would permit indemnification.

In addition, we have entered and intend to continue to enter into separate indemnification agreements with certain of our directors and executive officers that are, in some cases, broader than the specific indemnification provisions provided by Delaware law and our charter documents, and may provide additional procedural protection. These agreements will require us, among other things, to:

indemnify officers and directors against certain liabilities that may arise because of their status as officers and directors;

advance expenses, as incurred, to officers and directors in connection with a legal proceeding subject to limited exceptions; and

cover officers and directors under any general or directors’ and officers’ liability insurance policy maintained by us.

We believe that these provisions and agreements are necessary to attract and retain qualified persons as directors and executive officers. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling our company pursuant to the foregoing provisions, the opinion of the Securities and Exchange Commission is that such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.

In addition, we maintain standard policies of insurance under which coverage is provided to our directors and officers against loss arising from claims made by reason of breach of duty or other wrongful act, and to us with respect to payments which may be made by us to such directors and officers pursuant to the above indemnification provisions or otherwise as a matter of law.

PLAN OF DISTRIBUTION

The selling stockholders may, from time to time, sell any or all of their shares of common stock on any stock exchange, market or trading facility on which the shares are traded or in private transactions. These sales may be at fixed or negotiated prices. The selling stockholders may use any one or more of the following methods when selling shares:

ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;

block trades in which the broker-dealer will attempt to sell the shares as agent but may position and resell a portion of the block as principal to facilitate the transaction;

purchases by a broker-dealer as principal and resale by the broker-dealer for its account;

an exchange distribution in accordance with the rules of the applicable exchange;

privately negotiated transactions;

short sales effected after the date the registration statement of which this Prospectus is a part is declared effective by the SEC;

broker-dealers may agree with the selling stockholders to sell a specified number of such shares at a stipulated price per share;

a combination of any such methods of sale; and

any other method permitted pursuant to applicable law.

Table of Contents

The selling stockholders may also sell shares under Rule 144 under the Securities Act, if available, rather than under this prospectus.

Broker-dealers engaged by the selling stockholders may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions or discounts from the selling stockholders (or, if any broker-dealer acts as agent for the purchaser of shares, from the purchaser) in amounts to be negotiated. The selling stockholders do not expect these commissions and discounts to exceed what is customary in the types of transactions involved. Any profits on the resale of shares of common stock by a broker-dealer acting as principal might be deemed to be underwriting discounts or commissions under the Securities Act. Discounts, concessions, commissions and similar selling expenses, if any, attributable to the sale of shares will be borne by a selling stockholder. The selling stockholders may agree to indemnify any agent, dealer or broker-dealer that participates in transactions involving sales of the shares if liabilities are imposed on that person under the Securities Act.

The selling stockholders may from time to time pledge or grant a security interest in some or all of the shares of common stock owned by them and, if they default in the performance of their secured obligations, the pledgees or secured parties may offer and sell the shares of common stock from time to time under this prospectus after we have filed a supplement to this prospectus under Rule 424(b)(3) or other applicable provision of the Securities Act of 1933 supplementing or amending the list of selling stockholders to include the pledgee, transferee or other successors in interest as selling stockholders under this prospectus.

The selling stockholders also may transfer the shares of common stock in other circumstances, in which case the transferees, pledgees or other successors in interest will be the selling beneficial owners for purposes of this prospectus and may sell the shares of common stock from time to time under this prospectus after we have filed a supplement to this prospectus under Rule 424(b)(3) or other applicable provision of the Securities Act of 1933 supplementing or amending the list of selling stockholders to include the pledgee, transferee or other successors in interest as selling stockholders under this prospectus.

The selling stockholders and any broker-dealers or agents that are involved in selling the shares of common stock may be deemed to be “underwriters” within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers or agents and any profit on the resale of the shares of common stock purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act.

We are required to pay all fees and expenses incident to the registration of the shares of common stock. We have agreed to indemnify the selling stockholders against certain losses, claims, damages and liabilities, including liabilities under the Securities Act.

The selling stockholders have advised us that they have not entered into any agreements, understandings or arrangements with any underwriters or broker-dealers regarding the sale of their shares of common stock, nor is there an underwriter or coordinating broker acting in connection with a proposed sale of shares of common stock by any selling stockholder. If we are notified by any selling stockholder that any material arrangement has been entered into with a broker-dealer for the sale of shares of common stock, if required, we will file a supplement to this prospectus. If the selling stockholders use this prospectus for any sale of the shares of common stock, they will be subject to the prospectus delivery requirements of the Securities Act.

In order to comply with the securities laws of some states, if applicable, the common stock may be sold in these jurisdictions only through registered or licensed brokers or dealers. In addition, in some states the common stock may not be sold unless it has been registered or qualified for sale or an exemption from registration or qualification requirements is available and is complied with.

We have advised the selling stockholders that the anti-manipulation rules of Regulation M under the Securities Exchange Act of 1034, as amended, may apply to sales of shares in the market and to the activities of the selling stockholders and their affiliates. In addition, to the extent applicable we will make copies of this prospectus (as it may be supplemented or amended from time to time) available to the selling stockholders for the purpose of satisfying the prospectus delivery requirements of the Securities Act. The selling stockholders may indemnify any broker-dealer that participates in transactions involving the sale of the shares against certain liabilities, including liabilities arising under the Securities Act.

We have agreed with the selling stockholders to keep the registration statement of which this prospectus constitutes a part effective until the earlier of (1) such time as all of the shares covered by this prospectus have been disposed of pursuant to and in accordance with the registration statement and (2) one year from the date of this prospectus.

Table of Contents

MANAGEMENT'S DISCUSSION AND ANALYSIS

For the Year Ended June 30, 2021 and 2020:

Forward-Looking statements. Certain statements contained in this report are not based on historical facts, but are forward-looking statements that are based upon various assumptions about future conditions. Actual events in the future could differ materially from those described in the forward-looking information. Numerous unknown factors and future events could cause such differences, including but not limited to, product demand, market acceptance, success of marketing strategy, success of expansion efforts, impact of competition, adverse economic conditions, and other factors affecting the Company’s business that are beyond the Company’s control, which are discussed elsewhere in this report. Consequently, no forward-looking statement can be guaranteed. The Company undertakes no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise. This Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the Company’s financial statements and the related notes included elsewhere in this report.

Overview. The Company’s results reflect the results from the Benchtop Laboratory Equipment Operations and the Bioprocessing Systems Operations, which includes two months of results for Aquila, following its acquisition on April 29, 2021. The Company realized a loss from continuing operations before income tax benefit of $4,055,000 for fiscal 2021 compared to a loss of $667,400 for fiscal 2020, primarily due to increased operating expenses of its Bioprocessing Systems Operations, which included significant amounts for product development, sales and marketing, costs related to the acquisition of Aquila, and non-cash compensation expense related to stock options, partially offset by the profits generated by increased sales of the Benchtop Laboratory Equipment Operations. The results also reflected a loss before income tax benefit for discontinued operations of $769,900 compared to $472,500 in fiscal 2020. On November 30, 2020, the Company sold substantially all of the assets of its Catalyst Research Instruments Operations which was operated through its wholly-owned subsidiary, Altamira Instruments, Inc.

The challenges posed by the COVID-19 pandemic on the global economy began to take effect and impact the Company’s operations at the end of the third quarter of the year ended June 30, 2020. At that time, the Company took appropriate action and put plans in place to diminish the effects of COVID-19 on its operations, enabling the Company to continue to operate with minor or temporary disruptions to its operations. The Company took immediate action as it pertains to COVID-19 preparedness by implementing the Center for Disease Control’s guidelines for employers in order to protect the Company’s employees’ health and safety, with actions such as implementing work from home, social distancing in the workplace, requiring self-quarantine for any employee showing symptoms, wearing face coverings, and training employees on maintaining a healthy work environment. The Bioprocessing Systems Operations’ SBI facility was shut down temporarily due to state mandates, however, the impact on operations was immaterial, and the Company has been able to retain its employees without furloughs or layoffs, in part, due to the Company’ receipt of two loans under the Federal Government’s Paycheck Protection Program (“PPP”). The Company received $563,800 and $433,800 in April 2020 and March 2021, respectively, under this program administered by the U.S. Small Business Administration through its bank. The first loan was forgiven in June 2021 except for $32,700 which was repaid. The remaining loan bears interest at 1% per annum and matures in March 2026 and contains no collateral or guarantee requirements. The Company expects to apply for and receive forgiveness for the majority of the second loan. The Bioprocessing Systems Operations’ German operation, which was acquired on April 29, 2021,was negatively impacted in its ability to secure new orders because Aquila had historically relied on face-to-face meetings at trade shows for its sales opportunities. While it has participated in virtual trade shows, management believes that certain sales opportunities are lost as a result. The Company has not experienced and does not anticipate any material impact on its ability to collect its accounts receivable due to the nature of its customers, which are primarily distributors of laboratory equipment and supplies which have benefitted from the Pandemic due to the nature of the products and have the ability to pay. However, there is a delay in the receipt of a receivable from a customer related to the Company’s discontinued operations due to a delay in the Company’s ability to complete the installation of equipment purchased by the customer, as a result of the Pandemic. The Company has not experienced and does not anticipate any material impairment to its tangible and intangible assets, system of internal controls, or delivery and distribution of its products as a result of COVID-19, however the ultimate impact of COVID-19 on the Company’s business, results of operations, financial condition and cash flows is dependent on future developments, including the duration or worsening of the pandemic and the related length of its impact on the global economy, which are uncertain and cannot be predicted at this time. The Company is currently experiencing some delays from its supply chain which is having an impact on delayed delivery of some products, however this is deemed temporary and does not affect the Company’s major product – the Vortex-Genie 2. In addition, due to the travel restrictions imposed by the United States and other governments worldwide, Company personnel may be restricted from traveling to conduct its operations including site visits, customer visits and installations, vendor facility visits, and other sales and marketing related travel that can negatively impact the Company.

Results of Operations. Net revenues for fiscal 2021 increased $1,990,800 (25.6%) to $9,775,200 from $7,784,400 for fiscal 2020, reflecting an increase of $2,260,000 in net sales of Benchtop Laboratory Equipment Operations, in part related to its products being used in COVID-19 related research and testing, and a decrease of $269,200 in net revenues of the Bioprocessing Systems Operations, primarily due to decreased royalties earned during the current year period due to expiring patents.

The gross profit percentage for fiscal 2021 of 50.9% approximated fiscal 2020’s gross profit percentage of 50.6%.

Table of Contents

General and administrative expenses for fiscal 2021 increased by approximately $1,753,100 (77.0%) to $4,028,500 compared to $2,275,400 for fiscal 2020 due primarily to compensation-related costs resulting from stock option grants and increased costs from the Bioprocessing Systems Operations in part due to the acquisition of Aquila in the fourth quarter of fiscal 2021.

Selling expenses for fiscal 2021 increased approximately $2,846,100 (240.0%) to $4,031,900 from $1,185,800 for fiscal 2020, primarily due to increased sales and marketing expenses incurred by the Bioprocessing Systems operations for sales and marketing personnel, sales and marketing activities, and compensation-related costs resulting from stock option grants.

Research and development expenses increased $484,100 (42.5%) to $1,623,800 for fiscal 2021 compared to $1,139,700 for fiscal 2020, due to increased product development expenditures by the Bioprocessing Systems operations, including such expenditures incurred by Aquila since its acquisition in the fourth quarter of fiscal 2021, partially offset by decreased product development expenditures incurred by the Benchtop Laboratory Equipment Operations.

Total other income (loss), net was $653,800 for fiscal 2021 compared to $(3,900) in fiscal 2020. This increase was due primarily to the $531,100 forgiveness of the first PPP loan received by the Company, and increased interest income resulting from increased investment securities balances.

The Company reflected income tax benefit for continuing operations of $945,000 for fiscal 2021 compared to income tax benefit of $214,000 for fiscal 2020, primarily due to the loss incurred.

As a result of the foregoing, the Company recorded a net loss from continuing operations of $3,110,000 for fiscal 2021 compared to a net loss from continuing operations of $453,400 for fiscal 2020.

The Company reflected a net loss from discontinued operations of $562,500 for fiscal 2021, compared to a $249,900 loss for fiscal 2020, primarily due to loss on the sale of the majority of the operation’s assets during the current fiscal year.

As a result of the above, the Company recorded a net loss of $3,672,500 for fiscal 2021 compared to a net loss of $703,300 for fiscal 2020.

Liquidity and Capital Resources. Cash and cash equivalents increased by $2,115,500 to $9,675,200 as of June 30, 2021 from $7,559,700 as of June 30, 2020. The Company received $563,800 and $433,800 in April 2020 and March 2021, respectively, under the Payroll Protection Program administered by the U.S. Small Business Administration through its bank. The first loan was forgiven in June 2021 except for $32,700 which was repaid. The remaining loan bears interest at 1% per annum and matures in March 2026 and contains no collateral or guarantee requirements. The Company expects to apply for and receive forgiveness for the majority of the second loan. In April and June of 2021, the Company received a total of $16,074,000, net of issuance costs, from the sale of its Common Stock as further described in Note 15 of the financial statements in Item 8. The Company expects that it will be able to meet its cash flow needs during the next 12 months from cash derived from its operations and cash on-hand.

Net cash used in operating activities was $3,301,500 for fiscal 2021 compared to net cash used in operating activities of $168,100 for fiscal 2020, primarily due to the net loss for the current year. Net cash used in investing activities was $10,884,000 for fiscal 2021 compared to $84,100 for fiscal 2020 due mainly to acquisition of Aquila in the current year and purchase of investment securities. Net cash provided by financing activities was $16,310,200 for fiscal 2021 compared to $6,209,400 during fiscal 2020 due mainly to proceeds from issuance of stock and the proceeds from the Payroll Protection Program loan.

The Company's working capital increased by $5,595,800 to $16,144,300 as of June 30, 2021 compared to $10,548,500, as of June 30, 2020, primarily due to the cash received from the equity financings.

Table of Contents

For Three and Nine Months Ended March 31, 2022 and 2021:

Overview. The Company’s results reflect those of the Benchtop Laboratory Equipment Operations and the Bioprocessing Systems Operations, which includes the results for Aquila following its acquisition on April 29, 2021. The Company realized a loss from continuing operations before income tax benefit of $1,844,600 for the three months ended March 31, 2022 compared to a $1,830,200 loss for the three months ended March 31, 2021, and a loss before income tax benefit of $4,698,200 for the nine months ended March 31, 2022 compared to a loss of $2,205,200 for the nine months ended March 31, 2021, primarily due to increased operating expenses of its Bioprocessing Systems Operations, which included significant expenditures for product development, sales and marketing, and non-cash compensation expense related to stock options.

COVID-19 Pandemic. The Company has not experienced and does not expect to experience any material impact on its ability to collect its accounts receivable due to the nature of its customers, which are primarily distributors of laboratory equipment and supplies, and pharmaceutical companies, which have benefitted from the Pandemic due to the nature of the products and have the ability to pay. The Company also has not experienced and does not expect to experience any material impairment to its tangible and intangible assets or system of internal controls, however the ultimate impact of COVID-19 on the Company’s business, results of operations, financial condition and cash flows is dependent on future developments, including the duration or worsening of the pandemic, which are uncertain and cannot be predicted at this time. The Company has experienced supply chain disruptions which has had an impact on its operations causing delayed delivery of some products to its customers, and production inefficiencies. As of March 31, 2022, the Company had a total backlog of approximately $747,000 in benchtop laboratory equipment orders, which approximated the backlog level as of March 31, 2021.

In addition, due to the travel restrictions imposed by the United States and other governments worldwide, Company personnel had been and may be restricted in the future from traveling to conduct its operations including trade shows, Company facility visits, customer visits and installations, vendor facility visits, and other sales and marketing related travel that can negatively impact the Company. The operations of Aquila were negatively affected in their ability to secure new orders because Aquila had historically relied on face-to-face meetings at trade shows for its sales opportunities. While it has participated in virtual trade shows, management believes that certain sales opportunities were lost as a result. The Company has recently started to attend in-person trade shows.

Results of Operations.

The Three Months Ended March 31, 2022 Compared With The Three Months Ended March 31, 2021

Net revenues for the three months ended March 31, 2022 increased $356,300 (14.2%) to $2,864,900 from $2,508,600 for the three months ended March 31, 2021, reflecting an increase of $287,400 in net revenues due primarily to product revenues derived from sale of Aquila bioprocessing products, and $68,900 in sales from the Benchtop Laboratory Equipment Operations due to increased sales of its Torbal brand products. The Benchtop Laboratory Equipment Operations sales reflected $580,100 of Torbal brand net product sales for the three months ended March 31, 2022, compared to $466,200 for the three months ended March 31, 2021 primarily due to increased sales of its automated VIVID pill counter.

The gross profit percentage on a combined basis was 54.0% for the three months ended March 31, 2022 compared to 54.3% for the three months ended March 31, 2021, due primarily to decreased margins for the Benchtop Laboratory Equipment Operations resulting from increased costs for labor and materials.

General and administrative expenses for the three months ended March 31, 2022 increased by $224,800 (16.2%) to $1,610,400 from $1,385,600 for the three months ended March 31, 2021 due primarily to costs incurred by the Bioprocessing Systems Operations which includes Aquila which was acquired in April 2021.

Selling expenses for the three months ended March 31, 2022 decreased $332,100 (24.0%) to $1,054,000 from $1,386,100 for the three months ended March 31, 2021. The decrease was due primarily to extensive use of sales and marketing consultants in the prior year period compared to lower cost employees in the current year period, and decreased stock option compensation-related costs for the Bioprocessing Systems Operations in the current year period.

Table of Contents

Research and development expenses increased by $174,500 (38.8%) to $624,500 for the three months ended March 31, 2022 compared to $450,000 for the three months ended March 31, 2021, due primarily to product development costs incurred by the Bioprocessing Systems Operations, including additional expenditures of the Aquila operation which was acquired in April 2021.

Total other expense, net, for the three months ended March 31, 2022 was $102,300, compared to $28,600 of total other income, net, for the three months ended March 31, 2021. The decrease was due primarily to realized losses on investment securities during the current year period.

The Company reflected a total income tax benefit of $317,200 and $378,200 for the three months ended March 31, 2022, and 2021, respectively.

As a result of the foregoing, the Company recorded a net loss from continuing operations of $1,527,400 for the three months ended March 31, 2022 compared to a net loss from continuing operations of $1,452,000 for the three months ended March 31, 2021.

The Company reflected a loss from discontinued operations of $7,600 for the three months ended March 31, 2022, compared to a gain of $16,400 for the three months ended March 31, 2021, due to miscellaneous expenses incurred during the current year period.

The Nine Months Ended March 31, 2022 Compared With The Nine Months Ended March 31, 2021

Net revenues for the nine months ended March 31, 2022 increased $1,378,400 (19.0%) to $8,623,500 from $7,245,100 for the nine months ended March 31, 2021, reflecting an increase of $716,000 in revenues from the Bioprocessing Systems Operations due primarily to sales of Aquila products, and an increase of $662,400 in revenue of the Benchtop Laboratory Equipment due to increased sales of its Genie and Torbal brand products. The Benchtop Laboratory Equipment sales reflected $1,825,400 of Torbal brand product sales for the nine months ended March 31, 2022, compared to $1,560,700 for the nine months ended March 31, 2021, primarily due to increased sales of its automated VIVID pill counter.

The gross profit percentage on a combined basis was 51.8% for the nine months ended March 31, 2022 compared to 52.8% for the nine months ended March 31, 2021, due primarily to decreased margins for the Benchtop Laboratory Equipment Operations resulting from increased costs for labor and materials.

General and administrative expenses for the nine months ended March 31, 2022 increased by $2,000,600 (81.9%) to $4,442,300 from $2,441,700 for the nine months ended March 31, 2021, due primarily to costs incurred by the Bioprocessing Systems Operations which includes the Aquila operation which was acquired in April 2021.

Selling expenses for the nine months ended March 31, 2022 increased $337,900 (12.7%) to $2,996,800 from $2,658,900 for the nine months ended March 31, 2021, due primarily to the Bioprocessing Systems Operations which includes the Aquila operation which was acquired in April 2021.

Research and development expenses increased by $1,117,300 (109.1%) to $2,141,300 for the nine months ended March 31, 2022 compared to $1,024,000 for the nine months ended March 31, 2021, mainly due to product development costs incurred by the Bioprocessing Systems Operations’ Aquila operation which was acquired in the fourth quarter of fiscal 2021.

Total other income, net, for the nine months ended March 31, 2022, was $413,300 reflecting $433,800 loan forgiveness for the Company’s second PPP Loan, compared to $93,700 for the nine months ended March 31, 2021.

The Company reflected income tax benefits for continuing operations of $1,054,500 for the nine months ended March 31, 2022 compared to income tax benefit of $472,300 for the nine months ended March 31, 2021, primarily due to the increased loss.

As a result of the foregoing, the Company recorded a net loss from continuing operations of $3,643,700 for the nine months ended March 31, 2022, compared to a net loss from continuing operations of $1,732,900 for the nine months ended March 31, 2021.

The Company reflected a gain from discontinued operations of $3,400 for the nine months ended March 31, 2022, compared to a loss of $578,500 for the nine months ended March 31, 2021, due to miscellaneous income earned during the current year period and the loss on disposal of assets of the discontinued operation in the prior year period.

Liquidity and Capital Resources.

Cash and cash equivalents decreased by $5,607,200 to $4,068,000 as of March 31, 2022 from $9,675,200 as of June 30, 2021, due primarily to the Company's purchase of investment securities and the loss during the period, net of cash received on the issuance of common stock and warrants.

Table of Contents

Net cash used in operating activities was $3,695,300 for the nine months ended March 31, 2022 compared to $2,592,500 during the nine months ended March 31, 2021, primarily as a result of the increased loss incurred for the current period. Net cash used in investing activities was $4,548,600 for the nine months ended March 31, 2022 compared to $4,763,100 used during the nine months ended March 31, 2021 due to a decrease of purchases and redemptions of investments. Net cash provided by financing activities was $2,727,200 for the nine months ended March 31, 2022, compared to $423,400 provided during the nine months ended March 31, 2021, primarily due to the proceeds received on the issuance of common stock and warrants.

The Company’s working capital increased by $245,100 to $16,389,400 as of March 31, 2022 compared to $16,144,300, as of June 30, 2021, primarily due to a net decrease of $284,300 in current liabilities, that consist of a decrease of approximately $881,900 in accrued expense and other liabilities and a increase of $597,600 in accounts payable and a net decrease of $39,200 in current assets, that consist of a decrease of approximately $1,583,200, net of cash proceeds received on the issuance of common stock and warrants and cash used in operating and investing activities, a increase of approximately of $1,391,000 in inventory, a increase of approximately $418,000 in accounts receivable and a decrease of $265,000 in prepaid and other assets.

LEGAL MATTERS

The validity of the shares of common stock offered in this prospectus is being passed upon for us by Reitler Kailas & Rosenblatt LLP, New York, New York.

EXPERTS

Nussbaum Berg Klein & Wolpow, CPAs LLP, our independent registered public accounting firm, has audited our consolidated financial statements included in our Annual Report on Form 10-K for the fiscal year ended June 30, 2021, as set forth in their report, which is included in our Annual Report on Form 10-K for the fiscal year ended June 30, 2021, which financial statements are incorporated herewith in this prospectus, and by reference. Our consolidated financial statements are incorporated by reference in reliance on Nussbaum Berg Klein & Wolpow, CPAs LLP’s report, given on their authority as experts in accounting and auditing.

WHERE YOU CAN FIND ADDITIONAL INFORMATION

We are subject to the information requirements of the Exchange Act and we therefore file periodic reports, proxy statements and other information with the SEC relating to our business, financial statements and other matters. The reports, proxy statements and other information we file may be inspected and copied at prescribed rates at the SEC’s Public Reference Room located at 100 F Street, N.E., Washington, D.C. 20549. You may obtain information on the operation of the SEC’s Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC also maintains a website that contains reports, proxy and information statements and other information regarding issuers like us that file electronically with the SEC. The address of the SEC’s website is http://www.sec.gov.

This prospectus constitutes part of a registration statement on Form S-1 filed under the Securities Act with respect to the shares of common stock covered hereby. As permitted by the SEC’s rules, this prospectus omits some of the information, exhibits and undertakings included in the registration statement. You may read and copy the information omitted from this prospectus but contained in the registration statement, as well as the periodic reports and other information we file with the SEC, at the public reference room and web site of the SEC referred to above. You may also access our filings with the SEC on our web site is located at http://www.scientificindustries.com. The information contained on our web site is not part of this prospectus.

Statements contained in this prospectus as to the contents of any contract or other document are not necessarily complete, and in each instance we refer you to the copy of the contract or other document filed or incorporated by reference as an exhibit to the registration statement or as an exhibit to our Exchange Act filings, each such statement being qualified in all respects by such reference.

DOCUMENTS INCORPORATED BY REFERENCE

The SEC allows us to “incorporate by reference” information into this document. This means that we can disclose important information to you by referring you to another document filed separately with the SEC. The information incorporated by reference is considered to be a part of this document, except for any information superseded by information that is included directly in this document or incorporated by reference subsequent to the date of this document.

Table of Contents

This prospectus incorporates by reference the documents listed below:

•

our Annual Report on Form 10-K for the year ended June 30, 2021, filed with the SEC on October 14, 2021;

•

our Quarterly Reports on Form 10-Q filed with the SEC on November 15, 2021, February 16, and May 16, 2022;

•

our Current Reports on Form 8-K filed with the SEC on December 10, 2021, February 7, February 25, March 2, April 5, and April 13, 2022; and

•

the description of our common stock contained on Form 8-A, filed with the SEC approximately in December 1954, including any amendments or reports filed for the purpose of updating the description.

In addition, all documents subsequently filed by us with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, prior to the termination of the offering, shall be deemed to be incorporated by reference into this prospectus; provided, however, that all reports, exhibits and other information that we “furnish” to the SEC will not be considered incorporated by reference into this prospectus. Any statement contained in a document incorporated by reference in this prospectus or any prospectus supplement shall be deemed to be modified or superseded to the extent that a statement contained herein, therein or in any other subsequently filed document that also is incorporated by reference herein or therein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus or any prospectus supplement.

We will provide to you at no cost a copy of any and all of the information incorporated by reference into the registration statement of which this prospectus is a part. You may make a request for copies of this information in writing or by telephone. Requests should be directed to:

Scientific Industries, Inc.

80 Orville Drive, Suite 102

Bohemia, New York 11716

Attn: Corporate Secretary

Exhibits to the filings will not be sent, however, unless those exhibits have specifically been incorporated by reference in this prospectus.

Copies of the documents incorporated by reference may also be found on our website at www.scientificindusties.com. Except with respect to the documents expressly incorporated by reference above which are accessible at our website, the information contained on our website is not a part of and should not be construed as being incorporated by reference into, this prospectus.

Table of Contents

SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES

AS OF AND FOR THE YEARS ENDED JUNE 30, 2021 AND 2020

CONTENTS

		Page

Report of independent registered public accounting firm		23

Consolidated financial statements:

Balance sheets		24

Statements of comprehensive loss		25

Statements of changes in stockholders’ equity		26

Statements of cash flows		27

Notes to financial statements		28 - 51

SCIENTIFIC INDUSTRIES, INC.

AND SUBSIDIARIES

FINANCIAL STATEMENTS AND REPORT OF

INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

AS OF AND FOR THE YEARS ENDED

JUNE 30, 2021 AND 2020

Report of Independent Registered Public Accounting Firm

Board of Directors and Stockholders’

Scientific Industries, Inc.

Bohemia, New York

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Scientific Industries, Inc. and its subsidiaries (the “Company”) as of June 30, 2021 and 2020, the related consolidated statements of comprehensive loss, changes in stockholders' equity and cash flows for the years then ended, and the related notes to the consolidated financial statements and schedules (collectively, the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of June 30, 2021 and 2020, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.

Basis for Opinion

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the auditing standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit Matter

The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to those charged with governance and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.

Business Combination

As described in Note 16 to the financial statements, the Company completed its acquisition of Aquila biolabs GmbH (“Aquila”) on April 29, 2021, for a total purchase price of $7,880,100, resulting in the addition of $6,655,415 of intangible assets. The acquisition was accounted for as a business combination.

The principal considerations for our determination that the valuation of acquired intangible assets is a critical audit matter is that the valuation of the acquired intangible assets was considered especially challenging and required significant auditor judgment due to the complex determination by management of the appropriate assumptions, such as discount rates, revenue projections, and projected profit margins, for the valuation of the acquired intangible assets. The Company, utilizing third-party specialists, used income valuation models including Relief from Royalty Method and the Multi-Period Excess Earning Method (MPEEM) to measure the identified intangible assets. This required a high degree of auditor judgment and an increased extent of effort, including the need to involve professionals having expertise in the valuation of acquired intangible assets, when performing audit procedures to evaluate management’s judgments and conclusions related to the valuation of the intangible assets.

To test the estimated fair values of the identified intangible assets, our audit procedures included, among others, reading the underlying agreements, testing management’s application of the relevant accounting guidance, and involving a specialist to assist us in the evaluation of the Company’s valuation methodology and testing of the significant assumptions used by the Company to develop forecasted results for Aquila, including projected revenue growth and operating margins. For example, we compared the significant assumptions to current industry, market and economic trends. Additionally, we tested the completeness and accuracy of the underlying data supporting the significant assumptions and estimates.

/s/ Nussbaum Berg Klein & Wolpow, CPAs LLP

We have served as the Company’s auditor since 1991.

Melville, New York

October 14, 2021

SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES

BALANCE SHEETS

AS OF JUNE 30, 2021 AND 2020

ASSETS

	2021			2020
Current assets:
Cash and cash equivalents	$	9,675,200		$	7,559,700
Investment securities		3,744,600			331,800
Trade accounts receivable, less allowance for doubtful accounts of $15,600 and $11,600, respectively		1,294,700			1,064,000
Inventories		2,977,100			2,541,000
Income tax receivable		333,300			334,800
Prepaid expenses and other current assets		350,900			112,400
Assets of discontinued operations		55,300			793,000

Total current assets		18,431,100			12,736,700

Property and equipment, net		412,600			278,300

Intangible assets, net		2,557,800			128,700

Goodwill		4,395,400			257,300

Operating lease right-of-use assets		665,300			803,300

Other assets		54,300			56,000

Deferred taxes		2,489,900			537,100

Total assets	$	29,006,400		$	14,797,400

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities:
Accounts payable	$	453,500		$	334,600
Accrued expenses and taxes		633,500			679,000
Contract liabilities		0			20,000
Contingent consideration, current portion		136,600			111,000
Bank overdraft		321,700			43,100
Lease liabilities, current portion		270,500			195,800
PPP Loan Payable		433,800			563,800
Liabilities of discontinued operations		37,200			240,900

Total current liabilities		2,286,800			2,188,200

Lease liabilities, less current portion		460,500			640,800
Contingent consideration payable, less current portion		23,400			247,000
Other long-term liabilities		10,900			0

Total liabilities		2,781,600			3,076,000

Stockholders’ equity:
Common stock, $0.05 par value; 15,000,000 shares authorized; 6,477,945 and 2,881,065 shares issued; 6,458,143 and 2,861,263 shares outstanding in 2021 and 2020, respectively		324,000			144,100
Additional paid-in capital		26,613,500			8,608,300
Accumulated other comprehensive loss		(9,200	)		0
Retained earnings ( accumulated deficit)		(651,100	)		3,021,400
		26,277,200			11,773,800
Less common stock held in treasury at cost, 19,802 shares		52,400			52,400

Total stockholders’ equity		26,224,800			11,721,400

Total liabilities and stockholders’ equity	$	29,006,400		$	14,797,400

See notes to consolidated financial statements.

SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

FOR THE YEARS ENDED JUNE 30, 2021 AND 2020

	2021			2020

Revenues	$	9,775,200		$	7,784,400

Cost of revenues		4,799,800			3,847,000

Gross profit		4,975,400			3,937,400

Operating expenses:
General and administrative		4,028,500			2,275,400
Selling		4,031,900			1,185,800
Research and development		1,623,800			1,139,700

Total operating expenses		9,684,200			4,600,900

Loss from operations		(4,708,800	)		(663,500	)

Other income (expense):
Interest income		82,200			12,600
Other income (expense), net		571,600			(16,500	)

Total other income (expense), net		653,800			(3,900	)

Loss from continuing operations before income tax benefit		(4,055,000	)		(667,400	)

Income tax benefit, deferred		(945,000	)		(214,000	)

Loss from continuing operations		(3,110,000	)		(453,400	)

Discontinued operations (Note 17):

Loss from discontinued operations, net of tax		(562,500	)		(249,900	)

Net loss		(3,672,500	)		(703,300	)
Other comprehensive loss:
Foreign currency translation adjustment		(9,200	)		-
Comprehensive loss	$	(3,681,700	)	$	(703,300	)
Basic and diluted loss per common share:
Continuing operations	$	(0.97	)	$	(0.30	)
Discontinued operations	$	(0.18	)	$	(0.16	)
Consolidated operations	$	(1.15	)	$	(0.46	)

See notes to consolidated financial statements.

SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY

FOR THE YEARS ENDED JUNE 30, 2021 AND 2020

					Additional		Accumulated Other									Total
	Common Stock				Paid-in		Comprehensive		Retained			Treasury Stock				Stockholders’
	Shares		Amount		Capital		Income (Loss)		Earnings			Shares		Amount		Equity

Balance, July 1, 2019		1,513,914		75,700		2,592,700		-		3,724,700			19,802		52,400		6,340,700

Net loss		-		-		-		-		(703,300	)		-		-		(703,300	)

Issuance of Common Stock and Warrants, net of issuance costs (Note 15)		1,349,850		67,500		5,936,900		-		-			-		-		6,004,400

Stock options exercised		17,301		900		12,900		-		-			-		-		13,800

Stock-based compensation		-		-		65,800		-		-			-		-		65,800

Balance, June 30, 2020		2,881,065	$	144,100	$	8,608,300		-	$	3,021,400			19,802	$	52,400	$	11,721,400

Net loss	-		-		-		-			(3,672,500	)	-		-		(3,672,500	)

Foreign currency translation adjustment	-		-		-		(9,200	)		-		-		-		(9,200	)

Issuance of Common Stock and Warrants, net of issuance costs (Note 15)	3,595,880		179,800		15,894,200		-			-		-		-		16,074,000

Stock options exercised	1,000		100		3,000		-			-		-		-		3,100

Stock-based compensation	-		-		2,108,000		-			-		-		-		2,108,000

Balance, June 30, 2021	6,477,945	$	324,000	$	26,613,500	$	(9,200	)	$	(651,100	)	19,802	$	52,400	$	26,224,800

See notes to consolidated financial statements.

SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE YEARS ENDED JUNE 30, 2021 AND 2020

	2021			2020
Operating activities:
Net loss	$	(3,672,500	)	$	(703,300	)
Adjustments to reconcile net loss to net cash used in operating activities:
Gain on sale of investment securities		(35,600	)		(4,400	)
Depreciation and amortization		251,500			160,900
Deferred income tax benefit		(1,152,500	)		(106,000	)
Unrealized holding loss on investment securities		10,400			12,400
Loss on disposal of subsidiary		405,400			-
Provision for bad debt		4,000			3,400
Extinguishment of debt		(531,100	)		-
Gain on sale of fixed assets		-			(300	)
Stock-based compensation		2,108,000			65,800
Change in fair value of contingent consideration		(30,000	)		112,600
Changes in operating assets and liabilities:
Trade accounts receivable		(75,500	)		906,800
Inventories		(560,000	)		(292,400	)
Income tax receivable		1,500			(334,800	)
Prepaid expenses and other assets		(211,400	)		(22,400	)
Right-of-use assets		138,000			(803,300	)
Accounts payable		79,600			(214,400	)
Lease liabilities		(105,600	)		867,700
Accrued expenses		(195,200	)		191,500
Contract liabilities		(20,000	)		89,000
Other long-term liabilities		10,900			-
Bank overdraft		278,600			(96,900	)

Total adjustments		371,000			535,200

Net cash used in operating activities		(3,301,500	)		(168,100	)

Investing activities:
Purchase of investment securities		(9,569,000	)		(63,400	)
Redemption of investment securities		6,181,400			55,000
Proceeds from sale of fixed assets		-			1,000
Capital expenditures		(198,700	)		(50,900	)
Proceeds from sale of Altamira		440,000			-
Purchase of Aquila, net of cash acquired		(7,679,000	)		-
Purchase of intangible assets		(58,700	)		(25,800	)

Net cash used in investing activities		(10,884,000	)		(84,100	)

Financing activities:
Repayment of 1st Payroll Protection Plan loan		(32,700	)		-
Proceeds from 2nd Payroll Protection Plan loan		433,800			563,800
Proceeds from issuance of common stock and warrants		17,080,400			6,004,400
Issuance costs - common stock and warrants		(1,006,400	)		-
Proceeds from exercise of stock options		3,100			13,800
Payments for contingent consideration		(168,000	)		(372,600	)

Net cash provided by financing activities		16,310,200			6,209,400

Effect of changes in foreign currency exchange rates on cash and cash eqivalents		(9,200	)		-

Net increase in cash and cash equivalents		2,115,500			5,957,200

Cash and cash equivalents, beginning of year		7,559,700			1,602,500

Cash and cash equivalents, end of year	$	9,675,200		$	7,559,700

Supplemental disclosures:
Cash paid during the period for:
Income taxes	$	2,500		$	40,900

See notes to consolidated financial statements.

SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AS OF AND FOR THE YEARS ENDED JUNE 30, 2021 AND 2020

1. Summary of Significant Accounting Policies

Nature of Business

Scientific Industries, Inc. and its subsidiaries (the “Company”) design, manufacture, and market a variety of benchtop laboratory equipment and bioprocessing products. The Company is headquartered in Bohemia, New York where it produces benchtop laboratory equipment. Additionally, the Company has two other locations in Pittsburgh, Pennsylvania and Baesweiller, Germany, where it designs and produces a variety of bioprocessing products, and an administrative facility in Orangeburg, New York related to sales and marketing. The products, which are sold to customers worldwide, include mixers, shakers, stirrers, refrigerated incubators, pharmacy balances and scales, force gauges, bioprocessing-sensors and analytical tools. The Company also sublicenses certain patents and technology under a license agreement with the University of Maryland, Baltimore County, and receives royalty fees from sublicenses (see Note 1- Revenue Recognition).

COVID-19 Pandemic

The challenges posed by the COVID-19 pandemic on the global economy began to take effect and impacted the Company’s operations at the end of the third quarter of the year ended June 30, 2020. At that time, the Company took appropriate action and put plans in place to diminish the effects of COVID-19 on its operations, enabling the Company to continue to operate with minor or temporary disruptions to its operations. The Company took immediate action as it pertains to COVID-19 preparedness by implementing the Center for Disease Control’s guidelines for employers in order to protect the Company’s employees’ health and safety, with actions such as implementing work from home, social distancing in the workplace, requiring self-quarantine for any employee showing symptoms, wearing face coverings, and training employees on maintaining a healthy work environment. The Bioprocessing Systems Operations’ SBI facility was shut down temporarily due to state mandates, however, the impact on operations was immaterial, and the Company has been able to retain its employees without furloughs or layoffs, in part, due to the Company’ receipt of two loans under the Federal Government’s Small Business Administration Paycheck Protection Program. The Company received $563,800 and $433,800 in Payroll Protection Program loans in April 2020 and March 2021, respectively. The first loan was forgiven in June 2021 except for $32,700 which was repaid by the Company. The Company expects to apply and receive forgiveness for the second loan. The operations of aquila biolabs GmbH ("Aquila") which was acquired on April 29, 2021 was negatively impacted in its ability to secure new orders because Aquila had historically relied on face-to-face meetings at trade shows for its sales opportunities. While it has participated in virtual trade shows, management believes that certain sales opportunities are lost as a result. The Company has not experienced and does not anticipate any material impact on its ability to collect its accounts receivable due to the nature of its customers, which are primarily distributors of laboratory equipment and supplies which have benefitted from the Pandemic due to the nature of the products and have the ability to pay. The Company has not experienced and does not anticipate any material impairment to its tangible and intangible assets, system of internal controls, or delivery and distribution of its products as a result of COVID-19, however the ultimate impact of COVID-19 on the Company’s business, results of operations, financial condition and cash flows is dependent on future developments, including the duration or worsening of the pandemic and the related length of its impact on the global economy, which are uncertain and cannot be predicted at this time. The Company is currently experiencing some delays from its supply chain which is having an impact on delayed delivery of some products, however this is deemed temporary and does not affect the Company’s major product – the Vortex-Genie 2. In addition, due to the travel restrictions imposed by the United States and other governments worldwide, Company personnel may be restricted from traveling to conduct its operations including site visits, customer visits and installations, vendor facility visits, and other sales and marketing related travel that can negatively impact the Company.

Principles of Consolidation

The accompanying consolidated financial statements include the accounts of Scientific Industries, Inc., Scientific Packaging Industries, Inc., an inactive wholly-owned subsidiary, Altamira Instruments, Inc. (“Altamira”), a Delaware corporation and wholly-owned subsidiary (discontinued operation as of November 30, 2020), and Scientific Bioprocessing Holdings, Inc. (“SBHI”), a newly incorporated Delaware corporation and its wholly-owned subsidiaries, Scientific Bioprocessing, Inc. (“SBI”), a Delaware corporation, and Aquila, a German corporation, which was acquired on April 29, 2021, (all collectively referred to as the “Company”). On April 30, 2021 Scientific Industries, Inc. contributed 100% of the stock of Scientific Bioprocessing, Inc. to its wholly owned subsidiary Scientific Bioprocessing Holdings, Inc. All material intercompany balances and transactions have been eliminated in consolidation.

SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

AS OF AND FOR THE YEARS ENDED JUNE 30, 2021 AND 2020

1. Summary of Significant Accounting Policies (Continued)

Revenue Recognition

The Company recognizes revenue in accordance with Financial Accounting Standards Board ('FASB") Accounting Standards Codification (“ASC”) Topic 606 “Revenue from Contracts with Customers, (“ASC 606”). In accordance with ASC 606, the Company accounts for a customer contract when both parties have approved the contract and are committed to perform their respective obligations, each party’s rights can be identified, payment terms can be identified, the contract has commercial substance, and it is probable that the Company will collect substantially all of the consideration to which it is entitled. Revenue is recognized when, or as, performance obligations are satisfied by transferring control of a promised product or service to a customer.

All of the Company's contracts have a single performance obligation. As permitted by ASC 606, the Company does not disclose the amount of unsatisfied performance obligations for client contracts with an original expected length of one year or less.

The Company determines revenue recognition through the following steps:

	·	Identification of the contract, or contracts, with a customer

	·	Identification of the performance obligations in the contract

	·	Determination of the transaction price

	·	Allocation of the transaction price to the performance obligations in the contract

	·	Recognition of revenue when, or as, a performance obligation is satisfied

Nature of Products and Services

We generate revenues from the following sources: (1) Benchtop Laboratory Equipment and (2) Bioprocessing Systems.

	Benchtop Laboratory Equipment		Bioprocessing Systems		Consolidated
June 30, 2021:

Revenues	$	9,043,600		731,600	$	9,775,200

Foreign Sales		3,483,700		684,600		4,168,300

	Benchtop Laboratory Equipment		Bioprocessing Systems		Consolidated
June 30, 2020:

Revenues	$	6,783,600	$	1,000,800	$	7,784,400

Foreign Sales		2,589,800		1,000,400		3,590,200

SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

AS OF AND FOR THE YEARS ENDED JUNE 30, 2021 AND 2020

1. Summary of Significant Accounting Policies (Continued)

Revenue Recognition (Continued)

Nature of Products and Services (Continued)

Benchtop laboratory equipment sales comprise primarily of standard benchtop laboratory equipment to laboratory equipment distributors, or to end users primarily via e-commerce. The sales cycle from time of receipt of order to shipment is very short varying from a day to a few weeks. Customers either pay by credit card (online sales) or Net 30-90, depending on the customer. Once the item is shipped under the FOB terms specified in the order, which is primarily “FOB Factory”, other than a standard warranty, there are no other obligations to the customer. Warranty usually comprises of one to two year parts and labor and is deemed immaterial. Revenue is recognized at a point in time when the risks and rewards of ownership have tranferred to the customer, which is generally upon shipment.

Bioprocessing revenues consist of royalty revenues generated through SBI and product revenues generated primarily through Aquila. Royalty revenues are earned by the Company under a licensing agreement from a single licensee and its sublicenses. The license agreement includes two United States patents and a European Union patent (through December 2019). In January 2020, the European Union patent which was due to expire in August 2020, was terminated and the Company will only receive royalties under the United States patents through December 2023, which will result in a material reduction in total royalties expected to be received. The Company is obligated to pay 50% of all royalties earned to the entity that licenses the intellectual property to the Company. Royalty revenue requires significant judgement in estimating royalty revenue to be recognized during the year.

The Company has made the following accounting policy elections and elected to use certain practical expedients, as permitted by the FASB, in applying ASC 606: 1) All revenues are recorded net of returns, allowances, customer discounts, and incentives; 2) Although sales and other taxes are immaterial, the Company accounts for amounts collected from customers for sales and other taxes, if any, net of related amounts remitted to tax authorities; 3) the Company expenses costs to obtain a contract as they are incurred if the expected period of benefit, and therefore the amortization period, is one year or less; 4) the Company accounts for shipping and handling activities that occur after control transfers to the customer as a fulfillment cost rather than an additional promised service and these fulfillment costs fall within selling expenses; 5) the Company is always considered the principal and never an agent, because it has full control and responsibility until title is transferred to the customer; 6) the Company does not assess whether promised goods or services are performance obligations if they are immaterial in the context of the contract with the customer such as is the case with catalyst instruments.

SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

AS OF AND FOR THE YEARS ENDED JUNE 30, 2021 AND 2020

1. Summary of Significant Accounting Policies (Continued)

Cash and Cash Equivalents

The Company considers all highly liquid debt instruments purchased with original maturities of 90 days or less to be cash equivalents. At times, cash balances may be in excess of the Federal Deposit Insurance Corporation (“FDIC”) insurance limit. As of June 30, 2021, and 2020, $8,922,800 and $6,729,300 respectively of cash balances were in excess of such limit.

Reclasses

Certain amounts on the balance sheet as of June 30, 2021 and 2020 pertaining to inventories, property and equipment, goodwill, accounts payable, accrued expenses, contract liabilities, and operating leases liabilities were reclassed as assets and liabilities of discontinued operations due to the sale of the Company's wholly owned subsidiary, Altamira Instruments, Inc. on November 30, 2020.

Accounts Receivable

In order to record the Company’s accounts receivable at their net realizable value, the Company must assess their collectability. A considerable amount of judgment is required in order to make this assessment, including an analysis of historical bad debts and other adjustments, a review of the aging of the Company’s receivables, and the current creditworthiness of the Company’s customers. The Company has recorded allowances for receivables which it considered uncollectible, including amounts for the resolution of potential credit and other collection issues such as disputed invoices and customer satisfaction claims. However, depending on how such potential issues are resolved, or if the financial condition of any of the Company’s customers was to deteriorate and its ability to make required payments became impaired, increases in these allowances may be required. The Company actively manages its accounts receivable to minimize credit risk. The Company does not obtain collateral for its accounts receivable. Based on its assessment, the Company concluded that there are no collection issues related to the COVID-19 Pandemic.

Contract Liabilities

Contract liabilities consists of billings or payments received in advance of revenue recognition and is recognized as the revenue recognition criteria are met. Amounts that have been invoiced are initially recorded in accounts receivable and contract liabilities. The Company invoices its customers in accordance with the terms of the underlying contract. Accordingly, the contract liabilities balance does not represent the total contract value of outstanding arrangements. Contract liabilities that are expected to be recognized during the subsequent 12-month period are recorded as current and the remaining portion as noncurrent. Contract liabilities were not significant at June 30, 2021 and 2020, respectively.

Investment Securities

Investment securities consist of equity securities and mutual funds with realized gains and losses recorded using the specific identification method. Changes in fair value are recorded as unrealized holding gains or losses in other income (loss), net on the statement of comprehensive loss. The Company determines the cost of the investment sold based on an average cost basis at the individual security level and records the interest income and realized gains or losses on the sale of these investments in other income (loss), net.

Inventories

Inventories are valued at the lower of cost (determined on a first-in, first-out basis) or net realizable value, and have been reduced by an allowance for excess and obsolete inventories. The estimate is based on management’s review of inventories on hand compared to estimated future usage and sales. Cost of work-in-process and finished goods inventories include material, labor and manufacturing overhead.

SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

AS OF AND FOR THE YEARS ENDED JUNE 30, 2021 AND 2020

1. Summary of Significant Accounting Policies (Continued)

Property and Equipment

Property and equipment are stated at cost. Depreciation of property and equipment is provided for primarily by the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized by the straight-line method over the remaining term of the related lease or the estimated useful lives of the assets, whichever is shorter.

Research and Development Expenses

Research and development expenses are expensed as incurred and consist principally of internal and external costs which includes the cost of patent licenses, contract research services, laboratory supplies, in-process research and development acquired, as well as product developments and enhancements.

Finite Lived Intangible Assets

Intangible assets consist primarily of acquired technology, customer relationships, non-compete agreements, patents, licenses, websites, and in process research and development (“IPR&D”), trademarks and trade names. All finite lived intangible assets are amortized on a straight-line basis over the estimated useful lives of the respective assets, generally 3 to 10 years. The Company continually evaluates the remaining estimated useful lives of intangible assets that are being amortized to determine whether events or circumstances warrant a revision to the remaining period of amortization.

Goodwill and Indefinite Lived Intangible Assets

Goodwill represents the excess of purchase price over the fair value of identifiable net assets acquired in a business combination. Goodwill and indefinite lived intangible assets are tested for impairment at least annually in accordance with the provisions of ASC 350, “Intangibles-Goodwill and Other” (“ASC 350”). ASC 350 requires that goodwill be tested for impairment at the reporting unit level (operating segment or one level below an operating segment) on an annual basis and between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value. Application of the goodwill impairment test requires judgment, including the identification of reporting units, assignment of assets and liabilities to reporting units, assignment of goodwill to reporting units, and determination of the fair value of each reporting unit. The Company tests goodwill and long-lived assets annually as of June 30, the last day of its fiscal year, unless an event occurs that would cause the Company to believe the value is impaired at an interim date. The Company concluded as of June 30, 2021 and 2020, there was no impairment of goodwill or indefinite lived intangible assets.

Impairment of Long-Lived Assets

The Company follows the provisions of ASC No. 360, “Property, Plant and Equipment - Impairment or Disposal of Long-Lived Assets (“ASC 360"). ASC 360 which requires evaluation of the need for an impairment charge relating to long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If an evaluation for impairment is required, the estimated future undiscounted cash flows associated with the asset would be compared to the asset’s carrying amount to determine if a write down to a new depreciable basis is required. If required, an impairment charge is recorded based on an estimate of future discounted cash flows. The Company concluded as of June 30, 2021 and 2020, there was no impairment of long-lived assets.

SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

AS OF AND FOR THE YEARS ENDED JUNE 30, 2021 AND 2020

1. Summary of Significant Accounting Policies (Continued)

Income Taxes

The Company and its subsidiaries file a consolidated U.S. federal income tax return. Income taxes are accounted for under the asset and liability method. The Company provides for federal, and state income taxes currently payable, as well as for those deferred due to timing differences between reporting income and expenses for financial statement purposes versus tax purposes. Deferred tax assets and liabilities are recognized for the future tax consequences attributed to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted income tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect of a change in income tax rates is recognized as income or expense in the period that includes the enactment date.

The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs.

Advertising

Advertising costs are expensed as incurred. Advertising expense amounted to $399,700 and $218,700 for the years ended June 30, 2021 and 2020, respectively.

Stock Compensation Plan

The Company has a ten-year stock option plan (the “2012 Plan”) which provides for the grant of options to purchase up to 1,193,000 shares of the Company’s Common Stock, par value $.05 per share (“Common Stock”), plus up to 57,000 shares under options previously granted under the 2002 Stock Option Plan of the Company (the “Prior Plan”).

The 2012 Plan provides for the granting of incentive or non-incentive stock options as defined in the 2012 Plan through 2022. Incentive stock options may be granted to employees at an exercise price equal to 100% (or 110% if the optionee owns directly or indirectly more than 10% of the outstanding voting stock) of the fair market value of the shares of Common Stock on the date of the grant. Non-incentive stock options shall be granted at the fair market value of the shares of Common Stock on the date of grant. At June 30, 2021 and 2020, 5,243 and 147,414 shares respectively, of Common Stock were available for grant of options under the 2012 Plan.

Stock-based compensation is accounted for in accordance with ASC No. 718 “Compensation-Stock Compensation” (“ASC No. 718”) which requires compensation costs related to stock-based payment transactions to be recognized. The amount of compensation cost is measured based on the grant-date fair value of the equity issued and expensed ratably over the requisite service period.

SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

AS OF AND FOR THE YEARS ENDED JUNE 30, 2021 AND 2019

1. Summary of Significant Accounting Policies (Continued)

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission requires management to make estimates and judgments that affect the amounts reported in the financial statements and accompanying notes. Estimates are used for, but not limited to, the allowance for doubtful accounts, slow-moving inventory reserves, depreciation and amortization, assumptions made in valuing equity instruments, fair value of stock options, the fair values of intangibles and goodwill, and provision or benefit for income taxes. The actual results experienced by the Company may differ materially from management’s estimates.

Earnings (Loss) Per Common Share

Basic earnings or loss per common share is computed by dividing net income (loss) by the weighted-average number of shares outstanding. Diluted earnings per common share includes the dilutive effect of stock options, if any. Since the Company was in a loss position during the years ended June 30, 2021 and 2020, respectively, basic net loss per share is the same as dilutive net loss per share as the inclusion of the weighted-average number of all potential dilutive common shares which consists of stock options and warrants are anti-dilutive.

Recent Accounting Pronouncements

In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes, which is designed to simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. ASU No. 2020-12 is effective for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years; this ASU allows for early adoption in any interim period after issuance of the update. The Company is currently evaluating the impact of adopting this guidance.

Adopted Accounting Pronouncement

In August 2018, the FASB issued Accounting Standards Update ("ASU") 2018-13, "Fair Value Measurement (Topic 820): Disclosure Framework Changes to the Disclosure Requirements for Fair Value Measurement", which is part of the FASB disclosure framework project to improve the effectiveness of disclosures in the notes to the financial statements. The amendments in the new guidance remove, modify, and add certain disclosure requirements related to fair value measurements covered in Topic 820, "Fair Value Measurement." The new standard is effective for fiscal years beginning after December 15, 2019. Early adoption is permitted for either the entire standard or only the requirements that modify or eliminate the disclosure requirements, with certain requirements applied prospectively, and all other requirements applied retrospectively to all periods presented.

In February 2016, the FASB issued ASU No. 2016-02, Leases, which replaces previous lease guidance in its entirety with ASC 842 and requires lessees to recognize lease assets and lease liabilities for those arrangements classified as operating leases under previous guidance, with the exception of leases with a term of twelve months or less. The Company adopted ASU No. 2016-02 on July 1, 2019 using the additional transition method, which allows prior periods to be presented under previous lease accounting guidance. Refer to Note 11, "Leases", for related disclosures.

SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

AS OF AND FOR THE YEARS ENDED JUNE 30, 2021 AND 2020

2. Segment Information

The Company views its operations as two segments: the manufacture and marketing of standard benchtop laboratory equipment for research in university, hospital and industrial laboratories sold primarily through laboratory equipment distributors and laboratory and pharmacy balances and scales (“Benchtop Laboratory Equipment Operations”), and the design and marketing of bioprocessing systems and products and related royalty income (“Bioprocessing Systems”).

Segment information is reported as follows:

	Benchtop Laboratory Equipment		Bioprocessing Systems			Corporate and Other			Consolidated
June 30, 2021:

Revenues	$	9,043,600	$	731,600		$	-		$	9,775,200

Foreign Sales		3,483,700		684,600			_			4,168,300

Income (Loss) From Operations		1,461,300		(4,828,600	)		(1,341,400	)		(4,708,800	)

Assets		14,783,000		8,735,100			5,488,300			29,006,400

Long-Lived Asset Expenditures		60,500		196,900			-			257,400

Depreciation and Amortization		103,100		148,400			-			251,500

	Benchtop Laboratory Equipment		Bioprocessing Systems			Corporate and Other			Consolidated
June 30, 2020:

Revenues	$	6,783,600	$	1,000,800		$	-		$	7,784,400

Foreign Sales		2,589,800		1,000,400			-			3,590,200

Income (Loss) From Operations		449,700		(727,500	)		(385,700	)		(663,500	)

Assets		12,232,600		546,100			2,018,700			14,797,400

Long-Lived Asset Expenditures		36,000		40,700			-			76,700

Depreciation and Amortization		116,900		42,700			-			159,600

SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

AS OF AND FOR THE YEARS ENDED JUNE 30, 2021 AND 2020

3. Fair Value of Financial Instruments

The FASB defines the fair value of financial instruments as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value measurements do not include transaction costs.

The accounting guidance also expands the disclosure requirements around fair value and establishes a fair value hierarchy for valuation inputs. The hierarchy prioritizes the inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market. Each fair value measurement is reported in one of the three levels, which is determined by the lowest level input that is significant to the fair value measurement in its entirety. These levels are described below:

Level 1 Inputs that are based upon unadjusted quoted prices for identical instruments traded in active markets.

Level 2 Quoted prices in markets that are not considered to be active or financial instruments for which all significant inputs are observable, either directly or indirectly.

Level 3 Prices or valuation that require inputs that are both significant to the fair value measurement and unobservable.

In valuing assets and liabilities, the Company is required to maximize the use of quoted market prices and minimize the use of unobservable inputs. The Company calculated the fair value of its Level 1 and 2 instruments based on the exchange traded price of similar or identical instruments where available or based on other observable instruments. These calculations take into consideration the credit risk of both the Company and its counterparties. The Company has not changed its valuation techniques in measuring the fair value of any financial assets and liabilities during the period.

The fair value of the contingent consideration obligations is based on a probability weighted approach derived from the estimates of earn-out criteria and the probability assessment with respect to the likelihood of achieving those criteria. The measurement is based on significant inputs that are not observable in the market, therefore, the Company classifies this liability as Level 3 in the following table.

The following tables set forth by level within the fair value hierarchy the Company’s financial assets that were accounted for at fair value on a recurring basis at June 30, 2021 and 2020 according to the valuation techniques the Company used to determine their fair values:

	Fair Value at June 30,		Fair Value Measurements Using Inputs Considered as
	2021		Level 1		Level 2		Level 3
Assets:
Cash and cash equivalents	$	9,675,200	$	9,675,200	$	-	$	-
Investment securities		3,744,600		2,920,600		824,000		-

Total	$	13,419,800	$	12,595,800	$	824,000	$	-

Liabilities:
Contingent consideration	$	160,000	$	-			$ 160,000

			Fair Value Measurements Using Inputs Considered as
	Fair Value at June 30, 2020		Level 1		Level 2		Level 3
Assets:
Cash and cash equivalents	$	7,559,700	$	7,559,700	$	-	$	-
Investment securities		331,800		331,800		-		-

Total	$	7,891,500	$	7,891,500	$	-	$	-

Liabilities:
Contingent consideration	$	358,000	$	-			$ 358,000

SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

AS OF AND FOR THE YEARS ENDED JUNE 30, 2021 AND 2020

3. Fair Value of Financial Instruments (Continued)

The following table sets forth an analysis of changes during the years ended June 30, 2021 and 2020, respectively, in Level 3 financial liabilities of the Company:

	2021			2020

Beginning balance	$	358,000		$	618,000
Increase (decrease) in contingent consideration liability		(30,000	)		112,600
Payments		(168,000	)		(372,600	)

Ending balance	$	160,000		$	358,000

The Company’s contingent obligations require cash payments to the sellers of certain acquired operations based on royalty payments received or operating results achieved. These contingent considerations are classified as liabilities and the liabilities are remeasured to an estimated fair value at each reporting date. During the years ended June 30, 2021 and 2020, the Company recorded an increase (decrease) in the estimated fair value of contingent liabilities of approximately ($30,000) and $112,600, respectively related to its Bioprocessing Systems Operations segment.

Investments in marketable securities by security type at June 30, 2021 and 2020 consisted of the following:

	Cost		Fair Value		Unrealized Holding Gain (Loss)
At June 30, 2021:

Equity securities	$	102,200	$	154,100	$	51,900
Mutual funds		2,752,400		2,766,500		14,100
Debt securities		832,700		824,000		(8,700	)

	$	3,687,300	$	3,744,600	$	57,300

	Cost		Fair Value		Unrealized Holding Gain (Loss)
At June 30, 2020:

Equity securities	$	77,600	$	101,900	$	24,300
Mutual funds		250,300		229,900		(20,400	)

	$	327,900	$	331,800	$	3,900

SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

AS OF AND FOR THE YEARS ENDED JUNE 30, 2021 AND 2020

4. Inventories

	2021		2020

Raw materials	$	2,170,400	$	1,726,400
Work-in-process		39,600		35,700
Finished goods		767,100		778,900

	$	2,977,100	$	2,541,000

5. Property and Equipment

	Useful Lives
	(Years)		2021		2020

Automobiles		5	$	22,000	$	22,000
Computer equipment	3-5			233,500		215,300
Machinery and equipment	3-7			1,047,600		847,500
Furniture and fixtures	4-10			148,800		142,300
Leasehold improvements	3-10			64,400		50,300

				1,516,300		1,277,400
Less accumulated depreciation and amortization				1,103,700		999,100

			$	412,600	$	278,300

Depreciation expense was $104,600 and $88,700 for the years ended June 30, 2021 and 2020, respectively.

6. Goodwill and Finite Lived Intangible Assets

Goodwill represents the excess of the purchase price over the fair value of the net assets acquired in connection with the Company’s acquisitions. Goodwill amounted to $4,395,400 at June 30, 2021 and 257,300 at June 30, 2020, all of which is expected to be deductible for tax purposes.

The components of finite lived intangible assets are as follows:

	Useful Lives	Cost		Accumulated Amortization		Net
At June 30, 2021:

Technology, trademarks	5-10 yrs.	$	364,700	$	362,200	$	2,500
Trade names	3-6 yrs.		592,300		152,600		439,700
Websites	3-7 yrs.		210,000		210,000		-
Customer relationships	4-10 yrs.		372,200		102,400		269,800
Sublicense agreements	10 yrs.		294,000		283,000		11,000
Non-compete agreements	4-5 yrs.		1,060,500		308,600		751,900
IPR&D	3-5 yrs.		852,100		134,800		717,300
Patents	5-7 yrs.		591,500		225,900		365,600

		$	4,337,300	$	1,779,500	$	2,557,800

SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

AS OF AND FOR THE YEARS ENDED JUNE 30, 2021 AND 2020

6. Goodwill and Finite Lived Intangible Assets (Continued)

Useful
Lives

Cost

Accumulated Amortization

Net

At June 30, 2020:

Technology, trademarks

5/10 yrs.

$ 664,700

$ 662,000

$ 2,700

Trade names

6 yrs.

140,000

140,000

-

Websites

5 yrs.

210,000

210,000

-

Customer relationships

9/10 yrs.

357,000

321,400

35,600

Sublicense agreements

10 yrs.

294,000

253,600

40,400

Non-compete agreements

5 yrs.

384,000

384,000

-

IPR&D

3 yrs.

110,000

110,000

-

Patents

5 yrs.

246,600

196,600

50,000

$ 2,406,300

$ 2,277,600

$ 128,700

Total amortization expense was $146,900 and $72,000 in 2021 and 2020, respectively.

Estimated future amortization expense of intangible assets as of June 30, 2021 is as follows:

Year Ended June 30,

2022	$	525,700
2023		520,000
2024		508,800
2025		473,100
2026		530,200

Total	$	2,557,800

7. Line of Credit

The Company has a Demand Line of Credit through December 2021 with First National Bank of Pennsylvania which provides for borrowings of up to $300,000 for regular working capital needs, bearing interest at prime, currently 3.25%. The agreement does not contain financial covenants and borrowings are secured by a pledge of substantially all of the assets of the Company. As of June 30, 2021 and 2020, there were no borrowings outstanding under the line.

8. Payroll Protection Program Loan

The Company received $563,800 and $433,800 in Payroll Protection Program loans in April 2020 and March 2021, respectively, pursuant to the Paycheck Protection Program loan (“PPP”) administered by the U.S. Small Business Administration through its bank. The first loan was forgiven in June 2021, and reflected as other income in the accompanying statements of comprehensive loss , except for $32,700 which was repaid by the Company. The remaining loan bears interest at 1% per annum and matures in March 2026 and contains no collateral or guarantee requirements. The Company expects to apply and receive forgiveness for the second loan.

SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

AS OF AND FOR THE YEARS ENDED JUNE 30, 2021 AND 2020

9. Employee Benefit Plans

The Company has a 401(k) profit sharing plan covering all its employees, which provides for voluntary employee salary contributions not to exceed the statutory limitations provided by the Internal Revenue Code. The plan provides for Company matching contribution equal to 100% of employee’s deferral up to 3% of pay, plus 50% of employee’s deferral over 3% of pay up to 5%. Total matching contributions amounted to $90,700 and $84,100 for the years ended June 30, 2021 and 2020, respectively.

10. Commitments and Contingencies

The Company has a three-year employment contract with its President, effective July 1, 2017, which was extended by mutual agreement for each one year periods ending June 30, 2021 and 2022. The agreement provided for an annual base salary of $175,000 for the year ended June 30, 2018, with subsequent annual increases of 3% or the percentage increase in Consumer Price Index (“CPI”), whichever is higher, plus $25,000 cash bonus for the year ended June 30, 2018, and a discretionary bonus for subsequent years. Bonuses totaling $100,000 and $50,000 were awarded for the years ended June 30, 2021 and 2020, respectively. The agreement also provided for a grant of options to purchase 25,000 shares of the Company’s stock, which were granted during the year ended June 30, 2018.

No shares were granted during the year ended June 30, 2021, and 215,366 shares were authorized to be granted by the Board of Directors during the year ended June 30, 2020, which shares were not available and subject to amendment to the Company’s 2012 Stock Option Plan which was approved in February 2021. The agreement also contains a provision that within one year of a change of control, if either the Company terminates the employment for any reason other than for "cause" or the Presidents terminates her employment for "good reason", the President will have the right to receive a lump sum payment equal to three times the average of her total annual compensation paid for the last five years preceding such termination.

The Company has a three-year employment contract with its President of the Genie Products Division of the Benchtop Laboratory Equipment Operations and Corporate Secretary effective July 1, 2017, which was extended by mutual agreement for each one year period ending June 30, 2021 and 2022. The agreement provides for an annual base salary of $153,000 for the year ended June 30, 2018, with subsequent annual increases of 3% or percentage increase in the CPI, whichever is higher, plus $10,000 cash bonus for the year ended June 30, 2018, and a discretionary bonus for subsequent years. No bonus was awarded for the year ended June 30, 2021 and a $5,000 bonus was awarded in 2020. The agreement also provides for a grant of options to purchase 7,500 shares of the Company’s stock, which were granted during the year ended June 30, 2018. No options were granted during the year ended June 30, 2021 or 2020.

The Company has a three-year employment contract with its President and Director of Marketing of Torbal Products Division of the Benchtop Laboratory Equipment Operations and Director of Marketing effective July 1, 2017, which was extended by mutual agreement for each one year periods ending June 30, 2021 and 2022. The agreement provides for an annual base salary of $157,000 for the year ended June 30, 2018, with subsequent annual increases of 4% or percentage increase in the CPI, whichever is higher, plus $10,000 cash bonus for the year ended June 30, 2018 and subsequent years, subject to a minimum increase of 5% in the divisions’ EBITDA for the related year. The agreement also provides for a grant of options to purchase 7,500 shares of the Company’s stock, which were granted during the year ended June 30, 2018. No options were granted during the year ended June 30, 2021 or 2020. A performance-based bonus of $10,000 was awarded during the years ended June 30, 2020. No bonus was awarded for the year ended June 30, 2021.

SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

AS OF AND FOR THE YEARS ENDED JUNE 30, 2021 AND 2020

10. Commitments and Contingencies (Continued)

The Company has a three-year employment contract with its President of Scientific Bioprocessing, Inc., effective July 1, 2020. The agreement provides for an annual base salary of $175,000, with subsequent annual increases of 3% or percentage increase in Consumer Price Index (“CPI”), whichever is higher, plus discretionary bonuses. The agreement also provides for a grant of options to purchase 215,366 shares which were authorized to be granted by the Board of Directors during the year ended June 30, 2020, which shares were not available and subject to amendment to the Company’s 2012 Stock Option Plan which was approved in February 2021. Prior to July 1, 2020, the officer had a consulting agreement, which terminated upon becoming an employee of the Company. Consulting fees paid under this agreement amounted to $145,000 for the year ended June 30, 2020, respectively plus stock options valued at $36,000 were granted as part of the total compensation under the consulting agreement, for the year ended June 30, 2020. Bonuses amounting to $100,000 were awarded during the year ended June 30, 2021 and $50,000 in 2020. The employment agreement contains termination provisions stipulating that if the Company terminates the employment other than for death, disability, or cause (as such term is defined therein), or if employee resigns for “good reason”(as such term is defined in the agreement) , the Company shall pay severance payments equal to either one year’s salary at the rate of the compensation at the time of termination is employee is terminated within 12 months of the date of the agreement or six months’ salary is the employee is terminated after 12 months of the date of the agreement, continue to pay the regular benefits provided by the Company for the period equal to the length of the severance payments and pay a pro rata portion of any bonus achieved prior to such termination of employment.

On April 30, 2021, the Company entered into an employment agreement with each of the four managing directors and sellers of Aquila for an indefinite term, which can be terminated by either party upon six months’ written notice in accordance with German law. The agreements, which are identical, stipulate that in calendar year 2021, the employees will receive a salary of 105,000 euros, and a guaranteed bonus of 45,000 euros for a total of 150,000 euros per year on a pro-rata basis, and in calendar year 2022, they will receive a salary of 105,000 euros and a bonus of 45,000 euros, subject to the achievement by Aquila of certain targets. In addition, the employment agreements included a one time retention bonus of 10,000 euros upon closing of the acquisition which was paid in May 2021 by Aquila, and a retention bonus of 25,000 euros if the employee does not terminate his employment with the Company within two years after the agreement date or the Company does not terminate his employment for good cause.

The Company has a consulting agreement, which expires on December 31, 2021, with a Director of the Company and his affiliate for product development consulting services. The agreement provides that the consultant be paid a monthly retainer fee of $9,000, plus a grant of 20,000 options which were awarded during the year ended June 30, 2020. Consulting expense related to this agreement amounted to $108,000 and $76,200 for the years ended June 30, 2021 and 2020, respectively.

On July 20, 2020, the Company entered into a two-year consulting agreement with a Director and Chairman of the Board of SBI for consulting on strategic matters of the Company’s Bioprocessing Systems Operations. The agreement provided that the consultant be paid a monthly retainer of 5,000 euros which was increased to 12,500 euros effective March 2021 plus the issuance of 125,000 stock options of the Company which were awarded during the year ended June 30, 2021. Consulting expense related to this agreement amounted to $207,900 for the year ended June 30, 2021 and none in 2020, respectively.

The Company is required to make payments of 30% of the net royalties received from the license and sublicense acquired in the SBI acquisition in fiscal 2014 through December 2023, at which time the related patents will expire. Total contingent consideration payments made for this acquisition amounted to $168,000 and $372,600 for the years ended June 30, 2021 and 2020, respectively.

SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

AS OF AND FOR THE YEARS ENDED JUNE 30, 2021 AND 2020

10. Commitments and Contingencies (Continued)

The fair value of contingent consideration estimated to be paid as of June 30, 2021 is as follows:

Year ended June 30,	Amount

2022	$	136,600
2023		12,000
2024		11,400

		160,000

11. Leases

On July 1, 2019, the Company adopted the new accounting pronouncement as it relates to its leases which requires a lessee to recognize all long-term leases on its balance sheet as a liability for its lease obligation, measured at the present value of lease payments not yet paid, and a corresponding asset representing its right to use the underlying asset over the lease term and expands disclosure of key information about leasing arrangements.

The Company leases certain properties consisting principally of a facility in Bohemia, New York (headquarters) through January 2025 which was amended in September 2021 to increase the space by approximately 25% and lease term through approximately October 2028, a facility in Pittsburgh, Pennsylvania for its Bioprocessing Systems Operations through May 2023, and a facility for sales and administration in Orangeburg, New York through October 2022. The Company had a lease for its discontinued operations through November 2020. There are no renewal options with any of the leases, no residual values or significant restrictions or covenants other than those customary in such arrangements, and no non-cash activities, and any rent escalations incorporated within the leases are included in the calculation of the future minimum lease payments, as further described below. All of the Company’s leases are deemed operating leases.

The Company determines whether an agreement contains a lease at inception based on the Company’s right to obtain substantially all of the economic benefits from the use of the identified asset and its right to direct the use of the identified asset. Lease liabilities represent the present value of future lease payments and the Right-Of-Use (“ROU”) assets represent the Company’s right to use the underlying assets for the respective lease terms. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term. The ROU asset is further adjusted to account for previously recorded lease expenses such as deferred rent and other lease liabilities. As the Company’s leases do not provide an implicit rate, the Company used its incremental borrowing rate of 5.0% as the discount rate to calculate the present value of future lease payments, which was the interest rate that its bank would charge for a similar loan.

SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

AS OF AND FOR THE YEARS ENDED JUNE 30, 2021 AND 2020

11. Leases (Continued)

The Company elected not to recognize a ROU asset and a lease liability for leases with an initial term of twelve months or less. In addition to minimum lease payments, certain leases require payment of a proportionate share of real estate taxes and certain building operating expenses or payments based on an excess of a specified base. These variable lease costs are not included in the measurement of the ROU asset or lease liability due to unpredictability of the payment amount and are recorded as lease expenses in the period incurred. The Company’s lease agreements do not contain residual value guarantees.

The Company elected available practical expedients for existing or expired contracts of lessees wherein the Company is not required to reassess whether such contracts contain leases, the lease classification or the initial direct costs. The Company is not utilizing the practical expedient which allows the use of hindsight by lessees and lessors in determining the lease term and in assessing impairment of its ROU assets. The Company utilized the transition method allowing entities to only apply the new lease standard in the year of adoption.

As of June 30, 2021, the weighted-average remaining lease term for operating lease liabilities was approximately 2.68 years and the weighted-average discount rate was 5.0%. Total cash payments under these leases were $289,100 for the year ended June 30, 2021, of which $277,300 was recorded as lease expense.

The Company’s approximate future minimum rental payments under all leases existing at June 30, 2021, through January 2025 are as follows:

Year ended June 30,	Amount

2022	$	260,300
2023		245,300
2024		195,900
2025		91,600

Total future minimum payments	$	793,100
Less: Imputed interest		(62,100	)
Total Present Value of Operating Lease Liabilities	$	731,000

12. Income Taxes

The reconciliation of the provision for income taxes at the federal statutory rate of 21% to the actual tax benefit for the applicable fiscal year was as follows:

	2021			2020

Computed “expected” income tax benefit	$	(1,014,300	)	$	(239,400	)
Research and development credits		(93,900	)		(89,400	)
Rate changes and NOL carrybacks		-			(122,600	)
Incentive Stock Option Expense		59,500			13,800
PPP Loan Forgiveness		(111,700	)		0
Other, net		(7,900	)		1,000

Income tax benefit	$	(1,152,500	)	$	(436,600	)

SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

AS OF AND FOR THE YEARS ENDED JUNE 30, 2021 AND 2020

12. Income Taxes (Continued)

Deferred tax assets and liabilities consist of the following:

	2021			2020
Deferred tax assets:
Amortization of intangible assets, including goodwill	$	374,000		$	329,700
Research and development credits		164,600			89,400
Various accruals		64,600			150,700
Stock options expense		383,200			-
Net operating loss		1,515,800			-
Other		24,900			19,400
		2,527,100			589,200
Deferred tax liability:
Depreciation of property and amortization of goodwill		(37,200	)		(52,100	)

Net deferred tax assets	$	2,489,900		$	537,100

The Company has incurred cumulatively $715,800 of US net operating losses and $800,300 of German net operating losses as of June 30, 2021. These will be carried forward indefinitely without expiration, until fully utilized. The company expects to fully utilize these losses to offset taxable income in future years.

ASC No. 740 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC No. 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. As of June 30, 2021 and 2020, the Company did not have any unrecognized tax benefits related to various federal and state income tax matters.

The Company’s policy is to recognize interest and penalties on any unrecognized tax benefits as a component of income tax expense. The Company does not have any accrued interest or penalties associated with any unrecognized tax benefits. The Company is subject to U.S. federal income tax, as well as various state jurisdictions. The Company is currently open to audit under the statute of limitations by the federal and state jurisdictions for the years ended June 30, 2018 and after. The Company does not anticipate any material amount of unrecognized tax benefits within the next 12 months.

13. Stock Options

Equity awards are measured at each reporting period. Compensation costs are recognized over the period that an employee provides service in exchange for the award. During the years ended June 30, 2021 and 2020, the Company granted 1,094,171 and 25,881 options, respectively, to employees that had a fair value of $7,929,600 and $144,500, respectively. The fair value of the options granted during the years ended June 30, 2021 and 2020, were determined using the Black-Scholes-Merton option-pricing model. The weighted average assumptions used for the years ended June 30, 2021 and 2020, was an expected life of 10 years; risk free interest rate of 1.40% and .89%; volatility of 66% and 74%, and dividend yield of 0% and .08%, respectively. The Company declared no dividends for the years ending June 30, 2021 or 2020. The weighted-average fair value per share of the options granted during the years ended June 30, 2021 and 2020, was $7.25 and $5.58, respectively, and total stock-based compensation costs were $2,108,000 and $65,800 for the years ended June 30, 2021 and 2020, respectively. Stock-based compensation costs related to nonvested awards expected to be recognized in the future are $5,935,000 and $113,400 as of June 30, 2021 and 2020, respectively.

The stockholders approved an amendment to the Company’s 2012 Stock Option Plan (“Plan”) to increase the number of shares available under the Plan by 943,000 shares, from 307,000 to 1,250,000 shares, which, together with 150,000 shares that were added to the Plan in 2020, were registered by the Company on a Form S-8 Registration Statement with the Securities and Exchange Commission on March 15, 2021. The Company’s Board of Directors authorized and approved the grant of Stock Options in June 2020 and July 2020 to three key officers, subject to availability of option shares. In February 2021, upon availability, the Company issued these stock options to the Company’s Chairman of the Board, its Chief Executive Officer and President, and the Vice President of Sales-Americas of Company’s Bioprocessing Systems.

SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

AS OF AND FOR THE YEARS ENDED JUNE 30, 2021 AND 2020

13. Stock Options (Continued)

Option activity is summarized as follows:

	June 30, 2021					June 30, 2020

				Weighted-					Weighted-
				Average					Average
				Exercise					Exercise
	Shares			Price		Shares			Price
Shares under option:
Outstanding, beginning of year		96,586		$	4.35		97,205		$	3.24
Granted		1,094,171			9.07		25,881			7.47
Exercised		(1,000	)		3.05		(24,000	)		3.35
Forfeited		(9,000	)		3.11		(2,500	)		3.08

Outstanding, end of year		1,180,757		$	8.73		96,586		$	4.35

Options exercisable at year-end		296,821		$	7.69		49,236		$	3.29

Weighted average fair value per share of options granted during the fiscal year				$	7.25				$	5.58

SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

AS OF AND FOR THE YEARS ENDED JUNE 30, 2021 AND 2020

13. Stock Options (Continued)

As of June 30, 2021 Options Outstanding

As of June 30, 2021 Exercisable

Weighted-

Average

Weighted-

Weighted-

Range

Remaining

Average

Average

Exercise

Number

Contractual

Exercise

Number

Exercise

Prices

Outstanding

Life (Years)

Price

Outstanding

Price

$5.35 - $ 11.30

1,120,052

9.35

$ 9.03

238,351

$ 8.76

$2.91 - $ 4.65

60,705

5.28

$ 3.36

58,470

$ 3.32

1,180,757

296,821

		As of June 30, 2020 Options Outstanding						As of June 30, 2020 Exercisable
				Weighted-
				Average		Weighted-				Weighted-
Range				Remaining		Average				Average
Exercise		Number		Contractual		Exercise		Number		Exercise
Prices		Outstanding		Life (Years)		Price		Outstanding		Price

	$5.35- $ 11.30		25,881		9.87	$	7.47		-	$	0.00

	$2.91- $ 4.65		70,705		6.46	$	3.33		49,236	$	3.29

			96,586						49,236

SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

AS OF AND FOR THE YEARS ENDED JUNE 30, 2021 AND 2020

14. Earnings (Loss) Per Common Share

The Company presents the computation of earnings per share (“EPS”) on a basic basis. Basic EPS is computed by dividing net income or loss by the weighted average number of shares outstanding during the reported period. Diluted EPS is computed similarly to basic EPS, except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential additional common shares that were dilutive had been issued. Common shares are excluded from the calculation if they are determined to be anti-dilutive. The following table sets forth the weighted average number of common shares outstanding for each period presented.

	2021			2020

Weighted average number of common shares outstanding		3,189,602			1,515,103
Effect of dilutive securities:		-			-
Weighted average number of dilutive common shares outstanding		3,189,602			1,515,103

Basic and Diluted loss per common share:

Continuing operations	$	(0.97	)	$	(0.30	)
Discontinued operations	$	(0.18	)	$	(0.16	)
Consolidated operations	$	(1.15	)	$	(0.46	)

Approximately 88,691 and 2,481,783 shares of the Company's common stock issuable upon the exercise of stock options and warrants, respectively, were excluded from the calculation because the effect would be anti-dilutive due to the loss for the year ended June 30, 2021. Approximately 54,513 and 1,349,850 shares of the Company's common stock issuable upon the exercise of stock options and warrants, respectively, were excluded from the calculation because the effect would be anti-dilutive due to the loss for the year ended June 30, 2020.

SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

AS OF AND FOR THE YEARS ENDED JUNE 30, 2021 AND 2020

15. Equity

At the 2020 Annual Meeting of Stockholders, the stockholders of the Company approved an amendment to the Certificate of Incorporation of the Company to increase the number of authorized shares of the Company’s Common stock by 3,000,000 shares from 7,000,000 to 10,000,000 shares, and a further amendment was approved by a majority of the Company’s shareholders on June 17, 2021 increasing the authorized shares to 15,000,000.

On June 18, 2020, the Company entered into a securities purchase agreement in the amount of $6,074,400 with several accredited investors for the sale and issuance of 1,349,850 shares of the Company’s Common Stock at an offering price of $4.50 per share and warrants to purchase up to 1,349,850 shares of the Company’s Common Stock exercisable at $9.0 0 per share. The issuance cost realated to this stock issuance amounted to approximately $70,000. The proceeds were used to fund the operations of the Company’s Bioprocessing Systems Operations. The warrants were immediately exercisable and expire five years from the date of issuance. If at any time commencing twelve months from the date of the agreement, but before the expiration of the warrant, the volume weighted average price of the Company’s Common Stock exceeds $18 per share for each of thirty consecutive days, the Company may at any time in its sole discretion, call for the exercise of the Warrants, in their entirety.

On April 29, 2021, the Company received proceeds of approximately $7,580,400 from the sale of its securities to private investors upon the issuance of 1,595,880 shares of the Company’s Common Stock at an offering price of $4.75 per share which included warrants to purchase up to 797,940 shares of the Company’s Common Stock exercisable at $9.50 per share. The issuance costs related to this stock issuance amounted to approximately $581,000. In June 2021, the Company received an additional $9.5 million through the sale of an additional 2,000,000 shares of the Company’s Common Stock at $4.75 per share which also included warrants to purchase up to 999,993 of the Company's Common Stock exercisable at $9.50 per share. The issuance costs related to this stock issuance amounted to approximately $425,400. These warrants are exercisable immediately and expire five years from date of issuance. The Company utilized the services of brokers for both transactions and incurred a total of approximately $1.0 million in issuance related costs for broker and legal fees. The Company was required under a registration rights agreement to register the shares, which it did through an S-1 Registration Statement filed with the Securities and Exchange Commission, which became effective on August 13, 2021. The proceeds were used for the Aquila acquisition with the remainder being used to fund the Bioprocessing Systems Operations.

SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

AS OF AND FOR THE YEARS ENDED JUNE 30, 2021 AND 2020

16. Acquisition of Aquila Biolabs GmbH

Effective April 29, 2021, pursuant to a Stock Purchase Agreement ("SPA") the Company acquired all the outstanding capital stock of Aquila biolabs GmbH, a German start-up company engaged from its facility in Baesweiler, Germany in the design, production, and sale of bioprocessing systems and products which focus on the control and analysis of bioprocesses in bioreactors and incubation shakers for an aggregate purchase price of $7,880,100 in cash upon closing. Aquila’s principal customers are universities, pharmaceutical companies, and industrial companies. The products are sold primarily on a direct basis and to a lesser extent, through distributors.

The acquisition was accounted for under the acquisition method of accounting in accordance with Accounting Standards Codification (“ASC”) 805, Business Combinations (“ASC 805”) in which the Company is treated as the accounting acquirer. In accordance with ASC 805, the assets acquired and liabilities assumed have been measured at fair value.

For purposes of measuring the estimated fair value, where applicable, of the assets acquired and liabilities assumed, as reflected in the unaudited pro forma condensed consolidated financial information, the guidance in ASC 820, Fair Value Measurements and Disclosures (“ASC 820”) has been applied, which establishes a framework for measuring fair value. In accordance with ASC 820, fair value is an exit price and is defined as “the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.” Under ASC 805, acquisition-related transaction costs and acquisition-related restructuring charges are not included as components of consideration transferred but are accounted for as expenses in the period in which the costs are incurred.

Management of the Company allocated the purchase price based on its valuation of the assets acquired and liabilities assumed as follows:

	Amount			Useful life
Fair value of assets acquired

Current assets:

Cash and cash equivalents	$	201,100
Accounts receivable		159,200
Inventory		187,500
Prepaid expenses and other current assets		25,400
Property, plant and equipment		40,200
Deferred tax asset		800,300
Tradename		452,300		6 years
Non-compete agreements		784,500		4 years
IPR&D		742,100		5 years
Customer relationships		252,200		9 years
Patents and other intangibles		286,200		7 years
Total assets acquired	$	3,931,000

Fair value of liabilities assumed:

Accounts payable	$	(39,300	)
Accrued expenses		(90,300	)
Other current liabilities		(59,400	)
Total liabilities assumed		(189,000	)

Total identifiable net assets		3,742,000
Fair value of consideration transferred		7,880,100
Goodwill	$	4,138,100

SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

AS OF AND FOR THE YEARS ENDED JUNE 30, 2021 AND 2020

16. Acquisition of Aquila Biolabs GmbH (continued)

Accounting Periods Presented

Aquila’s fiscal year ended on December 31. Its historical results have been aligned to more closely conform to the Company’s June 30 fiscal year end by taking Aquila’s interim financial results for six months ended December 31, 2019 and for the six months ended June 30, 2020. In addition, certain historical Aquila balances have been reclassified to conform to the pro forma consolidated presentation. There were no transactions between the two companies during the period presented. No pro forma adjustments were made to conform Aquila’s accounting policies which follow Germany’s generally accepted accounting principles (“German GAAP”) to the Company’s accounting principles, as any differences were deemed immaterial.

Unaudited Pro forma information is as follows:


(In $000’s)	6/30/2020
Revenues	$	9,346
Net loss		(1,650	)
Earnings per share
Diluted	$	(0.37	)
Basic		(0.37	)

These pro forma results do not represent financial results that would have been realized had the acquisition actually occurred on July 1, 2019, nor are they intended to be a projection of future results. For additional information, please refer to the Company’s current report on Form 8-KA, filed on July12, 2021.

17. Discontinued Operations

Effective November 30, 2020, the Company, as part of its strategic shift to becoming a life sciences tool provider, sold its Catalyst Research Instruments Operations reporting segment through the sale by Altamira of substantially all of its assets, which comprised of fixed assets, and inventory to Beijing JWGB Sci. & Tech. Co. Ltd., a corporation formed under the laws of the People’s Republic of China (“JWGB”) for $440,000 payable in cash through January 2021, resulting in a $405,400 pre-tax loss. In order to preserve business continuity for the buyer, Altamira agreed to purchase certain components on behalf of JWGB for which JWGB agreed to reimburse Altamira. At March 31, 2021, JWGB paid the full $440,000 purchase price and $28,500 for component purchases made on its behalf. The Company retained all its receivables and payables related to sales made prior to November 30, 2020, certain inventory related to two work-in-process orders which will be shipped by the end of the fiscal year ending June 30, 2021, product warranty and other miscellaneous liabilities related to certain employee benefits, and expenses related to the closure of the Altamira facility, which was substantially completed at the end of December 2020.

As a result of the disposal described above, the operating results of the former Catalyst Research Instruments Operations segment have been presented as discontinued operations in the balance sheets, the statements of operations, and the statements of cash flows, as detailed below.

Assets:	June 30, 2021		June 30, 2020
Accounts receivable	$	52,000	$	-
Inventories		3,300		343,700
Property and equipment, net		-		1,400
Goodwill		-		447,900

Discontinued operations	$	55,300	$	793,000

SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

AS OF AND FOR THE YEARS ENDED JUNE 30, 2021 AND 2020

17. Discontinued Operations (continued)

Liabilities:

June 30, 2021

June 30, 2020

Accounts payable

$ -

$ 20,100

Accrued expenses and taxes

20,700

120,700

Contract liabilities

16,500

69,000

Operating lease liabilities, current portion

-

31,100

$ 37,200

$ 240,900

	Years Ended
	June 30, 2021			June 30, 2020
Revenues	$	387,700		$	785,900
Cost of goods sold		471,800			869,900
Gross profit		(84,100	)		(84,000	)
Selling, general and administrative expenses		280,400			388,500
Loss from operations		(364,500	)		(472,500	)
Loss on disposal		(405,400	)		--
Loss before income tax benefit		(769,900	)		(472,500	)
Income tax benefit, all deferred		(207,400	)		(222,600	)
Net income (loss) attributable to discontinued operations	$	(562,500	)	$	(249,900	)

In our Consolidated Statements of Cash Flows, the cash flows from discontinued operations are not separately classified. Cash (used) and provided by operating activities from discontinued operations for year ended June 30, 2021 and June 30, 2020 was ($75,000) and $66,100, respectively. Cash provided by investing activities from discontinued operations for the year ended June 30, 2021 was $440,000 and $2,200 for the year ended June 30, 2020. There was no cash provided or used by the discontinued operations for financing activities for both the current and prior year periods.

SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

	March 31, 2022			June 30, 2021
	(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	4,068,000		$	9,675,200
Investment securities		7,768,600			3,744,600
Trade accounts receivable, less allowance for doubtful accounts of $15,600 at March 31, 2022 and June 30, 2021		1,712,900			1,294,700
Inventories		4,367,900			2,977,100
Income tax receivable		161,100			333,300
Prepaid expenses and other current assets		312,800			350,900
Assets of discontinued operations		600			55,300
Total current assets		18,391,900			18,431,100

Property and equipment, net		566,900			412,600
Goodwill		4,395,400			4,395,400
Other intangible assets, net		2,216,300			2,557,800
Deferred taxes		3,445,300			2,489,900
Operating lease right-of-use assets		1,448,600			665,300
Other assets		62,400			54,300

Total assets	$	30,526,800		$	29,006,400

LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	1,051,100		$	453,500
Accrued expenses		661,100			633,500
Contingent consideration		117,500			136,600
Bank overdraft		40,600			321,700
Lease liabilities, current portion		124,300			270,500
Paycheck Protection Program loan		-			433,800
Liabilities of discontinued operations		7,900			37,200
Total current liabilities		2,002,500			2,286,800

Contingent consideration payable, less current portion		-			23,400
Lease liabilities, less current portion		1,388,100			460,500
Other long-term liabilities		-			10,900

Total liabilities		3,390,600			2,781,600

Shareholders’ equity:
Common stock, $0.05 par value; 20,000,000 and 15,000,000 shares authorized; 7,023,401 and 6,477,945 shares issued; 7,003,599 and 6,458,143 shares outstanding at March 31, 2022 and June 30, 2021		351,200			324,000
Additional paid-in capital		31,233,600			26,613,500
Accumulated comprehensive loss		(104,800	)		(9,200	)
Accumulated deficit		(4,291,400	)		(651,100	)
		27,188,600			26,277,200
Less common stock held in treasury at cost, 19,802 shares		52,400			52,400
Total shareholders’ equity		27,136,200			26,224,800

Total liabilities and shareholders’ equity	$	30,526,800		$	29,006,400

See notes to unaudited condensed consolidated financial statements.

Table of Contents

SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED)

	For the Three Month Period Ended March 31,			For the Three Month Period Ended March 31,			For the Nine Month Period Ended March 31,			For the Nine Month Period Ended March 31,
	2022			2021			2022			2021

Revenues	$	2,864,900		$	2,508,600		$	8,623,500		$	7,245,100

Cost of revenues		1,318,300			1,145,700			4,154,600			3,419,400

Gross profit		1,546,600			1,362,900			4,468,900			3,825,700

Operating expenses:
General and administrative		1,610,400			1,385,600			4,442,300			2,441,700
Selling		1,054,000			1,386,100			2,996,800			2,658,900
Research and development		624,500			450,000			2,141,300			1,024,000

Total operating expenses		3,288,900			3,221,700			9,580,400			6,124,600

Loss from operations		(1,742,300	)		(1,858,800	)		(5,111,500	)		(2,298,900	)

Other income (expense):
Other income (expense), net		(102,700	)		6,100			363,500			22,300
Interest income		400			22,500			49,800			71,400
Total other income (expense), net		(102,300	)		28,600			413,300			93,700

Loss from continuing operations before income tax benefit		(1,844,600	)		(1,830,200	)		(4,698,200	)		(2,205,200	)

Income tax benefit, current		(95,100	)		-			(95,100	)		-
Income tax benefit, deferred		(222,100	)		(378,200	)		(959,400	)		(472,300	)
Total income tax benefit		(317,200	)		(378,200	)		(1,054,500	)		(472,300	)

Loss from continuing operations		(1,527,400	)		(1,452,000	)		(3,643,700	)		(1,732,900	)

Discontinued operations (Note 9):

Gain (loss) from discontinued operations, net of tax		(7,600	)		16,400			3,400			(578,500	)

Net loss	$	(1,535,000	)	$	(1,435,600	)	$	(3,640,300	)	$	(2,311,400	)

Comprehensive loss:

Unrealized holding loss on investment securities, net of tax		(4,700	)		-			(5,100	)		-
Foreign currency translation adjustment		(194,500	)		-			(90,500	)		-
Comprehensive loss		(199,200	)		-			(95,600	)		-

Total comprehensive loss	$	(1,734,200	)	$	(1,435,600	)	$	(3,735,900	)	$	(2,311,400	)

Basic loss per common share:

Continuing operations	$	(0.23	)	$	(0.51	)	$	(0.56	)	$	(0.61	)
Discontinued operations	$	(0.00	)	$	0.01		$	0.00		$	(0.20	)
Consolidated operations	$	(0.23	)	$	(0.50	)	$	(0.56	)	$	(0.81	)

See notes to unaudited condensed consolidated financial statements.

Table of Contents

SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY (UNAUDITED)

	Common Stock				Additional		Accumulated Other Comprehensive						Treasury Stock				Total
	Shares		Amount		Paid-in Capital		Income (Loss)			Accumulated Deficit			Shares		Amount		Stockholders' Equity

Balance July 1, 2021		6,477,945	$	324,000	$	26,613,500	$	(9,200	)	$	(651,100	)		19,802	$	52,400	$	26,224,800

Net loss		-		-		-		-			(1,208,800	)		-		-		(1,208,800	)

Foreign currency translation adjustment		-		-		-		34,100			-			-		-		34,100

Unrealized holding gain on investment securities, net of tax		-		-		-		2,200			-			-		-		2,200

Stock-based compensation		-		-		675,400		-			-			-		-		675,400

Balance, September 30, 2021		6,477,945		324,000		27,288,900		27,100			(1,859,900	)		19,802		52,400		25,727,700

Net loss		-		-		-		-			(896,500	)		-		-		(896,500	)

Foreign currency translation adjustment		-		-		-		69,900			-			-		-		69,900

Unrealized holding gain on investment securities, net of tax		-		-		-		(2,600	)		-			-		-		(2,600	)

Stock-based compensation		-		-		591,000		-			-			-		-		591,000
Balance, December 31, 2021		6,477,945		324,000		27,879,900		94,400			(2,756,400	)		19,802		52,400		25,489,500

Net loss		-		-		-		-			(1,535,000	)		-		-		(1,535,000	)

Issuance of Common Stock and Warrants, net of issuance costs		545,456		27,200		2,700,000		-			-			-		-		2,727,200

Foreign currency translation adjustment		-		-				(194,500	)		-			-		-		(194,500	)

Unrealized holding loss on investment securities, net of tax		-		-		-		(4,700	)		-			-		-		(4,700	)

Stock-based compensation		-		-		653,700		-			-			-		-		653,700

Balance, March 31, 2022		7,023,401	$	351,200	$	31,233,600	$	(104,800	)	$	(4,291,400	)		19,802	$	52,400	$	27,136,200

Table of Contents

SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY (CONTINUED)

(UNAUDITED)

	Common Stock				Additional Paid-in		Retained			Treasury Stock				Total Stockholders'
	Shares		Amount		Capital		Earnings			Shares		Amount		Equity

Balance July 1, 2020		2,881,065	$	144,100	$	8,608,300	$	3,021,400			19,802	$	52,400	$	11,721,400

Net loss		-		-		-		(263,300	)		-		-		(263,300	)

Stock-based compensation		-		-		61,300		-			-		-		61,300

Balance, September 30, 2020		2,881,065		144,100		8,669,600		2,758,100			19,802		52,400		11,519,400

Net loss		-		-		-		(612,500	)		-		-		(612,500	)

Stock-based compensation		-		-		76,100		-			-		-		76,100
Balance, December 31, 2020		2,881,065		144,100		8,745,700		2,145,600			19,802		52,400		10,983,000

Net loss		-		-		-		(1,435,600	)		-		-		(1,435,600	)

Stock-based compensation		-		-		1,292,000		-			-		-		1,292,000

Stock options exercised		1,000		100		2,900		-			-		-		3,000

Balance, March 31, 2021		2,882,065	$	144,200	$	10,040,600	$	710,000			19,802	$	52,400	$	10,842,400

Table of Contents

SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

	For the Nine Month Period March 31, 2022			For the Nine Month Period March 31, 2021
Operating activities:

Net loss	$	(3,640,300	)	$	(2,311,400	)
Adjustments to reconcile net loss to net cash used in operating activities:
Loss/(Gain) on sale of investments		11,100			(34,600	)
Unrealized holding loss on investments		102,800			18,900
Extinguishment of debt		(433,800	)		-
Depreciation and amortization		581,800			126,700
Deferred income taxes		(955,400	)		(652,300	)
Loss on disposal of subsidiary		-			405,400
Stock-based compensation		1,920,100			1,429,400
Change in fair value of contingent consideration		(42,500	)		(118,500	)
Changes in operating assets and liabilities:
Trade accounts receivable		(328,700	)		(758,500	)
Inventories		(1,383,900	)		(697,700	)
Carrying value of right of use assets		(783,300	)		87,700
Income tax receivable		172,200			(1,500	)
Prepaid and other current assets		(127,700	)		57,400
Accounts payable		585,500			142,600
Contract liabilities		796,100			(20,000	)
Lease liabilities		-			(51,000	)
Bank overdraft		(281,100	)		7,500
Other assets		107,100			-
Discontinued operations		25,400			-
Accrued expenses		(20,700	)		(222,600	)
Total adjustments		(55,000	)		(281,100	)
Net cash used in operating activities		(3,695,300	)		(2,592,500	)

Investing activities:

Redemption of investment securities		1,278,500			1,631,000
Purchase of investment securities		(5,422,700	)		(6,609,200	)
Proceeds from sale of assets of discontinued operations		-			440,000
Capital expenditures		(337,400	)		(183,700	)
Purchase of other intangible assets		(67,000	)		(41,200	)
Net cash used in investing activities		(4,548,600	)		(4,763,100	)

Financing activities:

Proceeds from issuance of common stock		3,000,000			-
Issuance costs of common stock and warrants		(272,800	)		-
Payments of contingent consideration		-			(13,400	)
Proceeds from Payroll Protection Program		-			433,800
Proceeds from stock options exercised		-			3,000
Net cash provided by financing activities		2,727,200			423,400

Effect of changes in foreign currency exchange rates		(90,500	)		-

Net decrease in cash and cash equivalents		(5,607,200	)		(6,932,200	)
Cash and cash equivalents, beginning of year		9,675,200			7,559,700
Cash and cash equivalents, end of period	$	4,068,000		$	627,500

Table of Contents

SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (CONTINUED)

(UNAUDITED)

	For the Nine Month Period March 31, 2022		For the Nine Month Period March 31, 2021
SUPPLEMENTAL DISCLOSURES:

Cash paid during the period for:
Income taxes	$	-	$	2,500
Noncash financing activities:
Record right-of-use assets	$	941,300	$	-
Record lease liabilities	$	941,300	$	-

Table of Contents

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

General

The accompanying unaudited interim condensed consolidated financial statements are prepared pursuant to the Securities and Exchange Commission’s rules and regulations for reporting on Form 10-Q. Accordingly, certain information and notes required by accounting principles generally accepted in the United States for complete financial statements are not included herein. The Company believes all adjustments necessary for a fair presentation of these interim statements have been included and that they are of a normal and recurring nature. These interim statements should be read in conjunction with the Company’s consolidated financial statements and notes thereto, included in its Annual Report on Form 10-K for the fiscal year ended June 30, 2021. The results for the three and nine months ended March 31, 2022 are not necessarily an indication of the results for the full fiscal year ending June 30, 2022.

1. Significant Accounting Policies

Principles of Consolidation

The accompanying consolidated financial statements include the accounts of Scientific Industries, Inc., its wholly- owned subsidiary, Scientific Bioprocessing Holdings, Inc. (“SBHI”), SBHI’s wholly-owned subsidiaries, Scientific Bioprocessing, Inc. (“SBI”), and aquila biolabs GmbH (“Aquila”), a German corporation, which was acquired on April 29, 2021, Scientific Packaging Industries, Inc., an inactive wholly-owned subsidiary, and Altamira Instruments, Inc. (“Altamira”), and wholly-owned subsidiary (accounted for as a discontinued operation as of November 30, 2020) (all collectively referred to as the “Company”). All material intercompany balances and transactions have been eliminated in consolidation.

COVID-19 Pandemic

The challenges posed by the COVID-19 pandemic on the global economy began to take effect and adversely affected the Company’s operations at the end of the third quarter of the fiscal year ended June 30, 2020. At that time, the Company took appropriate action and put plans in place to diminish the adverse effects of COVID-19 on its operations, enabling the Company to continue to operate with minor or temporary disruptions to its operations. The Company took immediate action pertaining to COVID-19 preparedness by implementing the US Center for Disease Control’s guidelines for employers in order to protect the Company’s employees’ health and safety, with actions such as implementing work from home, social distancing in the workplace, requiring self-quarantine for any employee showing symptoms, wearing face coverings, and training employees on maintaining a healthy work environment. The Company experienced supply chain disruptions which had an impact on its operations causing delayed delivery of some products to its customers, and production inefficiencies. SBI’s facility was shut down temporarily due to state mandates, however, the impact on operations was minimal, and the Company was able to retain its employees without furloughs or layoffs, in part, due to the Company’s receipt of two loans under the Federal Government’s Small Business Administration Paycheck Protection Program (“PPP”).

The Company received $563,800 and $433,800 in PPP loans in April 2020 and March 2021, respectively. The first loan was forgiven in June 2021 except for $32,700 which was repaid by the Company and the second loan was forgiven in full in December 2021. The Company elected to account for its PPP Loans in accordance with Accounting Standards Codification (“ASC”), Topic 470 Debt, with interest, if any, accrued in accordance with the interest method under ASC 835-30, Imputation of Interest. Initially, the Company recognized the entire loan amounts as liabilities on its balance sheets and remained as liabilities until either the Company was legally released from its obligations or paid the lender. Once the loans were forgiven, the amounts forgiven were recorded in the Company’s statement of operations as “Other Income.”

Adopted Accounting Pronouncements

In December 2019, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2019-12, “Simplifying the Accounting for Income Taxes”, which is designed to simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. ASU No. 2019-12 is effective for fiscal years beginning after December 15, 2020. The adoption of this standard as of July 1, 2021 did not have a material impact on the Company’s financial statements.

Recently Issued Accounting Pronouncements

The Company has implemented all new accounting pronouncements that are in effect and is evaluating any that may impact its financial statements. The Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

Table of Contents

2. Revenue

The Company generates revenues from the following sources: (1) Benchtop Laboratory Equipment, and (2) Bioprocessing Systems. The following table summarizes the Company’s disaggregation of revenues for the three and nine months ended March 31, 2022 and 2021.

	Benchtop Laboratory Equipment		Bioprocessing Systems		Consolidated
Three Months Ended March 31, 2022:

Revenues	$	2,434,600	$	430,300	$	2,864,900

Foreign Sales		783,600		269,700		1,053,300

	Benchtop Laboratory Equipment		Bioprocessing Systems		Consolidated
Three Months Ended March 31, 2021:

Revenues	$	2,365,700	$	142,900	$	2,508,600

Foreign Sales		942,200		102,600		1,044,800

	Benchtop Laboratory Equipment		Bioprocessing Systems		Consolidated
Nine Months Ended March 31, 2022:

Revenues	$	7,465,700	$	1,157,800	$	8,623,500

Foreign Sales		2,814,700		791,200		3,605,900

	Benchtop Laboratory Equipment		Bioprocessing Systems		Consolidated
Nine Months Ended March 31, 2021:

Revenues	$	6,803,300	$	441,800	$	7,245,100

Foreign Sales		2,724,800		395,000		3,119,800

Benchtop Laboratory Equipment sales are comprised primarily of standard benchtop laboratory equipment sold to laboratory equipment distributors, or directly to end users primarily online via the Company’s website. The sales cycle from time of receipt of order to shipment ranges from a day to a few weeks. Customers either pay by credit card (online sales) or Net 30-90 days, depending on the customer. Once the item is shipped under the terms specified in the order, which is primarily “FOB Factory”, other than a standard warranty, there are no other obligations to the customer. The standard warranty is typically one or two years, covering parts and labor, and is deemed immaterial. Revenue is recognized at the point in time when the risks and rewards of ownership have transferred to the customer, which is generally upon shipment.

Bioprocessing Systems revenues consist of royalty revenues generated through SBI and product revenues generated primarily through Aquila. Royalty revenues are earned by the Company under a licensing agreement from a single licensee and its sublicenses. The license agreement included two United States patents, which expired in August 2021. The Company is obligated to pay 50% of all royalties earned to the entity that licensed the intellectual property to the Company.

Table of Contents

3. Segment Information and Concentrations

The Company views its operations as two segments: the manufacture and marketing of standard benchtop laboratory equipment for research in university, hospital and industrial laboratories sold primarily through laboratory equipment distributors and laboratory and pharmacy balances and scales (“Benchtop Laboratory Equipment Operations”); and the design, manufacture, and marketing of bioprocessing systems and products (“Bioprocessing Systems”) and related royalty income.

Segment information is reported as follows:

	Benchtop Laboratory Equipment		Bioprocessing Systems			Corporate And Other			Consolidated
Three Months Ended March 31, 2022:

Revenues	$	2,434,600	$	430,300		$	-		$	2,864,900

Foreign Sales		783,600		269,700			-			1,053,300

Income (Loss) From Operations		247,300		(1,651,700	)		(337,900	)		(1,742,300	)

Assets		10,231,100		10,024,261			10,271,439			30,526,800

Long-Lived Asset Expenditures		16,500		158,000			-			174,500

Depreciation and Amortization		24,600		229,900			-			254,500

	Benchtop Laboratory Equipment		Bioprocessing Systems			Corporate And Other			Consolidated
Three Months Ended March 31, 2021:

Revenues	$	2,365,700	$	142,900		$	-		$	2,508,600

Foreign Sales		942,200		102,600			-			1,044,800

Income (Loss) From Operations		394,700		(1,323,900	)		(929,600	)		(1,858,800	)

Assets		5,979,400		1,281,200			6,639,700			13,900,300

Long-Lived Asset Expenditures		18,600		92,100			-			110,700

Depreciation and Amortization		30,000		16,700			-			46,700

Table of Contents

Approximately 50% and 55% of net sales from Benchtop Laboratory Equipment Operations (42% and 52% of total revenues) for the three months ended March 31, 2022 and 2021, respectively, were derived from sales of the Company’s main product, the Vortex-Genie 2 mixer, excluding accessories.

Approximately 24% and 20% of total Benchtop Laboratory Equipment Operations sales (20% and 19% of total revenues) were derived from the Torbal Scales Division for the three months ended March 31, 2022 and 2021, respectively. For the three months ended March 31, 2022 and 2021, respectively, three customers accounted for approximately 19% and 26% of net sales of the Benchtop Laboratory Equipment Operations (16% and 25% of the Company’s total revenues), respectively.

	Benchtop Laboratory Equipment		Bioprocessing Systems			Corporate And Other			Consolidated
Nine Months Ended March 31, 2022:

Revenues	$	7,465,700	$	1,157,800		$	-		$	8,623,500

Foreign Sales		2,814,700		791,200			-			3,605,900

Income (Loss) From Operations		1,107,000		(5,091,300	)		(1,127,200	)		(5,111,500	)

Assets		10,231,100		10,024,261			10,271,439			30,526,800

Long-Lived Asset Expenditures		83,100		321,300			-			404,400

Depreciation and Amortization		71,200		510,600			-			581,800

	Benchtop Laboratory Equipment		Bioprocessing Systems			Corporate And Other			Consolidated
Nine Months Ended March 31, 2021:

Revenues	$	6,803,300	$	441,800		$	-		$	7,245,100

Foreign Sales		2,724,800		395,000			-			3,119,800

Income (Loss) From Operations		1,347,100		(2,598,000	)		(1,048,000	)		(2,298,900	)

Assets		5,979,400		1,281,200			6,639,700			13,900,300

Long-Lived Asset Expenditures		54,100		170,800			-			224,900

Depreciation and Amortization		79,700		46,500			500			126,700

Table of Contents

Approximately 49% and 51% of total Benchtop Laboratory Equipment Operations sales (42% and 47% of total revenues) for the nine months ended March 31, 2022 and 2021, respectively, were derived from sales of the Company’s main product, the Vortex-Genie 2 mixer, excluding accessories.

Approximately 24% and 23% for both periods of total Benchtop Laboratory Equipment Operations sales (21% and 21% of total revenues) were derived from the Torbal Scales Division for the nine months ended March 31, 2022 and 2021, respectively.

For each of the nine-month periods ended March 31, 2022 and 2021, three customers accounted for approximately 20% and 23% of net sales of the Benchtop Laboratory Equipment Operations (17% and 21% of the Company’s total revenues), respectively.

4. Fair Value of Financial Instruments

The fair value of the contingent consideration obligations are based on a probability-weighted approach derived from the estimates of earn-out criteria and the probability assessment with respect to the likelihood of achieving those criteria. The measurement is based on significant inputs that are not observable in the market, therefore, the Company classifies this liability as Level 3 in the following table.

Table of Contents

The following tables set forth by level within the fair value hierarchy the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis at March 31, 2022 and June 30, 2021 according to the valuation techniques the Company used to estimate their fair values:

	Fair Value at		Fair Value Measurements Using Inputs Considered as
	March 31, 2022		Level 1		Level 2		Level 3
Assets:
Cash and cash equivalents	$	4,068,000	$	4,068,000	$	-	$	-
Investment securities		7,768,600		6,796,500		972,100		-

Total	$	11,836,600	$	10,864,500	$	972,100	$	-

Liabilities:
Contingent consideration	$	117,500	$	-	$	-	$	117,500

	Fair Value at		Fair Value Measurements Using Inputs Considered as
	June 30, 2021		Level 1		Level 2		Level 3
Assets:
Cash and cash equivalents	$	9,675,200	$	9,675,200	$	-	$	-
Investment securities		3,744,600		2,920,600		824,000		-

Total	$	13,419,800	$	12,595,800	$	824,000	$	-

Liabilities:
Contingent consideration	$	160,000	$	-	$	-	$	160,000

Investments in marketable securities by security type at March 31, 2022 and June 30, 2021 consisted of the following:

	Cost		Fair Value		Unrealized Holding Gain (Loss)
At March 31, 2022:
Equity securities	$	118,900	$	176,900	$	58,000
Mutual funds		6,708,300		6,619,600		(88,700	)
Debt securities		977,200		972,100		(5,100	)
	$	7,804,400		7,768,600		(35,800	)

	Cost		Fair Value		Unrealized Holding Gain (Loss)
At June 30, 2021:
Equity securities	$	102,200	$	154,100	$	51,900
Mutual funds		2,752,400		2,766,500		14,100
Debt securities		832,700		824,000		(8,700	)
	$	3,687,300	$	3,744,600	$	57,300

Table of Contents

5. Inventories

	March 31, 2022		June 30, 2021
Raw materials	$	3,058,100	$	2,170,400
Work-in-process		106,400		39,600
Finished goods		1,203,400		767,100
	$	4,367,900	$	2,977,100

6. Goodwill and Finite Lived Intangible Assets

Goodwill amounted to $4,395,400 at March 31, 2022 and June 30, 2021, all of which is expected to be deductible for tax purposes.

The components of finite-lived intangible assets are as follows:

	Useful Lives	Cost		Accumulated Amortization		Net
At March 31, 2022:
Technology, trademarks	5-10 yrs.	$	817,000	$	431,800	$	385,200
Trade names	3-6 yrs.		140,000		140,000		-
Websites	3-7 yrs.		210,000		210,000		-
Customer relationships	4-10 yrs.		372,200		133,100		239,100
Sublicense agreements	10 yrs.		294,000		294,000		-
Non-compete agreements	4-5 yrs.		1,060,500		455,300		605,200
In-process research and development	3-5 yrs.		917,600		249,600		668,000
Patents	5-7 yrs.		593,000		274,200		318,800

		$	4,404,300	$	2,188,000	$	2,216,300

	Useful Lives	Cost		Accumulated Amortization		Net
At June 30, 2021:
Technology, trademarks	5-10 yrs.	$	364,700	$	362,200	$	2,500
Trade names	3-6 yrs.		592,300		152,600		439,700
Websites	3-7 yrs.		210,000		210,000		-
Customer relationships	4-10 yrs.		372,200		102,400		269,800
Sublicense agreements	10 yrs.		294,000		283,000		11,000
Non-compete agreements	4-5 yrs.		1,060,500		308,600		751,900
In-process research and development	3-5 yrs.		852,100		134,800		717,300
Patents	5-7 yrs.		591,500		225,900		365,600

		$	4,337,300	$	1,779,500	$	2,557,800

Total amortization expense was $134,600 and $16,000 for the three months ended March 31, 2022 and 2021, respectively, and $408,500 and $48,500 for the nine months ended March 31, 2022 and 2021, respectively. As of March 31, 2022, estimated future amortization expense related to intangible assets is $134,300 for the remainder of the fiscal year ending June 30, 2022, $520,900 for fiscal 2023, $518,900 for fiscal 2024, $485,100 for fiscal 2025, $284,600 for fiscal 2026 and $137,500 thereafter.

Table of Contents

7. Loss Per Common Share

The Company presents the computation of earnings per share (“EPS”) on a basic basis. Basic EPS is computed by dividing net income, if any, by the weighted average number of shares outstanding during the reported period. Diluted EPS is computed similarly to basic EPS, except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential additional common shares that were dilutive had been issued. Common shares are excluded from the calculation if they are determined to be anti-dilutive; accordingly, no dilution is shown for loss periods. The following table sets forth the weighted average number of common shares outstanding for each period presented.

	For the Three Month Period Ended March 31, 2022			For the Three Month Period Ended March 31, 2021			For the Nine Month Period Ended March 31, 2022			For the Nine Month Period Ended March 31, 2021
Weighted average number of common shares outstanding		6,633,901			2,861,607			6,544,112			2,861,376
Effect of dilutive securities		-			-			-			-
Weighted average number of dilutive common shares outstanding		6,633,901			2,861,607			6,544,112			2,861,376
Basic and diluted loss per common share:

Continuing operations	$	(0.23	)	$	(0.51	)	$	(0.56	)	$	(0.61	)
Discontinued operations	$	-		$	0.01		$	-		$	(0.20	)
Consolidated operations	$	(0.23	)	$	(0.50	)	$	(0.56	)	$	(0.81	)

Approximately 3,452,542 and 3,451,461 shares of the Company’s common stock issuable upon the exercise of options and warrants, respectively, were excluded from the calculation because the effect would be anti-dilutive due to the loss for the three and nine months ended March 31, 2022.

Approximately 259,357 and 1,349,850 shares of the Company’s common stock issuable upon the exercise of options and warrants, respectively, were excluded from the calculation because the effect would be anti-dilutive due to the loss for the three and nine months ended March 31, 2021.

8. Leases

The Company leases certain properties consisting principally of (i) a facility in Bohemia, New York (headquarters) through October 2028, (ii) a facility in Pittsburgh, Pennsylvania for SBI’s Bioprocessing Systems Operations through May 2023, and (iii) a facility for sales and administration in Orangeburg, New York through October 2022. There are no renewal options with any of the leases, no residual values or significant restrictions or covenants other than those customary in such arrangements, and no non-cash activities; and any rent escalations incorporated within the leases are included in the calculation of the future minimum lease payments, as further described below.

The Company determines whether an agreement contains a lease at inception based on the Company’s right to obtain substantially all of the economic benefits from the use of the identified asset and its right to direct the use of the identified asset. Lease liabilities represent the present value of future lease payments and the Right-Of-Use (“ROU”) assets represent the Company’s right to use the underlying assets for the respective lease terms. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term. Each ROU asset is further adjusted to account for previously recorded lease expenses such as deferred rent and other lease liabilities. As the Company’s leases do not provide an implicit rate, the Company used its incremental borrowing rate of 5.0% as the discount rate to calculate the present value of future lease payments, which was the interest rate that its bank would charge for a similar loan.

Table of Contents

The Company elected not to recognize a ROU asset or a lease liability for leases with an initial term of twelve months or less. In addition to minimum lease payments, certain leases require payment of a proportionate share of real estate taxes and certain building operating expenses or payments based on an excess of a specified base. These variable lease costs are not included in the measurement of the ROU asset or lease liability due to unpredictability of the payment amount and are recorded as lease expenses in the period incurred. The Company’s lease agreements do not contain residual value guarantees.

The Company elected available practical expedients for existing or expired contracts of lessees whereby the Company is not required to reassess whether such contracts contain leases, the lease classification or the initial direct costs. The Company is not utilizing the practical expedient which allows the use of hindsight by lessees and lessors in determining the lease term and in assessing impairment of its ROU assets. The Company utilized the transition method allowing entities to only apply the new lease standard in the year of adoption.

As of March 31, 2022, the weighted-average remaining lease term for operating lease liabilities was approximately 5.32 years and the weighted-average discount rate was 5.0%. Total cash payments under these leases were approximately $82,000 and $240,200, for the three and nine months ended March 31, 2022 of which $81,800 and $226,300 was recorded as leases expense, respectively.

The Company’s approximate future minimum rental payments under all leases existing at March 31, 2022 through October 2028 are as follows:

Fiscal year ending June 30,	Amount
Remainder of 2022	$	82,200
2023		311,400
2024		247,600
2025		255,000
2026		262,700
Thereafter		609,600
Total future minimum payments		1,768,500
Less imputed interest		(256,100	)
Total Present Value of Operating Lease Liabilities	$	1,512,400

9. Discontinued Operations

Effective November 30, 2020, as part of its strategic shift to becoming a life sciences tool provider, the Company sold its operations relating to the manufacture and marketing of custom-made catalyst research instruments for universities, government laboratories, and chemical petrochemical companies sold on direct basis (the “Catalyst Research Instruments Operations”) through the sale by Altamira of substantially all of its assets and inventory to Beijing JWGB Sci. & Tech. Co. Ltd., a corporation formed under the laws of the People’s Republic of China (“JWGB”) for $440,000 which was fully paid in cash by January 2021, resulting in a $405,400 pre-tax loss. To preserve business continuity for the buyer, Altamira agreed to purchase certain components on behalf of JWGB for which JWGB agreed to reimburse Altamira. The Company retained all its receivables and payables related to sales made prior to November 30, 2020, certain inventory related to two work-in-process orders which have been shipped, product warranty and other miscellaneous liabilities related to certain employee benefits, and expenses related to the closure of the Altamira facility, which was completed at the end of December 2020.

Table of Contents

Assets:	March 31, 2022		June 30, 2021
Cash	$	600	$	-
Accounts receivable		-		52,000
Inventories		-		3,300

	$	600	$	55,300

Liabilities:	March 31, 2022		June 30, 2021
Accrued expenses and taxes	$	-	$	20,700
Contract liabilities		7,900		16,500

	$	7,900	$	37,200

	Three Months Ended					Nine Months Ended
	March 31,2022			March 31,2021		March 31,2022		March 31,2021
Revenues	$	-		$	107,800	$	20,600	$	387,700
Cost of goods sold		6,900			78,800		10,300		458,500
Gross profit (loss)		(6,900	)		29,000		10,300		(70,800	)
Selling, general and administrative expenses		700			12,600		2,900		282,200
Income (loss) from operations		(7,600	)		16,400		7,400		(353,000	)
Loss on disposal		-			-		-		(405,400	)
Income (loss) before income tax benefit		(7,600	)		16,400		7,400		(758,400	)
Income tax expense (benefit)		-			-		4,000		(179,900	)
Net income (loss) attributable to discontinued operations	$	(7,600	)	$	16,400	$	3,400	$	(578,500	)

In our Consolidated Statements of Cash Flows, the cash flows from discontinued operations are not separately classified. Cash provided by (used in) operating activities from discontinued operations for nine months ended March 31, 2022 and March 31, 2021 was $25,400 and $(502,900), respectively.

Cash provided by investing activities from discontinued operations for the nine months ended March 31, 2022 was none and $440,000 for the nine months ended March 31, 2021.

There was no cash provided by or used in financing activities for either period.

10. Acquisition of Aquila Biolabs GmbH

Effective April 29, 2021, the Company acquired all the outstanding capital stock of Aquila, a German start-up company engaged from its facility in Baesweiler, Germany in the design, production, and sale of bioprocessing systems and products which focus on the control and analysis of bioprocesses in bioreactors and incubation shakers for an aggregate purchase price of $7,880,100 in cash upon closing. Aquila’s principal customers are universities, pharmaceutical companies, and industrial companies. Aquila’s products are sold primarily on a direct basis and to a lesser extent, through distributors.

The acquisition was accounted for in accordance with ASC 805, Business Combinations (“ASC 805”) in which the Company is treated as the accounting acquirer. Accordingly, the assets acquired and liabilities assumed were measured at estimated fair value.

Table of Contents

Management of the Company allocated the purchase price based on its estimated valuation of the assets acquired and liabilities assumed as follows:

	Amount			Useful life
Fair value of assets acquired:
Current assets:
Cash and cash equivalents	$	201,100
Accounts receivable		159,200
Inventory		187,500
Prepaid expenses and other current assets		25,400
Property, plant and equipment		40,200
Deferred tax asset		800,300
Tradename		452,300		6 years
Non-compete agreements		784,500		4 years
In-process research and development		742,100		5 years
Customer relationships		252,200		9 years
Patents and other intangibles		286,200		7 years
Total assets acquired	$	3,931,000

Fair value of liabilities assumed:
Accounts payable	$	(39,300	)
Accrued expenses		(90,300	)
Other current liabilities		(59,400	)
Total liabilities assumed	$	(189,000	)

Total identifiable net assets	$	3,742,000
Fair value of consideration transferred		7,880,100
Goodwill	$	4,138,100

11. Paycheck Protection Program Loan

The Company received a second $433,800 PPP loan in March 2021, pursuant to the PPP loan administered by the U.S. Small Business Administration through its bank. The full amount of this loan was forgiven in December 2021, and is reflected as other income (extinguishment of debt) in the accompanying statements of operations and comprehensive loss.

12. Equity

Authorized Shares

On February 25, 2022, at the Company’s Annual Stockholders Meeting, the stockholders of the Company approved an amendment to its Certificate of Incorporation to increase the number of authorized shares of the Company’s common stock by 5,000,000 shares from 15,000,000 to 20,000,000 shares.

In addition, the stockholders also approved the adoption of the Company’s 2022 Equity Incentive Plan (“Plan”) providing for the issuance of up to 1,750,000 shares plus outstanding options granted under the Company’s 2012 Stock Option Plan that expire or are forfeited. The Plan provides various stock awards including incentive and nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, and other stock awards, which can be awarded to employees and directors of the Company and its subsidiaries.

Issuance and Sale of Common Stock

On March 2, 2022, the Company entered into a Securities Purchase Agreement with certain private investors pursuant to which the Company issued and sold an aggregate of 545,456 shares of common stock and warrants to purchase up to an additional 274,727 shares of common stock, at an offering price of $5.50 per share, for a gross consideration of $3,000,000. The issuance cost related to this private placement stock issuance amounted to approximately $272,800. Under the terms of Securities Purchase Agreement between the Company and the investors, the Company must use commercially reasonable efforts to file a registration statement with the SEC within 90 days of the closing date to register for resale the shares of common stock sold in the private offering, including the shares of common stock issuable upon the exercise of the warrants. As of March 31, 2022, the Company had not yet filed a registration statement with respect to the offering.

Table of Contents

818,183 Shares

Common Stock

PROSPECTUS

Table of Contents

PART II

INFORMATION NOT REQUIRED IN PROSPECTUS

ITEM 13.

OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION

Our estimated expenses in connection with the issuance and distribution of the securities being registered are:

SEC Registration Fee	$	380
Accounting Fees and Expenses	$	7,500
Legal Fees and Expenses	$	10,000
Miscellaneous Fees and Expenses	$	1,000

Total	$	18,880

ITEM 14.

INDEMNIFICATION OF OFFICERS AND DIRECTORS

Section 102(b)(7) of the Delaware General Corporation Law, or DGCL, provides that a corporation may, in its original certificate of incorporation or an amendment thereto, eliminate or limit the personal liability of a director for violations of the director’s fiduciary duty, except (1) for any breach of the director’s duty of loyalty to the corporation or its stockholders, (2) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (3) pursuant to Section 174 of the DGCL, which provides for liability of directors for unlawful payments of dividends or unlawful stock purchases or redemptions or (4) for any transaction from which a director derived an improper personal benefit.

Our amended certificate of incorporation as currently in effect provides for the indemnification of directors to the fullest extent permissible under Delaware law.

Our amended and restated bylaws as currently in effect provide for the indemnification of officers and directors acting on our behalf if this person acted in good faith and in a manner reasonably believed to be in and not opposed to our best interest, and, with respect to any criminal action or proceeding, the indemnified party had no reason to believe his or her conduct was unlawful.

In addition, we have entered into separate indemnification agreements with certain of our executive officers and directors. Such agreements may require us, among other things, to advance expenses and otherwise indemnify our executive officers and directors against certain liabilities that may arise by reason of their status or service as executive officers or directors, to the fullest extent permitted by law. We intend to enter into indemnification agreements with any new directors and executive officers in the future.

We have purchased and intend to maintain insurance on behalf of us and any person who is or was a director or officer against any loss arising from any claim asserted against him or her and incurred by him or her in that capacity, subject to certain exclusions and limits of the amount of coverage.

Table of Contents

ITEM 15.

RECENT SALES OF UNREGISTERED SECURITIES

The information regarding the Securities Purchase Agreements in “Description of Private Placements” is herein incorporated by reference. The securities issued pursuant to the Securities Purchase Agreements were issued pursuant to the exemption from registration provide by Section 4(a) (2) of the Securities Act.

Stock Options and Common Stock Issuances

Since July 1, 2021, the Company granted stock options under our 2012 Stock Option Plan to purchase an aggregate of 60,000 shares of our common stock at a weighted-average exercise price of $5.85 per share, to certain employees, consultants and directors. Of these, stock options to purchase an aggregate of 2,780 shares have been cancelled without being exercised. The Company granted stock options under our 2022 Stock Option plan to purchase an aggregate of 40,000 shares of our common stock at a weighted-average exercise price of $5.80 per share, to certain employees.

Securities Act Exemptions

We deemed the grants of stock options and issuances of common stock upon exercise of such options described above under “—Stock Options and Common Stock Issuances” to be exempt from registration under the Securities Act in reliance on Rule 701 of the Securities Act as offers and sales of securities under compensatory benefit plans and contracts relating to compensation in compliance with Rule 701. Each of the recipients of securities in any transaction exempt from registration either received or had adequate access, through employment, business or other relationships, to information about us.

All certificates representing the securities issued in the transactions described in this Item 15 included appropriate legends setting forth that the securities had not been offered or sold pursuant to a registration statement and describing the applicable restrictions on transfer of the securities. There were no underwriters employed in connection with any of the transactions set forth in this Item 15.

ITEM 16.

EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

Exhibit No.		Description
3(a)		Certificate of Incorporation of the Company as amended (incorporated by reference to Exhibit 1(a-1) to the Company's General Form for Registration of Securities on Form 10 filed with the SEC on February 14, 1973)
3(b)		Certificate of Amendment of the Company’s Certificate of Incorporation, as filed on January 28, 1985 (incorporated by reference to Exhibit 3(a) to the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 1985)
3(c)		By-Laws of the Company, as restated and amended (incorporated by reference to Exhibit 3(ii) to the Company’s Current Report on Form 8-K filed on January 6, 2003 and Exhibit 3(ii) to the Company’s Current Report on Form 8-K filed on December 5, 2007).
3(d)		Second Amended and Restated By-Laws of Scientific Industries, Inc. (filed as Exhibit 3.2 to the Company’s Current Report on Form 8-K filed on August 10, 2020 and incorporated by reference thereto).
3(e)		Certificate of Amendment of the Company’s Certificate of Incorporation, as filed on June 21, 2021 (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on June 21, 2021).
4.1		Specimen Common Stock certificate of Scientific Industries, Inc. (incorporated by reference to Exhibit 4.1 to the registrant’s Registration Statement on Form S-1, as amended (File No. 333-188209)).
4.2		Form of Warrants issued by the Company on June 18, 2020 to the Purchasers listed in that certain Securities Purchase Agreement dated as of June 18, 2020 (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed with the SEC on June 19, 2020)
4.3		Form of Warrants issued by the Company on April 29, 2021 to the Purchasers listed in that certain Securities Purchase Agreement dated as of April 28, 2021 (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed with the SEC on April 30, 2021)
4.4		Form of Warrants issued by the Company on June 18, 2021 to the Purchasers listed in that certain Securities Purchase Agreement dated as of June 18, 2021(incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed with the SEC on June 21, 2021)
4.5		Form of Warrants issued by the Company on March 2, 2022 to the Purchasers listed in that certain Securities Purchase Agreement dated as of March 2, 2022 (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed with the SEC on March 2, 2022)
4.6		Registration Rights Agreement, dated as of April 29, 2021, by and among the Company and the Investors named therein (incorporated by reference to Exhibit 4.2 to the Company’s Current Report on Form 8-K filed with the SEC on April 30, 2021)

Table of Contents

4.7		Amendment No. 1 to Registration Rights Agreement, dated as of June 18, 2021, by and among the Company and the Investors named therein (incorporated by reference to Exhibit 4.1A to the Company’s Current Report on Form 8-K filed with the SEC on June 19, 2020)
4.8		Registration Rights Agreement, dated as of March 2, 2022, by and among the Company and the Investors named therein (incorporated by reference to Exhibit 4.2 to the Company’s Current Report on Form 8-K filed with the SEC on March 2, 2022)
4.9		Form of Joinder Agreement (incorporated by reference to Exhibit 4.1B to the Company’s Current Report on Form 8-K filed with the SEC on June 21, 2021)
5.1		Opinion of Reitler Kailas & Rosenblatt LLP*
10.1		Securities Purchase Agreement, dated as of June 18, 2020, by and among the Company and the Purchasers named therein (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on June 19, 2020)
10.2		Securities Purchase Agreement, dated as of April 28, 20203 by and among the Company and the Purchasers named therein (incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K filed with the SEC on April 30, 2021)
10.3		Securities Purchase Agreement, dated as of June 18, 2021 by and among the Company and the Purchasers named therein (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on June 21, 2021)
10.4		Securities Purchase Agreement, dated as of March 2, 2022 by and among the Company and the Purchasers named therein (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on March 2, 2022)
23.1		Consent of Nussbaum Berg Klein & Wolpow, CPAs LLP**
23.2		Consent of Reitler Kailas & Rosenblatt LLP (included in Exhibit 5.1)*
24.1		Power of Attorney (included on the signature page of this Registration Statement)*
107		Filing Fee Table**

* To be filed by amendment

**Filed herewith

ITEM 17.

UNDERTAKINGS

The undersigned registrant hereby undertakes:

(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

(i) To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;

(ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Securities and Exchange Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and

(iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

(2) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

(4) That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A (§230.430A of this chapter), shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use.

Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act of 1933 and will be governed by the final adjudication of such issue.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-1 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Bohemia, State of New York, on this 27^th day of May 2022.

	SCIENTIFIC INDUSTRIES, INC.

	By:	/s/ Helena R. Santos
	Name:	Helena R. Santos
	Title:	President and Chief Executive Officer

KNOW ALL BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Helena R. Santos and John A. Moore, and each of them, his true and lawful agent, proxy and attorney-in-fact, with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to (i) act on, sign and file with the Securities and Exchange Commission any and all amendments (including post-effective amendments) to this registration statement together with all schedules and exhibits thereto and any subsequent registration statement filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended, together with all schedules and exhibits thereto, (ii) act on, sign and file such certificates, instruments, agreements and other documents as may be necessary or appropriate in connection therewith, (iii) act on and file any supplement to any prospectus included in this registration statement or any such amendment or any subsequent registration statement filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended and (iv) take any and all actions which may be necessary or appropriate to be done, as fully for all intents and purposes as he might or could do in person, hereby approving, ratifying and confirming all that such agent, proxy and attorney-in-fact or any of his substitutes may lawfully do or cause to be done by virtue thereof.

Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

Signature	Title	Date

/s/ Helena R. Santos	President, Chief Executive Officer, and Treasurer	May 27^th 2022
Helena R. Santos

/s/ Reginald Averilla	Chief Financial Officer	May 27^th 2022
Reginald Averilla

/s/ John A. Moore	Chairman of the Board	May 27^th 2022
John A. Moore

/s/ Joseph G. Cremonese	Director	May 27^th 2022
Joseph G. Cremonese

/s/ Marcus Frampton	Director	May 27^th 2022
Marcus Frampton

/s/ Christopher Cox	Director	May 27^th 2022
Christopher Cox

/s/ Dr. Juergen Schumacher	Director	May 27^th 2022
Dr. Juergen Schumacher

EX-23.1 2 scnd_ex231.htm EX-23.1 scnd_ex231.htm

EXHIBIT 23.1

Consent of Independent Registered Public Accounting Firm

We consent to the use in this Registration Statement on Form S-1 of Scientific Industries, Inc. and Subsidiaries of our report dated October 14, 2021, relating to the consolidated financial statements of Scientific Industries, Inc. and Subsidiaries as of and for the years ended June 30, 2021 and 2020, appearing in the Prospectus, which is part of this Registration Statement.

We also consent to the reference to our firm under the heading "Experts" in such Prospectus.

Nussbaum Berg Klein & Wolpow, CPAs LLP

/s/ Nussbaum Berg Klein & Wolpow, CPAs LLP

Melville, New York

May 27, 2022

EX-FILING FEES 3 scnd_ex107.htm FILING FEE TABLE scnd_ex107.htm

EXHIBIT 107

Calculation of Filing Fee Tables

Form S-1

(Form Type)

Scientific Industries, Inc.

(Exact Name of Registrant as Specified in its Charter)

Table 1: Newly Registered and Carry Forward Securities]

	Security Type	Security Class Title	Fee Calculation or Carry Forward Rule			Amount Registered		Proposed Maximum Ofering Price Per Unit (1)		Proposed Maximum Aggregate Offering Price		Fee Rate		Amount of Registration Fee
Fees to be Paid	Equity	common stock		457	(c)		818,183	$	5.00		4,090,915		0.0000928888	$	380
		Total Offering Amounts									4,090,915			$	380
		Total Fees Previously Paid													0
		Total Fee Offsets													0
		Net Fee Due												$	380

(1) Estimated solely for purposes of calculating the registration fee pursuant to Rule 457(c) under the Securities Act, based on average of bid and asked price per share of the common stock as reported on the Over-the-Counter Bulletin Board on May 23, 2022.

EX-101.SCH 4 scnd-20220331.xsd XBRL TAXONOMY EXTENSION SCHEMA 000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS link:presentationLink link:calculationLink link:definitionLink 000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS EQUITY link:presentationLink link:calculationLink link:definitionLink 000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 000007 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 000008 - Disclosure - Revenue link:presentationLink link:calculationLink link:definitionLink 000009 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 000010 - Disclosure - Fair Value of Financial Instruments link:presentationLink link:calculationLink link:definitionLink 000011 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 000012 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 000013 - Disclosure - Goodwill and Other Intangible Assets link:presentationLink link:calculationLink link:definitionLink 000014 - Disclosure - Lines of Credit link:presentationLink link:calculationLink link:definitionLink 000015 - Disclosure - Payroll Protection Program Loan link:presentationLink link:calculationLink link:definitionLink 000016 - Disclosure - Loss Per Common Share link:presentationLink link:calculationLink link:definitionLink 000017 - Disclosure - Employee Benefit Plans link:presentationLink link:calculationLink link:definitionLink 000018 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 000019 - Disclosure - Discontinued Operations link:presentationLink link:calculationLink link:definitionLink 000020 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 000021 - Disclosure - Acquisition of Aquila Biolabs GmbH link:presentationLink link:calculationLink link:definitionLink 000022 - Disclosure - Paycheck Protection Program Loan link:presentationLink link:calculationLink link:definitionLink 000023 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 000024 - Disclosure - Stock Options link:presentationLink link:calculationLink link:definitionLink 000025 - Disclosure - Equity link:presentationLink link:calculationLink link:definitionLink 000026 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 000027 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 000028 - Disclosure - Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 000029 - Disclosure - Segment Information and Concentrations (Tables) link:presentationLink link:calculationLink link:definitionLink 000030 - Disclosure - Fair Value of Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 000031 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 000032 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 000033 - Disclosure - Goodwill and Other Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 000034 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 000035 - Disclosure - Earnings (Loss) Per Common Share (Tables) link:presentationLink link:calculationLink link:definitionLink 000036 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 000037 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 000038 - Disclosure - Stock Options (Tables) link:presentationLink link:calculationLink link:definitionLink 000039 - Disclosure - Discontinued Operations (Tables) link:presentationLink link:calculationLink link:definitionLink 000040 - Disclosure - Acquisition of Aquila Biolabs GmbH (Tables) link:presentationLink link:calculationLink link:definitionLink 000041 - Disclosure - Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 000042 - Disclosure - Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000043 - Disclosure - Revenues (Details) link:presentationLink link:calculationLink link:definitionLink 000044 - Disclosure - Revenues (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000045 - Disclosure - Segment Information and Concentrations (Details) link:presentationLink link:calculationLink link:definitionLink 000046 - Disclosure - Segment Information and Concentrations (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000047 - Disclosure - Fair Value of Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 000048 - Disclosure - Fair Value of Financial Instruments (Details 1) link:presentationLink link:calculationLink link:definitionLink 000049 - Disclosure - Fair Value of Financial Instruments (Details 2) link:presentationLink link:calculationLink link:definitionLink 000050 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 000051 - Disclosure - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 000052 - Disclosure - Property and Equipment (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000053 - Disclosure - Goodwill and Finite Lived Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 000054 - Disclosure - Goodwill and Finite Lived Intangible Assets (Details 1) link:presentationLink link:calculationLink link:definitionLink 000055 - Disclosure - Goodwill and Finite Lived Intangible Assets (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000056 - Disclosure - Loss Per Common Share (Details) link:presentationLink link:calculationLink link:definitionLink 000057 - Disclosure - Loss Per Common Share (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000058 - Disclosure - Leases (Details) link:presentationLink link:calculationLink link:definitionLink 000059 - Disclosure - Leases (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000060 - Disclosure - Discontinued Operations (Details) link:presentationLink link:calculationLink link:definitionLink 000061 - Disclosure - Discontinued Operations (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000062 - Disclosure - Acquisition of Aquila Biolabs GmbH (Details) link:presentationLink link:calculationLink link:definitionLink 000063 - Disclosure - Acquisition of Aquila Biolabs GmbH (Details 1) link:presentationLink link:calculationLink link:definitionLink 000064 - Disclosure - Acquisition of Aquila Biolabs GmbH (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000065 - Disclosure - Paycheck Protection Program Loan (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000066 - Disclosure - Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000067 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 000068 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 000069 - Disclosure - Income Taxes (Details 1) link:presentationLink link:calculationLink link:definitionLink 000070 - Disclosure - Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 000071 - Disclosure - Stock Options (Details 1) link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 scnd-20220331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Amendment Flag Entity Small Business Entity Emerging Growth Company Entity Filer Category Entity Incorporation State Country Code Entity Tax Identification Number Entity Address Address Line 1 Entity Address Address Line 2 Entity Address City Or Town Entity Address State Or Province Entity Address Postal Zip Code City Area Code Local Phone Number CONDENSED CONSOLIDATED BALANCE SHEETS Current assets: Cash and cash equivalents Investment securities Trade accounts receivable, less allowance for doubtful accounts of $15,600 at March 31, 2022 and June 30, 2021 Inventories [Inventory, Net] Income tax receivable Prepaid expenses and other current assets Assets of discontinued operations Total current assets [Assets, Current] Property and equipment, net Goodwill Intangible assets, net Other intangible assets, net Deferred taxes Operating lease right-of-use assets Other assets Total assets [Assets] Current liabilities: Accounts payable Accrued expenses Contract liabilities Contingent consideration Bank overdraft Lease liabilities, current portion Paycheck Protection Program loan Liabilities of discontinued operations Total current liabilities [Liabilities, Current] Contingent consideration payable, less current portion Lease liabilities, less current portion Other long-term liabilities Total liabilities [Liabilities] Shareholders' equity: Common stock, $.05 par value; 20,000,000 and 15,000,000 shares authorized; 7,023,401 and 6,477,945 shares issued; 7,003,599 and 6,458,143 shares outstanding at March 31, 2022 and June 30, 2021 Additional paid-in capital Accumulated comprehensive loss Accumulated deficit Total [Stockholders' Equity before Treasury Stock] Less common stock held in treasury at cost, 19,802 shares Total shareholders' equity [Stockholders' Equity Attributable to Parent] Total liabilities and shareholders' equity [Liabilities and Equity] Allowance doubtful accounts Shareholders' equity: Common stock,par value Common stock, authorized shares Common stock, issued shares Common stock, outstanding shares Stock held in treasury, shares CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Revenues Cost of revenues Gross profit [Gross Profit] Operating expenses: General and administrative Selling Research and development Total operating expenses [Operating Expenses] Loss from operations [Operating Income (Loss)] Other income (expense): Other income (expense), net Interest income Total other income (expense), net [Total other income (expense), net] Loss from continuing operations before income tax benefit [Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest] Income tax benefit, current Income tax benefit, deferred Total Income tax benefit [Income Tax Expense (Benefit)] Loss from continuing operations Discontinued operations (Note 9): Gain (loss) from discontinued operations, net of tax Net loss [Net Income (Loss) Attributable to Parent] Comprehensive loss: Unrealized holding loss on investment securities, net of tax Foreign currency translation adjustment Comprehensive loss Total comprehensive loss [Other Comprehensive Income (Loss), before Reclassifications, Net of Tax] Basic loss per common share: Continuing operations Discontinued operations Consolidated operations CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS EQUITY Statement [Table] Statement [Line Items] Equity Components [Axis] Common Stock Treasury Stock Additional Paid-In Capital Accumulated Other Comprehensive Income (Loss) Accumulated Deficit Retained Earnings Balance, shares [Shares, Issued] Balance, amount Net loss Issuance of Common Stock and Warrants, net of issuance costs, shares Issuance of Common Stock and Warrants, net of issuance costs, amount Stock options exercised, shares Stock options exercised, amount Stock-based compensation Foreign currency translation adjustment Unrealized holding gain on investment securities, net of tax Balance, shares Balance, amount CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Operating activities: Net loss Adjustments to reconcile net loss to net cash used in operating activities: Loss/(Gain) on sale of investments Unrealized holding loss on investments Extinguishment of debt [Extinguishment of Debt, Amount] Depreciation and amortization Deferred income tax benefit Provision for bad debt Loss on disposal of subsidiary Gain on sale of fixed assets Stock-based compensation [Share-based Payment Arrangement, Noncash Expense] Change in fair value of contingent consideration Changes in operating assets and liabilities: Trade accounts receivable Inventories [Increase (Decrease) in Inventories] Carrying value of right of use assets Income tax receivable [Increase (Decrease) in Income Taxes Receivable] Prepaid and other current assets Right-of-use assets Accounts payable [Increase (Decrease) in Accounts Payable] Contract liabilities [Increase (Decrease) in Customer Advances] Lease liabilities Bank overdraft [Proceeds from (Repayments of) Bank Overdrafts] Other assets [Other assets] Discontinued operations [Discontinued Operation, Provision for Loss (Gain) on Disposal, Net of Tax] Accrued expenses [Increase (Decrease) in Accrued Liabilities] Other long-term liabilities [Increase (Decrease) in Other Noncurrent Liabilities] Total adjustments Net cash used in operating activities [Net Cash Provided by (Used in) Operating Activities] Investing activities: Redemption of investment securities Purchase of investment securities [Payments to Acquire Available-for-sale Securities] Proceeds from sale of fixed assets Proceeds from sale of assets of discontinued operations Capital expenditures [Payments to Acquire Property, Plant, and Equipment] Proceeds from sale Altamaria Purchase of Aquila, net of cash acquired Purchase of other intangible assets [Payments to Acquire Intangible Assets] Net cash used in investing activities [Net Cash Provided by (Used in) Investing Activities] Financing activities: Repayment of 1st Payroll Protection Plan loan [Repayments of Notes Payable] Proceeds from issuance of common stock Issuance of common stock and warrants, net of issuance costs Issuance costs of common stock and warrants [Issuance costs of common stock and warrants] Payments of contingent consideration Proceeds from Payroll Protection Program Proceeds from stock options exercised Net cash provided by financing activities [Net Cash Provided by (Used in) Financing Activities] Effect of changes in foreign currency exchange rates Net decrease in cash and cash equivalents [Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect] Cash and cash equivalents, beginning of year Cash and cash equivalents, end of period SUPPLEMENTAL DISCLOSURES Income taxes Record right-of-use assets Record lease liabilities Summary of Significant Accounting Policies Summary of Significant Accounting Policies EX-101.CAL 6 scnd-20220331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.PRE 7 scnd-20220331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EX-101.DEF 8 scnd-20220331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE GRAPHIC 9 scnd_s1img1.jpg begin 644 scnd_s1img1.jpg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end XML 10 R1.htm IDEA: XBRL DOCUMENT v3.22.1

Cover
9 Months Ended

Mar. 31, 2022

Cover [Abstract]

Entity Registrant Name SCIENTIFIC INDUSTRIES, INC.

Entity Central Index Key 0000087802

Document Type S-1

Amendment Flag false

Entity Small Business true

Entity Emerging Growth Company false

Entity Filer Category Non-accelerated Filer

Entity Incorporation State Country Code DE

Entity Tax Identification Number 04-2217279

Entity Address Address Line 1 80 Orville Drive

Entity Address Address Line 2 Suite 102

Entity Address City Or Town Bohemia

Entity Address State Or Province NY

Entity Address Postal Zip Code 11716

City Area Code 631

Local Phone Number 567-4700

X

- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Area code of city
+ References
No definition available.
+ Details

Name: dei_CityAreaCode

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Cover page.
+ References
No definition available.
+ Details

Name: dei_CoverAbstract

Namespace Prefix: dei_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details

Name: dei_EntityAddressAddressLine1

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Address Line 2 such as Street or Suite number
+ References
No definition available.
+ Details

Name: dei_EntityAddressAddressLine2

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Name of the City or Town
+ References
No definition available.
+ Details

Name: dei_EntityAddressCityOrTown

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details

Name: dei_EntityAddressPostalZipCode

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Name of the state or province.
+ References
No definition available.
+ Details

Name: dei_EntityAddressStateOrProvince

Namespace Prefix: dei_

Data Type: dei:stateOrProvinceItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityEmergingGrowthCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details

Name: dei_EntityIncorporationStateCountryCode

Namespace Prefix: dei_

Data Type: dei:edgarStateCountryItemType

Balance Type: na

Period Type: duration

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicates that the company is a Smaller Reporting Company (SRC).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntitySmallBusiness

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityTaxIdentificationNumber

Namespace Prefix: dei_

Data Type: dei:employerIdItemType

Balance Type: na

Period Type: duration

X

- Definition
Local phone number for entity.
+ References
No definition available.
+ Details

Name: dei_LocalPhoneNumber

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

XML 11 R2.htm IDEA: XBRL DOCUMENT v3.22.1

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)

Mar. 31, 2022

Jun. 30, 2021

Jun. 30, 2020

Current assets:

Cash and cash equivalents $ 4,068,000 $ 9,675,200 $ 7,559,700

Investment securities 7,768,600 3,744,600 331,800

Trade accounts receivable, less allowance for doubtful accounts of $15,600 at March 31, 2022 and June 30, 2021 1,712,900 1,294,700 1,064,000

Inventories 4,367,900 2,977,100 2,541,000

Income tax receivable 161,100 333,300 334,800

Prepaid expenses and other current assets 312,800 350,900 112,400

Assets of discontinued operations 600 55,300 793,000

Total current assets 18,391,900 18,431,100 12,736,700

Property and equipment, net 566,900 412,600 278,300

Goodwill 4,395,400 4,395,400 257,300

Intangible assets, net 2,216,300 2,557,800 128,700

Other intangible assets, net 2,216,300 2,557,800

Deferred taxes 3,445,300 2,489,900 537,100

Operating lease right-of-use assets 1,448,600 665,300 803,300

Other assets 62,400 54,300 56,000

Total assets 30,526,800 29,006,400 14,797,400

Current liabilities:

Accounts payable 1,051,100 453,500 334,600

Accrued expenses 661,100 633,500 679,000

Contract liabilities 0 20,000

Contingent consideration 117,500 136,600 111,000

Bank overdraft 40,600 321,700 43,100

Lease liabilities, current portion 124,300 270,500 195,800

Paycheck Protection Program loan 0 433,800 563,800

Liabilities of discontinued operations 7,900 37,200 240,900

Total current liabilities 2,002,500 2,286,800 2,188,200

Contingent consideration payable, less current portion 0 23,400 247,000

Lease liabilities, less current portion 1,388,100 460,500 640,800

Other long-term liabilities 0 10,900 0

Total liabilities 3,390,600 2,781,600 3,076,000

Shareholders' equity:

Common stock, $.05 par value; 20,000,000 and 15,000,000 shares authorized; 7,023,401 and 6,477,945 shares issued; 7,003,599 and 6,458,143 shares outstanding at March 31, 2022 and June 30, 2021 351,200 324,000 144,100

Additional paid-in capital 31,233,600 26,613,500 8,608,300

Accumulated comprehensive loss (104,800) (9,200) 0

Accumulated deficit (4,291,400) (651,100) 3,021,400

Total 27,188,600 26,277,200 11,773,800

Less common stock held in treasury at cost, 19,802 shares 52,400 52,400 52,400

Total shareholders' equity 27,136,200 26,224,800 11,721,400

Total liabilities and shareholders' equity $ 30,526,800 $ 29,006,400 $ 14,797,400

X

- References
No definition available.
+ Details

Name: scnd_ContingentConsiderationPayableCurrent

Namespace Prefix: scnd_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: scnd_ContingentConsiderationPayableLessCurrentPortion

Namespace Prefix: scnd_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: scnd_DeferredTaxAssetNetNoncurrent

Namespace Prefix: scnd_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: scnd_PaycheckProtectionProgramLoan

Namespace Prefix: scnd_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766
+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522
+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(4))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(3))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14A
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(ii)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580
+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(1))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_AdditionalPaidInCapitalCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599
+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.9)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756
+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=123351718&loc=d3e2473-110228

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230
+ Details

Name: us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of investment in debt and equity securities categorized neither as trading securities nor held-to-maturity securities and intended be sold or mature one year or operating cycle, if longer.
+ References
No definition available.
+ Details

Name: us-gaap_AvailableForSaleSecuritiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of payments made in excess of existing cash balances, which will be honored by the bank but reflected as a loan to the entity. Overdrafts generally have a very short time frame for correction or repayment and are therefore more similar to short-term bank financing than trade financing.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=99376301&loc=d3e1243-112600

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_BankOverdrafts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The current portion of prepayments received from customers for goods or services to be provided in the future.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CustomerAdvancesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(10)(1))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266
+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying amount as of the balance sheet date of income taxes previously overpaid to tax authorities (such as U.S. Federal, state and local tax authorities) representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes. Also called income tax refund receivable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(8))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(10))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910
+ Details

Name: us-gaap_IncomeTaxReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19-26)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756
+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(23))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(25))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(32))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612
+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.21)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=123351718&loc=d3e2473-110228

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760
+ Details

Name: us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiabilityCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiabilityNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's right to use underlying asset under operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseRightOfUseAsset

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of noncurrent assets classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.17)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other.
+ References
No definition available.
+ Details

Name: us-gaap_OtherIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.24)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(7))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(8))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 360
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (g)(2)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(i)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total amount of stockholders' equity (deficit) items including stock value, paid in capital, retained earnings and including equity attributable to noncontrolling interests and before deducting the carrying value of treasury stock.
+ References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityBeforeTreasuryStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29,30)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655
+ Details

Name: us-gaap_TreasuryStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 12 R3.htm IDEA: XBRL DOCUMENT v3.22.1

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)

Mar. 31, 2022

Jun. 30, 2021

Jun. 30, 2020

CONDENSED CONSOLIDATED BALANCE SHEETS

Allowance doubtful accounts $ 15,600 $ 15,600 $ 11,600

Shareholders' equity:

Common stock,par value $ 0.05 $ 0.05 $ 0.05

Common stock, authorized shares 20,000,000 15,000,000 15,000,000

Common stock, issued shares 7,023,401 6,477,945 2,881,065

Common stock, outstanding shares 7,003,599 6,458,143 2,861,263

Stock held in treasury, shares 19,802 19,802 19,802

X

- Definition
Amount of allowance for credit loss on accounts receivable, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(4)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 20
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446
+ Details

Name: us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfFinancialPositionAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29,30)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655
+ Details

Name: us-gaap_TreasuryStockShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

XML 13 R4.htm IDEA: XBRL DOCUMENT v3.22.1

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended

Mar. 31, 2022

Mar. 31, 2021

Mar. 31, 2022

Mar. 31, 2021

Jun. 30, 2021

Jun. 30, 2020

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

Revenues $ 2,864,900 $ 2,508,600 $ 8,623,500 $ 7,245,100 $ 9,775,200 $ 7,784,400

Cost of revenues 1,318,300 1,145,700 4,154,600 3,419,400 4,799,800 3,847,000

Gross profit 1,546,600 1,362,900 4,468,900 3,825,700 4,975,400 3,937,400

Operating expenses:

General and administrative 1,610,400 1,385,600 4,442,300 2,441,700 4,028,500 2,275,400

Selling 1,054,000 1,386,100 2,996,800 2,658,900 4,031,900 1,185,800

Research and development 624,500 450,000 2,141,300 1,024,000 1,623,800 1,139,700

Total operating expenses 3,288,900 3,221,700 9,580,400 6,124,600 9,684,200 4,600,900

Loss from operations (1,742,300) (1,858,800) (5,111,500) (2,298,900) (4,708,800) (663,500)

Other income (expense):

Other income (expense), net (102,700) 6,100 363,500 22,300 571,600 12,600

Interest income 400 22,500 49,800 71,400 82,200 16,500

Total other income (expense), net (102,300) 28,600 413,300 93,700 653,800 (3,900)

Loss from continuing operations before income tax benefit (1,844,600) (1,830,200) (4,698,200) (2,205,200) (4,055,000) (667,400)

Income tax benefit, current (95,100) 0 (95,100) 0

Income tax benefit, deferred (222,100) (378,200) (959,400) (472,300) (945,000) (214,000)

Total Income tax benefit (317,200) (378,200) (1,054,500) (472,300) (1,152,500) (436,600)

Loss from continuing operations (1,527,400) (1,452,000) (3,643,700) (1,732,900) (3,110,000) (453,400)

Discontinued operations (Note 9):

Gain (loss) from discontinued operations, net of tax (7,600) 16,400 3,400 (578,500) (562,500) (249,900)

Net loss (1,535,000) (1,435,600) (3,640,300) (2,311,400) (3,672,500) (703,300)

Comprehensive loss:

Unrealized holding loss on investment securities, net of tax (4,700) 0 (5,100) 0

Foreign currency translation adjustment (194,500) 0 (90,500) 0 (9,200)

Comprehensive loss (199,200) 0 (95,600) 0

Total comprehensive loss $ (1,734,200) $ (1,435,600) $ (3,735,900) $ (2,311,400) $ (3,681,700) $ (703,300)

Basic loss per common share:

Continuing operations $ (0.23) $ (0.51) $ (0.56) $ (0.61) $ (0.97) $ (0.30)

Discontinued operations (0.00) 0.01 0.00 (0.20) (0.18) (0.16)

Consolidated operations $ (0.23) $ (0.50) $ (0.56) $ (0.81) $ (1.15) $ (0.46)

X

- References
No definition available.
+ Details

Name: scnd_ComprehensiveGain

Namespace Prefix: scnd_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: scnd_EarningPerShareBasicAndDiluted

Namespace Prefix: scnd_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: scnd_NonoperatingIncomeExpensenet

Namespace Prefix: scnd_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: scnd_UnrealizedHoldingLossOnInvestmentSecuritiesNetOfTax

Namespace Prefix: scnd_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate cost of goods produced and sold and services rendered during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2)
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756
+ Details

Name: us-gaap_CostOfRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.Fact.1)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(1)(Note 1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.Fact.2)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319
+ Details

Name: us-gaap_DeferredIncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of other deferred income tax expense (benefit) pertaining to income (loss) from continuing operations. For example, but not limited to, acquisition-date income tax benefits or expenses recognized from changes in the acquirer's valuation allowance for its previously existing deferred tax assets resulting from a business combination and adjustments to beginning-of-year balance of a valuation allowance because of a change in circumstance causing a change in judgment about the realizability of the related deferred tax asset in future periods.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(1)(Note 1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.7)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817
+ Details

Name: us-gaap_DeferredOtherTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareBasicAndDilutedAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227
+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1,2)
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599
+ Details

Name: us-gaap_GrossProfit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax of income (loss) from continuing operations attributable to the parent.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=123454820&loc=SL4613673-111683

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.13)
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794
+ Details

Name: us-gaap_IncomeLossFromContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 940
-SubTopic 20
-Section 25
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(8))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260
+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(11))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(20))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-03(13))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868656-224227

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794
+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsPerBasicShare

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 3B
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759
+ Details

Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(12))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(14))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227
+ Details

Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeStatementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.7)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(9))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).
+ References
No definition available.
+ Details

Name: us-gaap_InterestAndOtherIncome

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax, before reclassification adjustments of other comprehensive income (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14A
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 10A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossTaxAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OtherNonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.
+ References
No definition available.
+ Details

Name: us-gaap_OtherOperatingIncomeExpenseNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 912
-SubTopic 730
-Section 25
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227
+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Expenses recognized in the period that are directly related to the selling and distribution of products or services.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227
+ Details

Name: us-gaap_SellingExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 14 R5.htm IDEA: XBRL DOCUMENT v3.22.1

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS EQUITY - USD ($)

Total

Common Stock

Treasury Stock

Additional Paid-In Capital

Accumulated Other Comprehensive Income (Loss)

Accumulated Deficit Retained Earnings

Balance, shares at Jun. 30, 2019 1,513,914 19,802

Balance, amount at Jun. 30, 2019 $ 6,340,700 $ 75,700 $ 52,400 $ 2,592,700 $ 3,724,700

Net loss (703,300) (703,300)

Issuance of Common Stock and Warrants, net of issuance costs, shares 1,349,850

Issuance of Common Stock and Warrants, net of issuance costs, amount 6,004,400 $ 67,500 5,936,900

Stock options exercised, shares 17,301

Stock options exercised, amount 13,800 $ 900 12,900

Stock-based compensation 65,800 65,800

Unrealized holding gain on investment securities, net of tax 12,400

Balance, shares at Jun. 30, 2020 2,881,065 19,802

Balance, amount at Jun. 30, 2020 11,721,400 $ 144,100 $ 52,400 8,608,300 3,021,400

Net loss (2,311,400)

Foreign currency translation adjustment 0

Unrealized holding gain on investment securities, net of tax 18,900

Balance, shares at Mar. 31, 2021 2,882,065 19,802

Balance, amount at Mar. 31, 2021 10,842,400 $ 144,200 $ 52,400 10,040,600 710,000

Balance, shares at Jun. 30, 2020 2,881,065 19,802

Balance, amount at Jun. 30, 2020 11,721,400 $ 144,100 $ 52,400 8,608,300 3,021,400

Net loss (3,672,500) 0 $ 0 (3,672,500)

Issuance of Common Stock and Warrants, net of issuance costs, shares 3,595,880

Issuance of Common Stock and Warrants, net of issuance costs, amount 16,074,000 $ 179,800 0 15,894,200 0

Stock options exercised, shares 1,000

Stock options exercised, amount 3,100 $ 100 0 3,000 0

Stock-based compensation 2,108,000 0 0 2,108,000 0

Foreign currency translation adjustment (9,200) $ 0 $ 0 0 (9,200) 0

Unrealized holding gain on investment securities, net of tax 10,400

Balance, shares at Jun. 30, 2021 6,477,945 19,802

Balance, amount at Jun. 30, 2021 26,224,800 $ 324,000 $ 52,400 26,613,500 (9,200) (651,100)

Balance, shares at Jul. 01, 2020 2,881,065 19,802

Balance, amount at Jul. 01, 2020 11,721,400 $ 144,100 $ 52,400 8,608,300 3,021,400

Net loss (263,300) (263,300)

Stock-based compensation 61,300 61,300

Balance, shares at Sep. 30, 2020 2,881,065 19,802

Balance, amount at Sep. 30, 2020 11,519,400 $ 144,100 $ 52,400 8,669,600 2,758,100

Net loss (612,500) (612,500)

Stock-based compensation 76,100 76,100

Balance, shares at Dec. 31, 2020 2,881,065 19,802

Balance, amount at Dec. 31, 2020 10,983,000 $ 144,100 $ 52,400 8,745,700 2,145,600

Net loss (1,435,600) (1,435,600)

Stock options exercised, shares 1,000

Stock options exercised, amount 3,000 $ 100 2,900

Stock-based compensation 1,292,000 1,292,000

Foreign currency translation adjustment 0

Balance, shares at Mar. 31, 2021 2,882,065 19,802

Balance, amount at Mar. 31, 2021 10,842,400 $ 144,200 $ 52,400 10,040,600 710,000

Balance, shares at Jun. 30, 2021 6,477,945 19,802

Balance, amount at Jun. 30, 2021 26,224,800 $ 324,000 $ 52,400 26,613,500 (9,200) (651,100)

Net loss (3,640,300)

Foreign currency translation adjustment (90,500)

Unrealized holding gain on investment securities, net of tax 102,800

Balance, shares at Mar. 31, 2022 7,023,401 19,802

Balance, amount at Mar. 31, 2022 27,136,200 $ 351,200 $ 52,400 31,233,600 (104,800) (4,291,400)

Balance, shares at Jul. 01, 2021 6,477,945 19,802

Balance, amount at Jul. 01, 2021 26,224,800 $ 324,000 $ 52,400 26,613,500 (9,200) (651,100)

Net loss (1,208,800) 0 0 0 0 (1,208,800)

Stock-based compensation 675,400 0 0 675,400 0 0

Foreign currency translation adjustment 34,100 0 0 0 34,100 0

Unrealized holding gain on investment securities, net of tax 2,200 $ 0 $ 0 0 2,200 0

Balance, shares at Sep. 30, 2021 6,477,945 19,802

Balance, amount at Sep. 30, 2021 25,727,700 $ 324,000 $ 52,400 27,288,900 27,100 (1,859,900)

Net loss (896,500) 0 0 0 0 (896,500)

Stock-based compensation 591,000 0 0 591,000 0 0

Foreign currency translation adjustment 69,900 0 0 0 69,900 0

Unrealized holding gain on investment securities, net of tax (2,600) $ 0 $ 0 0 (2,600) 0

Balance, shares at Dec. 31, 2021 6,477,945 19,802

Balance, amount at Dec. 31, 2021 25,489,500 $ 324,000 $ 52,400 27,879,900 94,400 (2,756,400)

Net loss (1,535,000) $ 0 0 0 0 (1,535,000)

Issuance of Common Stock and Warrants, net of issuance costs, shares 545,456

Issuance of Common Stock and Warrants, net of issuance costs, amount 2,727,200 $ 27,200 0 2,700,000 0 0

Stock-based compensation 653,700 0 0 653,700 0 0

Foreign currency translation adjustment (194,500) 0 0 (194,500) 0

Unrealized holding gain on investment securities, net of tax (4,700) $ 0 $ 0 0 (4,700) 0

Balance, shares at Mar. 31, 2022 7,023,401 19,802

Balance, amount at Mar. 31, 2022 $ 27,136,200 $ 351,200 $ 52,400 $ 31,233,600 $ (104,800) $ (4,291,400)

X

- Definition
Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 20
-Section 55
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 20
-Section 55
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899
+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 10A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644
+ Details

Name: us-gaap_SharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(2)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Value of stock issued as a result of the exercise of stock options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of unrealized gain (loss) on investment.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585
+ Details

Name: us-gaap_UnrealizedGainLossOnInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 15 R6.htm IDEA: XBRL DOCUMENT v3.22.1

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
9 Months Ended 12 Months Ended

Mar. 31, 2022

Mar. 31, 2021

Jun. 30, 2021

Jun. 30, 2020

Operating activities:

Net loss $ (3,640,300) $ (2,311,400) $ (3,672,500) $ (703,300)

Adjustments to reconcile net loss to net cash used in operating activities:

Loss/(Gain) on sale of investments 11,100 (34,600) (35,600) (4,400)

Unrealized holding loss on investments 102,800 18,900 10,400 12,400

Extinguishment of debt (433,800) 0 (531,100)

Depreciation and amortization 581,800 126,700 251,500 160,900

Deferred income tax benefit (955,400) (652,300) (1,152,500) (106,000)

Provision for bad debt 4,000 3,400

Loss on disposal of subsidiary 0 405,400 405,400

Gain on sale of fixed assets (300)

Stock-based compensation 1,920,100 1,429,400 2,108,000 65,800

Change in fair value of contingent consideration (42,500) (118,500) (30,000) 112,600

Changes in operating assets and liabilities:

Trade accounts receivable (328,700) (758,500) (75,500) 906,800

Inventories (1,383,900) (697,700) (560,000) (292,400)

Carrying value of right of use assets 783,300 87,700

Income tax receivable 172,200 (1,500) 1,500 (334,800)

Prepaid and other current assets (127,700) 57,400 (211,400) (22,400)

Right-of-use assets 138,000 (803,300)

Accounts payable 585,500 142,600 79,600 (214,400)

Contract liabilities 796,100 (20,000) (20,000) 89,000

Lease liabilities 0 (51,000) (105,600) 867,700

Bank overdraft (281,100) 7,500 278,600 (96,900)

Other assets 107,100 0

Discontinued operations 25,400 0

Accrued expenses (20,700) (222,600) (195,200) 191,500

Other long-term liabilities 10,900 0

Total adjustments (55,000) (281,100) 371,000 535,200

Net cash used in operating activities (3,695,300) (2,592,500) (3,301,500) (168,100)

Investing activities:

Redemption of investment securities 1,278,500 1,631,000 6,181,400 55,000

Purchase of investment securities (5,422,700) (6,609,200) (9,569,000) (63,400)

Proceeds from sale of fixed assets 0 1,000

Proceeds from sale of assets of discontinued operations 0 440,000

Capital expenditures (337,400) (183,700) (198,700) (50,900)

Proceeds from sale Altamaria 440,000 0

Purchase of Aquila, net of cash acquired (7,679,000) 0

Purchase of other intangible assets (67,000) (41,200) (58,700) (25,800)

Net cash used in investing activities (4,548,600) (4,763,100) (10,884,000) (84,100)

Financing activities:

Repayment of 1st Payroll Protection Plan loan (32,700)

Proceeds from issuance of common stock $ 3,000,000 0

Issuance of common stock and warrants, net of issuance costs $ 17,080,400 6,004,400

Issuance costs of common stock and warrants (272,800) (1,006,400)

Payments of contingent consideration $ 0 (13,400) $ (168,000) (372,600)

Proceeds from Payroll Protection Program 0 433,800 433,800 563,800

Proceeds from stock options exercised 0 3,000 3,100 13,800

Net cash provided by financing activities 2,727,200 423,400 16,310,200 6,209,400

Effect of changes in foreign currency exchange rates (90,500) 0 (9,200)

Net decrease in cash and cash equivalents (5,607,200) (6,932,200) 2,115,500 5,957,200

Cash and cash equivalents, beginning of year 9,675,200 7,559,700 7,559,700 1,602,500

Cash and cash equivalents, end of period 4,068,000 627,500 9,675,200 7,559,700

SUPPLEMENTAL DISCLOSURES

Income taxes 0 2,500 $ 2,500 $ 40,900

Record right-of-use assets 941,300 0

Record lease liabilities $ 941,300 $ 0

X

- References
No definition available.
+ Details

Name: scnd_DeferredIncomeTaxExpenseBenefit1

Namespace Prefix: scnd_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: scnd_IncreaseDecreaseInLeaseLiabilities

Namespace Prefix: scnd_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: scnd_IncreaseDecreaseInOtherAssets

Namespace Prefix: scnd_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: scnd_IncreaseDecreaseInRightOfUseAssets

Namespace Prefix: scnd_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: scnd_IssuanceCostsOfCommonStockAndWarrants

Namespace Prefix: scnd_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: scnd_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts

Namespace Prefix: scnd_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Custom Element.
+ References
No definition available.
+ Details

Name: scnd_PaymentsOfContingentConsideration

Namespace Prefix: scnd_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: scnd_ProceedsFromSaleOfAssetsOfDiscontinuedOperations

Namespace Prefix: scnd_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: scnd_RecordLeaseLiabilitiesNonCashFinacingActivities

Namespace Prefix: scnd_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: scnd_RecordRightOfUseAssetsNonCashFinacingActivities

Namespace Prefix: scnd_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Custom Element.
+ References
No definition available.
+ Details

Name: scnd_RedemptionOfInvestmentSecuritiesAvailableForSale

Namespace Prefix: scnd_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: scnd_SupplementalDisclosureAbstract

Namespace Prefix: scnd_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The sum of adjustments which are added to or deducted from net income or loss, including the portion attributable to noncontrolling interest, to reflect cash provided by or used in operating activities, in accordance with the indirect cash flow method.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 230
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585
+ Details

Name: us-gaap_DepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4A
-Subparagraph (b)(1)
-URI http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959
+ Details

Name: us-gaap_DerivativeGainLossOnDerivativeNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 3B
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759
+ Details

Name: us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 230
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906
+ Details

Name: us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Gross amount of debt extinguished.
+ References
No definition available.
+ Details

Name: us-gaap_ExtinguishmentOfDebtAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585
+ Details

Name: us-gaap_GainLossOnSaleOfInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585
+ Details

Name: us-gaap_GainLossOnSaleOfPropertyPlantEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of gain (loss) on sale or disposal of assets utilized in financial service operations.
+ References
No definition available.
+ Details

Name: us-gaap_GainsLossesOnSalesOfAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585
+ Details

Name: us-gaap_IncomeTaxesPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the amount of prepayments by customers for goods or services to be provided at a later date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInCustomerAdvances

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInIncomeTaxesReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInInventories

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase (decrease) in noncurrent operating liabilities classified as other.
+ References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of amortization expense for right-of-use asset from operating lease.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585
+ Details

Name: us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash outflow to acquire debt and equity securities not classified as either held-to-maturity securities or trading securities which would be classified as available-for-sale securities and reported at fair value, with unrealized gains and losses excluded from earnings and reported in a separate component of shareholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (a),(b)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquireAvailableForSaleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquireIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow associated with principal collections from a borrowing supported by a written promise to pay an obligation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585
+ Details

Name: us-gaap_ProceedsFromCollectionOfNotesReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585
+ Details

Name: us-gaap_ProceedsFromDivestitureOfBusinesses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from the additional capital contribution to the entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The net cash inflow or outflow from the excess drawing from an existing cash balance, which will be honored by the bank but reflected as a loan to the drawer.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 9
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3098-108585
+ Details

Name: us-gaap_ProceedsFromRepaymentsOfBankOverdrafts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585
+ Details

Name: us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash inflow from exercise of option under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of expense related to estimated loss from loan and lease transactions.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04.11)
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 50
-Paragraph 11B
-Subparagraph (c)(2)
-URI http://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524
+ Details

Name: us-gaap_ProvisionForLoanAndLeaseLosses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash outflow for a borrowing supported by a written promise to pay an obligation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585
+ Details

Name: us-gaap_RepaymentsOfNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of noncash expense for share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585
+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of unrealized gain (loss) on investment.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585
+ Details

Name: us-gaap_UnrealizedGainLossOnInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 16 R7.htm IDEA: XBRL DOCUMENT v3.22.1

Summary of Significant Accounting Policies
9 Months Ended 12 Months Ended

Mar. 31, 2022

Jun. 30, 2021

Summary of Significant Accounting Policies

Summary of Significant Accounting Policies
1. Significant Accounting Policies

Principles of Consolidation

The accompanying consolidated financial statements include the accounts of Scientific Industries, Inc., its wholly- owned subsidiary, Scientific Bioprocessing Holdings, Inc. (“SBHI”), SBHI’s wholly-owned subsidiaries, Scientific Bioprocessing, Inc. (“SBI”), and aquila biolabs GmbH (“Aquila”), a German corporation, which was acquired on April 29, 2021, Scientific Packaging Industries, Inc., an inactive wholly-owned subsidiary, and Altamira Instruments, Inc. (“Altamira”), and wholly-owned subsidiary (accounted for as a discontinued operation as of November 30, 2020) (all collectively referred to as the “Company”). All material intercompany balances and transactions have been eliminated in consolidation.

COVID-19 Pandemic

The challenges posed by the COVID-19 pandemic on the global economy began to take effect and adversely affected the Company’s operations at the end of the third quarter of the fiscal year ended June 30, 2020. At that time, the Company took appropriate action and put plans in place to diminish the adverse effects of COVID-19 on its operations, enabling the Company to continue to operate with minor or temporary disruptions to its operations. The Company took immediate action pertaining to COVID-19 preparedness by implementing the US Center for Disease Control’s guidelines for employers in order to protect the Company’s employees’ health and safety, with actions such as implementing work from home, social distancing in the workplace, requiring self-quarantine for any employee showing symptoms, wearing face coverings, and training employees on maintaining a healthy work environment. The Company experienced supply chain disruptions which had an impact on its operations causing delayed delivery of some products to its customers, and production inefficiencies. SBI’s facility was shut down temporarily due to state mandates, however, the impact on operations was minimal, and the Company was able to retain its employees without furloughs or layoffs, in part, due to the Company’s receipt of two loans under the Federal Government’s Small Business Administration Paycheck Protection Program (“PPP”).

The Company received $563,800 and $433,800 in PPP loans in April 2020 and March 2021, respectively. The first loan was forgiven in June 2021 except for $32,700 which was repaid by the Company and the second loan was forgiven in full in December 2021. The Company elected to account for its PPP Loans in accordance with Accounting Standards Codification (“ASC”), Topic 470 Debt, with interest, if any, accrued in accordance with the interest method under ASC 835-30, Imputation of Interest. Initially, the Company recognized the entire loan amounts as liabilities on its balance sheets and remained as liabilities until either the Company was legally released from its obligations or paid the lender. Once the loans were forgiven, the amounts forgiven were recorded in the Company’s statement of operations as “Other Income.”

Adopted Accounting Pronouncements

In December 2019, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2019-12, “Simplifying the Accounting for Income Taxes”, which is designed to simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. ASU No. 2019-12 is effective for fiscal years beginning after December 15, 2020. The adoption of this standard as of July 1, 2021 did not have a material impact on the Company’s financial statements.

Recently Issued Accounting Pronouncements

The Company has implemented all new accounting pronouncements that are in effect and is evaluating any that may impact its financial statements. The Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

1. Summary of Significant Accounting Policies

Nature of Business

Scientific Industries, Inc. and its subsidiaries (the “Company”) design, manufacture, and market a variety of benchtop laboratory equipment and bioprocessing products. The Company is headquartered in Bohemia, New York where it produces benchtop laboratory equipment. Additionally, the Company has two other locations in Pittsburgh, Pennsylvania and Baesweiller, Germany, where it designs and produces a variety of bioprocessing products, and an administrative facility in Orangeburg, New York related to sales and marketing. The products, which are sold to customers worldwide, include mixers, shakers, stirrers, refrigerated incubators, pharmacy balances and scales, force gauges, bioprocessing-sensors and analytical tools. The Company also sublicenses certain patents and technology under a license agreement with the University of Maryland, Baltimore County, and receives royalty fees from sublicenses (see Note 1- Revenue Recognition).

COVID-19 Pandemic

The challenges posed by the COVID-19 pandemic on the global economy began to take effect and impacted the Company’s operations at the end of the third quarter of the year ended June 30, 2020. At that time, the Company took appropriate action and put plans in place to diminish the effects of COVID-19 on its operations, enabling the Company to continue to operate with minor or temporary disruptions to its operations. The Company took immediate action as it pertains to COVID-19 preparedness by implementing the Center for Disease Control’s guidelines for employers in order to protect the Company’s employees’ health and safety, with actions such as implementing work from home, social distancing in the workplace, requiring self-quarantine for any employee showing symptoms, wearing face coverings, and training employees on maintaining a healthy work environment. The Bioprocessing Systems Operations’ SBI facility was shut down temporarily due to state mandates, however, the impact on operations was immaterial, and the Company has been able to retain its employees without furloughs or layoffs, in part, due to the Company’ receipt of two loans under the Federal Government’s Small Business Administration Paycheck Protection Program. The Company received $563,800 and $433,800 in Payroll Protection Program loans in April 2020 and March 2021, respectively. The first loan was forgiven in June 2021 except for $32,700 which was repaid by the Company. The Company expects to apply and receive forgiveness for the second loan. The operations of aquila biolabs GmbH ("Aquila") which was acquired on April 29, 2021 was negatively impacted in its ability to secure new orders because Aquila had historically relied on face-to-face meetings at trade shows for its sales opportunities. While it has participated in virtual trade shows, management believes that certain sales opportunities are lost as a result. The Company has not experienced and does not anticipate any material impact on its ability to collect its accounts receivable due to the nature of its customers, which are primarily distributors of laboratory equipment and supplies which have benefitted from the Pandemic due to the nature of the products and have the ability to pay. The Company has not experienced and does not anticipate any material impairment to its tangible and intangible assets, system of internal controls, or delivery and distribution of its products as a result of COVID-19, however the ultimate impact of COVID-19 on the Company’s business, results of operations, financial condition and cash flows is dependent on future developments, including the duration or worsening of the pandemic and the related length of its impact on the global economy, which are uncertain and cannot be predicted at this time. The Company is currently experiencing some delays from its supply chain which is having an impact on delayed delivery of some products, however this is deemed temporary and does not affect the Company’s major product – the Vortex-Genie 2. In addition, due to the travel restrictions imposed by the United States and other governments worldwide, Company personnel may be restricted from traveling to conduct its operations including site visits, customer visits and installations, vendor facility visits, and other sales and marketing related travel that can negatively impact the Company.

Principles of Consolidation

The accompanying consolidated financial statements include the accounts of Scientific Industries, Inc., Scientific Packaging Industries, Inc., an inactive wholly-owned subsidiary, Altamira Instruments, Inc. (“Altamira”), a Delaware corporation and wholly-owned subsidiary (discontinued operation as of November 30, 2020), and Scientific Bioprocessing Holdings, Inc. (“SBHI”), a newly incorporated Delaware corporation and its wholly-owned subsidiaries, Scientific Bioprocessing, Inc. (“SBI”), a Delaware corporation, and Aquila, a German corporation, which was acquired on April 29, 2021, (all collectively referred to as the “Company”). On April 30, 2021 Scientific Industries, Inc. contributed 100% of the stock of Scientific Bioprocessing, Inc. to its wholly owned subsidiary Scientific Bioprocessing Holdings, Inc. All material intercompany balances and transactions have been eliminated in consolidation.
Revenue Recognition

The Company recognizes revenue in accordance with Financial Accounting Standards Board ('FASB") Accounting Standards Codification (“ASC”) Topic 606 “Revenue from Contracts with Customers, (“ASC 606”). In accordance with ASC 606, the Company accounts for a customer contract when both parties have approved the contract and are committed to perform their respective obligations, each party’s rights can be identified, payment terms can be identified, the contract has commercial substance, and it is probable that the Company will collect substantially all of the consideration to which it is entitled. Revenue is recognized when, or as, performance obligations are satisfied by transferring control of a promised product or service to a customer.

All of the Company's contracts have a single performance obligation. As permitted by ASC 606, the Company does not disclose the amount of unsatisfied performance obligations for client contracts with an original expected length of one year or less.

The Company determines revenue recognition through the following steps:

·
Identification of the contract, or contracts, with a customer

·
Identification of the performance obligations in the contract

·
Determination of the transaction price

·
Allocation of the transaction price to the performance obligations in the contract

·
Recognition of revenue when, or as, a performance obligation is satisfied

Nature of Products and Services

We generate revenues from the following sources: (1) Benchtop Laboratory Equipment and (2) Bioprocessing Systems.

Benchtop Laboratory Equipment

Bioprocessing
Systems

Consolidated

June 30, 2021:

Revenues

$ 9,043,600

731,600

$ 9,775,200

Foreign Sales

3,483,700

684,600

4,168,300

Benchtop Laboratory Equipment

Bioprocessing
Systems

Consolidated

June 30, 2020:

Revenues

$ 6,783,600

$ 1,000,800

$ 7,784,400

Foreign Sales

2,589,800

1,000,400

3,590,200

Benchtop laboratory equipment sales comprise primarily of standard benchtop laboratory equipment to laboratory equipment distributors, or to end users primarily via e-commerce. The sales cycle from time of receipt of order to shipment is very short varying from a day to a few weeks. Customers either pay by credit card (online sales) or Net 30-90, depending on the customer. Once the item is shipped under the FOB terms specified in the order, which is primarily “FOB Factory”, other than a standard warranty, there are no other obligations to the customer. Warranty usually comprises of one to two year parts and labor and is deemed immaterial. Revenue is recognized at a point in time when the risks and rewards of ownership have tranferred to the customer, which is generally upon shipment.

Bioprocessing revenues consist of royalty revenues generated through SBI and product revenues generated primarily through Aquila. Royalty revenues are earned by the Company under a licensing agreement from a single licensee and its sublicenses. The license agreement includes two United States patents and a European Union patent (through December 2019). In January 2020, the European Union patent which was due to expire in August 2020, was terminated and the Company will only receive royalties under the United States patents through December 2023, which will result in a material reduction in total royalties expected to be received. The Company is obligated to pay 50% of all royalties earned to the entity that licenses the intellectual property to the Company. Royalty revenue requires significant judgement in estimating royalty revenue to be recognized during the year.

The Company has made the following accounting policy elections and elected to use certain practical expedients, as permitted by the FASB, in applying ASC 606: 1) All revenues are recorded net of returns, allowances, customer discounts, and incentives; 2) Although sales and other taxes are immaterial, the Company accounts for amounts collected from customers for sales and other taxes, if any, net of related amounts remitted to tax authorities; 3) the Company expenses costs to obtain a contract as they are incurred if the expected period of benefit, and therefore the amortization period, is one year or less; 4) the Company accounts for shipping and handling activities that occur after control transfers to the customer as a fulfillment cost rather than an additional promised service and these fulfillment costs fall within selling expenses; 5) the Company is always considered the principal and never an agent, because it has full control and responsibility until title is transferred to the customer; 6) the Company does not assess whether promised goods or services are performance obligations if they are immaterial in the context of the contract with the customer such as is the case with catalyst instruments.
Cash and Cash Equivalents

The Company considers all highly liquid debt instruments purchased with original maturities of 90 days or less to be cash equivalents. At times, cash balances may be in excess of the Federal Deposit Insurance Corporation (“FDIC”) insurance limit. As of June 30, 2021, and 2020, $8,922,800 and $6,729,300 respectively of cash balances were in excess of such limit.

Reclasses

Certain amounts on the balance sheet as of June 30, 2021 and 2020 pertaining to inventories, property and equipment, goodwill, accounts payable, accrued expenses, contract liabilities, and operating leases liabilities were reclassed as assets and liabilities of discontinued operations due to the sale of the Company's wholly owned subsidiary, Altamira Instruments, Inc. on November 30, 2020.

Accounts Receivable

In order to record the Company’s accounts receivable at their net realizable value, the Company must assess their collectability. A considerable amount of judgment is required in order to make this assessment, including an analysis of historical bad debts and other adjustments, a review of the aging of the Company’s receivables, and the current creditworthiness of the Company’s customers. The Company has recorded allowances for receivables which it considered uncollectible, including amounts for the resolution of potential credit and other collection issues such as disputed invoices and customer satisfaction claims. However, depending on how such potential issues are resolved, or if the financial condition of any of the Company’s customers was to deteriorate and its ability to make required payments became impaired, increases in these allowances may be required. The Company actively manages its accounts receivable to minimize credit risk. The Company does not obtain collateral for its accounts receivable. Based on its assessment, the Company concluded that there are no collection issues related to the COVID-19 Pandemic.

Contract Liabilities

Contract liabilities consists of billings or payments received in advance of revenue recognition and is recognized as the revenue recognition criteria are met. Amounts that have been invoiced are initially recorded in accounts receivable and contract liabilities. The Company invoices its customers in accordance with the terms of the underlying contract. Accordingly, the contract liabilities balance does not represent the total contract value of outstanding arrangements. Contract liabilities that are expected to be recognized during the subsequent 12-month period are recorded as current and the remaining portion as noncurrent. Contract liabilities were not significant at June 30, 2021 and 2020, respectively.

Investment Securities

Investment securities consist of equity securities and mutual funds with realized gains and losses recorded using the specific identification method. Changes in fair value are recorded as unrealized holding gains or losses in other income (loss), net on the statement of comprehensive loss. The Company determines the cost of the investment sold based on an average cost basis at the individual security level and records the interest income and realized gains or losses on the sale of these investments in other income (loss), net.

Inventories

Inventories are valued at the lower of cost (determined on a first-in, first-out basis) or net realizable value, and have been reduced by an allowance for excess and obsolete inventories. The estimate is based on management’s review of inventories on hand compared to estimated future usage and sales. Cost of work-in-process and finished goods inventories include material, labor and manufacturing overhead.
Property and Equipment

Property and equipment are stated at cost. Depreciation of property and equipment is provided for primarily by the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized by the straight-line method over the remaining term of the related lease or the estimated useful lives of the assets, whichever is shorter.

Research and Development Expenses

Research and development expenses are expensed as incurred and consist principally of internal and external costs which includes the cost of patent licenses, contract research services, laboratory supplies, in-process research and development acquired, as well as product developments and enhancements.

Finite Lived Intangible Assets

Intangible assets consist primarily of acquired technology, customer relationships, non-compete agreements, patents, licenses, websites, and in process research and development (“IPR&D”), trademarks and trade names. All finite lived intangible assets are amortized on a straight-line basis over the estimated useful lives of the respective assets, generally 3 to 10 years. The Company continually evaluates the remaining estimated useful lives of intangible assets that are being amortized to determine whether events or circumstances warrant a revision to the remaining period of amortization.

Goodwill and Indefinite Lived Intangible Assets

Goodwill represents the excess of purchase price over the fair value of identifiable net assets acquired in a business combination. Goodwill and indefinite lived intangible assets are tested for impairment at least annually in accordance with the provisions of ASC 350, “Intangibles-Goodwill and Other” (“ASC 350”). ASC 350 requires that goodwill be tested for impairment at the reporting unit level (operating segment or one level below an operating segment) on an annual basis and between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value. Application of the goodwill impairment test requires judgment, including the identification of reporting units, assignment of assets and liabilities to reporting units, assignment of goodwill to reporting units, and determination of the fair value of each reporting unit. The Company tests goodwill and long-lived assets annually as of June 30, the last day of its fiscal year, unless an event occurs that would cause the Company to believe the value is impaired at an interim date. The Company concluded as of June 30, 2021 and 2020, there was no impairment of goodwill or indefinite lived intangible assets.

Impairment of Long-Lived Assets

The Company follows the provisions of ASC No. 360, “Property, Plant and Equipment - Impairment or Disposal of Long-Lived Assets (“ASC 360"). ASC 360 which requires evaluation of the need for an impairment charge relating to long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If an evaluation for impairment is required, the estimated future undiscounted cash flows associated with the asset would be compared to the asset’s carrying amount to determine if a write down to a new depreciable basis is required. If required, an impairment charge is recorded based on an estimate of future discounted cash flows. The Company concluded as of June 30, 2021 and 2020, there was no impairment of long-lived assets.
Income Taxes

The Company and its subsidiaries file a consolidated U.S. federal income tax return. Income taxes are accounted for under the asset and liability method. The Company provides for federal, and state income taxes currently payable, as well as for those deferred due to timing differences between reporting income and expenses for financial statement purposes versus tax purposes. Deferred tax assets and liabilities are recognized for the future tax consequences attributed to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted income tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect of a change in income tax rates is recognized as income or expense in the period that includes the enactment date.

The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs.

Advertising

Advertising costs are expensed as incurred. Advertising expense amounted to $399,700 and $218,700 for the years ended June 30, 2021 and 2020, respectively.

Stock Compensation Plan

The Company has a ten-year stock option plan (the “2012 Plan”) which provides for the grant of options to purchase up to 1,193,000 shares of the Company’s Common Stock, par value $.05 per share (“Common Stock”), plus up to 57,000 shares under options previously granted under the 2002 Stock Option Plan of the Company (the “Prior Plan”).

The 2012 Plan provides for the granting of incentive or non-incentive stock options as defined in the 2012 Plan through 2022. Incentive stock options may be granted to employees at an exercise price equal to 100% (or 110% if the optionee owns directly or indirectly more than 10% of the outstanding voting stock) of the fair market value of the shares of Common Stock on the date of the grant. Non-incentive stock options shall be granted at the fair market value of the shares of Common Stock on the date of grant. At June 30, 2021 and 2020, 5,243 and 147,414 shares respectively, of Common Stock were available for grant of options under the 2012 Plan.

Stock-based compensation is accounted for in accordance with ASC No. 718 “Compensation-Stock Compensation” (“ASC No. 718”) which requires compensation costs related to stock-based payment transactions to be recognized. The amount of compensation cost is measured based on the grant-date fair value of the equity issued and expensed ratably over the requisite service period.
Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission requires management to make estimates and judgments that affect the amounts reported in the financial statements and accompanying notes. Estimates are used for, but not limited to, the allowance for doubtful accounts, slow-moving inventory reserves, depreciation and amortization, assumptions made in valuing equity instruments, fair value of stock options, the fair values of intangibles and goodwill, and provision or benefit for income taxes. The actual results experienced by the Company may differ materially from management’s estimates.

Earnings (Loss) Per Common Share

Basic earnings or loss per common share is computed by dividing net income (loss) by the weighted-average number of shares outstanding. Diluted earnings per common share includes the dilutive effect of stock options, if any. Since the Company was in a loss position during the years ended June 30, 2021 and 2020, respectively, basic net loss per share is the same as dilutive net loss per share as the inclusion of the weighted-average number of all potential dilutive common shares which consists of stock options and warrants are anti-dilutive.

Recent Accounting Pronouncements

In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes, which is designed to simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. ASU No. 2020-12 is effective for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years; this ASU allows for early adoption in any interim period after issuance of the update. The Company is currently evaluating the impact of adopting this guidance.

Adopted Accounting Pronouncement

In August 2018, the FASB issued Accounting Standards Update ("ASU") 2018-13, "Fair Value Measurement (Topic 820): Disclosure Framework Changes to the Disclosure Requirements for Fair Value Measurement", which is part of the FASB disclosure framework project to improve the effectiveness of disclosures in the notes to the financial statements. The amendments in the new guidance remove, modify, and add certain disclosure requirements related to fair value measurements covered in Topic 820, "Fair Value Measurement." The new standard is effective for fiscal years beginning after December 15, 2019. Early adoption is permitted for either the entire standard or only the requirements that modify or eliminate the disclosure requirements, with certain requirements applied prospectively, and all other requirements applied retrospectively to all periods presented.

In February 2016, the FASB issued ASU No. 2016-02, Leases, which replaces previous lease guidance in its entirety with ASC 842 and requires lessees to recognize lease assets and lease liabilities for those arrangements classified as operating leases under previous guidance, with the exception of leases with a term of twelve months or less. The Company adopted ASU No. 2016-02 on July 1, 2019 using the additional transition method, which allows prior periods to be presented under previous lease accounting guidance. Refer to Note 11, "Leases", for related disclosures.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for all significant accounting policies of the reporting entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-URI http://asc.fasb.org/topic&trid=2122369
+ Details

Name: us-gaap_SignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 17 R8.htm IDEA: XBRL DOCUMENT v3.22.1

Revenue
9 Months Ended

Mar. 31, 2022

Revenue

Revenue
2. Revenue

The Company generates revenues from the following sources: (1) Benchtop Laboratory Equipment, and (2) Bioprocessing Systems. The following table summarizes the Company’s disaggregation of revenues for the three and nine months ended March 31, 2022 and 2021.

Benchtop Laboratory Equipment

Bioprocessing Systems

Consolidated

Three Months Ended March 31, 2022:

Revenues

$ 2,434,600

$ 430,300

$ 2,864,900

Foreign Sales

783,600

269,700

1,053,300

Benchtop Laboratory Equipment

Bioprocessing Systems

Consolidated

Three Months Ended March 31, 2021:

Revenues

$ 2,365,700

$ 142,900

$ 2,508,600

Foreign Sales

942,200

102,600

1,044,800

Benchtop Laboratory Equipment

Bioprocessing Systems

Consolidated

Nine Months Ended March 31, 2022:

Revenues

$ 7,465,700

$ 1,157,800

$ 8,623,500

Foreign Sales

2,814,700

791,200

3,605,900

Benchtop Laboratory Equipment

Bioprocessing Systems

Consolidated

Nine Months Ended March 31, 2021:

Revenues

$ 6,803,300

$ 441,800

$ 7,245,100

Foreign Sales

2,724,800

395,000

3,119,800

Benchtop Laboratory Equipment sales are comprised primarily of standard benchtop laboratory equipment sold to laboratory equipment distributors, or directly to end users primarily online via the Company’s website. The sales cycle from time of receipt of order to shipment ranges from a day to a few weeks. Customers either pay by credit card (online sales) or Net 30-90 days, depending on the customer. Once the item is shipped under the terms specified in the order, which is primarily “FOB Factory”, other than a standard warranty, there are no other obligations to the customer. The standard warranty is typically one or two years, covering parts and labor, and is deemed immaterial. Revenue is recognized at the point in time when the risks and rewards of ownership have transferred to the customer, which is generally upon shipment.

Bioprocessing Systems revenues consist of royalty revenues generated through SBI and product revenues generated primarily through Aquila. Royalty revenues are earned by the Company under a licensing agreement from a single licensee and its sublicenses. The license agreement included two United States patents, which expired in August 2021. The Company is obligated to pay 50% of all royalties earned to the entity that licensed the intellectual property to the Company.

X

- References
No definition available.
+ Details

Name: scnd_Revenue

Namespace Prefix: scnd_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: scnd_RevenueAbstract

Namespace Prefix: scnd_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 18 R9.htm IDEA: XBRL DOCUMENT v3.22.1

Segment Information
9 Months Ended 12 Months Ended

Mar. 31, 2022

Jun. 30, 2021

Segment Information

Segment Information
3. Segment Information and Concentrations

The Company views its operations as two segments: the manufacture and marketing of standard benchtop laboratory equipment for research in university, hospital and industrial laboratories sold primarily through laboratory equipment distributors and laboratory and pharmacy balances and scales (“Benchtop Laboratory Equipment Operations”); and the design, manufacture, and marketing of bioprocessing systems and products (“Bioprocessing Systems”) and related royalty income.

Segment information is reported as follows:

Benchtop Laboratory Equipment

Bioprocessing Systems

Corporate And Other

Consolidated

Three Months Ended March 31, 2022:

Revenues

$ 2,434,600

$ 430,300

$ -

$ 2,864,900

Foreign Sales

783,600

269,700

-

1,053,300

Income (Loss) From Operations

247,300

(1,651,700 )

(337,900 )

(1,742,300 )

Assets

10,231,100

10,024,261

10,271,439

30,526,800

Long-Lived Asset Expenditures

16,500

158,000

-

174,500

Depreciation and Amortization

24,600

229,900

-

254,500

Benchtop Laboratory Equipment

Bioprocessing Systems

Corporate And Other

Consolidated

Three Months Ended March 31, 2021:

Revenues

$ 2,365,700

$ 142,900

$ -

$ 2,508,600

Foreign Sales

942,200

102,600

-

1,044,800

Income (Loss) From Operations

394,700

(1,323,900 )

(929,600 )

(1,858,800 )

Assets

5,979,400

1,281,200

6,639,700

13,900,300

Long-Lived Asset Expenditures

18,600

92,100

-

110,700

Depreciation and Amortization

30,000

16,700

-

46,700

Approximately 50% and 55% of net sales from Benchtop Laboratory Equipment Operations (42% and 52% of total revenues) for the three months ended March 31, 2022 and 2021, respectively, were derived from sales of the Company’s main product, the Vortex-Genie 2 mixer, excluding accessories.

Approximately 24% and 20% of total Benchtop Laboratory Equipment Operations sales (20% and 19% of total revenues) were derived from the Torbal Scales Division for the three months ended March 31, 2022 and 2021, respectively. For the three months ended March 31, 2022 and 2021, respectively, three customers accounted for approximately 19% and 26% of net sales of the Benchtop Laboratory Equipment Operations (16% and 25% of the Company’s total revenues), respectively.

Benchtop Laboratory Equipment

Bioprocessing Systems

Corporate And Other

Consolidated

Nine Months Ended March 31, 2022:

Revenues

$ 7,465,700

$ 1,157,800

$ -

$ 8,623,500

Foreign Sales

2,814,700

791,200

-

3,605,900

Income (Loss) From Operations

1,107,000

(5,091,300 )

(1,127,200 )

(5,111,500 )

Assets

10,231,100

10,024,261

10,271,439

30,526,800

Long-Lived Asset Expenditures

83,100

321,300

-

404,400

Depreciation and Amortization

71,200

510,600

-

581,800

Benchtop Laboratory Equipment

Bioprocessing Systems

Corporate And Other

Consolidated

Nine Months Ended March 31, 2021:

Revenues

$ 6,803,300

$ 441,800

$ -

$ 7,245,100

Foreign Sales

2,724,800

395,000

-

3,119,800

Income (Loss) From Operations

1,347,100

(2,598,000 )

(1,048,000 )

(2,298,900 )

Assets

5,979,400

1,281,200

6,639,700

13,900,300

Long-Lived Asset Expenditures

54,100

170,800

-

224,900

Depreciation and Amortization

79,700

46,500

500

126,700

Approximately 49% and 51% of total Benchtop Laboratory Equipment Operations sales (42% and 47% of total revenues) for the nine months ended March 31, 2022 and 2021, respectively, were derived from sales of the Company’s main product, the Vortex-Genie 2 mixer, excluding accessories.

Approximately 24% and 23% for both periods of total Benchtop Laboratory Equipment Operations sales (21% and 21% of total revenues) were derived from the Torbal Scales Division for the nine months ended March 31, 2022 and 2021, respectively.

For each of the nine-month periods ended March 31, 2022 and 2021, three customers accounted for approximately 20% and 23% of net sales of the Benchtop Laboratory Equipment Operations (17% and 21% of the Company’s total revenues), respectively.

2. Segment Information

The Company views its operations as two segments: the manufacture and marketing of standard benchtop laboratory equipment for research in university, hospital and industrial laboratories sold primarily through laboratory equipment distributors and laboratory and pharmacy balances and scales (“Benchtop Laboratory Equipment Operations”), and the design and marketing of bioprocessing systems and products and related royalty income (“Bioprocessing Systems”).

Segment information is reported as follows:

Benchtop Laboratory Equipment

Bioprocessing Systems

Corporate and Other

Consolidated

June 30, 2021:

Revenues

$ 9,043,600

$ 731,600

$ -

$ 9,775,200

Foreign Sales

3,483,700

684,600

_

4,168,300

Income (Loss) From Operations

1,461,300

(4,828,600 )

(1,341,400 )

(4,708,800 )

Assets

14,783,000

8,735,100

5,488,300

29,006,400

Long-Lived Asset Expenditures

60,500

196,900

-

257,400

Depreciation and Amortization

103,100

148,400

-

251,500

Benchtop Laboratory Equipment

Bioprocessing Systems

Corporate and Other

Consolidated

June 30, 2020:

Revenues

$ 6,783,600

$ 1,000,800

$ -

$ 7,784,400

Foreign Sales

2,589,800

1,000,400

-

3,590,200

Income (Loss) From Operations

449,700

(727,500 )

(385,700 )

(663,500 )

Assets

12,232,600

546,100

2,018,700

14,797,400

Long-Lived Asset Expenditures

36,000

40,700

-

76,700

Depreciation and Amortization

116,900

42,700

-

159,600

X

- References
No definition available.
+ Details

Name: us-gaap_SegmentReportingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI http://asc.fasb.org/topic&trid=2134510
+ Details

Name: us-gaap_SegmentReportingDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 19 R10.htm IDEA: XBRL DOCUMENT v3.22.1

Fair Value of Financial Instruments
9 Months Ended 12 Months Ended

Mar. 31, 2022

Jun. 30, 2021

Fair Value of Financial Instruments

Fair Value of Financial Instruments
4. Fair Value of Financial Instruments

In valuing assets and liabilities, the Company is required to maximize the use of quoted market prices and minimize the use of unobservable inputs. The Company calculated the fair value of its Level 1 and 2 instruments based on the exchange traded price of similar or identical instruments where available or based on other observable instruments. These calculations take into consideration the credit risk of both the Company and its counterparties. The Company has not changed its valuation techniques in measuring the fair value of any financial assets or liabilities during the period.

The fair value of the contingent consideration obligations are based on a probability-weighted approach derived from the estimates of earn-out criteria and the probability assessment with respect to the likelihood of achieving those criteria. The measurement is based on significant inputs that are not observable in the market, therefore, the Company classifies this liability as Level 3 in the following table.
The following tables set forth by level within the fair value hierarchy the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis at March 31, 2022 and June 30, 2021 according to the valuation techniques the Company used to estimate their fair values:

Fair Value at

Fair Value Measurements Using Inputs Considered as

March 31,
2022

Level 1

Level 2

Level 3

Assets:

Cash and cash equivalents

$ 4,068,000

$ 4,068,000

$ -

$ -

Investment securities

7,768,600

6,796,500

972,100

-

Total

$ 11,836,600

$ 10,864,500

$ 972,100

$ -

Liabilities:

Contingent consideration

$ 117,500

$ -

$ -

$ 117,500

Fair Value at

Fair Value Measurements Using Inputs Considered as

June 30,
2021

Level 1

Level 2

Level 3

Assets:

Cash and cash equivalents

$ 9,675,200

$ 9,675,200

$ -

$ -

Investment securities

3,744,600

2,920,600

824,000

-

Total

$ 13,419,800

$ 12,595,800

$ 824,000

$ -

Liabilities:

Contingent consideration

$ 160,000

$ -

$ -

$ 160,000

Investments in marketable securities by security type at March 31, 2022 and June 30, 2021 consisted of the following:

Cost

Fair Value

Unrealized
Holding
Gain (Loss)

At March 31, 2022:

Equity securities

$ 118,900

$ 176,900

$ 58,000

Mutual funds

6,708,300

6,619,600

(88,700 )
 Debt securities

977,200

972,100

(5,100 )

$ 7,804,400

7,768,600

(35,800 )

Cost

Fair Value

Unrealized
Holding
Gain (Loss)

At June 30, 2021:

Equity securities

$ 102,200

$ 154,100

$ 51,900

Mutual funds

2,752,400

2,766,500

14,100

Debt securities

832,700

824,000

(8,700 )

$ 3,687,300

$ 3,744,600

$ 57,300

3. Fair Value of Financial Instruments

The FASB defines the fair value of financial instruments as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value measurements do not include transaction costs.

The accounting guidance also expands the disclosure requirements around fair value and establishes a fair value hierarchy for valuation inputs. The hierarchy prioritizes the inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market. Each fair value measurement is reported in one of the three levels, which is determined by the lowest level input that is significant to the fair value measurement in its entirety. These levels are described below:

Level 1 Inputs that are based upon unadjusted quoted prices for identical instruments traded in active markets.

Level 2 Quoted prices in markets that are not considered to be active or financial instruments for which all significant inputs are observable, either directly or indirectly.

Level 3 Prices or valuation that require inputs that are both significant to the fair value measurement and unobservable.

In valuing assets and liabilities, the Company is required to maximize the use of quoted market prices and minimize the use of unobservable inputs. The Company calculated the fair value of its Level 1 and 2 instruments based on the exchange traded price of similar or identical instruments where available or based on other observable instruments. These calculations take into consideration the credit risk of both the Company and its counterparties. The Company has not changed its valuation techniques in measuring the fair value of any financial assets and liabilities during the period.

The fair value of the contingent consideration obligations is based on a probability weighted approach derived from the estimates of earn-out criteria and the probability assessment with respect to the likelihood of achieving those criteria. The measurement is based on significant inputs that are not observable in the market, therefore, the Company classifies this liability as Level 3 in the following table.

The following tables set forth by level within the fair value hierarchy the Company’s financial assets that were accounted for at fair value on a recurring basis at June 30, 2021 and 2020 according to the valuation techniques the Company used to determine their fair values:

Fair Value at June 30,

Fair Value Measurements Using Inputs Considered as

2021

Level 1

Level 2

Level 3

Assets:

Cash and cash equivalents

$ 9,675,200

$ 9,675,200

$ -

$ -

Investment securities

3,744,600

2,920,600

824,000

-

Total

$ 13,419,800

$ 12,595,800

$ 824,000

$ -

Liabilities:

Contingent consideration

$ 160,000

$ -

$ 160,000

Fair Value Measurements Using Inputs Considered as

Fair Value at June 30, 2020

Level 1

Level 2

Level 3

Assets:

Cash and cash equivalents

$ 7,559,700

$ 7,559,700

$ -

$ -

Investment securities

331,800

331,800

-

-

Total

$ 7,891,500

$ 7,891,500

$ -

$ -

Liabilities:

Contingent consideration

$ 358,000

$ -

$ 358,000

The following table sets forth an analysis of changes during the years ended June 30, 2021 and 2020, respectively, in Level 3 financial liabilities of the Company:

2021

2020

Beginning balance

$ 358,000

$ 618,000

Increase (decrease) in contingent consideration liability

(30,000 )

112,600

Payments

(168,000 )

(372,600 )

Ending balance

$ 160,000

$ 358,000

The Company’s contingent obligations require cash payments to the sellers of certain acquired operations based on royalty payments received or operating results achieved. These contingent considerations are classified as liabilities and the liabilities are remeasured to an estimated fair value at each reporting date. During the years ended June 30, 2021 and 2020, the Company recorded an increase (decrease) in the estimated fair value of contingent liabilities of approximately ($30,000) and $112,600, respectively related to its Bioprocessing Systems Operations segment.

Investments in marketable securities by security type at June 30, 2021 and 2020 consisted of the following:

Cost

Fair Value

Unrealized Holding Gain (Loss)

At June 30, 2021:

Equity securities

$ 102,200

$ 154,100

$ 51,900

Mutual funds

2,752,400

2,766,500

14,100

Debt securities

832,700

824,000

(8,700 )

$ 3,687,300

$ 3,744,600

$ 57,300

Cost

Fair Value

Unrealized Holding Gain (Loss)

At June 30, 2020:

Equity securities

$ 77,600

$ 101,900

$ 24,300

Mutual funds

250,300

229,900

(20,400 )

$ 327,900

$ 331,800

$ 3,900

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 20 R11.htm IDEA: XBRL DOCUMENT v3.22.1

Inventories
9 Months Ended 12 Months Ended

Mar. 31, 2022

Jun. 30, 2021

Inventories

Inventories
5. Inventories

March 31,
2022

June 30,
2021

Raw materials

$ 3,058,100

$ 2,170,400

Work-in-process

106,400

39,600

Finished goods

1,203,400

767,100

$ 4,367,900

$ 2,977,100

4. Inventories

2021

2020

Raw materials

$ 2,170,400

$ 1,726,400

Work-in-process

39,600

35,700

Finished goods

767,100

778,900

$ 2,977,100

$ 2,541,000

X

- References
No definition available.
+ Details

Name: us-gaap_InventoryDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-URI http://asc.fasb.org/topic&trid=2126998
+ Details

Name: us-gaap_InventoryDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 21 R12.htm IDEA: XBRL DOCUMENT v3.22.1

Property and Equipment
12 Months Ended

Jun. 30, 2021

Property and Equipment

Property and Equipment
5. Property and Equipment

Useful Lives

(Years)

2021

2020

Automobiles

5

$ 22,000

$ 22,000

Computer equipment

 3-5

233,500

215,300

Machinery and equipment

 3-7

1,047,600

847,500

Furniture and fixtures

 4-10

148,800

142,300

Leasehold improvements

 3-10

64,400

50,300

1,516,300

1,277,400

Less accumulated depreciation and amortization

1,103,700

999,100

$ 412,600

$ 278,300

Depreciation expense was $104,600 and $88,700 for the years ended June 30, 2021 and 2020, respectively.

X

- References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 958
-SubTopic 360
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-URI http://asc.fasb.org/topic&trid=2155823

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 958
-SubTopic 360
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 958
-SubTopic 360
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916
+ Details

Name: us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 22 R13.htm IDEA: XBRL DOCUMENT v3.22.1

Goodwill and Other Intangible Assets
9 Months Ended 12 Months Ended

Mar. 31, 2022

Jun. 30, 2021

Goodwill and Other Intangible Assets

Goodwill and Other Intangible Assets
6. Goodwill and Finite Lived Intangible Assets

Goodwill amounted to $4,395,400 at March 31, 2022 and June 30, 2021, all of which is expected to be deductible for tax purposes.

The components of finite-lived intangible assets are as follows:

Useful Lives

Cost

Accumulated Amortization

Net

At March 31, 2022:

Technology, trademarks

5-10 yrs.

$ 817,000

$ 431,800

$ 385,200

Trade names

3-6 yrs.

140,000

140,000

-

Websites

3-7 yrs.

210,000

210,000

-

Customer relationships

4-10 yrs.

372,200

133,100

239,100

Sublicense agreements

10 yrs.

294,000

294,000

-

Non-compete agreements

4-5 yrs.

1,060,500

455,300

605,200

In-process research and development

3-5 yrs.

917,600

249,600

668,000

Patents

5-7 yrs.

593,000

274,200

318,800

$ 4,404,300

$ 2,188,000

$ 2,216,300

Useful Lives

Cost

Accumulated Amortization

Net

At June 30, 2021:

Technology, trademarks

5-10 yrs.

$ 364,700

$ 362,200

$ 2,500

Trade names

3-6 yrs.

592,300

152,600

439,700

Websites

3-7 yrs.

210,000

210,000

-

Customer relationships

4-10 yrs.

372,200

102,400

269,800

Sublicense agreements

10 yrs.

294,000

283,000

11,000

Non-compete agreements

4-5 yrs.

1,060,500

308,600

751,900

In-process research and development

3-5 yrs.

852,100

134,800

717,300

Patents

5-7 yrs.

591,500

225,900

365,600

$ 4,337,300

$ 1,779,500

$ 2,557,800

Total amortization expense was $134,600 and $16,000 for the three months ended March 31, 2022 and 2021, respectively, and $408,500 and $48,500 for the nine months ended March 31, 2022 and 2021, respectively. As of March 31, 2022, estimated future amortization expense related to intangible assets is $134,300 for the remainder of the fiscal year ending June 30, 2022, $520,900 for fiscal 2023, $518,900 for fiscal 2024, $485,100 for fiscal 2025, $284,600 for fiscal 2026 and $137,500 thereafter.

6. Goodwill and Finite Lived Intangible Assets

Goodwill represents the excess of the purchase price over the fair value of the net assets acquired in connection with the Company’s acquisitions. Goodwill amounted to $4,395,400 at June 30, 2021 and 257,300 at June 30, 2020, all of which is expected to be deductible for tax purposes.

The components of finite lived intangible assets are as follows:

Useful
Lives

Cost

Accumulated Amortization

Net

At June 30, 2021:

Technology, trademarks

5-10 yrs.

$ 364,700

$ 362,200

$ 2,500

Trade names

3-6 yrs.

592,300

152,600

439,700

Websites

3-7 yrs.

210,000

210,000

-

Customer relationships

4-10 yrs.

372,200

102,400

269,800

Sublicense agreements

10 yrs.

294,000

283,000

11,000

Non-compete agreements

4-5 yrs.

1,060,500

308,600

751,900

IPR&D

3-5 yrs.

852,100

134,800

717,300

Patents

5-7 yrs.

591,500

225,900

365,600

$ 4,337,300

$ 1,779,500

$ 2,557,800

Useful
Lives

Cost

Accumulated Amortization

Net

At June 30, 2020:

Technology, trademarks

5/10 yrs.

$ 664,700

$ 662,000

$ 2,700

Trade names

6 yrs.

140,000

140,000

-

Websites

5 yrs.

210,000

210,000

-

Customer relationships

9/10 yrs.

357,000

321,400

35,600

Sublicense agreements

10 yrs.

294,000

253,600

40,400

Non-compete agreements

5 yrs.

384,000

384,000

-

IPR&D

3 yrs.

110,000

110,000

-

Patents

5 yrs.

246,600

196,600

50,000

$ 2,406,300

$ 2,277,600

$ 128,700

Total amortization expense was $146,900 and $72,000 in 2021 and 2020, respectively.

Estimated future amortization expense of intangible assets as of June 30, 2021 is as follows:

Year Ended June 30,

2022

$ 525,700

2023

520,000

2024

508,800

2025

473,100

2026

530,200

Total

$ 2,557,800

X

- References
No definition available.
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for goodwill.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-URI http://asc.fasb.org/subtopic&trid=2144439
+ Details

Name: us-gaap_GoodwillDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 23 R14.htm IDEA: XBRL DOCUMENT v3.22.1

Lines of Credit
12 Months Ended

Jun. 30, 2021

Lines of Credit

Lines of credit
7. Line of Credit

The Company has a Demand Line of Credit through December 2021 with First National Bank of Pennsylvania which provides for borrowings of up to $300,000 for regular working capital needs, bearing interest at prime, currently 3.25%. The agreement does not contain financial covenants and borrowings are secured by a pledge of substantially all of the assets of the Company. As of June 30, 2021 and 2020, there were no borrowings outstanding under the line.

X

- Definition
The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI http://asc.fasb.org/topic&trid=2208564

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1E
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611
+ Details

Name: us-gaap_DebtDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_LineOfCreditFacilityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 24 R15.htm IDEA: XBRL DOCUMENT v3.22.1

Payroll Protection Program Loan
12 Months Ended

Jun. 30, 2021

Payroll Protection Program Loan

Payroll Protection Program Loan
8. Payroll Protection Program Loan

The Company received $563,800 and $433,800 in Payroll Protection Program loans in April 2020 and March 2021, respectively, pursuant to the Paycheck Protection Program loan (“PPP”) administered by the U.S. Small Business Administration through its bank. The first loan was forgiven in June 2021, and reflected as other income in the accompanying statements of comprehensive loss , except for $32,700 which was repaid by the Company. The remaining loan bears interest at 1% per annum and matures in March 2026 and contains no collateral or guarantee requirements. The Company expects to apply and receive forgiveness for the second loan.

X

- References
No definition available.
+ Details

Name: us-gaap_LoansPayableAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for short-term debt.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI http://asc.fasb.org/topic&trid=2208564
+ Details

Name: us-gaap_ShortTermDebtTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 25 R16.htm IDEA: XBRL DOCUMENT v3.22.1

Loss Per Common Share
9 Months Ended 12 Months Ended

Mar. 31, 2022

Jun. 30, 2021

Loss Per Common Share

Loss Per Common Share
7. Loss Per Common Share

The Company presents the computation of earnings per share (“EPS”) on a basic basis. Basic EPS is computed by dividing net income, if any, by the weighted average number of shares outstanding during the reported period. Diluted EPS is computed similarly to basic EPS, except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential additional common shares that were dilutive had been issued. Common shares are excluded from the calculation if they are determined to be anti-dilutive; accordingly, no dilution is shown for loss periods. The following table sets forth the weighted average number of common shares outstanding for each period presented.

For the Three Month Period Ended March 31, 2022

For the Three Month Period Ended March 31, 2021

For the Nine Month Period Ended March 31, 2022

For the Nine Month Period Ended March 31, 2021

Weighted average number of common shares outstanding

6,633,901

2,861,607

6,544,112

2,861,376

Effect of dilutive securities

-

-

-

-

Weighted average number of dilutive common shares outstanding

6,633,901

2,861,607

6,544,112

2,861,376

Basic and diluted loss per common share:

Continuing operations

$ (0.23 )

$ (0.51 )

$ (0.56 )

$ (0.61 )
Discontinued operations

$ -

$ 0.01

$ -

$ (0.20 )
Consolidated operations

$ (0.23 )

$ (0.50 )

$ (0.56 )

$ (0.81 )

Approximately 3,452,542 and 3,451,461 shares of the Company’s common stock issuable upon the exercise of options and warrants, respectively, were excluded from the calculation because the effect would be anti-dilutive due to the loss for the three and nine months ended March 31, 2022.

Approximately 259,357 and 1,349,850 shares of the Company’s common stock issuable upon the exercise of options and warrants, respectively, were excluded from the calculation because the effect would be anti-dilutive due to the loss for the three and nine months ended March 31, 2021.

14. Earnings (Loss) Per Common Share

The Company presents the computation of earnings per share (“EPS”) on a basic basis. Basic EPS is computed by dividing net income or loss by the weighted average number of shares outstanding during the reported period. Diluted EPS is computed similarly to basic EPS, except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential additional common shares that were dilutive had been issued. Common shares are excluded from the calculation if they are determined to be anti-dilutive. The following table sets forth the weighted average number of common shares outstanding for each period presented.

2021

2020

Weighted average number of common shares outstanding

3,189,602

1,515,103

Effect of dilutive securities:

-

-

Weighted average number of dilutive common shares outstanding

3,189,602

1,515,103

Basic and Diluted loss per common share:

Continuing operations

$ (0.97 )

$ (0.30 )
Discontinued operations

$ (0.18 )

$ (0.16 )
Consolidated operations

$ (1.15 )

$ (0.46 )

Approximately 88,691 and 2,481,783 shares of the Company's common stock issuable upon the exercise of stock options and warrants, respectively, were excluded from the calculation because the effect would be anti-dilutive due to the loss for the year ended June 30, 2021. Approximately 54,513 and 1,349,850 shares of the Company's common stock issuable upon the exercise of stock options and warrants, respectively, were excluded from the calculation because the effect would be anti-dilutive due to the loss for the year ended June 30, 2020.

X

- References
No definition available.
+ Details

Name: scnd_LossPerCommonShareabstract

Namespace Prefix: scnd_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for earnings per share.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-URI http://asc.fasb.org/topic&trid=2144383

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257
+ Details

Name: us-gaap_EarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 26 R17.htm IDEA: XBRL DOCUMENT v3.22.1

Employee Benefit Plans
12 Months Ended

Jun. 30, 2021

Employee Benefit Plans

Employee Benefit Plans
9. Employee Benefit Plans

The Company has a 401(k) profit sharing plan covering all its employees, which provides for voluntary employee salary contributions not to exceed the statutory limitations provided by the Internal Revenue Code. The plan provides for Company matching contribution equal to 100% of employee’s deferral up to 3% of pay, plus 50% of employee’s deferral over 3% of pay up to 5%. Total matching contributions amounted to $90,700 and $84,100 for the years ended June 30, 2021 and 2020, respectively.

X

- Definition
The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-URI http://asc.fasb.org/topic&trid=2228938

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 712
-URI http://asc.fasb.org/topic&trid=2197446

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 710
-URI http://asc.fasb.org/topic&trid=2127225

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-URI http://asc.fasb.org/topic&trid=2235017
+ Details

Name: us-gaap_CompensationAndEmployeeBenefitPlansTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_CompensationAndRetirementDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 27 R18.htm IDEA: XBRL DOCUMENT v3.22.1

Leases
9 Months Ended 12 Months Ended

Mar. 31, 2022

Jun. 30, 2021

Leases

Leases
8. Leases

The Company leases certain properties consisting principally of (i) a facility in Bohemia, New York (headquarters) through October 2028, (ii) a facility in Pittsburgh, Pennsylvania for SBI’s Bioprocessing Systems Operations through May 2023, and (iii) a facility for sales and administration in Orangeburg, New York through October 2022. There are no renewal options with any of the leases, no residual values or significant restrictions or covenants other than those customary in such arrangements, and no non-cash activities; and any rent escalations incorporated within the leases are included in the calculation of the future minimum lease payments, as further described below.

The Company determines whether an agreement contains a lease at inception based on the Company’s right to obtain substantially all of the economic benefits from the use of the identified asset and its right to direct the use of the identified asset. Lease liabilities represent the present value of future lease payments and the Right-Of-Use (“ROU”) assets represent the Company’s right to use the underlying assets for the respective lease terms. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term. Each ROU asset is further adjusted to account for previously recorded lease expenses such as deferred rent and other lease liabilities. As the Company’s leases do not provide an implicit rate, the Company used its incremental borrowing rate of 5.0% as the discount rate to calculate the present value of future lease payments, which was the interest rate that its bank would charge for a similar loan.
The Company elected not to recognize a ROU asset or a lease liability for leases with an initial term of twelve months or less. In addition to minimum lease payments, certain leases require payment of a proportionate share of real estate taxes and certain building operating expenses or payments based on an excess of a specified base. These variable lease costs are not included in the measurement of the ROU asset or lease liability due to unpredictability of the payment amount and are recorded as lease expenses in the period incurred. The Company’s lease agreements do not contain residual value guarantees.

The Company elected available practical expedients for existing or expired contracts of lessees whereby the Company is not required to reassess whether such contracts contain leases, the lease classification or the initial direct costs. The Company is not utilizing the practical expedient which allows the use of hindsight by lessees and lessors in determining the lease term and in assessing impairment of its ROU assets. The Company utilized the transition method allowing entities to only apply the new lease standard in the year of adoption.

As of March 31, 2022, the weighted-average remaining lease term for operating lease liabilities was approximately 5.32 years and the weighted-average discount rate was 5.0%. Total cash payments under these leases were approximately $82,000 and $240,200, for the three and nine months ended March 31, 2022 of which $81,800 and $226,300 was recorded as leases expense, respectively.

The Company’s approximate future minimum rental payments under all leases existing at March 31, 2022 through October 2028 are as follows:

Fiscal year ending June 30,

Amount

Remainder of 2022

$ 82,200

2023

311,400

2024

247,600

2025

255,000

2026

262,700

Thereafter

609,600

Total future minimum payments

1,768,500

Less imputed interest

(256,100 )
Total Present Value of Operating Lease Liabilities

$ 1,512,400

11. Leases

On July 1, 2019, the Company adopted the new accounting pronouncement as it relates to its leases which requires a lessee to recognize all long-term leases on its balance sheet as a liability for its lease obligation, measured at the present value of lease payments not yet paid, and a corresponding asset representing its right to use the underlying asset over the lease term and expands disclosure of key information about leasing arrangements.

The Company leases certain properties consisting principally of a facility in Bohemia, New York (headquarters) through January 2025 which was amended in September 2021 to increase the space by approximately 25% and lease term through approximately October 2028, a facility in Pittsburgh, Pennsylvania for its Bioprocessing Systems Operations through May 2023, and a facility for sales and administration in Orangeburg, New York through October 2022. The Company had a lease for its discontinued operations through November 2020. There are no renewal options with any of the leases, no residual values or significant restrictions or covenants other than those customary in such arrangements, and no non-cash activities, and any rent escalations incorporated within the leases are included in the calculation of the future minimum lease payments, as further described below. All of the Company’s leases are deemed operating leases.

The Company determines whether an agreement contains a lease at inception based on the Company’s right to obtain substantially all of the economic benefits from the use of the identified asset and its right to direct the use of the identified asset. Lease liabilities represent the present value of future lease payments and the Right-Of-Use (“ROU”) assets represent the Company’s right to use the underlying assets for the respective lease terms. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term. The ROU asset is further adjusted to account for previously recorded lease expenses such as deferred rent and other lease liabilities. As the Company’s leases do not provide an implicit rate, the Company used its incremental borrowing rate of 5.0% as the discount rate to calculate the present value of future lease payments, which was the interest rate that its bank would charge for a similar loan.
The Company elected not to recognize a ROU asset and a lease liability for leases with an initial term of twelve months or less. In addition to minimum lease payments, certain leases require payment of a proportionate share of real estate taxes and certain building operating expenses or payments based on an excess of a specified base. These variable lease costs are not included in the measurement of the ROU asset or lease liability due to unpredictability of the payment amount and are recorded as lease expenses in the period incurred. The Company’s lease agreements do not contain residual value guarantees.

The Company elected available practical expedients for existing or expired contracts of lessees wherein the Company is not required to reassess whether such contracts contain leases, the lease classification or the initial direct costs. The Company is not utilizing the practical expedient which allows the use of hindsight by lessees and lessors in determining the lease term and in assessing impairment of its ROU assets. The Company utilized the transition method allowing entities to only apply the new lease standard in the year of adoption.

As of June 30, 2021, the weighted-average remaining lease term for operating lease liabilities was approximately 2.68 years and the weighted-average discount rate was 5.0%. Total cash payments under these leases were $289,100 for the year ended June 30, 2021, of which $277,300 was recorded as lease expense.

The Company’s approximate future minimum rental payments under all leases existing at June 30, 2021, through January 2025 are as follows:

Year ended June 30,

Amount

2022

$ 260,300

2023

245,300

2024

195,900

2025

91,600

Total future minimum payments

$ 793,100

Less: Imputed interest

(62,100 )
Total Present Value of Operating Lease Liabilities

$ 731,000

X

- References
No definition available.
+ Details

Name: us-gaap_LeasesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-URI http://asc.fasb.org/topic&trid=2208923
+ Details

Name: us-gaap_LeasesOfLesseeDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 28 R19.htm IDEA: XBRL DOCUMENT v3.22.1

Discontinued Operations
9 Months Ended 12 Months Ended

Mar. 31, 2022

Jun. 30, 2021

Discontinued Operations

Discontinued Operations
9. Discontinued Operations

Effective November 30, 2020, as part of its strategic shift to becoming a life sciences tool provider, the Company sold its operations relating to the manufacture and marketing of custom-made catalyst research instruments for universities, government laboratories, and chemical petrochemical companies sold on direct basis (the “Catalyst Research Instruments Operations”) through the sale by Altamira of substantially all of its assets and inventory to Beijing JWGB Sci. & Tech. Co. Ltd., a corporation formed under the laws of the People’s Republic of China (“JWGB”) for $440,000 which was fully paid in cash by January 2021, resulting in a $405,400 pre-tax loss. To preserve business continuity for the buyer, Altamira agreed to purchase certain components on behalf of JWGB for which JWGB agreed to reimburse Altamira. The Company retained all its receivables and payables related to sales made prior to November 30, 2020, certain inventory related to two work-in-process orders which have been shipped, product warranty and other miscellaneous liabilities related to certain employee benefits, and expenses related to the closure of the Altamira facility, which was completed at the end of December 2020.
As a result of the disposal described above, the operating results of the former Catalyst Research Instruments Operations segment have been presented as discontinued operations in the balance sheets, the statements of operations, and the statements of cash flows, as detailed below.

Assets:

March 31,
2022

June 30,
2021

Cash

$ 600

$ -

Accounts receivable

-

52,000

Inventories

-

3,300

$ 600

$ 55,300

Liabilities:

March 31,
2022

June 30,
2021

Accrued expenses and taxes

$ -

$ 20,700

Contract liabilities

7,900

16,500

$ 7,900

$ 37,200

Three Months Ended

Nine Months Ended

March 31,2022

March 31,2021

March 31,2022

March 31,2021

Revenues

$ -

$ 107,800

$ 20,600

$ 387,700

Cost of goods sold

6,900

78,800

10,300

458,500

Gross profit (loss)

(6,900 )

29,000

10,300

(70,800 )
Selling, general and administrative expenses

700

12,600

2,900

282,200

Income (loss) from operations

(7,600 )

16,400

7,400

(353,000 )
Loss on disposal

-

-

-

(405,400 )
Income (loss) before income tax benefit

(7,600 )

16,400

7,400

(758,400 )
Income tax expense (benefit)

-

-

4,000

(179,900 )
Net income (loss) attributable to discontinued operations

$ (7,600 )

$ 16,400

$ 3,400

$ (578,500 )

In our Consolidated Statements of Cash Flows, the cash flows from discontinued operations are not separately classified. Cash provided by (used in) operating activities from discontinued operations for nine months ended March 31, 2022 and March 31, 2021 was $25,400 and $(502,900), respectively.

Cash provided by investing activities from discontinued operations for the nine months ended March 31, 2022 was none and $440,000 for the nine months ended March 31, 2021.

There was no cash provided by or used in financing activities for either period.

17. Discontinued Operations

Effective November 30, 2020, the Company, as part of its strategic shift to becoming a life sciences tool provider, sold its Catalyst Research Instruments Operations reporting segment through the sale by Altamira of substantially all of its assets, which comprised of fixed assets, and inventory to Beijing JWGB Sci. & Tech. Co. Ltd., a corporation formed under the laws of the People’s Republic of China (“JWGB”) for $440,000 payable in cash through January 2021, resulting in a $405,400 pre-tax loss. In order to preserve business continuity for the buyer, Altamira agreed to purchase certain components on behalf of JWGB for which JWGB agreed to reimburse Altamira. At March 31, 2021, JWGB paid the full $440,000 purchase price and $28,500 for component purchases made on its behalf. The Company retained all its receivables and payables related to sales made prior to November 30, 2020, certain inventory related to two work-in-process orders which will be shipped by the end of the fiscal year ending June 30, 2021, product warranty and other miscellaneous liabilities related to certain employee benefits, and expenses related to the closure of the Altamira facility, which was substantially completed at the end of December 2020.

As a result of the disposal described above, the operating results of the former Catalyst Research Instruments Operations segment have been presented as discontinued operations in the balance sheets, the statements of operations, and the statements of cash flows, as detailed below.

Assets:

June 30, 2021

June 30, 2020

Accounts receivable

$ 52,000

$ -

Inventories

3,300

343,700

Property and equipment, net

-

1,400

Goodwill

-

447,900

Discontinued operations

$ 55,300

$ 793,000

Liabilities:

June 30, 2021

June 30, 2020

Accounts payable

$ -

$ 20,100

Accrued expenses and taxes

20,700

120,700

Contract liabilities

16,500

69,000

Operating lease liabilities, current portion

-

31,100

$ 37,200

$ 240,900

Years Ended

June 30, 2021

June 30, 2020

Revenues

$ 387,700

$ 785,900

Cost of goods sold

471,800

869,900

Gross profit

(84,100 )

(84,000 )
Selling, general and administrative expenses

280,400

388,500

Loss from operations

(364,500 )

(472,500 )
Loss on disposal

(405,400 )

--

Loss before income tax benefit

(769,900 )

(472,500 )
Income tax benefit, all deferred

(207,400 )

(222,600 )
Net income (loss) attributable to discontinued operations

$ (562,500 )

$ (249,900 )

In our Consolidated Statements of Cash Flows, the cash flows from discontinued operations are not separately classified. Cash (used) and provided by operating activities from discontinued operations for year ended June 30, 2021 and June 30, 2020 was ($75,000) and $66,100, respectively. Cash provided by investing activities from discontinued operations for the year ended June 30, 2021 was $440,000 and $2,200 for the year ended June 30, 2020. There was no cash provided or used by the discontinued operations for financing activities for both the current and prior year periods.

X

- References
No definition available.
+ Details

Name: us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-URI http://asc.fasb.org/topic&trid=2155823

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-URI http://asc.fasb.org/subtopic&trid=2122178
+ Details

Name: us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 29 R20.htm IDEA: XBRL DOCUMENT v3.22.1

Commitments and Contingencies
12 Months Ended

Jun. 30, 2021

Commitments and Contingencies

Commitments and Contingencies
10. Commitments and Contingencies

The Company has a three-year employment contract with its President, effective July 1, 2017, which was extended by mutual agreement for each one year periods ending June 30, 2021 and 2022. The agreement provided for an annual base salary of $175,000 for the year ended June 30, 2018, with subsequent annual increases of 3% or the percentage increase in Consumer Price Index (“CPI”), whichever is higher, plus $25,000 cash bonus for the year ended June 30, 2018, and a discretionary bonus for subsequent years. Bonuses totaling $100,000 and $50,000 were awarded for the years ended June 30, 2021 and 2020, respectively. The agreement also provided for a grant of options to purchase 25,000 shares of the Company’s stock, which were granted during the year ended June 30, 2018.

No shares were granted during the year ended June 30, 2021, and 215,366 shares were authorized to be granted by the Board of Directors during the year ended June 30, 2020, which shares were not available and subject to amendment to the Company’s 2012 Stock Option Plan which was approved in February 2021. The agreement also contains a provision that within one year of a change of control, if either the Company terminates the employment for any reason other than for "cause" or the Presidents terminates her employment for "good reason", the President will have the right to receive a lump sum payment equal to three times the average of her total annual compensation paid for the last five years preceding such termination.

The Company has a three-year employment contract with its President of the Genie Products Division of the Benchtop Laboratory Equipment Operations and Corporate Secretary effective July 1, 2017, which was extended by mutual agreement for each one year period ending June 30, 2021 and 2022. The agreement provides for an annual base salary of $153,000 for the year ended June 30, 2018, with subsequent annual increases of 3% or percentage increase in the CPI, whichever is higher, plus $10,000 cash bonus for the year ended June 30, 2018, and a discretionary bonus for subsequent years. No bonus was awarded for the year ended June 30, 2021 and a $5,000 bonus was awarded in 2020. The agreement also provides for a grant of options to purchase 7,500 shares of the Company’s stock, which were granted during the year ended June 30, 2018. No options were granted during the year ended June 30, 2021 or 2020.

The Company has a three-year employment contract with its President and Director of Marketing of Torbal Products Division of the Benchtop Laboratory Equipment Operations and Director of Marketing effective July 1, 2017, which was extended by mutual agreement for each one year periods ending June 30, 2021 and 2022. The agreement provides for an annual base salary of $157,000 for the year ended June 30, 2018, with subsequent annual increases of 4% or percentage increase in the CPI, whichever is higher, plus $10,000 cash bonus for the year ended June 30, 2018 and subsequent years, subject to a minimum increase of 5% in the divisions’ EBITDA for the related year. The agreement also provides for a grant of options to purchase 7,500 shares of the Company’s stock, which were granted during the year ended June 30, 2018. No options were granted during the year ended June 30, 2021 or 2020. A performance-based bonus of $10,000 was awarded during the years ended June 30, 2020. No bonus was awarded for the year ended June 30, 2021.
The Company has a three-year employment contract with its President of Scientific Bioprocessing, Inc., effective July 1, 2020. The agreement provides for an annual base salary of $175,000, with subsequent annual increases of 3% or percentage increase in Consumer Price Index (“CPI”), whichever is higher, plus discretionary bonuses. The agreement also provides for a grant of options to purchase 215,366 shares which were authorized to be granted by the Board of Directors during the year ended June 30, 2020, which shares were not available and subject to amendment to the Company’s 2012 Stock Option Plan which was approved in February 2021. Prior to July 1, 2020, the officer had a consulting agreement, which terminated upon becoming an employee of the Company. Consulting fees paid under this agreement amounted to $145,000 for the year ended June 30, 2020, respectively plus stock options valued at $36,000 were granted as part of the total compensation under the consulting agreement, for the year ended June 30, 2020. Bonuses amounting to $100,000 were awarded during the year ended June 30, 2021 and $50,000 in 2020. The employment agreement contains termination provisions stipulating that if the Company terminates the employment other than for death, disability, or cause (as such term is defined therein), or if employee resigns for “good reason”(as such term is defined in the agreement) , the Company shall pay severance payments equal to either one year’s salary at the rate of the compensation at the time of termination is employee is terminated within 12 months of the date of the agreement or six months’ salary is the employee is terminated after 12 months of the date of the agreement, continue to pay the regular benefits provided by the Company for the period equal to the length of the severance payments and pay a pro rata portion of any bonus achieved prior to such termination of employment.

On April 30, 2021, the Company entered into an employment agreement with each of the four managing directors and sellers of Aquila for an indefinite term, which can be terminated by either party upon six months’ written notice in accordance with German law. The agreements, which are identical, stipulate that in calendar year 2021, the employees will receive a salary of 105,000 euros, and a guaranteed bonus of 45,000 euros for a total of 150,000 euros per year on a pro-rata basis, and in calendar year 2022, they will receive a salary of 105,000 euros and a bonus of 45,000 euros, subject to the achievement by Aquila of certain targets. In addition, the employment agreements included a one time retention bonus of 10,000 euros upon closing of the acquisition which was paid in May 2021 by Aquila, and a retention bonus of 25,000 euros if the employee does not terminate his employment with the Company within two years after the agreement date or the Company does not terminate his employment for good cause.

The Company has a consulting agreement, which expires on December 31, 2021, with a Director of the Company and his affiliate for product development consulting services. The agreement provides that the consultant be paid a monthly retainer fee of $9,000, plus a grant of 20,000 options which were awarded during the year ended June 30, 2020. Consulting expense related to this agreement amounted to $108,000 and $76,200 for the years ended June 30, 2021 and 2020, respectively.

On July 20, 2020, the Company entered into a two-year consulting agreement with a Director and Chairman of the Board of SBI for consulting on strategic matters of the Company’s Bioprocessing Systems Operations. The agreement provided that the consultant be paid a monthly retainer of 5,000 euros which was increased to 12,500 euros effective March 2021 plus the issuance of 125,000 stock options of the Company which were awarded during the year ended June 30, 2021. Consulting expense related to this agreement amounted to $207,900 for the year ended June 30, 2021 and none in 2020, respectively.

The Company is required to make payments of 30% of the net royalties received from the license and sublicense acquired in the SBI acquisition in fiscal 2014 through December 2023, at which time the related patents will expire. Total contingent consideration payments made for this acquisition amounted to $168,000 and $372,600 for the years ended June 30, 2021 and 2020, respectively.
The fair value of contingent consideration estimated to be paid as of June 30, 2021 is as follows:

Year ended June 30,

Amount

2022

$ 136,600

2023

12,000

2024

11,400

160,000

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for commitments and contingencies.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-URI http://asc.fasb.org/topic&trid=2127136

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-URI http://asc.fasb.org/topic&trid=2144648

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 954
-SubTopic 440
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 30 R21.htm IDEA: XBRL DOCUMENT v3.22.1

Acquisition of Aquila Biolabs GmbH
9 Months Ended 12 Months Ended

Mar. 31, 2022

Jun. 30, 2021

Acquisition of Aquila Biolabs GmbH

Acquisition of Aquila Biolabs GmbH
10. Acquisition of Aquila Biolabs GmbH

Effective April 29, 2021, the Company acquired all the outstanding capital stock of Aquila, a German start-up company engaged from its facility in Baesweiler, Germany in the design, production, and sale of bioprocessing systems and products which focus on the control and analysis of bioprocesses in bioreactors and incubation shakers for an aggregate purchase price of $7,880,100 in cash upon closing. Aquila’s principal customers are universities, pharmaceutical companies, and industrial companies. Aquila’s products are sold primarily on a direct basis and to a lesser extent, through distributors.

The acquisition was accounted for in accordance with ASC 805, Business Combinations (“ASC 805”) in which the Company is treated as the accounting acquirer. Accordingly, the assets acquired and liabilities assumed were measured at estimated fair value.
For purposes of measuring the estimated fair value, where applicable, of the assets acquired and liabilities assumed, as reflected in the unaudited pro forma condensed consolidated financial information, the guidance in ASC 820, Fair Value Measurements and Disclosures (“ASC 820”) has been applied, which establishes a framework for measuring fair value. In accordance with ASC 820, fair value is an exit price and is defined as “the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.” Under ASC 805, acquisition-related transaction costs and acquisition-related restructuring charges are not included as components of consideration transferred but are accounted for as expenses in the period in which the costs are incurred.

Management of the Company allocated the purchase price based on its estimated valuation of the assets acquired and liabilities assumed as follows:

Amount

Useful life

Fair value of assets acquired:

Current assets:

Cash and cash equivalents

$ 201,100

Accounts receivable

159,200

Inventory

187,500

Prepaid expenses and other current assets

25,400

Property, plant and equipment

40,200

Deferred tax asset

800,300

Tradename

452,300

6 years

Non-compete agreements

784,500

4 years

In-process research and development

742,100

5 years

Customer relationships

252,200

9 years

Patents and other intangibles

286,200

7 years

Total assets acquired

$ 3,931,000

Fair value of liabilities assumed:

Accounts payable

$ (39,300 )

Accrued expenses

(90,300 )

Other current liabilities

(59,400 )

Total liabilities assumed

$ (189,000 )

Total identifiable net assets

$ 3,742,000

Fair value of consideration transferred

7,880,100

Goodwill

$ 4,138,100

16. Acquisition of Aquila Biolabs GmbH

Effective April 29, 2021, pursuant to a Stock Purchase Agreement ("SPA") the Company acquired all the outstanding capital stock of Aquila biolabs GmbH, a German start-up company engaged from its facility in Baesweiler, Germany in the design, production, and sale of bioprocessing systems and products which focus on the control and analysis of bioprocesses in bioreactors and incubation shakers for an aggregate purchase price of $7,880,100 in cash upon closing. Aquila’s principal customers are universities, pharmaceutical companies, and industrial companies. The products are sold primarily on a direct basis and to a lesser extent, through distributors.

The acquisition was accounted for under the acquisition method of accounting in accordance with Accounting Standards Codification (“ASC”) 805, Business Combinations (“ASC 805”) in which the Company is treated as the accounting acquirer. In accordance with ASC 805, the assets acquired and liabilities assumed have been measured at fair value.

For purposes of measuring the estimated fair value, where applicable, of the assets acquired and liabilities assumed, as reflected in the unaudited pro forma condensed consolidated financial information, the guidance in ASC 820, Fair Value Measurements and Disclosures (“ASC 820”) has been applied, which establishes a framework for measuring fair value. In accordance with ASC 820, fair value is an exit price and is defined as “the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.” Under ASC 805, acquisition-related transaction costs and acquisition-related restructuring charges are not included as components of consideration transferred but are accounted for as expenses in the period in which the costs are incurred.

Management of the Company allocated the purchase price based on its valuation of the assets acquired and liabilities assumed as follows:

Amount

Useful life

Fair value of assets acquired

Current assets:

Cash and cash equivalents

$ 201,100

Accounts receivable

159,200

Inventory

187,500

Prepaid expenses and other current assets

25,400

Property, plant and equipment

40,200

Deferred tax asset

800,300

Tradename

452,300

 6 years

Non-compete agreements

784,500

4 years

IPR&D

742,100

5 years

Customer relationships

252,200

9 years

Patents and other intangibles

286,200

7 years

Total assets acquired

$ 3,931,000

Fair value of liabilities assumed:

Accounts payable

$ (39,300 )

Accrued expenses

(90,300 )

Other current liabilities

(59,400 )

Total liabilities assumed

(189,000 )

Total identifiable net assets

3,742,000

Fair value of consideration transferred

7,880,100

Goodwill

$ 4,138,100

Accounting Periods Presented

Aquila’s fiscal year ended on December 31. Its historical results have been aligned to more closely conform to the Company’s June 30 fiscal year end by taking Aquila’s interim financial results for six months ended December 31, 2019 and for the six months ended June 30, 2020. In addition, certain historical Aquila balances have been reclassified to conform to the pro forma consolidated presentation. There were no transactions between the two companies during the period presented. No pro forma adjustments were made to conform Aquila’s accounting policies which follow Germany’s generally accepted accounting principles (“German GAAP”) to the Company’s accounting principles, as any differences were deemed immaterial.

Unaudited Pro forma information is as follows:

(In $000’s)

6/30/2020

Revenues

$ 9,346

Net loss

(1,650 )
Earnings per share

Diluted

$ (0.37 )
Basic

(0.37 )

These pro forma results do not represent financial results that would have been realized had the acquisition actually occurred on July 1, 2019, nor are they intended to be a projection of future results. For additional information, please refer to the Company’s current report on Form 8-KA, filed on July12, 2021.

X

- References
No definition available.
+ Details

Name: us-gaap_BusinessCombinationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463
+ Details

Name: us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 31 R22.htm IDEA: XBRL DOCUMENT v3.22.1

Paycheck Protection Program Loan
9 Months Ended

Mar. 31, 2022

Acquisition of Aquila Biolabs GmbH

Paycheck Protection Program Loan
11. Paycheck Protection Program Loan

The Company received a second $433,800 PPP loan in March 2021, pursuant to the PPP loan administered by the U.S. Small Business Administration through its bank. The full amount of this loan was forgiven in December 2021, and is reflected as other income (extinguishment of debt) in the accompanying statements of operations and comprehensive loss.

X

- References
No definition available.
+ Details

Name: scnd_PaycheckProtectionProgramLoantextblock

Namespace Prefix: scnd_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_BusinessCombinationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 32 R23.htm IDEA: XBRL DOCUMENT v3.22.1

Income Taxes
12 Months Ended

Jun. 30, 2021

Income Taxes

Income Taxes
12. Income Taxes

The reconciliation of the provision for income taxes at the federal statutory rate of 21% to the actual tax benefit for the applicable fiscal year was as follows:

2021

2020

Computed “expected” income tax benefit

$ (1,014,300 )

$ (239,400 )
Research and development credits

(93,900 )

(89,400 )
Rate changes and NOL carrybacks

-

(122,600 )
Incentive Stock Option Expense

59,500

13,800

PPP Loan Forgiveness

(111,700 )

0

Other, net

(7,900 )

1,000

Income tax benefit

$ (1,152,500 )

$ (436,600 )
Deferred tax assets and liabilities consist of the following:

2021

2020

Deferred tax assets:

Amortization of intangible assets, including goodwill

$ 374,000

$ 329,700

Research and development credits

164,600

89,400

Various accruals

64,600

150,700

Stock options expense

383,200

-

Net operating loss

1,515,800

-

Other

24,900

19,400

2,527,100

589,200

Deferred tax liability:

Depreciation of property and amortization of goodwill

(37,200 )

(52,100 )

Net deferred tax assets

$ 2,489,900

$ 537,100

The Company has incurred cumulatively $715,800 of US net operating losses and $800,300 of German net operating losses as of June 30, 2021. These will be carried forward indefinitely without expiration, until fully utilized. The company expects to fully utilize these losses to offset taxable income in future years.

ASC No. 740 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC No. 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. As of June 30, 2021 and 2020, the Company did not have any unrecognized tax benefits related to various federal and state income tax matters.

The Company’s policy is to recognize interest and penalties on any unrecognized tax benefits as a component of income tax expense. The Company does not have any accrued interest or penalties associated with any unrecognized tax benefits. The Company is subject to U.S. federal income tax, as well as various state jurisdictions. The Company is currently open to audit under the statute of limitations by the federal and state jurisdictions for the years ended June 30, 2018 and after. The Company does not anticipate any material amount of unrecognized tax benefits within the next 12 months.

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI http://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690
+ Details

Name: us-gaap_IncomeTaxDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 33 R24.htm IDEA: XBRL DOCUMENT v3.22.1

Stock Options
12 Months Ended

Jun. 30, 2021

Stock Options

Stock Options
13. Stock Options

Equity awards are measured at each reporting period. Compensation costs are recognized over the period that an employee provides service in exchange for the award. During the years ended June 30, 2021 and 2020, the Company granted 1,094,171 and 25,881 options, respectively, to employees that had a fair value of $7,929,600 and $144,500, respectively. The fair value of the options granted during the years ended June 30, 2021 and 2020, were determined using the Black-Scholes-Merton option-pricing model. The weighted average assumptions used for the years ended June 30, 2021 and 2020, was an expected life of 10 years; risk free interest rate of 1.40% and .89%; volatility of 66% and 74%, and dividend yield of 0% and .08%, respectively. The Company declared no dividends for the years ending June 30, 2021 or 2020. The weighted-average fair value per share of the options granted during the years ended June 30, 2021 and 2020, was $7.25 and $5.58, respectively, and total stock-based compensation costs were $2,108,000 and $65,800 for the years ended June 30, 2021 and 2020, respectively. Stock-based compensation costs related to nonvested awards expected to be recognized in the future are $5,935,000 and $113,400 as of June 30, 2021 and 2020, respectively.

The stockholders approved an amendment to the Company’s 2012 Stock Option Plan (“Plan”) to increase the number of shares available under the Plan by 943,000 shares, from 307,000 to 1,250,000 shares, which, together with 150,000 shares that were added to the Plan in 2020, were registered by the Company on a Form S-8 Registration Statement with the Securities and Exchange Commission on March 15, 2021. The Company’s Board of Directors authorized and approved the grant of Stock Options in June 2020 and July 2020 to three key officers, subject to availability of option shares. In February 2021, upon availability, the Company issued these stock options to the Company’s Chairman of the Board, its Chief Executive Officer and President, and the Vice President of Sales-Americas of Company’s Bioprocessing Systems.
Option activity is summarized as follows:

June 30, 2021

June 30, 2020

Weighted-

Weighted-

Average

Average

Exercise

Exercise

Shares

Price

Shares

Price

Shares under option:

Outstanding, beginning of year

96,586

$ 4.35

97,205

$ 3.24

Granted

1,094,171

9.07

25,881

7.47

Exercised

(1,000 )

3.05

(24,000 )

3.35

Forfeited

(9,000 )

3.11

(2,500 )

3.08

Outstanding, end of year

1,180,757

$ 8.73

96,586

$ 4.35

Options exercisable at year-end

296,821

$ 7.69

49,236

$ 3.29

Weighted average fair value per share of options granted during the fiscal year

$ 7.25

$ 5.58

As of June 30, 2021 Options Outstanding

As of June 30, 2021 Exercisable

Weighted-

Average

Weighted-

Weighted-

Range

Remaining

Average

Average

Exercise

Number

Contractual

Exercise

Number

Exercise

Prices

Outstanding

Life (Years)

Price

Outstanding

Price

$5.35 - $ 11.30

1,120,052

9.35

$ 9.03

238,351

$ 8.76

$2.91 - $ 4.65

60,705

5.28

$ 3.36

58,470

$ 3.32

1,180,757

296,821

As of June 30, 2020 Options Outstanding

As of June 30, 2020 Exercisable

Weighted-

Average

Weighted-

Weighted-

Range

Remaining

Average

Average

Exercise

Number

Contractual

Exercise

Number

Exercise

Prices

Outstanding

Life (Years)

Price

Outstanding

Price

$5.35- $ 11.30

25,881

9.87

$ 7.47

-

$ 0.00

$2.91- $ 4.65

70,705

6.46

$ 3.33

49,236

$ 3.29

96,586

49,236

X

- Definition
The entire disclosure for share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-URI http://asc.fasb.org/topic&trid=2228938
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 34 R25.htm IDEA: XBRL DOCUMENT v3.22.1

Equity
9 Months Ended 12 Months Ended

Mar. 31, 2022

Jun. 30, 2021

Stockholders Equity Abstract

Equity
12. Equity

Authorized Shares

On February 25, 2022, at the Company’s Annual Stockholders Meeting, the stockholders of the Company approved an amendment to its Certificate of Incorporation to increase the number of authorized shares of the Company’s common stock by 5,000,000 shares from 15,000,000 to 20,000,000 shares.

In addition, the stockholders also approved the adoption of the Company’s 2022 Equity Incentive Plan (“Plan”) providing for the issuance of up to 1,750,000 shares plus outstanding options granted under the Company’s 2012 Stock Option Plan that expire or are forfeited. The Plan provides various stock awards including incentive and nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, and other stock awards, which can be awarded to employees and directors of the Company and its subsidiaries.

Issuance and Sale of Common Stock

On March 2, 2022, the Company entered into a Securities Purchase Agreement with certain private investors pursuant to which the Company issued and sold an aggregate of 545,456 shares of common stock and warrants to purchase up to an additional 274,727 shares of common stock, at an offering price of $5.50 per share, for a gross consideration of $3,000,000. The issuance cost related to this private placement stock issuance amounted to approximately $272,800. Under the terms of Securities Purchase Agreement between the Company and the investors, the Company must use commercially reasonable efforts to file a registration statement with the SEC within 90 days of the closing date to register for resale the shares of common stock sold in the private offering, including the shares of common stock issuable upon the exercise of the warrants. As of March 31, 2022, the Company had not yet filed a registration statement with respect to the offering.

15. Equity

At the 2020 Annual Meeting of Stockholders, the stockholders of the Company approved an amendment to the Certificate of Incorporation of the Company to increase the number of authorized shares of the Company’s Common stock by 3,000,000 shares from 7,000,000 to 10,000,000 shares, and a further amendment was approved by a majority of the Company’s shareholders on June 17, 2021 increasing the authorized shares to 15,000,000.

On June 18, 2020, the Company entered into a securities purchase agreement in the amount of $6,074,400 with several accredited investors for the sale and issuance of 1,349,850 shares of the Company’s Common Stock at an offering price of $4.50 per share and warrants to purchase up to 1,349,850 shares of the Company’s Common Stock exercisable at $9.0 0 per share. The issuance cost realated to this stock issuance amounted to approximately $70,000. The proceeds were used to fund the operations of the Company’s Bioprocessing Systems Operations. The warrants were immediately exercisable and expire five years from the date of issuance. If at any time commencing twelve months from the date of the agreement, but before the expiration of the warrant, the volume weighted average price of the Company’s Common Stock exceeds $18 per share for each of thirty consecutive days, the Company may at any time in its sole discretion, call for the exercise of the Warrants, in their entirety.

On April 29, 2021, the Company received proceeds of approximately $7,580,400 from the sale of its securities to private investors upon the issuance of 1,595,880 shares of the Company’s Common Stock at an offering price of $4.75 per share which included warrants to purchase up to 797,940 shares of the Company’s Common Stock exercisable at $9.50 per share. The issuance costs related to this stock issuance amounted to approximately $581,000. In June 2021, the Company received an additional $9.5 million through the sale of an additional 2,000,000 shares of the Company’s Common Stock at $4.75 per share which also included warrants to purchase up to 999,993 of the Company's Common Stock exercisable at $9.50 per share. The issuance costs related to this stock issuance amounted to approximately $425,400. These warrants are exercisable immediately and expire five years from date of issuance. The Company utilized the services of brokers for both transactions and incurred a total of approximately $1.0 million in issuance related costs for broker and legal fees. The Company was required under a registration rights agreement to register the shares, which it did through an S-1 Registration Statement filed with the Securities and Exchange Commission, which became effective on August 13, 2021. The proceeds were used for the Aquila acquisition with the remainder being used to fund the Bioprocessing Systems Operations.

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI http://asc.fasb.org/topic&trid=2208762

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690
+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 35 R26.htm IDEA: XBRL DOCUMENT v3.22.1

Summary of Significant Accounting Policies (Policies)
9 Months Ended 12 Months Ended

Mar. 31, 2022

Jun. 30, 2021

Summary of Significant Accounting Policies

Nature of Operations
The accompanying consolidated financial statements include the accounts of Scientific Industries, Inc., its wholly- owned subsidiary, Scientific Bioprocessing Holdings, Inc. (“SBHI”), SBHI’s wholly-owned subsidiaries, Scientific Bioprocessing, Inc. (“SBI”), and aquila biolabs GmbH (“Aquila”), a German corporation, which was acquired on April 29, 2021, Scientific Packaging Industries, Inc., an inactive wholly-owned subsidiary, and Altamira Instruments, Inc. (“Altamira”), and wholly-owned subsidiary (accounted for as a discontinued operation as of November 30, 2020) (all collectively referred to as the “Company”). All material intercompany balances and transactions have been eliminated in consolidation.

Scientific Industries, Inc. and its subsidiaries (the “Company”) design, manufacture, and market a variety of benchtop laboratory equipment and bioprocessing products. The Company is headquartered in Bohemia, New York where it produces benchtop laboratory equipment. Additionally, the Company has two other locations in Pittsburgh, Pennsylvania and Baesweiller, Germany, where it designs and produces a variety of bioprocessing products, and an administrative facility in Orangeburg, New York related to sales and marketing. The products, which are sold to customers worldwide, include mixers, shakers, stirrers, refrigerated incubators, pharmacy balances and scales, force gauges, bioprocessing-sensors and analytical tools. The Company also sublicenses certain patents and technology under a license agreement with the University of Maryland, Baltimore County, and receives royalty fees from sublicenses (see Note 1- Revenue Recognition).

COVID-19 Pandemic
The challenges posed by the COVID-19 pandemic on the global economy began to take effect and adversely affected the Company’s operations at the end of the third quarter of the fiscal year ended June 30, 2020. At that time, the Company took appropriate action and put plans in place to diminish the adverse effects of COVID-19 on its operations, enabling the Company to continue to operate with minor or temporary disruptions to its operations. The Company took immediate action pertaining to COVID-19 preparedness by implementing the US Center for Disease Control’s guidelines for employers in order to protect the Company’s employees’ health and safety, with actions such as implementing work from home, social distancing in the workplace, requiring self-quarantine for any employee showing symptoms, wearing face coverings, and training employees on maintaining a healthy work environment. The Company experienced supply chain disruptions which had an impact on its operations causing delayed delivery of some products to its customers, and production inefficiencies. SBI’s facility was shut down temporarily due to state mandates, however, the impact on operations was minimal, and the Company was able to retain its employees without furloughs or layoffs, in part, due to the Company’s receipt of two loans under the Federal Government’s Small Business Administration Paycheck Protection Program (“PPP”).

The Company received $563,800 and $433,800 in PPP loans in April 2020 and March 2021, respectively. The first loan was forgiven in June 2021 except for $32,700 which was repaid by the Company and the second loan was forgiven in full in December 2021. The Company elected to account for its PPP Loans in accordance with Accounting Standards Codification (“ASC”), Topic 470 Debt, with interest, if any, accrued in accordance with the interest method under ASC 835-30, Imputation of Interest. Initially, the Company recognized the entire loan amounts as liabilities on its balance sheets and remained as liabilities until either the Company was legally released from its obligations or paid the lender. Once the loans were forgiven, the amounts forgiven were recorded in the Company’s statement of operations as “Other Income.”

The challenges posed by the COVID-19 pandemic on the global economy began to take effect and impacted the Company’s operations at the end of the third quarter of the year ended June 30, 2020. At that time, the Company took appropriate action and put plans in place to diminish the effects of COVID-19 on its operations, enabling the Company to continue to operate with minor or temporary disruptions to its operations. The Company took immediate action as it pertains to COVID-19 preparedness by implementing the Center for Disease Control’s guidelines for employers in order to protect the Company’s employees’ health and safety, with actions such as implementing work from home, social distancing in the workplace, requiring self-quarantine for any employee showing symptoms, wearing face coverings, and training employees on maintaining a healthy work environment. The Bioprocessing Systems Operations’ SBI facility was shut down temporarily due to state mandates, however, the impact on operations was immaterial, and the Company has been able to retain its employees without furloughs or layoffs, in part, due to the Company’ receipt of two loans under the Federal Government’s Small Business Administration Paycheck Protection Program. The Company received $563,800 and $433,800 in Payroll Protection Program loans in April 2020 and March 2021, respectively. The first loan was forgiven in June 2021 except for $32,700 which was repaid by the Company. The Company expects to apply and receive forgiveness for the second loan. The operations of aquila biolabs GmbH ("Aquila") which was acquired on April 29, 2021 was negatively impacted in its ability to secure new orders because Aquila had historically relied on face-to-face meetings at trade shows for its sales opportunities. While it has participated in virtual trade shows, management believes that certain sales opportunities are lost as a result. The Company has not experienced and does not anticipate any material impact on its ability to collect its accounts receivable due to the nature of its customers, which are primarily distributors of laboratory equipment and supplies which have benefitted from the Pandemic due to the nature of the products and have the ability to pay. The Company has not experienced and does not anticipate any material impairment to its tangible and intangible assets, system of internal controls, or delivery and distribution of its products as a result of COVID-19, however the ultimate impact of COVID-19 on the Company’s business, results of operations, financial condition and cash flows is dependent on future developments, including the duration or worsening of the pandemic and the related length of its impact on the global economy, which are uncertain and cannot be predicted at this time. The Company is currently experiencing some delays from its supply chain which is having an impact on delayed delivery of some products, however this is deemed temporary and does not affect the Company’s major product – the Vortex-Genie 2. In addition, due to the travel restrictions imposed by the United States and other governments worldwide, Company personnel may be restricted from traveling to conduct its operations including site visits, customer visits and installations, vendor facility visits, and other sales and marketing related travel that can negatively impact the Company.

Principles of consolidation
The accompanying consolidated financial statements include the accounts of Scientific Industries, Inc., Scientific Packaging Industries, Inc., an inactive wholly-owned subsidiary, Altamira Instruments, Inc. (“Altamira”), a Delaware corporation and wholly-owned subsidiary (discontinued operation as of November 30, 2020), and Scientific Bioprocessing Holdings, Inc. (“SBHI”), a newly incorporated Delaware corporation and its wholly-owned subsidiaries, Scientific Bioprocessing, Inc. (“SBI”), a Delaware corporation, and Aquila, a German corporation, which was acquired on April 29, 2021, (all collectively referred to as the “Company”). On April 30, 2021 Scientific Industries, Inc. contributed 100% of the stock of Scientific Bioprocessing, Inc. to its wholly owned subsidiary Scientific Bioprocessing Holdings, Inc. All material intercompany balances and transactions have been eliminated in consolidation.

Revenue Recognition
The Company recognizes revenue in accordance with Financial Accounting Standards Board ('FASB") Accounting Standards Codification (“ASC”) Topic 606 “Revenue from Contracts with Customers, (“ASC 606”). In accordance with ASC 606, the Company accounts for a customer contract when both parties have approved the contract and are committed to perform their respective obligations, each party’s rights can be identified, payment terms can be identified, the contract has commercial substance, and it is probable that the Company will collect substantially all of the consideration to which it is entitled. Revenue is recognized when, or as, performance obligations are satisfied by transferring control of a promised product or service to a customer.

All of the Company's contracts have a single performance obligation. As permitted by ASC 606, the Company does not disclose the amount of unsatisfied performance obligations for client contracts with an original expected length of one year or less.

The Company determines revenue recognition through the following steps:

·
Identification of the contract, or contracts, with a customer

·
Identification of the performance obligations in the contract

·
Determination of the transaction price

·
Allocation of the transaction price to the performance obligations in the contract

·
Recognition of revenue when, or as, a performance obligation is satisfied

Nature of Products and Services

We generate revenues from the following sources: (1) Benchtop Laboratory Equipment and (2) Bioprocessing Systems.

Benchtop Laboratory Equipment

Bioprocessing
Systems

Consolidated

June 30, 2021:

Revenues

$ 9,043,600

731,600

$ 9,775,200

Foreign Sales

3,483,700

684,600

4,168,300

Benchtop Laboratory Equipment

Bioprocessing
Systems

Consolidated

June 30, 2020:

Revenues

$ 6,783,600

$ 1,000,800

$ 7,784,400

Foreign Sales

2,589,800

1,000,400

3,590,200

Benchtop laboratory equipment sales comprise primarily of standard benchtop laboratory equipment to laboratory equipment distributors, or to end users primarily via e-commerce. The sales cycle from time of receipt of order to shipment is very short varying from a day to a few weeks. Customers either pay by credit card (online sales) or Net 30-90, depending on the customer. Once the item is shipped under the FOB terms specified in the order, which is primarily “FOB Factory”, other than a standard warranty, there are no other obligations to the customer. Warranty usually comprises of one to two year parts and labor and is deemed immaterial. Revenue is recognized at a point in time when the risks and rewards of ownership have tranferred to the customer, which is generally upon shipment.

Bioprocessing revenues consist of royalty revenues generated through SBI and product revenues generated primarily through Aquila. Royalty revenues are earned by the Company under a licensing agreement from a single licensee and its sublicenses. The license agreement includes two United States patents and a European Union patent (through December 2019). In January 2020, the European Union patent which was due to expire in August 2020, was terminated and the Company will only receive royalties under the United States patents through December 2023, which will result in a material reduction in total royalties expected to be received. The Company is obligated to pay 50% of all royalties earned to the entity that licenses the intellectual property to the Company. Royalty revenue requires significant judgement in estimating royalty revenue to be recognized during the year.

The Company has made the following accounting policy elections and elected to use certain practical expedients, as permitted by the FASB, in applying ASC 606: 1) All revenues are recorded net of returns, allowances, customer discounts, and incentives; 2) Although sales and other taxes are immaterial, the Company accounts for amounts collected from customers for sales and other taxes, if any, net of related amounts remitted to tax authorities; 3) the Company expenses costs to obtain a contract as they are incurred if the expected period of benefit, and therefore the amortization period, is one year or less; 4) the Company accounts for shipping and handling activities that occur after control transfers to the customer as a fulfillment cost rather than an additional promised service and these fulfillment costs fall within selling expenses; 5) the Company is always considered the principal and never an agent, because it has full control and responsibility until title is transferred to the customer; 6) the Company does not assess whether promised goods or services are performance obligations if they are immaterial in the context of the contract with the customer such as is the case with catalyst instruments.

Cash and Cash Equivalents
The Company considers all highly liquid debt instruments purchased with original maturities of 90 days or less to be cash equivalents. At times, cash balances may be in excess of the Federal Deposit Insurance Corporation (“FDIC”) insurance limit. As of June 30, 2021, and 2020, $8,922,800 and $6,729,300 respectively of cash balances were in excess of such limit.

Reclasses
Certain amounts on the balance sheet as of June 30, 2021 and 2020 pertaining to inventories, property and equipment, goodwill, accounts payable, accrued expenses, contract liabilities, and operating leases liabilities were reclassed as assets and liabilities of discontinued operations due to the sale of the Company's wholly owned subsidiary, Altamira Instruments, Inc. on November 30, 2020.

Accounts Receivable
In order to record the Company’s accounts receivable at their net realizable value, the Company must assess their collectability. A considerable amount of judgment is required in order to make this assessment, including an analysis of historical bad debts and other adjustments, a review of the aging of the Company’s receivables, and the current creditworthiness of the Company’s customers. The Company has recorded allowances for receivables which it considered uncollectible, including amounts for the resolution of potential credit and other collection issues such as disputed invoices and customer satisfaction claims. However, depending on how such potential issues are resolved, or if the financial condition of any of the Company’s customers was to deteriorate and its ability to make required payments became impaired, increases in these allowances may be required. The Company actively manages its accounts receivable to minimize credit risk. The Company does not obtain collateral for its accounts receivable. Based on its assessment, the Company concluded that there are no collection issues related to the COVID-19 Pandemic.

Recent Accounting Pronouncements
The Company has implemented all new accounting pronouncements that are in effect and is evaluating any that may impact its financial statements. The Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes, which is designed to simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. ASU No. 2020-12 is effective for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years; this ASU allows for early adoption in any interim period after issuance of the update. The Company is currently evaluating the impact of adopting this guidance.

Adopted Accounting Pronouncements
In December 2019, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2019-12, “Simplifying the Accounting for Income Taxes”, which is designed to simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. ASU No. 2019-12 is effective for fiscal years beginning after December 15, 2020. The adoption of this standard as of July 1, 2021 did not have a material impact on the Company’s financial statements.

In August 2018, the FASB issued Accounting Standards Update ("ASU") 2018-13, "Fair Value Measurement (Topic 820): Disclosure Framework Changes to the Disclosure Requirements for Fair Value Measurement", which is part of the FASB disclosure framework project to improve the effectiveness of disclosures in the notes to the financial statements. The amendments in the new guidance remove, modify, and add certain disclosure requirements related to fair value measurements covered in Topic 820, "Fair Value Measurement." The new standard is effective for fiscal years beginning after December 15, 2019. Early adoption is permitted for either the entire standard or only the requirements that modify or eliminate the disclosure requirements, with certain requirements applied prospectively, and all other requirements applied retrospectively to all periods presented.

In February 2016, the FASB issued ASU No. 2016-02, Leases, which replaces previous lease guidance in its entirety with ASC 842 and requires lessees to recognize lease assets and lease liabilities for those arrangements classified as operating leases under previous guidance, with the exception of leases with a term of twelve months or less. The Company adopted ASU No. 2016-02 on July 1, 2019 using the additional transition method, which allows prior periods to be presented under previous lease accounting guidance. Refer to Note 11, "Leases", for related disclosures.

Contract Liabilities
Contract liabilities consists of billings or payments received in advance of revenue recognition and is recognized as the revenue recognition criteria are met. Amounts that have been invoiced are initially recorded in accounts receivable and contract liabilities. The Company invoices its customers in accordance with the terms of the underlying contract. Accordingly, the contract liabilities balance does not represent the total contract value of outstanding arrangements. Contract liabilities that are expected to be recognized during the subsequent 12-month period are recorded as current and the remaining portion as noncurrent. Contract liabilities were not significant at June 30, 2021 and 2020, respectively.

Investment Securities
Investment securities consist of equity securities and mutual funds with realized gains and losses recorded using the specific identification method. Changes in fair value are recorded as unrealized holding gains or losses in other income (loss), net on the statement of comprehensive loss. The Company determines the cost of the investment sold based on an average cost basis at the individual security level and records the interest income and realized gains or losses on the sale of these investments in other income (loss), net.

Inventories
Inventories are valued at the lower of cost (determined on a first-in, first-out basis) or net realizable value, and have been reduced by an allowance for excess and obsolete inventories. The estimate is based on management’s review of inventories on hand compared to estimated future usage and sales. Cost of work-in-process and finished goods inventories include material, labor and manufacturing overhead.

Property and Equipment
Property and equipment are stated at cost. Depreciation of property and equipment is provided for primarily by the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized by the straight-line method over the remaining term of the related lease or the estimated useful lives of the assets, whichever is shorter.

Research and Development Expenses
Research and development expenses are expensed as incurred and consist principally of internal and external costs which includes the cost of patent licenses, contract research services, laboratory supplies, in-process research and development acquired, as well as product developments and enhancements.

Intangible Assets
Intangible assets consist primarily of acquired technology, customer relationships, non-compete agreements, patents, licenses, websites, and in process research and development (“IPR&D”), trademarks and trade names. All finite lived intangible assets are amortized on a straight-line basis over the estimated useful lives of the respective assets, generally 3 to 10 years. The Company continually evaluates the remaining estimated useful lives of intangible assets that are being amortized to determine whether events or circumstances warrant a revision to the remaining period of amortization.

Goodwill and Indefinite Lived Intangible Assets
Goodwill represents the excess of purchase price over the fair value of identifiable net assets acquired in a business combination. Goodwill and indefinite lived intangible assets are tested for impairment at least annually in accordance with the provisions of ASC 350, “Intangibles-Goodwill and Other” (“ASC 350”). ASC 350 requires that goodwill be tested for impairment at the reporting unit level (operating segment or one level below an operating segment) on an annual basis and between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value. Application of the goodwill impairment test requires judgment, including the identification of reporting units, assignment of assets and liabilities to reporting units, assignment of goodwill to reporting units, and determination of the fair value of each reporting unit. The Company tests goodwill and long-lived assets annually as of June 30, the last day of its fiscal year, unless an event occurs that would cause the Company to believe the value is impaired at an interim date. The Company concluded as of June 30, 2021 and 2020, there was no impairment of goodwill or indefinite lived intangible assets.

Impairment of Long-Lived Assets
The Company follows the provisions of ASC No. 360, “Property, Plant and Equipment - Impairment or Disposal of Long-Lived Assets (“ASC 360"). ASC 360 which requires evaluation of the need for an impairment charge relating to long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If an evaluation for impairment is required, the estimated future undiscounted cash flows associated with the asset would be compared to the asset’s carrying amount to determine if a write down to a new depreciable basis is required. If required, an impairment charge is recorded based on an estimate of future discounted cash flows. The Company concluded as of June 30, 2021 and 2020, there was no impairment of long-lived assets.

Income Taxes
The Company and its subsidiaries file a consolidated U.S. federal income tax return. Income taxes are accounted for under the asset and liability method. The Company provides for federal, and state income taxes currently payable, as well as for those deferred due to timing differences between reporting income and expenses for financial statement purposes versus tax purposes. Deferred tax assets and liabilities are recognized for the future tax consequences attributed to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted income tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect of a change in income tax rates is recognized as income or expense in the period that includes the enactment date.

The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs.

Advertising
Advertising costs are expensed as incurred. Advertising expense amounted to $399,700 and $218,700 for the years ended June 30, 2021 and 2020, respectively.

Stock Compensation Plan
The Company has a ten-year stock option plan (the “2012 Plan”) which provides for the grant of options to purchase up to 1,193,000 shares of the Company’s Common Stock, par value $.05 per share (“Common Stock”), plus up to 57,000 shares under options previously granted under the 2002 Stock Option Plan of the Company (the “Prior Plan”).

The 2012 Plan provides for the granting of incentive or non-incentive stock options as defined in the 2012 Plan through 2022. Incentive stock options may be granted to employees at an exercise price equal to 100% (or 110% if the optionee owns directly or indirectly more than 10% of the outstanding voting stock) of the fair market value of the shares of Common Stock on the date of the grant. Non-incentive stock options shall be granted at the fair market value of the shares of Common Stock on the date of grant. At June 30, 2021 and 2020, 5,243 and 147,414 shares respectively, of Common Stock were available for grant of options under the 2012 Plan.

Stock-based compensation is accounted for in accordance with ASC No. 718 “Compensation-Stock Compensation” (“ASC No. 718”) which requires compensation costs related to stock-based payment transactions to be recognized. The amount of compensation cost is measured based on the grant-date fair value of the equity issued and expensed ratably over the requisite service period.

Use of Estimates
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission requires management to make estimates and judgments that affect the amounts reported in the financial statements and accompanying notes. Estimates are used for, but not limited to, the allowance for doubtful accounts, slow-moving inventory reserves, depreciation and amortization, assumptions made in valuing equity instruments, fair value of stock options, the fair values of intangibles and goodwill, and provision or benefit for income taxes. The actual results experienced by the Company may differ materially from management’s estimates.

Earnings (Loss) Per Common Share
Basic earnings or loss per common share is computed by dividing net income (loss) by the weighted-average number of shares outstanding. Diluted earnings per common share includes the dilutive effect of stock options, if any. Since the Company was in a loss position during the years ended June 30, 2021 and 2020, respectively, basic net loss per share is the same as dilutive net loss per share as the inclusion of the weighted-average number of all potential dilutive common shares which consists of stock options and warrants are anti-dilutive.

X

- References
No definition available.
+ Details

Name: scnd_CovidPandemicPolicyTextBlock

Namespace Prefix: scnd_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: scnd_DescriptionOfNewAccountingPronouncementNotYetAdopted

Namespace Prefix: scnd_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for advertising cost.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 720
-SubTopic 35
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848
+ Details

Name: us-gaap_AdvertisingCostsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(1))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684
+ Details

Name: us-gaap_ConsolidationPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for deferred revenues at the end of the reporting period, and description and amounts of significant changes that occurred during the reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 430
-URI http://asc.fasb.org/topic&trid=2122452
+ Details

Name: us-gaap_DeferredRevenueDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257
+ Details

Name: us-gaap_EarningsPerSharePolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 05
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.CC)
-URI http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742
+ Details

Name: us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319
+ Details

Name: us-gaap_IncomeTaxPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 920
-SubTopic 350
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 920
-SubTopic 350
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 920
-SubTopic 350
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783
+ Details

Name: us-gaap_IntangibleAssetsFiniteLivedPolicy

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for determining where the cash flows related to the sale of inventory are classified in the statements of cash flows and explain the nature of the receivables, notes, and loans.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 55
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=123431969&loc=d3e4458-108587
+ Details

Name: us-gaap_InventoryCashFlowPolicy

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for investment classified as marketable security.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 320
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=123599081&loc=d3e62652-112803
+ Details

Name: us-gaap_MarketableSecuritiesPolicy

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-URI http://asc.fasb.org/topic&trid=2134479
+ Details

Name: us-gaap_NatureOfOperations

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 958
-SubTopic 360
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13(a))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 958
-SubTopic 360
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_PropertyPlantAndEquipmentPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534
+ Details

Name: us-gaap_ReceivablesPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for classifying current financial statements, which may be different from classifications in the prior year's financial statements. Disclose any material changes in classification including an explanation of the reason for the change and the areas impacted.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-URI http://asc.fasb.org/topic&trid=2122149
+ Details

Name: us-gaap_Reclassifications

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_ResearchAndDevelopmentExpensePolicy

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790
+ Details

Name: us-gaap_RevenueRecognitionPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b),(f)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901
+ Details

Name: us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592
+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 36 R27.htm IDEA: XBRL DOCUMENT v3.22.1

Summary of Significant Accounting Policies (Tables)
9 Months Ended 12 Months Ended

Mar. 31, 2022

Jun. 30, 2021

Summary of Significant Accounting Policies

Disaggregation of revenues

Benchtop Laboratory Equipment

Bioprocessing Systems

Consolidated

Three Months Ended March 31, 2022:

Revenues

$ 2,434,600

$ 430,300

$ 2,864,900

Foreign Sales

783,600

269,700

1,053,300

Benchtop Laboratory Equipment

Bioprocessing Systems

Consolidated

Three Months Ended March 31, 2021:

Revenues

$ 2,365,700

$ 142,900

$ 2,508,600

Foreign Sales

942,200

102,600

1,044,800

Benchtop Laboratory Equipment

Bioprocessing Systems

Consolidated

Nine Months Ended March 31, 2022:

Revenues

$ 7,465,700

$ 1,157,800

$ 8,623,500

Foreign Sales

2,814,700

791,200

3,605,900

Benchtop Laboratory Equipment

Bioprocessing Systems

Consolidated

Nine Months Ended March 31, 2021:

Revenues

$ 6,803,300

$ 441,800

$ 7,245,100

Foreign Sales

2,724,800

395,000

3,119,800

Benchtop Laboratory Equipment

Bioprocessing
Systems

Consolidated

June 30, 2021:

Revenues

$ 9,043,600

731,600

$ 9,775,200

Foreign Sales

3,483,700

684,600

4,168,300

Benchtop Laboratory Equipment

Bioprocessing
Systems

Consolidated

June 30, 2020:

Revenues

$ 6,783,600

$ 1,000,800

$ 7,784,400

Foreign Sales

2,589,800

1,000,400

3,590,200

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045
+ Details

Name: us-gaap_DisaggregationOfRevenueTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 37 R28.htm IDEA: XBRL DOCUMENT v3.22.1

Revenue (Tables)
9 Months Ended 12 Months Ended

Mar. 31, 2022

Jun. 30, 2021

Revenue (Tables)

Schedule Of Revenue

Benchtop Laboratory Equipment

Bioprocessing Systems

Consolidated

Three Months Ended March 31, 2022:

Revenues

$ 2,434,600

$ 430,300

$ 2,864,900

Foreign Sales

783,600

269,700

1,053,300

Benchtop Laboratory Equipment

Bioprocessing Systems

Consolidated

Three Months Ended March 31, 2021:

Revenues

$ 2,365,700

$ 142,900

$ 2,508,600

Foreign Sales

942,200

102,600

1,044,800

Benchtop Laboratory Equipment

Bioprocessing Systems

Consolidated

Nine Months Ended March 31, 2022:

Revenues

$ 7,465,700

$ 1,157,800

$ 8,623,500

Foreign Sales

2,814,700

791,200

3,605,900

Benchtop Laboratory Equipment

Bioprocessing Systems

Consolidated

Nine Months Ended March 31, 2021:

Revenues

$ 6,803,300

$ 441,800

$ 7,245,100

Foreign Sales

2,724,800

395,000

3,119,800

Benchtop Laboratory Equipment

Bioprocessing
Systems

Consolidated

June 30, 2021:

Revenues

$ 9,043,600

731,600

$ 9,775,200

Foreign Sales

3,483,700

684,600

4,168,300

Benchtop Laboratory Equipment

Bioprocessing
Systems

Consolidated

June 30, 2020:

Revenues

$ 6,783,600

$ 1,000,800

$ 7,784,400

Foreign Sales

2,589,800

1,000,400

3,590,200

X

- References
No definition available.
+ Details

Name: scnd_RevenueTablesAbstract

Namespace Prefix: scnd_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045
+ Details

Name: us-gaap_DisaggregationOfRevenueTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 38 R29.htm IDEA: XBRL DOCUMENT v3.22.1

Segment Information and Concentrations (Tables)
9 Months Ended 12 Months Ended

Mar. 31, 2022

Jun. 30, 2021

Segment Information

Segment information

Benchtop Laboratory Equipment

Bioprocessing Systems

Corporate And Other

Consolidated

Three Months Ended March 31, 2022:

Revenues

$ 2,434,600

$ 430,300

$ -

$ 2,864,900

Foreign Sales

783,600

269,700

-

1,053,300

Income (Loss) From Operations

247,300

(1,651,700 )

(337,900 )

(1,742,300 )

Assets

10,231,100

10,024,261

10,271,439

30,526,800

Long-Lived Asset Expenditures

16,500

158,000

-

174,500

Depreciation and Amortization

24,600

229,900

-

254,500

Benchtop Laboratory Equipment

Bioprocessing Systems

Corporate And Other

Consolidated

Three Months Ended March 31, 2021:

Revenues

$ 2,365,700

$ 142,900

$ -

$ 2,508,600

Foreign Sales

942,200

102,600

-

1,044,800

Income (Loss) From Operations

394,700

(1,323,900 )

(929,600 )

(1,858,800 )

Assets

5,979,400

1,281,200

6,639,700

13,900,300

Long-Lived Asset Expenditures

18,600

92,100

-

110,700

Depreciation and Amortization

30,000

16,700

-

46,700

Benchtop Laboratory Equipment

Bioprocessing Systems

Corporate And Other

Consolidated

Nine Months Ended March 31, 2022:

Revenues

$ 7,465,700

$ 1,157,800

$ -

$ 8,623,500

Foreign Sales

2,814,700

791,200

-

3,605,900

Income (Loss) From Operations

1,107,000

(5,091,300 )

(1,127,200 )

(5,111,500 )

Assets

10,231,100

10,024,261

10,271,439

30,526,800

Long-Lived Asset Expenditures

83,100

321,300

-

404,400

Depreciation and Amortization

71,200

510,600

-

581,800

Benchtop Laboratory Equipment

Bioprocessing Systems

Corporate And Other

Consolidated

Nine Months Ended March 31, 2021:

Revenues

$ 6,803,300

$ 441,800

$ -

$ 7,245,100

Foreign Sales

2,724,800

395,000

-

3,119,800

Income (Loss) From Operations

1,347,100

(2,598,000 )

(1,048,000 )

(2,298,900 )

Assets

5,979,400

1,281,200

6,639,700

13,900,300

Long-Lived Asset Expenditures

54,100

170,800

-

224,900

Depreciation and Amortization

79,700

46,500

500

126,700

Benchtop Laboratory Equipment

Bioprocessing Systems

Corporate and Other

Consolidated

June 30, 2021:

Revenues

$ 9,043,600

$ 731,600

$ -

$ 9,775,200

Foreign Sales

3,483,700

684,600

_

4,168,300

Income (Loss) From Operations

1,461,300

(4,828,600 )

(1,341,400 )

(4,708,800 )

Assets

14,783,000

8,735,100

5,488,300

29,006,400

Long-Lived Asset Expenditures

60,500

196,900

-

257,400

Depreciation and Amortization

103,100

148,400

-

251,500

Benchtop Laboratory Equipment

Bioprocessing Systems

Corporate and Other

Consolidated

June 30, 2020:

Revenues

$ 6,783,600

$ 1,000,800

$ -

$ 7,784,400

Foreign Sales

2,589,800

1,000,400

-

3,590,200

Income (Loss) From Operations

449,700

(727,500 )

(385,700 )

(663,500 )

Assets

12,232,600

546,100

2,018,700

14,797,400

Long-Lived Asset Expenditures

36,000

40,700

-

76,700

Depreciation and Amortization

116,900

42,700

-

159,600

X

- Definition
Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599
+ Details

Name: us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SegmentReportingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 39 R30.htm IDEA: XBRL DOCUMENT v3.22.1

Fair Value of Financial Instruments (Tables)
9 Months Ended 12 Months Ended

Mar. 31, 2022

Jun. 30, 2021

Fair Value of Financial Instruments

Fair value inputs

Fair Value at

Fair Value Measurements Using Inputs Considered as

March 31,
2022

Level 1

Level 2

Level 3

Assets:

Cash and cash equivalents

$ 4,068,000

$ 4,068,000

$ -

$ -

Investment securities

7,768,600

6,796,500

972,100

-

Total

$ 11,836,600

$ 10,864,500

$ 972,100

$ -

Liabilities:

Contingent consideration

$ 117,500

$ -

$ -

$ 117,500

Fair Value at

Fair Value Measurements Using Inputs Considered as

June 30,
2021

Level 1

Level 2

Level 3

Assets:

Cash and cash equivalents

$ 9,675,200

$ 9,675,200

$ -

$ -

Investment securities

3,744,600

2,920,600

824,000

-

Total

$ 13,419,800

$ 12,595,800

$ 824,000

$ -

Liabilities:

Contingent consideration

$ 160,000

$ -

$ -

$ 160,000

Fair Value at June 30,

Fair Value Measurements Using Inputs Considered as

2021

Level 1

Level 2

Level 3

Assets:

Cash and cash equivalents

$ 9,675,200

$ 9,675,200

$ -

$ -

Investment securities

3,744,600

2,920,600

824,000

-

Total

$ 13,419,800

$ 12,595,800

$ 824,000

$ -

Liabilities:

Contingent consideration

$ 160,000

$ -

$ 160,000

Fair Value Measurements Using Inputs Considered as

Fair Value at June 30, 2020

Level 1

Level 2

Level 3

Assets:

Cash and cash equivalents

$ 7,559,700

$ 7,559,700

$ -

$ -

Investment securities

331,800

331,800

-

-

Total

$ 7,891,500

$ 7,891,500

$ -

$ -

Liabilities:

Contingent consideration

$ 358,000

$ -

$ 358,000

Investments in marketable securitites

Cost

Fair Value

Unrealized
Holding
Gain (Loss)

At March 31, 2022:

Equity securities

$ 118,900

$ 176,900

$ 58,000

Mutual funds

6,708,300

6,619,600

(88,700 )
 Debt securities

977,200

972,100

(5,100 )

$ 7,804,400

7,768,600

(35,800 )

Cost

Fair Value

Unrealized
Holding
Gain (Loss)

At June 30, 2021:

Equity securities

$ 102,200

$ 154,100

$ 51,900

Mutual funds

2,752,400

2,766,500

14,100

Debt securities

832,700

824,000

(8,700 )

$ 3,687,300

$ 3,744,600

$ 57,300

Cost

Fair Value

Unrealized Holding Gain (Loss)

At June 30, 2021:

Equity securities

$ 102,200

$ 154,100

$ 51,900

Mutual funds

2,752,400

2,766,500

14,100

Debt securities

832,700

824,000

(8,700 )

$ 3,687,300

$ 3,744,600

$ 57,300

Cost

Fair Value

Unrealized Holding Gain (Loss)

At June 30, 2020:

Equity securities

$ 77,600

$ 101,900

$ 24,300

Mutual funds

250,300

229,900

(20,400 )

$ 327,900

$ 331,800

$ 3,900

Analysis of changes in Level 3 financial liabilities

2021

2020

Beginning balance

$ 358,000

$ 618,000

Increase (decrease) in contingent consideration liability

(30,000 )

112,600

Payments

(168,000 )

(372,600 )

Ending balance

$ 160,000

$ 358,000

X

- Definition
Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.
+ References
No definition available.
+ Details

Name: us-gaap_MarketableSecuritiesTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258
+ Details

Name: us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 40 R31.htm IDEA: XBRL DOCUMENT v3.22.1

Inventories (Tables)
9 Months Ended 12 Months Ended

Mar. 31, 2022

Jun. 30, 2021

Inventories

Inventories

March 31,
2022

June 30,
2021

Raw materials

$ 3,058,100

$ 2,170,400

Work-in-process

106,400

39,600

Finished goods

1,203,400

767,100

$ 4,367,900

$ 2,977,100

2021

2020

Raw materials

$ 2,170,400

$ 1,726,400

Work-in-process

39,600

35,700

Finished goods

767,100

778,900

$ 2,977,100

$ 2,541,000

X

- References
No definition available.
+ Details

Name: us-gaap_InventoryDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(c))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(b))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(a))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766
+ Details

Name: us-gaap_ScheduleOfInventoryCurrentTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 41 R32.htm IDEA: XBRL DOCUMENT v3.22.1

Property and Equipment (Tables)
12 Months Ended

Jun. 30, 2021

Property and Equipment

Schedule of property and equipment

Useful Lives

(Years)

2021

2020

Automobiles

5

$ 22,000

$ 22,000

Computer equipment

 3-5

233,500

215,300

Machinery and equipment

 3-7

1,047,600

847,500

Furniture and fixtures

 4-10

148,800

142,300

Leasehold improvements

 3-10

64,400

50,300

1,516,300

1,277,400

Less accumulated depreciation and amortization

1,103,700

999,100

$ 412,600

$ 278,300

X

- References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_PropertyPlantAndEquipmentTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 42 R33.htm IDEA: XBRL DOCUMENT v3.22.1

Goodwill and Other Intangible Assets (Tables)
9 Months Ended 12 Months Ended

Mar. 31, 2022

Jun. 30, 2021

Goodwill and Other Intangible Assets

Intangible assets

Useful Lives

Cost

Accumulated Amortization

Net

At March 31, 2022:

Technology, trademarks

5-10 yrs.

$ 817,000

$ 431,800

$ 385,200

Trade names

3-6 yrs.

140,000

140,000

-

Websites

3-7 yrs.

210,000

210,000

-

Customer relationships

4-10 yrs.

372,200

133,100

239,100

Sublicense agreements

10 yrs.

294,000

294,000

-

Non-compete agreements

4-5 yrs.

1,060,500

455,300

605,200

In-process research and development

3-5 yrs.

917,600

249,600

668,000

Patents

5-7 yrs.

593,000

274,200

318,800

$ 4,404,300

$ 2,188,000

$ 2,216,300

Useful Lives

Cost

Accumulated Amortization

Net

At June 30, 2021:

Technology, trademarks

5-10 yrs.

$ 364,700

$ 362,200

$ 2,500

Trade names

3-6 yrs.

592,300

152,600

439,700

Websites

3-7 yrs.

210,000

210,000

-

Customer relationships

4-10 yrs.

372,200

102,400

269,800

Sublicense agreements

10 yrs.

294,000

283,000

11,000

Non-compete agreements

4-5 yrs.

1,060,500

308,600

751,900

In-process research and development

3-5 yrs.

852,100

134,800

717,300

Patents

5-7 yrs.

591,500

225,900

365,600

$ 4,337,300

$ 1,779,500

$ 2,557,800

Useful
Lives

Cost

Accumulated Amortization

Net

At June 30, 2021:

Technology, trademarks

5-10 yrs.

$ 364,700

$ 362,200

$ 2,500

Trade names

3-6 yrs.

592,300

152,600

439,700

Websites

3-7 yrs.

210,000

210,000

-

Customer relationships

4-10 yrs.

372,200

102,400

269,800

Sublicense agreements

10 yrs.

294,000

283,000

11,000

Non-compete agreements

4-5 yrs.

1,060,500

308,600

751,900

IPR&D

3-5 yrs.

852,100

134,800

717,300

Patents

5-7 yrs.

591,500

225,900

365,600

$ 4,337,300

$ 1,779,500

$ 2,557,800

Useful
Lives

Cost

Accumulated Amortization

Net

At June 30, 2020:

Technology, trademarks

5/10 yrs.

$ 664,700

$ 662,000

$ 2,700

Trade names

6 yrs.

140,000

140,000

-

Websites

5 yrs.

210,000

210,000

-

Customer relationships

9/10 yrs.

357,000

321,400

35,600

Sublicense agreements

10 yrs.

294,000

253,600

40,400

Non-compete agreements

5 yrs.

384,000

384,000

-

IPR&D

3 yrs.

110,000

110,000

-

Patents

5 yrs.

246,600

196,600

50,000

$ 2,406,300

$ 2,277,600

$ 128,700

Estimated future amortization expense of intangible assets
Year Ended June 30,

2022

$ 525,700

2023

520,000

2024

508,800

2025

473,100

2026

530,200

Total

$ 2,557,800

X

- Definition
Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275
+ Details

Name: us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 43 R34.htm IDEA: XBRL DOCUMENT v3.22.1

Commitments and Contingencies (Tables)
12 Months Ended

Jun. 30, 2021

Commitments and Contingencies

Fair value of contingent consideration
Year ended June 30,

Amount

2022

$ 136,600

2023

12,000

2024

11,400

160,000

X

- References
No definition available.
+ Details

Name: scnd_FairValueOfContingentConsiderationTableTextBlock

Namespace Prefix: scnd_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 44 R35.htm IDEA: XBRL DOCUMENT v3.22.1

Earnings (Loss) Per Common Share (Tables)
9 Months Ended 12 Months Ended

Mar. 31, 2022

Jun. 30, 2021

Earnings (Loss) Per Common Share (Tables)

Loss per common share

For the Three Month Period Ended March 31, 2022

For the Three Month Period Ended March 31, 2021

For the Nine Month Period Ended March 31, 2022

For the Nine Month Period Ended March 31, 2021

Weighted average number of common shares outstanding

6,633,901

2,861,607

6,544,112

2,861,376

Effect of dilutive securities

-

-

-

-

Weighted average number of dilutive common shares outstanding

6,633,901

2,861,607

6,544,112

2,861,376

Basic and diluted loss per common share:

Continuing operations

$ (0.23 )

$ (0.51 )

$ (0.56 )

$ (0.61 )
Discontinued operations

$ -

$ 0.01

$ -

$ (0.20 )
Consolidated operations

$ (0.23 )

$ (0.50 )

$ (0.56 )

$ (0.81 )

2021

2020

Weighted average number of common shares outstanding

3,189,602

1,515,103

Effect of dilutive securities:

-

-

Weighted average number of dilutive common shares outstanding

3,189,602

1,515,103

Basic and Diluted loss per common share:

Continuing operations

$ (0.97 )

$ (0.30 )
Discontinued operations

$ (0.18 )

$ (0.16 )
Consolidated operations

$ (1.15 )

$ (0.46 )

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the effect of income (loss) on an entity's diluted earnings per share.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258
+ Details

Name: us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 45 R36.htm IDEA: XBRL DOCUMENT v3.22.1

Leases (Tables)
9 Months Ended 12 Months Ended

Mar. 31, 2022

Jun. 30, 2021

Leases

Future minimum rental payments
Fiscal year ending June 30,

Amount

Remainder of 2022

$ 82,200

2023

311,400

2024

247,600

2025

255,000

2026

262,700

Thereafter

609,600

Total future minimum payments

1,768,500

Less imputed interest

(256,100 )
Total Present Value of Operating Lease Liabilities

$ 1,512,400

Year ended June 30,

Amount

2022

$ 260,300

2023

245,300

2024

195,900

2025

91,600

Total future minimum payments

$ 793,100

Less: Imputed interest

(62,100 )
Total Present Value of Operating Lease Liabilities

$ 731,000

X

- References
No definition available.
+ Details

Name: us-gaap_LeasesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 46 R37.htm IDEA: XBRL DOCUMENT v3.22.1

Income Taxes (Tables)
12 Months Ended

Jun. 30, 2021

Income Taxes

Income tax reconciliation

2021

2020

Computed “expected” income tax benefit

$ (1,014,300 )

$ (239,400 )
Research and development credits

(93,900 )

(89,400 )
Rate changes and NOL carrybacks

-

(122,600 )
Incentive Stock Option Expense

59,500

13,800

PPP Loan Forgiveness

(111,700 )

0

Other, net

(7,900 )

1,000

Income tax benefit

$ (1,152,500 )

$ (436,600 )

Deferred tax assets and liabilities

2021

2020

Deferred tax assets:

Amortization of intangible assets, including goodwill

$ 374,000

$ 329,700

Research and development credits

164,600

89,400

Various accruals

64,600

150,700

Stock options expense

383,200

-

Net operating loss

1,515,800

-

Other

24,900

19,400

2,527,100

589,200

Deferred tax liability:

Depreciation of property and amortization of goodwill

(37,200 )

(52,100 )

Net deferred tax assets

$ 2,489,900

$ 537,100

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319
+ Details

Name: us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319
+ Details

Name: us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 47 R38.htm IDEA: XBRL DOCUMENT v3.22.1

Stock Options (Tables)
12 Months Ended

Jun. 30, 2021

Stock Options

Option activity

June 30, 2021

June 30, 2020

Weighted-

Weighted-

Average

Average

Exercise

Exercise

Shares

Price

Shares

Price

Shares under option:

Outstanding, beginning of year

96,586

$ 4.35

97,205

$ 3.24

Granted

1,094,171

9.07

25,881

7.47

Exercised

(1,000 )

3.05

(24,000 )

3.35

Forfeited

(9,000 )

3.11

(2,500 )

3.08

Outstanding, end of year

1,180,757

$ 8.73

96,586

$ 4.35

Options exercisable at year-end

296,821

$ 7.69

49,236

$ 3.29

Weighted average fair value per share of options granted during the fiscal year

$ 7.25

$ 5.58

Options outstanding

As of June 30, 2021 Options Outstanding

As of June 30, 2021 Exercisable

Weighted-

Average

Weighted-

Weighted-

Range

Remaining

Average

Average

Exercise

Number

Contractual

Exercise

Number

Exercise

Prices

Outstanding

Life (Years)

Price

Outstanding

Price

$5.35 - $ 11.30

1,120,052

9.35

$ 9.03

238,351

$ 8.76

$2.91 - $ 4.65

60,705

5.28

$ 3.36

58,470

$ 3.32

1,180,757

296,821

As of June 30, 2020 Options Outstanding

As of June 30, 2020 Exercisable

Weighted-

Average

Weighted-

Weighted-

Range

Remaining

Average

Average

Exercise

Number

Contractual

Exercise

Number

Exercise

Prices

Outstanding

Life (Years)

Price

Outstanding

Price

$5.35- $ 11.30

25,881

9.87

$ 7.47

-

$ 0.00

$2.91- $ 4.65

70,705

6.46

$ 3.33

49,236

$ 3.29

96,586

49,236

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 48 R39.htm IDEA: XBRL DOCUMENT v3.22.1

Discontinued Operations (Tables)
9 Months Ended 12 Months Ended

Mar. 31, 2022

Jun. 30, 2021

Discontinued Operations

Discontinued operations
Assets:

March 31,
2022

June 30,
2021

Cash

$ 600

$ -

Accounts receivable

-

52,000

Inventories

-

3,300

$ 600

$ 55,300

Liabilities:

March 31,
2022

June 30,
2021

Accrued expenses and taxes

$ -

$ 20,700

Contract liabilities

7,900

16,500

$ 7,900

$ 37,200

Three Months Ended

Nine Months Ended

March 31,2022

March 31,2021

March 31,2022

March 31,2021

Revenues

$ -

$ 107,800

$ 20,600

$ 387,700

Cost of goods sold

6,900

78,800

10,300

458,500

Gross profit (loss)

(6,900 )

29,000

10,300

(70,800 )
Selling, general and administrative expenses

700

12,600

2,900

282,200

Income (loss) from operations

(7,600 )

16,400

7,400

(353,000 )
Loss on disposal

-

-

-

(405,400 )
Income (loss) before income tax benefit

(7,600 )

16,400

7,400

(758,400 )
Income tax expense (benefit)

-

-

4,000

(179,900 )
Net income (loss) attributable to discontinued operations

$ (7,600 )

$ 16,400

$ 3,400

$ (578,500 )

Assets:

June 30, 2021

June 30, 2020

Accounts receivable

$ 52,000

$ -

Inventories

3,300

343,700

Property and equipment, net

-

1,400

Goodwill

-

447,900

Discontinued operations

$ 55,300

$ 793,000

Liabilities:

June 30, 2021

June 30, 2020

Accounts payable

$ -

$ 20,100

Accrued expenses and taxes

20,700

120,700

Contract liabilities

16,500

69,000

Operating lease liabilities, current portion

-

31,100

$ 37,200

$ 240,900

Years Ended

June 30, 2021

June 30, 2020

Revenues

$ 387,700

$ 785,900

Cost of goods sold

471,800

869,900

Gross profit

(84,100 )

(84,000 )
Selling, general and administrative expenses

280,400

388,500

Loss from operations

(364,500 )

(472,500 )
Loss on disposal

(405,400 )

--

Loss before income tax benefit

(769,900 )

(472,500 )
Income tax benefit, all deferred

(207,400 )

(222,600 )
Net income (loss) attributable to discontinued operations

$ (562,500 )

$ (249,900 )

X

- References
No definition available.
+ Details

Name: us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760
+ Details

Name: us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 49 R40.htm IDEA: XBRL DOCUMENT v3.22.1

Acquisition of Aquila Biolabs GmbH (Tables)
9 Months Ended 12 Months Ended

Mar. 31, 2022

Jun. 30, 2021

Acquisition of Aquila Biolabs GmbH

Purchase price allocation

Amount

Useful life

Fair value of assets acquired:

Current assets:

Cash and cash equivalents

$ 201,100

Accounts receivable

159,200

Inventory

187,500

Prepaid expenses and other current assets

25,400

Property, plant and equipment

40,200

Deferred tax asset

800,300

Tradename

452,300

6 years

Non-compete agreements

784,500

4 years

In-process research and development

742,100

5 years

Customer relationships

252,200

9 years

Patents and other intangibles

286,200

7 years

Total assets acquired

$ 3,931,000

Fair value of liabilities assumed:

Accounts payable

$ (39,300 )

Accrued expenses

(90,300 )

Other current liabilities

(59,400 )

Total liabilities assumed

$ (189,000 )

Total identifiable net assets

$ 3,742,000

Fair value of consideration transferred

7,880,100

Goodwill

$ 4,138,100

Amount

Useful life

Fair value of assets acquired

Current assets:

Cash and cash equivalents

$ 201,100

Accounts receivable

159,200

Inventory

187,500

Prepaid expenses and other current assets

25,400

Property, plant and equipment

40,200

Deferred tax asset

800,300

Tradename

452,300

 6 years

Non-compete agreements

784,500

4 years

IPR&D

742,100

5 years

Customer relationships

252,200

9 years

Patents and other intangibles

286,200

7 years

Total assets acquired

$ 3,931,000

Fair value of liabilities assumed:

Accounts payable

$ (39,300 )

Accrued expenses

(90,300 )

Other current liabilities

(59,400 )

Total liabilities assumed

(189,000 )

Total identifiable net assets

3,742,000

Fair value of consideration transferred

7,880,100

Goodwill

$ 4,138,100

Pro forma information

(In $000’s)

6/30/2020

Revenues

$ 9,346

Net loss

(1,650 )
Earnings per share

Diluted

$ (0.37 )
Basic

(0.37 )

X

- Definition
Tabular disclosure of the nature and amount of any material, nonrecurring adjustments directly attributable to the business combination(s) included in the reported pro forma revenue and earnings (supplemental pro forma information).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(4)
-URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463
+ Details

Name: us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463
+ Details

Name: us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_BusinessCombinationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 50 R41.htm IDEA: XBRL DOCUMENT v3.22.1

Significant Accounting Policies (Details) - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended

Mar. 31, 2022

Mar. 31, 2021

Mar. 31, 2022

Mar. 31, 2021

Jun. 30, 2021

Jun. 30, 2020

Revenues $ 2,864,900 $ 2,508,600 $ 8,623,500 $ 7,245,100 $ 9,775,200 $ 7,784,400

Benchtop Laboratory Equipment

Revenues 2,434,600 2,365,700 7,465,700 6,803,300 9,043,600 6,783,600

Foreign sales 783,600 942,200 2,814,700 2,724,800 3,483,700 2,589,800

Bioprocessing Systems

Revenues 430,300 142,900 1,157,800 441,800 731,600 1,000,800

Foreign sales $ 269,700 $ 102,600 $ 791,200 $ 395,000 684,600 1,000,400

Consolidated

Revenues 9,775,200 7,784,400

Foreign sales $ 4,168,300 $ 3,590,200

X

- Definition
Custom Element.
+ References
No definition available.
+ Details

Name: scnd_ForeignSales

Namespace Prefix: scnd_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227
+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=scnd_BenchtopLaboratoryEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=scnd_BioprocessingSystemsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=scnd_ConsolidatedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 51 R42.htm IDEA: XBRL DOCUMENT v3.22.1

Significant Accounting Policies (Details Narrative) - USD ($)
6 Months Ended 12 Months Ended

Dec. 31, 2021

Jun. 30, 2021

Jun. 30, 2020

Mar. 31, 2022

Mar. 31, 2021

Apr. 30, 2020

FDIC excess cash balance $ 8,922,800 $ 6,729,300

Advertising expense $ 399,700 $ 218,700

Common stock available for grant 5,243 147,414

Cash $ 0 $ 600

Payroll Protection Program [Member]

Repayment of loan $ 32,700

Cash $ 433,800 $ 563,800

X

- Definition
Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 720
-SubTopic 35
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848
+ Details

Name: us-gaap_AdvertisingExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 210
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 210
-Section 45
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840
+ Details

Name: us-gaap_Cash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.
+ References
No definition available.
+ Details

Name: us-gaap_CashUninsuredAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Cash outflows under financing arrangements with vendors (seller-financed debt), which had a maturity date at inception of more than one year (or more than one operating cycle, if longer); such debt may have arisen from purchases of property, plant and equipment or other productive assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585
+ Details

Name: us-gaap_RepaymentsOfLongtermLoansFromVendors

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_PlanNameAxis=scnd_PayrollProtectionProgramMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 52 R43.htm IDEA: XBRL DOCUMENT v3.22.1

Revenues (Details) - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended

Mar. 31, 2022

Mar. 31, 2021

Mar. 31, 2022

Mar. 31, 2021

Jun. 30, 2021

Jun. 30, 2020

Revenues $ 2,864,900 $ 2,508,600 $ 8,623,500 $ 7,245,100 $ 9,775,200 $ 7,784,400

Benchtop Laboratory Equipment

Revenues 2,434,600 2,365,700 7,465,700 6,803,300 9,043,600 6,783,600

Foreign Sales 783,600 942,200 2,814,700 2,724,800 3,483,700 2,589,800

Bioprocessing Systems

Revenues 430,300 142,900 1,157,800 441,800 731,600 1,000,800

Foreign Sales 269,700 102,600 791,200 395,000 684,600 1,000,400

Consolidated

Revenues 2,864,900 2,508,600 8,623,500 7,245,100 9,775,200 7,784,400

Foreign Sales $ 1,053,300 $ 1,044,800 $ 3,605,900 $ 3,119,800 $ 4,168,300 $ 3,590,200

X

- Definition
Custom Element.
+ References
No definition available.
+ Details

Name: scnd_ForeignSales

Namespace Prefix: scnd_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227
+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=scnd_BenchtopLaboratoryEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=scnd_BioprocessingSystemsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=scnd_ConsolidatedEntityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 53 R44.htm IDEA: XBRL DOCUMENT v3.22.1

Revenues (Details Narrative)
9 Months Ended

Mar. 31, 2022

Segment Information

Description of obligation The Company is obligated to pay 50% of all royalties earned to the entity that licensed the intellectual property to the Company.

X

- References
No definition available.
+ Details

Name: scnd_DescriptionOfObligation

Namespace Prefix: scnd_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SegmentReportingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 54 R45.htm IDEA: XBRL DOCUMENT v3.22.1

Segment Information and Concentrations (Details) - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended

Mar. 31, 2022

Mar. 31, 2021

Mar. 31, 2022

Mar. 31, 2021

Jun. 30, 2021

Jun. 30, 2020

Revenues $ 2,864,900 $ 2,508,600 $ 8,623,500 $ 7,245,100 $ 9,775,200 $ 7,784,400

Income (Loss) from Operations 405,400

Depreciation and Amortization and Impairment 581,800 126,700 251,500 160,900

Benchtop Laboratory Equipment

Revenues 2,434,600 2,365,700 7,465,700 6,803,300 9,043,600 6,783,600

Foreign Sales 783,600 942,200 2,814,700 2,724,800 3,483,700 2,589,800

Income (Loss) from Operations 247,300 394,700 1,107,000 1,347,100 1,461,300 449,700

Assets 10,231,100 5,979,400 10,231,100 5,979,400 14,783,000 12,232,600

Long-lived Asset Expenditures 16,500 18,600 83,100 54,100 60,500 36,000

Depreciation and Amortization and Impairment 24,600 30,000 71,200 79,700 103,100 116,900

Bioprocessing Systems

Revenues 430,300 142,900 1,157,800 441,800 731,600 1,000,800

Foreign Sales 269,700 102,600 791,200 395,000 684,600 1,000,400

Income (Loss) from Operations (1,651,700) (1,323,900) (5,091,300) (2,598,000) (4,828,600) (727,500)

Assets 10,024,261 1,281,200 10,024,261 1,281,200 8,735,100 546,100

Long-lived Asset Expenditures 158,000 92,100 321,300 170,800 196,900 40,700

Depreciation and Amortization and Impairment 229,900 16,700 510,600 46,500 148,400 42,700

Consolidated

Revenues 2,864,900 2,508,600 8,623,500 7,245,100 9,775,200 7,784,400

Foreign Sales 1,053,300 1,044,800 3,605,900 3,119,800 4,168,300 3,590,200

Income (Loss) from Operations (1,742,300) (1,858,800) (5,111,500) (2,298,900) (4,708,800) (663,500)

Assets 30,526,800 13,900,300 30,526,800 13,900,300 29,006,400 14,797,400

Long-lived Asset Expenditures 174,500 110,700 404,400 224,900 257,400 76,700

Depreciation and Amortization and Impairment 254,500 46,700 581,800 126,700 251,500 159,600

Corporate and Other [Member]

Revenues 0 0 0 0 0 0

Foreign Sales 0 0 0 0 0 0

Income (Loss) from Operations (337,900) (929,600) (1,127,200) (1,048,000) (1,341,400) (385,700)

Assets 10,271,439 6,639,700 10,271,439 6,639,700 5,488,300 2,018,700

Long-lived Asset Expenditures 0 0 0 0 $ 0 0

Depreciation and Amortization and Impairment $ 0 $ 0 $ 0 $ 500 $ 0

X

- References
No definition available.
+ Details

Name: scnd_AssetsNet1

Namespace Prefix: scnd_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Custom Element.
+ References
No definition available.
+ Details

Name: scnd_ForeignSales

Namespace Prefix: scnd_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: scnd_LonglivedAssetExpenditures

Namespace Prefix: scnd_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585
+ Details

Name: us-gaap_DepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 23: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 31: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686

Reference 32: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794
+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227
+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=scnd_BenchtopLaboratoryEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=scnd_BioprocessingSystemsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=scnd_ConsolidatedEntityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateAndOtherMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 55 R46.htm IDEA: XBRL DOCUMENT v3.22.1

Segment Information and Concentrations (Details Narrative)
3 Months Ended 9 Months Ended

Mar. 31, 2022

Mar. 31, 2021

Mar. 31, 2022

Mar. 31, 2021

Torbal Scales Division

Net sales percentage 24.00% 20.00% 24.00% 23.00%

Total revenue 20.00% 19.00% 21.00% 21.00%

Three Customerst [Member]

Net sales percentage 19.00% 26.00% 20.00% 23.00%

Total revenue 16.00% 25.00% 17.00% 21.00%

Benchtop Laboratory Operations Equipment [Member]

Net sales percentage 50.00% 55.00% 49.00% 51.00%

Total revenue 42.00% 52.00% 42.00% 47.00%

X

- Definition
For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592
+ Details

Name: us-gaap_ConcentrationRiskPercentage1

Namespace Prefix: us-gaap_

Data Type: dtr-types:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction.
+ References
No definition available.
+ Details

Name: us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction

Namespace Prefix: us-gaap_

Data Type: dtr-types:percentItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=scnd_TorbalScalesDivisionsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=scnd_ThreeCustomerstMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=scnd_BenchtopLaboratoryEquipmentOperationsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 56 R47.htm IDEA: XBRL DOCUMENT v3.22.1

Fair Value of Financial Instruments (Details) - USD ($)

Mar. 31, 2022

Jun. 30, 2021

Mar. 31, 2021

Jun. 30, 2020

Jun. 30, 2019

ASSETS

Cash and cash equivalents $ 4,068,000 $ 9,675,200 $ 627,500 $ 7,559,700 $ 1,602,500

Investment securities 7,768,600 3,744,600 331,800

Total 11,836,600 13,419,800 7,891,500

Liabilities:

Contingent consideration 117,500 160,000 358,000

Level 1

ASSETS

Cash and cash equivalents 4,068,000 9,675,200 7,559,700

Investment securities 6,796,500 2,920,600 331,800

Total 10,864,500 12,595,800 7,891,500

Liabilities:

Contingent consideration 0 0 0

Level 2

ASSETS

Cash and cash equivalents 0 0 0

Investment securities 972,100 824,000 0

Total 972,100 824,000 0

Liabilities:

Contingent consideration 0 0 0

Level 3

ASSETS

Cash and cash equivalents 0 0 0

Investment securities 0 0 0

Total 0 0

Liabilities:

Contingent consideration $ 117,500 $ 160,000 $ 358,000

X

- Definition
Custom Element.
+ References
No definition available.
+ Details

Name: scnd_ContingentConsideration1

Namespace Prefix: scnd_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258
+ Details

Name: us-gaap_AssetsFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of investment in debt and equity securities categorized neither as trading securities nor held-to-maturity securities and intended be sold or mature one year or operating cycle, if longer.
+ References
No definition available.
+ Details

Name: us-gaap_AvailableForSaleSecuritiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 57 R48.htm IDEA: XBRL DOCUMENT v3.22.1

Fair Value of Financial Instruments (Details 1) - USD ($)

Mar. 31, 2022

Jun. 30, 2021

Jun. 30, 2020

Cost $ 7,804,400 $ 3,687,300 $ 327,900

Fair value 7,768,600 3,744,600 331,800

Unrealized holding gain (loss) (35,800) 57,300 (3,900)

Equity Securities

Cost 118,900 102,200 77,600

Fair value 176,900 154,100 101,900

Unrealized holding gain (loss) (58,000) (51,900) (24,300)

Mutual Funds

Cost 6,708,300 2,752,400 250,300

Fair value 6,619,600 2,766,500 229,900

Unrealized holding gain (loss) 88,700 (14,100) $ 20,400

Debt Securities

Cost 977,200 832,700

Fair value 972,100 824,000

Unrealized holding gain (loss) $ (5,100) $ 8,700

X

- References
No definition available.
+ Details

Name: scnd_UnrealizedHoldingGainLoss

Namespace Prefix: scnd_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.
+ References
No definition available.
+ Details

Name: us-gaap_AvailableForSaleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.
+ References
No definition available.
+ Details

Name: us-gaap_AvailableForSaleSecuritiesAmortizedCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_InformationByCategoryOfDebtSecurityAxis=scnd_EquitySecuritieMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_InformationByCategoryOfDebtSecurityAxis=scnd_MutualFundsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_InformationByCategoryOfDebtSecurityAxis=scnd_DebtsSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 58 R49.htm IDEA: XBRL DOCUMENT v3.22.1

Fair Value of Financial Instruments (Details 2) - USD ($)
12 Months Ended

Jun. 30, 2021

Jun. 30, 2020

Fair Value of Financial Instruments

Beginning balance $ 358,000 $ 618,000

Increase (decrease) in contingent consideration liability (30,000) 112,600

Payments (168,000) (372,600)

Ending balance $ 160,000 $ 358,000

X

- References
No definition available.
+ Details

Name: scnd_IncreaseDecreaseInContingentLiabilities

Namespace Prefix: scnd_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: scnd_PaymentsForContingentLiabilities

Namespace Prefix: scnd_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 59 R50.htm IDEA: XBRL DOCUMENT v3.22.1

Inventories (Details) - USD ($)

Mar. 31, 2022

Jun. 30, 2021

Jun. 30, 2020

Inventories

Raw materials $ 3,058,100 $ 2,170,400 $ 1,726,400

Work-in-process 106,400 39,600 35,700

Finished goods 1,203,400 767,100 778,900

Inventory $ 4,367,900 $ 2,977,100 $ 2,541,000

X

- References
No definition available.
+ Details

Name: us-gaap_InventoryDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.BB)
-URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(a)(1))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryFinishedGoodsNetOfReserves

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.BB)
-URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(a)(4))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryRawMaterialsNetOfReserves

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.BB)
-URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(a)(3))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryWorkInProcessNetOfReserves

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 60 R51.htm IDEA: XBRL DOCUMENT v3.22.1

Property and Equipment (Details) - USD ($)
12 Months Ended

Jun. 30, 2021

Mar. 31, 2022

Jun. 30, 2020

Property and equipment, gross $ 1,516,300 $ 1,277,400

Less accumulated depreciation and amortization 1,103,700 999,100

Property and equipment, net 412,600 $ 566,900 278,300

Automobiles

Property and equipment, gross $ 22,000 22,000

Useful lives 5 years

Computer equipment

Property and equipment, gross $ 233,500 215,300

Computer equipment | Minimum

Useful lives 3 years

Computer equipment | Maximum

Useful lives 5 years

Machinery and equipment

Property and equipment, gross $ 1,047,600 847,500

Machinery and equipment | Minimum

Useful lives 3 years

Machinery and equipment | Maximum

Useful lives 7 years

Furniture and fixtures

Property and equipment, gross $ 148,800 142,300

Furniture and fixtures | Minimum

Useful lives 4 years

Furniture and fixtures | Maximum

Useful lives 10 years

Leasehold improvements

Property and equipment, gross $ 64,400 $ 50,300

Leasehold improvements | Minimum

Useful lives 3 years

Leasehold improvements | Maximum

Useful lives 10 years

X

- Definition
Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.14)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 360
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.
+ References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentUsefulLife

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=scnd_AutomobileMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 61 R52.htm IDEA: XBRL DOCUMENT v3.22.1

Property and Equipment (Details Narrative) - USD ($)
12 Months Ended

Jun. 30, 2021

Jun. 30, 2020

Property and Equipment

Depreciation expense $ 104,600 $ 88,700

X

- Definition
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585
+ Details

Name: us-gaap_Depreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 62 R53.htm IDEA: XBRL DOCUMENT v3.22.1

Goodwill and Finite Lived Intangible Assets (Details) - USD ($)
9 Months Ended 12 Months Ended

Mar. 31, 2022

Jun. 30, 2021

Jun. 30, 2020

Cost $ 4,404,300 $ 4,337,300 $ 2,406,300

Accumulated amortization 2,188,000 1,779,500 2,277,600

Net 2,216,300 2,557,800 128,700

Technology, trademarks

Cost 817,000 364,700 664,700

Accumulated amortization 431,800 362,200 662,000

Net $ 385,200 $ 2,500 $ 2,700

Technology, trademarks | Minimum

Useful life 5 years 5 years 5 years

Technology, trademarks | Maximum

Useful life 10 years 10 years 10 years

Trade names

Cost $ 140,000 $ 592,300 $ 140,000

Accumulated amortization 140,000 152,600 140,000

Net 0 439,700 $ 0

Useful life 6 years

Websites

Cost 210,000 210,000 $ 210,000

Accumulated amortization 210,000 210,000 210,000

Net $ 0 $ 0 $ 0

Useful life 5 years

Websites | Minimum

Useful life 3 years 3 years

Websites | Maximum

Useful life 7 years 7 years

Customer relationships

Cost $ 372,200 $ 372,200 $ 357,000

Accumulated amortization 133,100 102,400 321,400

Net $ 239,100 $ 269,800 $ 35,600

Customer relationships | Minimum

Useful life 4 years 4 years 9 years

Customer relationships | Maximum

Useful life 10 years 10 years 10 years

Sublicense agreements

Cost $ 294,000 $ 294,000 $ 294,000

Accumulated amortization 294,000 283,000 253,600

Net $ 0 $ 11,000 $ 40,400

Useful life 10 years 10 years 10 years

Non-compete agreements

Cost $ 1,060,500 $ 1,060,500 $ 384,000

Accumulated amortization 455,300 308,600 384,000

Net 605,200 751,900 $ 0

Useful life 5 years

IPR and D

Cost 917,600 852,100 $ 110,000

Accumulated amortization 249,600 134,800 110,000

Net $ 668,000 $ 717,300 $ 0

Useful life 3 years

IPR and D | Minimum

Useful life 3 years 3 years

IPR and D | Maximum

Useful life 5 years 5 years

Other intangible assets

Cost $ 593,000 $ 591,500 $ 246,600

Accumulated amortization 274,200 225,900 196,600

Net $ 318,800 $ 365,600 $ 50,000

Useful life 5 years

Other intangible assets | Minimum

Useful life 5 years 5 years

Other intangible assets | Maximum

Useful life 7 years 7 years

Trade names | Minimum

Useful life 3 years 3 years

Trade names | Maximum

Useful life 6 years 6 years

Non-compete agreements | Minimum

Useful life 4 years 4 years

Non-compete agreements | Maximum

Useful life 5 years 5 years

X

- Definition
Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetUsefulLife

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 928
-SubTopic 340
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=scnd_TrademarkMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=scnd_TradeNameMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=scnd_WebsitesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=scnd_LicensingAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=scnd_ContractualRightMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=scnd_IPRandDMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=scnd_OtherIntangiblesAssetsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=scnd_TradesNamesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=scnd_ContractualsRightsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 63 R54.htm IDEA: XBRL DOCUMENT v3.22.1

Goodwill and Finite Lived Intangible Assets (Details 1) - USD ($)

Mar. 31, 2022

Jun. 30, 2021

Jun. 30, 2020

Goodwill and Other Intangible Assets

2022 $ 134,300 $ 525,700

2023 520,900 520,000

2024 518,900 508,800

2025 485,100 473,100

2026 284,600 530,200

Total $ 2,216,300 $ 2,557,800 $ 128,700

X

- Definition
Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 64 R55.htm IDEA: XBRL DOCUMENT v3.22.1

Goodwill and Finite Lived Intangible Assets (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended

Mar. 31, 2022

Mar. 31, 2021

Mar. 31, 2022

Mar. 31, 2021

Jun. 30, 2021

Jun. 30, 2020

Goodwill and Other Intangible Assets

Goodwill $ 4,395,400 $ 4,395,400 $ 4,395,400 $ 257,300

Total amortization expense 134,600 $ 16,000 408,500 $ 48,500 146,900 $ 72,000

2022 134,300 134,300 525,700

2023 520,900 520,900 520,000

2024 518,900 518,900 508,800

2025 485,100 485,100 473,100

2026 284,600 284,600 $ 530,200

There after $ 137,500 $ 137,500

X

- Definition
The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585
+ Details

Name: us-gaap_AdjustmentForAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(10)(1))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266
+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 65 R56.htm IDEA: XBRL DOCUMENT v3.22.1

Loss Per Common Share (Details) - $ / shares
3 Months Ended 9 Months Ended 12 Months Ended

Mar. 31, 2022

Mar. 31, 2021

Mar. 31, 2022

Mar. 31, 2021

Jun. 30, 2021

Jun. 30, 2020

Earnings (Loss) Per Common Share (Tables)

Weighted average common shares outstanding 6,633,901 2,861,607 6,544,112 2,861,376 3,189,602 1,515,103

Weighted average dilutive common shares outstanding 6,633,901 2,861,607 6,544,112 2,861,376 3,189,602 1,515,103

Continuing operations $ (0.23) $ (0.51) $ (0.56) $ (0.61) $ (0.97) $ (0.30)

Discontinued operations 0 0.01 0.00 (0.20) (0.18) (0.16)

Consolidated operations $ (0.23) $ (0.50) $ (0.56) $ (0.81) $ (1.15) $ (0.46)

X

- References
No definition available.
+ Details

Name: scnd_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShares

Namespace Prefix: scnd_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: scnd_EarningPerShareBasicAndDiluted

Namespace Prefix: scnd_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: scnd_IncomeLossFromContinuingOperationPerBasicAndDilutedShare

Namespace Prefix: scnd_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: scnd_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted

Namespace Prefix: scnd_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256
+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 66 R57.htm IDEA: XBRL DOCUMENT v3.22.1

Loss Per Common Share (Details Narrative) - shares
3 Months Ended 9 Months Ended 12 Months Ended

Mar. 31, 2022

Mar. 31, 2021

Mar. 31, 2022

Mar. 31, 2021

Jun. 30, 2021

Jun. 30, 2020

Stock Options

Dilutive shares excluded 3,452,542 3,451,461 88,691 54,513

Warrants

Dilutive shares excluded 259,357 1,349,850 2,481,783 1,349,850

X

- Definition
Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=scnd_StockOptionsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=scnd_WarrantsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 67 R58.htm IDEA: XBRL DOCUMENT v3.22.1

Leases (Details) - USD ($)

Mar. 31, 2022

Jun. 30, 2021

Leases

Remainder of 2022 $ 82,200 $ 260,300

2023 311,400 245,300

2024 247,600 195,900

2025 255,000 91,600

2026 262,700

Thereafter 609,600

Total future minimum payments 1,768,500 793,100

Less: imputed interest (256,100) (62,100)

Total present value of operating lease liabilities $ 1,512,400 $ 731,000

X

- References
No definition available.
+ Details

Name: scnd_Thereafter

Namespace Prefix: scnd_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LeasesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of lessee's undiscounted obligation for lease payment for operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 68 R59.htm IDEA: XBRL DOCUMENT v3.22.1

Leases (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended

Mar. 31, 2022

Mar. 31, 2022

Jun. 30, 2021

Leases

Total cash payments under leases $ 82,000 $ 240,200 $ 289,100

Weighted-average remaining lease term 5 years 3 months 25 days 2 years 8 months 4 days

Weighted-average discount rate 5.00% 5.00%

Discount rate on lease 5.00% 5.00%

Lease expense $ 81,800 $ 226,300 $ 277,300

X

- References
No definition available.
+ Details

Name: scnd_OperatingLeaseWeightedAverageRemainingLeaseTerms

Namespace Prefix: scnd_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_LeasesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of operating lease expense. Excludes sublease income.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 4
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977
+ Details

Name: us-gaap_OperatingLeaseExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Weighted average discount rate for operating lease calculated at point in time.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (g)(4)
-URI http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971
+ Details

Name: us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent

Namespace Prefix: us-gaap_

Data Type: dtr-types:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Cash payments to lessor's for use of assets under operating leases.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585
+ Details

Name: us-gaap_PaymentsForRent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Restrictions on equity-based instruments during the vesting period, such as the inability to transfer unvested awards, are not taken into account in estimating the fair value of the award. However, restrictions that remain in effect after an award is vested, such as the inability to transfer or hedge vested options or a prohibition on the sale of outstanding vested shares (or other type of equity) for a period of time, affect the estimate of an award's fair value.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(v)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions

Namespace Prefix: us-gaap_

Data Type: dtr-types:percentItemType

Balance Type: na

Period Type: duration

XML 69 R60.htm IDEA: XBRL DOCUMENT v3.22.1

Discontinued Operations (Details) - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended

Mar. 31, 2022

Mar. 31, 2021

Mar. 31, 2022

Mar. 31, 2021

Jun. 30, 2021

Jun. 30, 2020

Assets:

Cash $ 600 $ 600 $ 0

Accounts receivable 0 0 52,000

Inventories 0 0 3,300 $ 343,700

Property and equipment, net 1,400

Goodwill 447,900

Discontinued operations 600 600 55,300 793,000

Liabilities:

Accrued expenses and taxes 0 0 20,700 120,700

Accounts payable 20,100

Contract liabilities 7,900 7,900 16,500 69,000

Operating lease liabilities, current portion 31,100

Liabilities of discontinued operations 7,900 7,900 37,200 240,900

Revenues 0 $ 107,800 20,600 $ 387,700 387,700 785,900

Cost of goods sold 6,900 78,800 10,300 458,500 471,800 869,900

Gross profit (loss) (6,900) 29,000 10,300 (70,800) (84,100) (84,000)

Selling, general and administrative expenses 700 12,600 2,900 282,200 280,400 388,500

Gain (loss) from operation (7,600) 16,400 7,400 (353,000) (364,500) (472,500)

Loss on disposal 0 0 0 (405,400) (405,400) 0

Income (loss) before income tax benefit (7,600) 16,400 7,400 (758,400) (769,900) (472,500)

Income tax expense (benefit) 0 0 4,000 (179,900) (207,400) (222,600)

Net income (loss) from attributable to discontinued operations $ (7,600) $ 16,400 $ 3,400 $ (578,500) $ (562,500) $ (249,900)

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=123351718&loc=d3e2473-110228

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230
+ Details

Name: us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 210
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 210
-Section 45
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840
+ Details

Name: us-gaap_Cash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 3B
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759
+ Details

Name: us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(12))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 3B
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(14))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227
+ Details

Name: us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 3B
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.7)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319
+ Details

Name: us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759
+ Details

Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount classified as accounts payable attributable to disposal group held for sale or disposed of.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759
+ Details

Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759
+ Details

Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760
+ Details

Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760
+ Details

Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount classified as goodwill attributable to disposal group held for sale or disposed of.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760
+ Details

Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of gross profit attributable to disposal group, including, but not limited to, discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760
+ Details

Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount classified as inventory attributable to disposal group held for sale or disposed of.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759
+ Details

Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760
+ Details

Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount classified as other liabilities attributable to disposal group held for sale or disposed of.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760
+ Details

Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=123351718&loc=d3e2510-110228

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760
+ Details

Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760
+ Details

Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760
+ Details

Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(12))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 3B
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109227538&loc=d3e44648-109337
+ Details

Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=123351718&loc=d3e2473-110228

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760
+ Details

Name: us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 70 R61.htm IDEA: XBRL DOCUMENT v3.22.1

Discontinued Operations (Details Narrative) - USD ($)
9 Months Ended 12 Months Ended

Mar. 31, 2022

Mar. 31, 2021

Jun. 30, 2021

Jun. 30, 2020

Discontinued Operations

Cash paid to the related party $ 440,000

Pre tax loss 405,400

Cash provided by (used in) operating activities 25,400 $ (502,900) $ (75,000) $ 66,100

Cash provided by investing activities from discontinued operations $ 0 $ 440,000 $ 440,000 $ 2,200

X

- Definition
Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760
+ Details

Name: us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760
+ Details

Name: us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(C))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k)(1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756
+ Details

Name: us-gaap_DueToRelatedPartiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 23: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 31: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686

Reference 32: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794
+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 71 R62.htm IDEA: XBRL DOCUMENT v3.22.1

Acquisition of Aquila Biolabs GmbH (Details) - USD ($)
1 Months Ended 12 Months Ended

Apr. 29, 2021

Jun. 30, 2021

Current assets:

Cash and cash equivalents $ 201,100 $ 201,100

Accounts receivable 159,200 159,200

Inventory 187,500 187,500

Prepaid expenses and other current assets 25,400 25,400

Property, plant and equipment 40,200 40,200

Deferred tax assets 800,300 800,300

Tradename 452,300 452,300

Non-compete agreements 784,500 784,500

In-process research and development 742,100 742,100

Customer relationships 252,200 252,200

Patents and other intangibles 286,200 286,200

Total assets acquired 3,931,000 3,931,000

Fair value of liabilities assumed:

Accounts payable (39,300) (39,300)

Accrued expenses (90,300) (90,300)

Other current liabilities (59,400) (59,400)

Total liabilities assumed (189,000) (189,000)

Total identifiable net assets 3,742,000 3,742,000

Fair value of consideration transferred 7,880,100 7,880,100

Goodwill $ 4,138,100 $ 4,138,100

Customer relationships

Fair value of liabilities assumed:

Useful life 9 years 9 years

Non-compete agreements

Fair value of liabilities assumed:

Useful life 4 years 4 years

Tradename

Fair value of liabilities assumed:

Useful life 6 years 6 years

In-process research and development

Fair value of liabilities assumed:

Useful life 5 years 5 years

Patents and Other Intangibles

Fair value of liabilities assumed:

Useful life 7 years 7 years

X

- References
No definition available.
+ Details

Name: scnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredCustomerRelationships

Namespace Prefix: scnd_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: scnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredIPRandD

Namespace Prefix: scnd_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: scnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredNonCompeteAgreements

Namespace Prefix: scnd_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: scnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTradeName

Namespace Prefix: scnd_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: scnd_FairValueOfLiabilitiesAssumedAbstract

Namespace Prefix: scnd_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275
+ Details

Name: us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 30
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 30
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477
+ Details

Name: us-gaap_BusinessCombinationConsiderationTransferred1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 25
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 35
-Paragraph 1
-Subparagraph b
-URI http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478
+ Details

Name: us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of assets acquired at the acquisition date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of deferred tax asset attributable to deductible temporary differences and carryforwards acquired at the acquisition date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The amount of inventory recognized as of the acquisition date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 55
-Paragraph 37
-URI http://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of liabilities assumed at the acquisition date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 55
-Paragraph 37
-URI http://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The amount of property, plant, and equipment recognized as of the acquisition date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 55
-Paragraph 37
-URI http://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267
+ Details

Name: us-gaap_GoodwillAcquiredDuringPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=scnd_ContractualRightMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=scnd_BusinessCombinationTradeNameMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=scnd_BusinessCombinationIPRDMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=scnd_BusinessCombinationPatentsAndOtherIntangiblesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 72 R63.htm IDEA: XBRL DOCUMENT v3.22.1

Acquisition of Aquila Biolabs GmbH (Details 1)
12 Months Ended

Jun. 30, 2020

USD ($)

$ / shares

Acquisition of Aquila Biolabs GmbH

Revenues | $ $ 9,346

Net loss | $ $ (1,650)

Earnings per share: Diluted | $ / shares $ (0.37)

Earnings per share: Basic | $ / shares $ (0.37)

X

- Definition
The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(3)
-URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(2)
-URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463
+ Details

Name: us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(3)
-URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(2)
-URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463
+ Details

Name: us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(3)
-URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(2)
-URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463
+ Details

Name: us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(2)
-URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(3)
-URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463
+ Details

Name: us-gaap_BusinessAcquisitionsProFormaRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_BusinessCombinationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 73 R64.htm IDEA: XBRL DOCUMENT v3.22.1

Acquisition of Aquila Biolabs GmbH (Details Narrative)
9 Months Ended

Mar. 31, 2022

USD ($)

Acquisition of Aquila Biolabs GmbH

Aggregate purchase price $ 7,880,100

X

- References
No definition available.
+ Details

Name: us-gaap_BusinessCombinationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net cash inflow or outflow associated with the aggregate amount of adjustment to the purchase price of a previous acquisition.
+ References
No definition available.
+ Details

Name: us-gaap_PaymentsForProceedsFromPreviousAcquisition

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 74 R65.htm IDEA: XBRL DOCUMENT v3.22.1

Paycheck Protection Program Loan (Details Narrative)

Mar. 31, 2021

USD ($)

Paycheck Protection Program Loan [Member]

Debt intrument, face amount $ 433,800

X

- Definition
Face (par) amount of debt instrument at time of issuance.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 55
-Paragraph 69C
-URI http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 55
-Paragraph 69B
-URI http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612
+ Details

Name: us-gaap_DebtInstrumentFaceAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_DebtInstrumentAxis=scnd_PaycheckProtectionProgramLoanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 75 R66.htm IDEA: XBRL DOCUMENT v3.22.1

Equity (Details Narrative) - USD ($)
1 Months Ended 9 Months Ended

Mar. 02, 2022

Feb. 25, 2022

Mar. 31, 2022

Mar. 31, 2021

Feb. 24, 2022

Jun. 30, 2021

Jun. 30, 2020

Equity (Details Narrative)

Common share authorized 20,000,000 20,000,000 15,000,000 15,000,000 15,000,000

Increase in authorized share 5,000,000

Offering price $ 5.50

Proceeds from common stock $ 3,000,000 $ 3,000,000 $ 0

Issuence and sold aggregate shares of common stock and warrants 545,456

Additional common stock purchased 274,727

Issuance cost $ 272,800

Issuance of shares 1,750,000

X

- References
No definition available.
+ Details

Name: scnd_AdditionalCommonStockPurchasedShare

Namespace Prefix: scnd_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The cash outflow for cost incurred directly with the issuance of an equity security.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585
+ Details

Name: us-gaap_PaymentsOfStockIssuanceCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from the additional capital contribution to the entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.
+ References
No definition available.
+ Details

Name: us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Price of a single share of a number of saleable stocks of a company.
+ References
No definition available.
+ Details

Name: us-gaap_SharePrice

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The increase (decrease) during the period in the number of shares issued.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 76 R67.htm IDEA: XBRL DOCUMENT v3.22.1

Commitments and Contingencies (Details)

Jun. 30, 2021

USD ($)

Commitments and Contingencies

2022 $ 136,600

2023 12,000

2024 11,400

Total $ 160,000

X

- References
No definition available.
+ Details

Name: scnd_FairValueContingentConsiderationDueCurrent

Namespace Prefix: scnd_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: scnd_FairValueContingentConsiderationDueInThreeYears

Namespace Prefix: scnd_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: scnd_FairValueContingentConsiderationDueInTwoYears

Namespace Prefix: scnd_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: scnd_FairValueContingentConsiderationMinimumPaymentsDue

Namespace Prefix: scnd_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 77 R68.htm IDEA: XBRL DOCUMENT v3.22.1

Income Taxes (Details) - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended

Mar. 31, 2022

Mar. 31, 2021

Mar. 31, 2022

Mar. 31, 2021

Jun. 30, 2021

Jun. 30, 2020

Income Taxes

Computed "expected" income tax (benefit) $ (1,014,300) $ (239,400)

Research and development credits (93,900) (89,400)

Rate changes and NOL carrybacks 0 (122,600)

Incentive stock option expense 59,500 13,800

PPP loan forgivness (111,700) 0

Other, net (7,900) 1,000

Income tax benefit $ (317,200) $ (378,200) $ (1,054,500) $ (472,300) $ (1,152,500) $ (436,600)

X

- Definition
Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 740
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=120384911&loc=d3e23163-113944
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.7)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(9))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=123427490&loc=d3e32059-109318

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319
+ Details

Name: us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319
+ Details

Name: us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319
+ Details

Name: us-gaap_IncomeTaxReconciliationOtherAdjustments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority noncontrolling interest income (loss), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, increase (decrease) in enacted tax rate, prior year income taxes, increase (decrease) in deferred tax asset valuation allowance, and other adjustments.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319
+ Details

Name: us-gaap_IncomeTaxReconciliationOtherReconcilingItems

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319
+ Details

Name: us-gaap_IncomeTaxReconciliationTaxCreditsResearch

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 78 R69.htm IDEA: XBRL DOCUMENT v3.22.1

Income Taxes (Details 1) - USD ($)

Jun. 30, 2021

Jun. 30, 2020

Deferred tax assets:

Amortization of intangibles $ 374,000 $ 329,700

Research and development credits 164,600 89,400

Various accruals 64,600 150,700

Stock options expense 383,200 0

Net operating loss 1,515,800 0

Other 24,900 19,400

Total 2,527,100 589,200

Deferred tax liability:

Depreciation of property and amortization of goodwill (37,200) (52,100)

Net deferred tax assets $ 2,489,900 $ 537,100

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.
+ References
No definition available.
+ Details

Name: us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_DeferredTaxAssetsGrossAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsLiabilitiesNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_DeferredTaxAssetsNetAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319
+ Details

Name: us-gaap_DeferredTaxAssetsOperatingLossCarryforwards

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319
+ Details

Name: us-gaap_DeferredTaxAssetsOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319
+ Details

Name: us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from compensation and benefits, classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319
+ Details

Name: us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319
+ Details

Name: us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319
+ Details

Name: us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 79 R70.htm IDEA: XBRL DOCUMENT v3.22.1

Stock Options (Details) - $ / shares
12 Months Ended

Jun. 30, 2021

Jun. 30, 2020

Stock Options

Number of Options Outstanding, Beginning 96,586 97,205

Number of Options Granted 1,094,171 25,881

Number of Options Exercised (1,000) (24,000)

Number of Options Forfeited (9,000) (2,500)

Number of Options Outstanding, Ending 1,180,757 96,586

Number of Options Exercisable 296,821 49,236

Weighted Average Exercise Price Outstanding, Beginning $ 4.35 $ 3.24

Weighted Average Exercise Price Granted 9.07 7.47

Weighted Average Exercise Price Exercised 3.05 3.35

Weighted Average Exercise Price Forfeited 3.11 3.08

Weighted Average Exercise Price Outstanding, Ending 8.73 4.35

Weighted Average Exercise Price Exercisable 7.69 3.29

Weighted average fair value per share of options granted $ 7.25 $ 5.58

X

- Definition
Custom Element.
+ References
No definition available.
+ Details

Name: scnd_NumberOfOptionsExercised

Namespace Prefix: scnd_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: scnd_NumberOfOptionsForfeited

Namespace Prefix: scnd_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which option holders acquired shares when converting their stock options into shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: duration

XML 80 R71.htm IDEA: XBRL DOCUMENT v3.22.1

Stock Options (Details 1) - $ / shares
12 Months Ended

Jun. 30, 2021

Jun. 30, 2020

Jun. 30, 2019

Number of Options Outstanding, Beginning 1,180,757 96,586 97,205

Weighted Average Exercise Price Outstanding, Beginning $ 8.73 $ 4.35 $ 3.24

Number of Options Exercisable 296,821 49,236

Weighted Average Exercise Price Exercisable $ 7.69 $ 3.29

Exercise Price Range 5.35 - 11.30

Number of Options Outstanding, Beginning 1,120,052 25,881

Weighted Average Exercise Price Outstanding, Beginning $ 9.03 $ 7.47

Number of Options Exercisable 238,351 0

Weighted Average Exercise Price Exercisable $ 8.76 $ 0.00

Weighted Average Remaining Contractual Life 9 years 4 months 6 days 9 years 10 months 13 days

Exercise Price Range 2.91 - 4.65

Number of Options Outstanding, Beginning 60,705 70,705

Weighted Average Exercise Price Outstanding, Beginning $ 3.36 $ 3.33

Number of Options Exercisable 58,470 49,236

Weighted Average Exercise Price Exercisable $ 3.32 $ 3.29

Weighted Average Remaining Contractual Life 5 years 3 months 10 days 6 years 5 months 15 days

X

- Definition
The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=scnd_ExercisePriceRange9Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=scnd_ExercisePriceRange10Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 81 scnd_s1_htm.xml IDEA: XBRL DOCUMENT 0000087802 2021-07-01 2022-03-31 0000087802 scnd:ExercisePriceRange10Member 2019-07-01 2020-06-30 0000087802 scnd:ExercisePriceRange9Member 2019-07-01 2020-06-30 0000087802 scnd:ExercisePriceRange10Member 2020-07-01 2021-06-30 0000087802 scnd:ExercisePriceRange9Member 2020-07-01 2021-06-30 0000087802 scnd:ExercisePriceRange10Member 2020-06-30 0000087802 scnd:ExercisePriceRange9Member 2020-06-30 0000087802 scnd:ExercisePriceRange10Member 2021-06-30 0000087802 scnd:ExercisePriceRange9Member 2021-06-30 0000087802 2022-03-01 2022-03-02 0000087802 2022-03-02 0000087802 2022-02-24 0000087802 2022-02-01 2022-02-25 0000087802 2022-02-25 0000087802 scnd:PaycheckProtectionProgramLoanMember 2021-03-31 0000087802 scnd:BusinessCombinationPatentsAndOtherIntangiblesMember 2020-07-01 2021-06-30 0000087802 scnd:BusinessCombinationPatentsAndOtherIntangiblesMember 2021-04-01 2021-04-29 0000087802 us-gaap:CustomerRelationshipsMember 2020-07-01 2021-06-30 0000087802 us-gaap:CustomerRelationshipsMember 2021-04-01 2021-04-29 0000087802 scnd:BusinessCombinationIPRDMember 2020-07-01 2021-06-30 0000087802 scnd:BusinessCombinationIPRDMember 2021-04-01 2021-04-29 0000087802 scnd:ContractualRightMember 2020-07-01 2021-06-30 0000087802 scnd:ContractualRightMember 2021-04-01 2021-04-29 0000087802 scnd:BusinessCombinationTradeNameMember 2020-07-01 2021-06-30 0000087802 scnd:BusinessCombinationTradeNameMember 2021-04-01 2021-04-29 0000087802 2021-04-01 2021-04-29 0000087802 2021-04-29 0000087802 scnd:WarrantsMember 2020-07-01 2021-03-31 0000087802 scnd:StockOptionsMember 2022-01-01 2022-03-31 0000087802 scnd:WarrantsMember 2019-07-01 2020-06-30 0000087802 scnd:WarrantsMember 2020-07-01 2021-06-30 0000087802 scnd:WarrantsMember 2021-01-01 2021-03-31 0000087802 scnd:StockOptionsMember 2020-07-01 2021-06-30 0000087802 scnd:StockOptionsMember 2019-07-01 2020-06-30 0000087802 scnd:StockOptionsMember 2021-07-01 2022-03-31 0000087802 srt:MaximumMember scnd:OtherIntangiblesAssetsMember 2020-07-01 2021-06-30 0000087802 srt:MaximumMember scnd:OtherIntangiblesAssetsMember 2021-07-01 2022-03-31 0000087802 srt:MinimumMember scnd:OtherIntangiblesAssetsMember 2020-07-01 2021-06-30 0000087802 srt:MinimumMember scnd:OtherIntangiblesAssetsMember 2021-07-01 2022-03-31 0000087802 srt:MaximumMember scnd:IPRandDMember 2020-07-01 2021-06-30 0000087802 srt:MaximumMember scnd:IPRandDMember 2021-07-01 2022-03-31 0000087802 srt:MinimumMember scnd:IPRandDMember 2020-07-01 2021-06-30 0000087802 srt:MinimumMember scnd:IPRandDMember 2021-07-01 2022-03-31 0000087802 srt:MaximumMember scnd:ContractualsRightsMember 2020-07-01 2021-06-30 0000087802 srt:MaximumMember scnd:ContractualsRightsMember 2021-07-01 2022-03-31 0000087802 srt:MinimumMember scnd:ContractualsRightsMember 2020-07-01 2021-06-30 0000087802 srt:MinimumMember scnd:ContractualsRightsMember 2021-07-01 2022-03-31 0000087802 scnd:OtherIntangiblesAssetsMember 2019-07-01 2020-06-30 0000087802 scnd:IPRandDMember 2019-07-01 2020-06-30 0000087802 scnd:ContractualRightMember 2019-07-01 2020-06-30 0000087802 scnd:LicensingAgreementMember 2019-07-01 2020-06-30 0000087802 scnd:LicensingAgreementMember 2020-07-01 2021-06-30 0000087802 scnd:LicensingAgreementMember 2021-07-01 2022-03-31 0000087802 srt:MaximumMember us-gaap:CustomerRelationshipsMember 2019-07-01 2020-06-30 0000087802 srt:MaximumMember us-gaap:CustomerRelationshipsMember 2020-07-01 2021-06-30 0000087802 srt:MaximumMember us-gaap:CustomerRelationshipsMember 2021-07-01 2022-03-31 0000087802 srt:MinimumMember us-gaap:CustomerRelationshipsMember 2019-07-01 2020-06-30 0000087802 srt:MinimumMember us-gaap:CustomerRelationshipsMember 2020-07-01 2021-06-30 0000087802 srt:MinimumMember us-gaap:CustomerRelationshipsMember 2021-07-01 2022-03-31 0000087802 srt:MaximumMember scnd:WebsitesMember 2020-07-01 2021-06-30 0000087802 srt:MaximumMember scnd:WebsitesMember 2021-07-01 2022-03-31 0000087802 srt:MinimumMember scnd:WebsitesMember 2020-07-01 2021-06-30 0000087802 srt:MinimumMember scnd:WebsitesMember 2021-07-01 2022-03-31 0000087802 srt:MaximumMember scnd:TradesNamesMember 2020-07-01 2021-06-30 0000087802 srt:MaximumMember scnd:TradesNamesMember 2021-07-01 2022-03-31 0000087802 srt:MinimumMember scnd:TradesNamesMember 2020-07-01 2021-06-30 0000087802 srt:MinimumMember scnd:TradesNamesMember 2021-07-01 2022-03-31 0000087802 scnd:WebsitesMember 2019-07-01 2020-06-30 0000087802 scnd:TradeNameMember 2019-07-01 2020-06-30 0000087802 srt:MaximumMember scnd:TrademarkMember 2019-07-01 2020-06-30 0000087802 srt:MaximumMember scnd:TrademarkMember 2020-07-01 2021-06-30 0000087802 srt:MaximumMember scnd:TrademarkMember 2021-07-01 2022-03-31 0000087802 srt:MinimumMember scnd:TrademarkMember 2021-07-01 2022-03-31 0000087802 srt:MinimumMember scnd:TrademarkMember 2020-07-01 2021-06-30 0000087802 srt:MinimumMember scnd:TrademarkMember 2019-07-01 2020-06-30 0000087802 scnd:OtherIntangiblesAssetsMember 2021-06-30 0000087802 scnd:IPRandDMember 2021-06-30 0000087802 scnd:ContractualRightMember 2021-06-30 0000087802 us-gaap:CustomerRelationshipsMember 2021-06-30 0000087802 scnd:TradeNameMember 2021-06-30 0000087802 scnd:TrademarkMember 2021-06-30 0000087802 scnd:OtherIntangiblesAssetsMember 2020-06-30 0000087802 scnd:OtherIntangiblesAssetsMember 2022-03-31 0000087802 scnd:IPRandDMember 2020-06-30 0000087802 scnd:IPRandDMember 2022-03-31 0000087802 scnd:ContractualRightMember 2020-06-30 0000087802 scnd:ContractualRightMember 2022-03-31 0000087802 scnd:LicensingAgreementMember 2021-06-30 0000087802 scnd:LicensingAgreementMember 2020-06-30 0000087802 scnd:LicensingAgreementMember 2022-03-31 0000087802 us-gaap:CustomerRelationshipsMember 2020-06-30 0000087802 us-gaap:CustomerRelationshipsMember 2022-03-31 0000087802 scnd:WebsitesMember 2021-06-30 0000087802 scnd:TrademarkMember 2020-06-30 0000087802 scnd:WebsitesMember 2020-06-30 0000087802 scnd:WebsitesMember 2022-03-31 0000087802 scnd:TradeNameMember 2020-06-30 0000087802 scnd:TradeNameMember 2022-03-31 0000087802 scnd:TrademarkMember 2022-03-31 0000087802 us-gaap:LeaseholdImprovementsMember 2021-06-30 0000087802 us-gaap:FurnitureAndFixturesMember 2021-06-30 0000087802 us-gaap:MachineryAndEquipmentMember 2021-06-30 0000087802 us-gaap:ComputerEquipmentMember 2021-06-30 0000087802 scnd:AutomobileMember 2021-06-30 0000087802 us-gaap:LeaseholdImprovementsMember 2020-06-30 0000087802 us-gaap:FurnitureAndFixturesMember 2020-06-30 0000087802 us-gaap:MachineryAndEquipmentMember 2020-06-30 0000087802 us-gaap:ComputerEquipmentMember 2020-06-30 0000087802 scnd:AutomobileMember 2020-06-30 0000087802 srt:MaximumMember us-gaap:LeaseholdImprovementsMember 2020-07-01 2021-06-30 0000087802 srt:MinimumMember us-gaap:LeaseholdImprovementsMember 2020-07-01 2021-06-30 0000087802 srt:MaximumMember us-gaap:FurnitureAndFixturesMember 2020-07-01 2021-06-30 0000087802 srt:MinimumMember us-gaap:FurnitureAndFixturesMember 2020-07-01 2021-06-30 0000087802 srt:MaximumMember us-gaap:MachineryAndEquipmentMember 2020-07-01 2021-06-30 0000087802 srt:MinimumMember us-gaap:MachineryAndEquipmentMember 2020-07-01 2021-06-30 0000087802 srt:MaximumMember us-gaap:ComputerEquipmentMember 2020-07-01 2021-06-30 0000087802 srt:MinimumMember us-gaap:ComputerEquipmentMember 2020-07-01 2021-06-30 0000087802 scnd:AutomobileMember 2020-07-01 2021-06-30 0000087802 scnd:DebtsSecuritiesMember 2022-03-31 0000087802 scnd:DebtsSecuritiesMember 2021-06-30 0000087802 scnd:MutualFundsMember 2021-06-30 0000087802 scnd:EquitySecuritieMember 2021-06-30 0000087802 scnd:EquitySecuritieMember 2020-06-30 0000087802 scnd:MutualFundsMember 2020-06-30 0000087802 scnd:MutualFundsMember 2022-03-31 0000087802 scnd:EquitySecuritieMember 2022-03-31 0000087802 us-gaap:FairValueInputsLevel3Member 2021-06-30 0000087802 us-gaap:FairValueInputsLevel2Member 2021-06-30 0000087802 us-gaap:FairValueInputsLevel1Member 2021-06-30 0000087802 us-gaap:FairValueInputsLevel3Member 2020-06-30 0000087802 us-gaap:FairValueInputsLevel3Member 2022-03-31 0000087802 us-gaap:FairValueInputsLevel2Member 2020-06-30 0000087802 us-gaap:FairValueInputsLevel2Member 2022-03-31 0000087802 us-gaap:FairValueInputsLevel1Member 2020-06-30 0000087802 us-gaap:FairValueInputsLevel1Member 2022-03-31 0000087802 scnd:BenchtopLaboratoryEquipmentOperationsMember 2020-07-01 2021-03-31 0000087802 scnd:BenchtopLaboratoryEquipmentOperationsMember 2021-01-01 2021-03-31 0000087802 scnd:BenchtopLaboratoryEquipmentOperationsMember 2022-01-01 2022-03-31 0000087802 scnd:BenchtopLaboratoryEquipmentOperationsMember 2021-07-01 2022-03-31 0000087802 scnd:TorbalScalesDivisionsMember 2020-07-01 2021-03-31 0000087802 scnd:TorbalScalesDivisionsMember 2021-01-01 2021-03-31 0000087802 scnd:TorbalScalesDivisionsMember 2021-07-01 2022-03-31 0000087802 scnd:ThreeCustomerstMember 2020-07-01 2021-03-31 0000087802 scnd:ThreeCustomerstMember 2022-01-01 2022-03-31 0000087802 scnd:ThreeCustomerstMember 2021-07-01 2022-03-31 0000087802 scnd:ThreeCustomerstMember 2021-01-01 2021-03-31 0000087802 scnd:TorbalScalesDivisionsMember 2022-01-01 2022-03-31 0000087802 us-gaap:CorporateAndOtherMember 2022-01-01 2022-03-31 0000087802 us-gaap:CorporateAndOtherMember 2020-07-01 2021-03-31 0000087802 us-gaap:CorporateAndOtherMember 2021-01-01 2021-03-31 0000087802 us-gaap:CorporateAndOtherMember 2019-07-01 2020-06-30 0000087802 us-gaap:CorporateAndOtherMember 2020-07-01 2021-06-30 0000087802 us-gaap:CorporateAndOtherMember 2021-07-01 2022-03-31 0000087802 scnd:ConsolidatedEntityMember 2020-07-01 2021-06-30 0000087802 scnd:ConsolidatedEntityMember 2019-07-01 2020-06-30 0000087802 scnd:ConsolidatedEntityMember 2021-01-01 2021-03-31 0000087802 scnd:BioprocessingSystemsMember 2021-01-01 2021-03-31 0000087802 scnd:BenchtopLaboratoryEquipmentMember 2021-01-01 2021-03-31 0000087802 scnd:ConsolidatedEntityMember 2020-07-01 2021-03-31 0000087802 scnd:BioprocessingSystemsMember 2020-07-01 2021-03-31 0000087802 scnd:BenchtopLaboratoryEquipmentMember 2020-07-01 2021-03-31 0000087802 scnd:ConsolidatedEntityMember 2022-01-01 2022-03-31 0000087802 scnd:BioprocessingSystemsMember 2022-01-01 2022-03-31 0000087802 scnd:BenchtopLaboratoryEquipmentMember 2022-01-01 2022-03-31 0000087802 scnd:ConsolidatedEntityMember 2021-07-01 2022-03-31 0000087802 scnd:BioprocessingSystemsMember 2021-07-01 2022-03-31 0000087802 scnd:BenchtopLaboratoryEquipmentMember 2021-07-01 2022-03-31 0000087802 scnd:PayrollProtectionProgramMember 2021-03-31 0000087802 scnd:PayrollProtectionProgramMember 2020-04-30 0000087802 scnd:PayrollProtectionProgramMember 2021-07-01 2021-12-31 0000087802 scnd:ConsolidatedMember 2019-07-01 2020-06-30 0000087802 scnd:ConsolidatedMember 2020-07-01 2021-06-30 0000087802 scnd:BioprocessingSystemsMember 2019-07-01 2020-06-30 0000087802 scnd:BioprocessingSystemsMember 2020-07-01 2021-06-30 0000087802 scnd:BenchtopLaboratoryEquipmentMember 2019-07-01 2020-06-30 0000087802 scnd:BenchtopLaboratoryEquipmentMember 2020-07-01 2021-06-30 0000087802 us-gaap:RetainedEarningsMember 2022-03-31 0000087802 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0000087802 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0000087802 us-gaap:TreasuryStockMember 2022-03-31 0000087802 us-gaap:CommonStockMember 2022-03-31 0000087802 us-gaap:TreasuryStockMember 2022-01-01 2022-03-31 0000087802 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0000087802 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0000087802 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0000087802 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0000087802 2021-12-31 0000087802 us-gaap:RetainedEarningsMember 2021-12-31 0000087802 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0000087802 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000087802 us-gaap:TreasuryStockMember 2021-12-31 0000087802 us-gaap:CommonStockMember 2021-12-31 0000087802 2021-10-01 2021-12-31 0000087802 us-gaap:TreasuryStockMember 2021-10-01 2021-12-31 0000087802 us-gaap:RetainedEarningsMember 2021-10-01 2021-12-31 0000087802 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-10-01 2021-12-31 0000087802 us-gaap:AdditionalPaidInCapitalMember 2021-10-01 2021-12-31 0000087802 us-gaap:CommonStockMember 2021-10-01 2021-12-31 0000087802 2021-09-30 0000087802 us-gaap:RetainedEarningsMember 2021-09-30 0000087802 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-30 0000087802 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0000087802 us-gaap:TreasuryStockMember 2021-09-30 0000087802 us-gaap:CommonStockMember 2021-09-30 0000087802 2021-07-02 2021-09-30 0000087802 us-gaap:TreasuryStockMember 2021-07-02 2021-09-30 0000087802 us-gaap:RetainedEarningsMember 2021-07-02 2021-09-30 0000087802 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-07-02 2021-09-30 0000087802 us-gaap:AdditionalPaidInCapitalMember 2021-07-02 2021-09-30 0000087802 us-gaap:CommonStockMember 2021-07-02 2021-09-30 0000087802 2021-07-01 0000087802 us-gaap:RetainedEarningsMember 2021-07-01 0000087802 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-07-01 0000087802 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 0000087802 us-gaap:TreasuryStockMember 2021-07-01 0000087802 us-gaap:CommonStockMember 2021-07-01 0000087802 2021-03-31 0000087802 us-gaap:RetainedEarningsMember 2021-03-31 0000087802 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0000087802 us-gaap:TreasuryStockMember 2021-03-31 0000087802 us-gaap:CommonStockMember 2021-03-31 0000087802 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0000087802 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0000087802 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0000087802 2020-12-31 0000087802 us-gaap:RetainedEarningsMember 2020-12-31 0000087802 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000087802 us-gaap:TreasuryStockMember 2020-12-31 0000087802 us-gaap:CommonStockMember 2020-12-31 0000087802 2020-10-01 2020-12-31 0000087802 us-gaap:RetainedEarningsMember 2020-10-01 2020-12-31 0000087802 us-gaap:AdditionalPaidInCapitalMember 2020-10-01 2020-12-31 0000087802 2020-09-30 0000087802 us-gaap:RetainedEarningsMember 2020-09-30 0000087802 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0000087802 us-gaap:TreasuryStockMember 2020-09-30 0000087802 us-gaap:CommonStockMember 2020-09-30 0000087802 2020-07-02 2020-09-30 0000087802 us-gaap:RetainedEarningsMember 2020-07-02 2020-09-30 0000087802 us-gaap:AdditionalPaidInCapitalMember 2020-07-02 2020-09-30 0000087802 2020-07-01 0000087802 us-gaap:RetainedEarningsMember 2020-07-01 0000087802 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 0000087802 us-gaap:TreasuryStockMember 2020-07-01 0000087802 us-gaap:CommonStockMember 2020-07-01 0000087802 us-gaap:RetainedEarningsMember 2021-06-30 0000087802 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0000087802 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0000087802 us-gaap:TreasuryStockMember 2021-06-30 0000087802 us-gaap:CommonStockMember 2021-06-30 0000087802 us-gaap:TreasuryStockMember 2020-07-01 2021-06-30 0000087802 us-gaap:RetainedEarningsMember 2020-07-01 2021-06-30 0000087802 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-01 2021-06-30 0000087802 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2021-06-30 0000087802 us-gaap:CommonStockMember 2020-07-01 2021-06-30 0000087802 us-gaap:RetainedEarningsMember 2020-06-30 0000087802 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0000087802 us-gaap:TreasuryStockMember 2020-06-30 0000087802 us-gaap:CommonStockMember 2020-06-30 0000087802 us-gaap:RetainedEarningsMember 2019-07-01 2020-06-30 0000087802 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2020-06-30 0000087802 us-gaap:CommonStockMember 2019-07-01 2020-06-30 0000087802 2019-06-30 0000087802 us-gaap:RetainedEarningsMember 2019-06-30 0000087802 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0000087802 us-gaap:TreasuryStockMember 2019-06-30 0000087802 us-gaap:CommonStockMember 2019-06-30 0000087802 2020-07-01 2021-03-31 0000087802 2020-07-01 2021-06-30 0000087802 2019-07-01 2020-06-30 0000087802 2021-01-01 2021-03-31 0000087802 2022-01-01 2022-03-31 0000087802 2021-06-30 0000087802 2020-06-30 0000087802 2022-03-31 iso4217:USD shares iso4217:USD shares pure 0000087802 false false 0.05 19802 405400 -20000 0 0 440000 0 0 433800 2500 The Company is obligated to pay 50% of all royalties earned to the entity that licensed the intellectual property to the Company. 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.00 0 0 0 0 0 0 387700 0 0 0 0 0 0 201100 159200 187500 25400 40200 800300 452300 784500 742100 252200 286200 3931000 3742000 7880100 4138100 0 0 0 1000 24000 0 0.00 3.29 S-1 SCIENTIFIC INDUSTRIES, INC. DE 04-2217279 80 Orville Drive Suite 102 Bohemia NY 11716 631 567-4700 Non-accelerated Filer true 9675200 7559700 3744600 331800 15600 11600 1294700 1064000 2977100 2541000 333300 334800 350900 112400 55300 793000 18431100 12736700 412600 278300 2557800 128700 4395400 257300 665300 803300 54300 56000 2489900 537100 29006400 14797400 453500 334600 633500 679000 0 20000 136600 111000 321700 43100 270500 195800 433800 563800 37200 240900 2286800 2188200 460500 640800 23400 247000 10900 0 2781600 3076000 0.05 15000000 2881065 2861263 324000 144100 26613500 8608300 -9200 0 -651100 3021400 26277200 11773800 19802 52400 52400 26224800 11721400 29006400 14797400 9775200 7784400 4799800 3847000 4975400 3937400 4028500 2275400 4031900 1185800 1623800 1139700 9684200 4600900 -4708800 -663500 82200 12600 571600 16500 653800 -3900 -4055000 -667400 -945000 -214000 -3110000 -453400 -562500 -249900 -3672500 -703300 -9200 0 -3681700 -703300 -0.97 -0.30 -0.18 -0.16 -1.15 -0.46 1513914 75700 2592700 0 3724700 19802 52400 6340700 0 0 0 -703300 0 -703300 1349850 67500 5936900 0 0 0 6004400 17301 900 12900 0 0 0 13800 0 65800 0 0 0 65800 2881065 144100 8608300 0 3021400 19802 52400 11721400 0 -3672500 0 -3672500 0 0 -9200 0 0 -9200 3595880 179800 15894200 0 0 16074000 1000 100 3000 0 0 3100 0 2108000 0 0 2108000 6477945 324000 26613500 -9200 -651100 19802 52400 26224800 -3672500 -703300 -35600 -4400 251500 160900 -1152500 -106000 10400 12400 405400 0 4000 3400 531100 0 0 -300 2108000 65800 -30000 112600 -75500 906800 -560000 -292400 1500 -334800 -211400 -22400 138000 -803300 79600 -214400 -105600 867700 -195200 191500 -20000 89000 10900 0 278600 -96900 371000 535200 -3301500 -168100 9569000 63400 6181400 55000 0 1000 198700 50900 440000 0 -7679000 0 58700 25800 -10884000 -84100 32700 0 433800 563800 17080400 6004400 1006400 0 3100 13800 -168000 -372600 16310200 6209400 -9200 0 2115500 5957200 7559700 1602500 9675200 7559700 2500 40900 1. Summary of Significant Accounting Policies Nature of Business Scientific Industries, Inc. and its subsidiaries (the “Company”) design, manufacture, and market a variety of benchtop laboratory equipment and bioprocessing products. The Company is headquartered in Bohemia, New York where it produces benchtop laboratory equipment. Additionally, the Company has two other locations in Pittsburgh, Pennsylvania and Baesweiller, Germany, where it designs and produces a variety of bioprocessing products, and an administrative facility in Orangeburg, New York related to sales and marketing. The products, which are sold to customers worldwide, include mixers, shakers, stirrers, refrigerated incubators, pharmacy balances and scales, force gauges, bioprocessing-sensors and analytical tools. The Company also sublicenses certain patents and technology under a license agreement with the University of Maryland, Baltimore County, and receives royalty fees from sublicenses (see Note 1- Revenue Recognition). COVID-19 Pandemic The challenges posed by the COVID-19 pandemic on the global economy began to take effect and impacted the Company’s operations at the end of the third quarter of the year ended June 30, 2020. At that time, the Company took appropriate action and put plans in place to diminish the effects of COVID-19 on its operations, enabling the Company to continue to operate with minor or temporary disruptions to its operations. The Company took immediate action as it pertains to COVID-19 preparedness by implementing the Center for Disease Control’s guidelines for employers in order to protect the Company’s employees’ health and safety, with actions such as implementing work from home, social distancing in the workplace, requiring self-quarantine for any employee showing symptoms, wearing face coverings, and training employees on maintaining a healthy work environment. The Bioprocessing Systems Operations’ SBI facility was shut down temporarily due to state mandates, however, the impact on operations was immaterial, and the Company has been able to retain its employees without furloughs or layoffs, in part, due to the Company’ receipt of two loans under the Federal Government’s Small Business Administration Paycheck Protection Program. The Company received $563,800 and $433,800 in Payroll Protection Program loans in April 2020 and March 2021, respectively. The first loan was forgiven in June 2021 except for $32,700 which was repaid by the Company. The Company expects to apply and receive forgiveness for the second loan. The operations of aquila biolabs GmbH ("Aquila") which was acquired on April 29, 2021 was negatively impacted in its ability to secure new orders because Aquila had historically relied on face-to-face meetings at trade shows for its sales opportunities. While it has participated in virtual trade shows, management believes that certain sales opportunities are lost as a result. The Company has not experienced and does not anticipate any material impact on its ability to collect its accounts receivable due to the nature of its customers, which are primarily distributors of laboratory equipment and supplies which have benefitted from the Pandemic due to the nature of the products and have the ability to pay. The Company has not experienced and does not anticipate any material impairment to its tangible and intangible assets, system of internal controls, or delivery and distribution of its products as a result of COVID-19, however the ultimate impact of COVID-19 on the Company’s business, results of operations, financial condition and cash flows is dependent on future developments, including the duration or worsening of the pandemic and the related length of its impact on the global economy, which are uncertain and cannot be predicted at this time. The Company is currently experiencing some delays from its supply chain which is having an impact on delayed delivery of some products, however this is deemed temporary and does not affect the Company’s major product – the Vortex-Genie 2. In addition, due to the travel restrictions imposed by the United States and other governments worldwide, Company personnel may be restricted from traveling to conduct its operations including site visits, customer visits and installations, vendor facility visits, and other sales and marketing related travel that can negatively impact the Company. Principles of Consolidation The accompanying consolidated financial statements include the accounts of Scientific Industries, Inc., Scientific Packaging Industries, Inc., an inactive wholly-owned subsidiary, Altamira Instruments, Inc. (“Altamira”), a Delaware corporation and wholly-owned subsidiary (discontinued operation as of November 30, 2020), and Scientific Bioprocessing Holdings, Inc. (“SBHI”), a newly incorporated Delaware corporation and its wholly-owned subsidiaries, Scientific Bioprocessing, Inc. (“SBI”), a Delaware corporation, and Aquila, a German corporation, which was acquired on April 29, 2021, (all collectively referred to as the “Company”). On April 30, 2021 Scientific Industries, Inc. contributed 100% of the stock of Scientific Bioprocessing, Inc. to its wholly owned subsidiary Scientific Bioprocessing Holdings, Inc. All material intercompany balances and transactions have been eliminated in consolidation.Revenue Recognition The Company recognizes revenue in accordance with Financial Accounting Standards Board ('FASB") Accounting Standards Codification (“ASC”) Topic 606 “Revenue from Contracts with Customers, (“ASC 606”). In accordance with ASC 606, the Company accounts for a customer contract when both parties have approved the contract and are committed to perform their respective obligations, each party’s rights can be identified, payment terms can be identified, the contract has commercial substance, and it is probable that the Company will collect substantially all of the consideration to which it is entitled. Revenue is recognized when, or as, performance obligations are satisfied by transferring control of a promised product or service to a customer. All of the Company's contracts have a single performance obligation. As permitted by ASC 606, the Company does not disclose the amount of unsatisfied performance obligations for client contracts with an original expected length of one year or less. The Company determines revenue recognition through the following steps: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"> </td><td style="width:4%;vertical-align:top;">·</td><td style="vertical-align:top;">Identification of the contract, or contracts, with a customer</td></tr><tr style="height:15px"><td> </td><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">·</td><td style="vertical-align:top;">Identification of the performance obligations in the contract</td></tr><tr style="height:15px"><td> </td><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">·</td><td style="vertical-align:top;">Determination of the transaction price</td></tr><tr style="height:15px"><td> </td><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">·</td><td style="vertical-align:top;">Allocation of the transaction price to the performance obligations in the contract</td></tr><tr style="height:15px"><td> </td><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">·</td><td style="vertical-align:top;">Recognition of revenue when, or as, a performance obligation is satisfied</td></tr></tbody></table> Nature of Products and Services We generate revenues from the following sources: (1) Benchtop Laboratory Equipment and (2) Bioprocessing Systems. <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Benchtop Laboratory Equipment</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Bioprocessing Systems</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Consolidated</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:bottom;">June 30, 2021:</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Revenues</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,043,600</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">731,600</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,775,200</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Foreign Sales</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,483,700</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">684,600</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,168,300</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Benchtop Laboratory Equipment</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Bioprocessing Systems</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Consolidated</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:bottom;">June 30, 2020:</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Revenues</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,783,600</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,000,800</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,784,400</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Foreign Sales</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,589,800</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,000,400</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,590,200</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table>Benchtop laboratory equipment sales comprise primarily of standard benchtop laboratory equipment to laboratory equipment distributors, or to end users primarily via e-commerce. The sales cycle from time of receipt of order to shipment is very short varying from a day to a few weeks. Customers either pay by credit card (online sales) or Net 30-90, depending on the customer. Once the item is shipped under the FOB terms specified in the order, which is primarily “FOB Factory”, other than a standard warranty, there are no other obligations to the customer. Warranty usually comprises of one to two year parts and labor and is deemed immaterial. Revenue is recognized at a point in time when the risks and rewards of ownership have tranferred to the customer, which is generally upon shipment. Bioprocessing revenues consist of royalty revenues generated through SBI and product revenues generated primarily through Aquila. Royalty revenues are earned by the Company under a licensing agreement from a single licensee and its sublicenses. The license agreement includes two United States patents and a European Union patent (through December 2019). In January 2020, the European Union patent which was due to expire in August 2020, was terminated and the Company will only receive royalties under the United States patents through December 2023, which will result in a material reduction in total royalties expected to be received. The Company is obligated to pay 50% of all royalties earned to the entity that licenses the intellectual property to the Company. Royalty revenue requires significant judgement in estimating royalty revenue to be recognized during the year. The Company has made the following accounting policy elections and elected to use certain practical expedients, as permitted by the FASB, in applying ASC 606: 1) All revenues are recorded net of returns, allowances, customer discounts, and incentives; 2) Although sales and other taxes are immaterial, the Company accounts for amounts collected from customers for sales and other taxes, if any, net of related amounts remitted to tax authorities; 3) the Company expenses costs to obtain a contract as they are incurred if the expected period of benefit, and therefore the amortization period, is one year or less; 4) the Company accounts for shipping and handling activities that occur after control transfers to the customer as a fulfillment cost rather than an additional promised service and these fulfillment costs fall within selling expenses; 5) the Company is always considered the principal and never an agent, because it has full control and responsibility until title is transferred to the customer; 6) the Company does not assess whether promised goods or services are performance obligations if they are immaterial in the context of the contract with the customer such as is the case with catalyst instruments.Cash and Cash Equivalents The Company considers all highly liquid debt instruments purchased with original maturities of 90 days or less to be cash equivalents. At times, cash balances may be in excess of the Federal Deposit Insurance Corporation (“FDIC”) insurance limit. As of June 30, 2021, and 2020, $8,922,800 and $6,729,300 respectively of cash balances were in excess of such limit. Reclasses Certain amounts on the balance sheet as of June 30, 2021 and 2020 pertaining to inventories, property and equipment, goodwill, accounts payable, accrued expenses, contract liabilities, and operating leases liabilities were reclassed as assets and liabilities of discontinued operations due to the sale of the Company's wholly owned subsidiary, Altamira Instruments, Inc. on November 30, 2020. Accounts Receivable In order to record the Company’s accounts receivable at their net realizable value, the Company must assess their collectability. A considerable amount of judgment is required in order to make this assessment, including an analysis of historical bad debts and other adjustments, a review of the aging of the Company’s receivables, and the current creditworthiness of the Company’s customers. The Company has recorded allowances for receivables which it considered uncollectible, including amounts for the resolution of potential credit and other collection issues such as disputed invoices and customer satisfaction claims. However, depending on how such potential issues are resolved, or if the financial condition of any of the Company’s customers was to deteriorate and its ability to make required payments became impaired, increases in these allowances may be required. The Company actively manages its accounts receivable to minimize credit risk. The Company does not obtain collateral for its accounts receivable. Based on its assessment, the Company concluded that there are no collection issues related to the COVID-19 Pandemic. Contract Liabilities Contract liabilities consists of billings or payments received in advance of revenue recognition and is recognized as the revenue recognition criteria are met. Amounts that have been invoiced are initially recorded in accounts receivable and contract liabilities. The Company invoices its customers in accordance with the terms of the underlying contract. Accordingly, the contract liabilities balance does not represent the total contract value of outstanding arrangements. Contract liabilities that are expected to be recognized during the subsequent 12-month period are recorded as current and the remaining portion as noncurrent. Contract liabilities were not significant at June 30, 2021 and 2020, respectively. Investment Securities Investment securities consist of equity securities and mutual funds with realized gains and losses recorded using the specific identification method. Changes in fair value are recorded as unrealized holding gains or losses in other income (loss), net on the statement of comprehensive loss. The Company determines the cost of the investment sold based on an average cost basis at the individual security level and records the interest income and realized gains or losses on the sale of these investments in other income (loss), net. Inventories Inventories are valued at the lower of cost (determined on a first-in, first-out basis) or net realizable value, and have been reduced by an allowance for excess and obsolete inventories. The estimate is based on management’s review of inventories on hand compared to estimated future usage and sales. Cost of work-in-process and finished goods inventories include material, labor and manufacturing overhead.Property and Equipment Property and equipment are stated at cost. Depreciation of property and equipment is provided for primarily by the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized by the straight-line method over the remaining term of the related lease or the estimated useful lives of the assets, whichever is shorter. Research and Development Expenses Research and development expenses are expensed as incurred and consist principally of internal and external costs which includes the cost of patent licenses, contract research services, laboratory supplies, in-process research and development acquired, as well as product developments and enhancements. Finite Lived Intangible Assets Intangible assets consist primarily of acquired technology, customer relationships, non-compete agreements, patents, licenses, websites, and in process research and development (“IPR&D”), trademarks and trade names. All finite lived intangible assets are amortized on a straight-line basis over the estimated useful lives of the respective assets, generally 3 to 10 years. The Company continually evaluates the remaining estimated useful lives of intangible assets that are being amortized to determine whether events or circumstances warrant a revision to the remaining period of amortization. Goodwill and Indefinite Lived Intangible Assets Goodwill represents the excess of purchase price over the fair value of identifiable net assets acquired in a business combination. Goodwill and indefinite lived intangible assets are tested for impairment at least annually in accordance with the provisions of ASC 350, “Intangibles-Goodwill and Other” (“ASC 350”). ASC 350 requires that goodwill be tested for impairment at the reporting unit level (operating segment or one level below an operating segment) on an annual basis and between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value. Application of the goodwill impairment test requires judgment, including the identification of reporting units, assignment of assets and liabilities to reporting units, assignment of goodwill to reporting units, and determination of the fair value of each reporting unit. The Company tests goodwill and long-lived assets annually as of June 30, the last day of its fiscal year, unless an event occurs that would cause the Company to believe the value is impaired at an interim date. The Company concluded as of June 30, 2021 and 2020, there was no impairment of goodwill or indefinite lived intangible assets. Impairment of Long-Lived Assets The Company follows the provisions of ASC No. 360, “Property, Plant and Equipment - Impairment or Disposal of Long-Lived Assets (“ASC 360"). ASC 360 which requires evaluation of the need for an impairment charge relating to long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If an evaluation for impairment is required, the estimated future undiscounted cash flows associated with the asset would be compared to the asset’s carrying amount to determine if a write down to a new depreciable basis is required. If required, an impairment charge is recorded based on an estimate of future discounted cash flows. The Company concluded as of June 30, 2021 and 2020, there was no impairment of long-lived assets.Income Taxes The Company and its subsidiaries file a consolidated U.S. federal income tax return. Income taxes are accounted for under the asset and liability method. The Company provides for federal, and state income taxes currently payable, as well as for those deferred due to timing differences between reporting income and expenses for financial statement purposes versus tax purposes. Deferred tax assets and liabilities are recognized for the future tax consequences attributed to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted income tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect of a change in income tax rates is recognized as income or expense in the period that includes the enactment date. The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. Advertising Advertising costs are expensed as incurred. Advertising expense amounted to $399,700 and $218,700 for the years ended June 30, 2021 and 2020, respectively. Stock Compensation Plan The Company has a ten-year stock option plan (the “2012 Plan”) which provides for the grant of options to purchase up to 1,193,000 shares of the Company’s Common Stock, par value $.05 per share (“Common Stock”), plus up to 57,000 shares under options previously granted under the 2002 Stock Option Plan of the Company (the “Prior Plan”). The 2012 Plan provides for the granting of incentive or non-incentive stock options as defined in the 2012 Plan through 2022. Incentive stock options may be granted to employees at an exercise price equal to 100% (or 110% if the optionee owns directly or indirectly more than 10% of the outstanding voting stock) of the fair market value of the shares of Common Stock on the date of the grant. Non-incentive stock options shall be granted at the fair market value of the shares of Common Stock on the date of grant. At June 30, 2021 and 2020, 5,243 and 147,414 shares respectively, of Common Stock were available for grant of options under the 2012 Plan. Stock-based compensation is accounted for in accordance with ASC No. 718 “Compensation-Stock Compensation” (“ASC No. 718”) which requires compensation costs related to stock-based payment transactions to be recognized. The amount of compensation cost is measured based on the grant-date fair value of the equity issued and expensed ratably over the requisite service period.Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission requires management to make estimates and judgments that affect the amounts reported in the financial statements and accompanying notes. Estimates are used for, but not limited to, the allowance for doubtful accounts, slow-moving inventory reserves, depreciation and amortization, assumptions made in valuing equity instruments, fair value of stock options, the fair values of intangibles and goodwill, and provision or benefit for income taxes. The actual results experienced by the Company may differ materially from management’s estimates. Earnings (Loss) Per Common Share Basic earnings or loss per common share is computed by dividing net income (loss) by the weighted-average number of shares outstanding. Diluted earnings per common share includes the dilutive effect of stock options, if any. Since the Company was in a loss position during the years ended June 30, 2021 and 2020, respectively, basic net loss per share is the same as dilutive net loss per share as the inclusion of the weighted-average number of all potential dilutive common shares which consists of stock options and warrants are anti-dilutive. Recent Accounting Pronouncements In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes, which is designed to simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. ASU No. 2020-12 is effective for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years; this ASU allows for early adoption in any interim period after issuance of the update. The Company is currently evaluating the impact of adopting this guidance. Adopted Accounting Pronouncement In August 2018, the FASB issued Accounting Standards Update ("ASU") 2018-13, "Fair Value Measurement (Topic 820): Disclosure Framework Changes to the Disclosure Requirements for Fair Value Measurement", which is part of the FASB disclosure framework project to improve the effectiveness of disclosures in the notes to the financial statements. The amendments in the new guidance remove, modify, and add certain disclosure requirements related to fair value measurements covered in Topic 820, "Fair Value Measurement." The new standard is effective for fiscal years beginning after December 15, 2019. Early adoption is permitted for either the entire standard or only the requirements that modify or eliminate the disclosure requirements, with certain requirements applied prospectively, and all other requirements applied retrospectively to all periods presented. In February 2016, the FASB issued ASU No. 2016-02, Leases, which replaces previous lease guidance in its entirety with ASC 842 and requires lessees to recognize lease assets and lease liabilities for those arrangements classified as operating leases under previous guidance, with the exception of leases with a term of twelve months or less. The Company adopted ASU No. 2016-02 on July 1, 2019 using the additional transition method, which allows prior periods to be presented under previous lease accounting guidance. Refer to Note 11, "Leases", for related disclosures. Scientific Industries, Inc. and its subsidiaries (the “Company”) design, manufacture, and market a variety of benchtop laboratory equipment and bioprocessing products. The Company is headquartered in Bohemia, New York where it produces benchtop laboratory equipment. Additionally, the Company has two other locations in Pittsburgh, Pennsylvania and Baesweiller, Germany, where it designs and produces a variety of bioprocessing products, and an administrative facility in Orangeburg, New York related to sales and marketing. The products, which are sold to customers worldwide, include mixers, shakers, stirrers, refrigerated incubators, pharmacy balances and scales, force gauges, bioprocessing-sensors and analytical tools. The Company also sublicenses certain patents and technology under a license agreement with the University of Maryland, Baltimore County, and receives royalty fees from sublicenses (see Note 1- Revenue Recognition). The challenges posed by the COVID-19 pandemic on the global economy began to take effect and impacted the Company’s operations at the end of the third quarter of the year ended June 30, 2020. At that time, the Company took appropriate action and put plans in place to diminish the effects of COVID-19 on its operations, enabling the Company to continue to operate with minor or temporary disruptions to its operations. The Company took immediate action as it pertains to COVID-19 preparedness by implementing the Center for Disease Control’s guidelines for employers in order to protect the Company’s employees’ health and safety, with actions such as implementing work from home, social distancing in the workplace, requiring self-quarantine for any employee showing symptoms, wearing face coverings, and training employees on maintaining a healthy work environment. The Bioprocessing Systems Operations’ SBI facility was shut down temporarily due to state mandates, however, the impact on operations was immaterial, and the Company has been able to retain its employees without furloughs or layoffs, in part, due to the Company’ receipt of two loans under the Federal Government’s Small Business Administration Paycheck Protection Program. The Company received $563,800 and $433,800 in Payroll Protection Program loans in April 2020 and March 2021, respectively. The first loan was forgiven in June 2021 except for $32,700 which was repaid by the Company. The Company expects to apply and receive forgiveness for the second loan. The operations of aquila biolabs GmbH ("Aquila") which was acquired on April 29, 2021 was negatively impacted in its ability to secure new orders because Aquila had historically relied on face-to-face meetings at trade shows for its sales opportunities. While it has participated in virtual trade shows, management believes that certain sales opportunities are lost as a result. The Company has not experienced and does not anticipate any material impact on its ability to collect its accounts receivable due to the nature of its customers, which are primarily distributors of laboratory equipment and supplies which have benefitted from the Pandemic due to the nature of the products and have the ability to pay. The Company has not experienced and does not anticipate any material impairment to its tangible and intangible assets, system of internal controls, or delivery and distribution of its products as a result of COVID-19, however the ultimate impact of COVID-19 on the Company’s business, results of operations, financial condition and cash flows is dependent on future developments, including the duration or worsening of the pandemic and the related length of its impact on the global economy, which are uncertain and cannot be predicted at this time. The Company is currently experiencing some delays from its supply chain which is having an impact on delayed delivery of some products, however this is deemed temporary and does not affect the Company’s major product – the Vortex-Genie 2. In addition, due to the travel restrictions imposed by the United States and other governments worldwide, Company personnel may be restricted from traveling to conduct its operations including site visits, customer visits and installations, vendor facility visits, and other sales and marketing related travel that can negatively impact the Company. The accompanying consolidated financial statements include the accounts of Scientific Industries, Inc., Scientific Packaging Industries, Inc., an inactive wholly-owned subsidiary, Altamira Instruments, Inc. (“Altamira”), a Delaware corporation and wholly-owned subsidiary (discontinued operation as of November 30, 2020), and Scientific Bioprocessing Holdings, Inc. (“SBHI”), a newly incorporated Delaware corporation and its wholly-owned subsidiaries, Scientific Bioprocessing, Inc. (“SBI”), a Delaware corporation, and Aquila, a German corporation, which was acquired on April 29, 2021, (all collectively referred to as the “Company”). On April 30, 2021 Scientific Industries, Inc. contributed 100% of the stock of Scientific Bioprocessing, Inc. to its wholly owned subsidiary Scientific Bioprocessing Holdings, Inc. All material intercompany balances and transactions have been eliminated in consolidation. The Company recognizes revenue in accordance with Financial Accounting Standards Board ('FASB") Accounting Standards Codification (“ASC”) Topic 606 “Revenue from Contracts with Customers, (“ASC 606”). In accordance with ASC 606, the Company accounts for a customer contract when both parties have approved the contract and are committed to perform their respective obligations, each party’s rights can be identified, payment terms can be identified, the contract has commercial substance, and it is probable that the Company will collect substantially all of the consideration to which it is entitled. Revenue is recognized when, or as, performance obligations are satisfied by transferring control of a promised product or service to a customer. All of the Company's contracts have a single performance obligation. As permitted by ASC 606, the Company does not disclose the amount of unsatisfied performance obligations for client contracts with an original expected length of one year or less. The Company determines revenue recognition through the following steps: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"> </td><td style="width:4%;vertical-align:top;">·</td><td style="vertical-align:top;">Identification of the contract, or contracts, with a customer</td></tr><tr style="height:15px"><td> </td><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">·</td><td style="vertical-align:top;">Identification of the performance obligations in the contract</td></tr><tr style="height:15px"><td> </td><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">·</td><td style="vertical-align:top;">Determination of the transaction price</td></tr><tr style="height:15px"><td> </td><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">·</td><td style="vertical-align:top;">Allocation of the transaction price to the performance obligations in the contract</td></tr><tr style="height:15px"><td> </td><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">·</td><td style="vertical-align:top;">Recognition of revenue when, or as, a performance obligation is satisfied</td></tr></tbody></table> Nature of Products and Services We generate revenues from the following sources: (1) Benchtop Laboratory Equipment and (2) Bioprocessing Systems. <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Benchtop Laboratory Equipment</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Bioprocessing Systems</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Consolidated</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:bottom;">June 30, 2021:</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Revenues</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,043,600</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">731,600</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,775,200</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Foreign Sales</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,483,700</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">684,600</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,168,300</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Benchtop Laboratory Equipment</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Bioprocessing Systems</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Consolidated</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:bottom;">June 30, 2020:</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Revenues</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,783,600</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,000,800</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,784,400</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Foreign Sales</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,589,800</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,000,400</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,590,200</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table>Benchtop laboratory equipment sales comprise primarily of standard benchtop laboratory equipment to laboratory equipment distributors, or to end users primarily via e-commerce. The sales cycle from time of receipt of order to shipment is very short varying from a day to a few weeks. Customers either pay by credit card (online sales) or Net 30-90, depending on the customer. Once the item is shipped under the FOB terms specified in the order, which is primarily “FOB Factory”, other than a standard warranty, there are no other obligations to the customer. Warranty usually comprises of one to two year parts and labor and is deemed immaterial. Revenue is recognized at a point in time when the risks and rewards of ownership have tranferred to the customer, which is generally upon shipment. Bioprocessing revenues consist of royalty revenues generated through SBI and product revenues generated primarily through Aquila. Royalty revenues are earned by the Company under a licensing agreement from a single licensee and its sublicenses. The license agreement includes two United States patents and a European Union patent (through December 2019). In January 2020, the European Union patent which was due to expire in August 2020, was terminated and the Company will only receive royalties under the United States patents through December 2023, which will result in a material reduction in total royalties expected to be received. The Company is obligated to pay 50% of all royalties earned to the entity that licenses the intellectual property to the Company. Royalty revenue requires significant judgement in estimating royalty revenue to be recognized during the year. The Company has made the following accounting policy elections and elected to use certain practical expedients, as permitted by the FASB, in applying ASC 606: 1) All revenues are recorded net of returns, allowances, customer discounts, and incentives; 2) Although sales and other taxes are immaterial, the Company accounts for amounts collected from customers for sales and other taxes, if any, net of related amounts remitted to tax authorities; 3) the Company expenses costs to obtain a contract as they are incurred if the expected period of benefit, and therefore the amortization period, is one year or less; 4) the Company accounts for shipping and handling activities that occur after control transfers to the customer as a fulfillment cost rather than an additional promised service and these fulfillment costs fall within selling expenses; 5) the Company is always considered the principal and never an agent, because it has full control and responsibility until title is transferred to the customer; 6) the Company does not assess whether promised goods or services are performance obligations if they are immaterial in the context of the contract with the customer such as is the case with catalyst instruments. <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Benchtop Laboratory Equipment</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Bioprocessing Systems</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Consolidated</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:bottom;">June 30, 2021:</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Revenues</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,043,600</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">731,600</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,775,200</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Foreign Sales</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,483,700</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">684,600</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,168,300</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Benchtop Laboratory Equipment</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Bioprocessing Systems</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Consolidated</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:bottom;">June 30, 2020:</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Revenues</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,783,600</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,000,800</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,784,400</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Foreign Sales</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,589,800</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,000,400</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,590,200</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table> 9043600 731600 9775200 3483700 684600 4168300 6783600 1000800 7784400 2589800 1000400 3590200 The Company considers all highly liquid debt instruments purchased with original maturities of 90 days or less to be cash equivalents. At times, cash balances may be in excess of the Federal Deposit Insurance Corporation (“FDIC”) insurance limit. As of June 30, 2021, and 2020, $8,922,800 and $6,729,300 respectively of cash balances were in excess of such limit. 8922800 6729300 Certain amounts on the balance sheet as of June 30, 2021 and 2020 pertaining to inventories, property and equipment, goodwill, accounts payable, accrued expenses, contract liabilities, and operating leases liabilities were reclassed as assets and liabilities of discontinued operations due to the sale of the Company's wholly owned subsidiary, Altamira Instruments, Inc. on November 30, 2020. In order to record the Company’s accounts receivable at their net realizable value, the Company must assess their collectability. A considerable amount of judgment is required in order to make this assessment, including an analysis of historical bad debts and other adjustments, a review of the aging of the Company’s receivables, and the current creditworthiness of the Company’s customers. The Company has recorded allowances for receivables which it considered uncollectible, including amounts for the resolution of potential credit and other collection issues such as disputed invoices and customer satisfaction claims. However, depending on how such potential issues are resolved, or if the financial condition of any of the Company’s customers was to deteriorate and its ability to make required payments became impaired, increases in these allowances may be required. The Company actively manages its accounts receivable to minimize credit risk. The Company does not obtain collateral for its accounts receivable. Based on its assessment, the Company concluded that there are no collection issues related to the COVID-19 Pandemic. Contract liabilities consists of billings or payments received in advance of revenue recognition and is recognized as the revenue recognition criteria are met. Amounts that have been invoiced are initially recorded in accounts receivable and contract liabilities. The Company invoices its customers in accordance with the terms of the underlying contract. Accordingly, the contract liabilities balance does not represent the total contract value of outstanding arrangements. Contract liabilities that are expected to be recognized during the subsequent 12-month period are recorded as current and the remaining portion as noncurrent. Contract liabilities were not significant at June 30, 2021 and 2020, respectively. Investment securities consist of equity securities and mutual funds with realized gains and losses recorded using the specific identification method. Changes in fair value are recorded as unrealized holding gains or losses in other income (loss), net on the statement of comprehensive loss. The Company determines the cost of the investment sold based on an average cost basis at the individual security level and records the interest income and realized gains or losses on the sale of these investments in other income (loss), net. Inventories are valued at the lower of cost (determined on a first-in, first-out basis) or net realizable value, and have been reduced by an allowance for excess and obsolete inventories. The estimate is based on management’s review of inventories on hand compared to estimated future usage and sales. Cost of work-in-process and finished goods inventories include material, labor and manufacturing overhead. Property and equipment are stated at cost. Depreciation of property and equipment is provided for primarily by the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized by the straight-line method over the remaining term of the related lease or the estimated useful lives of the assets, whichever is shorter. Research and development expenses are expensed as incurred and consist principally of internal and external costs which includes the cost of patent licenses, contract research services, laboratory supplies, in-process research and development acquired, as well as product developments and enhancements. Intangible assets consist primarily of acquired technology, customer relationships, non-compete agreements, patents, licenses, websites, and in process research and development (“IPR&D”), trademarks and trade names. All finite lived intangible assets are amortized on a straight-line basis over the estimated useful lives of the respective assets, generally 3 to 10 years. The Company continually evaluates the remaining estimated useful lives of intangible assets that are being amortized to determine whether events or circumstances warrant a revision to the remaining period of amortization. Goodwill represents the excess of purchase price over the fair value of identifiable net assets acquired in a business combination. Goodwill and indefinite lived intangible assets are tested for impairment at least annually in accordance with the provisions of ASC 350, “Intangibles-Goodwill and Other” (“ASC 350”). ASC 350 requires that goodwill be tested for impairment at the reporting unit level (operating segment or one level below an operating segment) on an annual basis and between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value. Application of the goodwill impairment test requires judgment, including the identification of reporting units, assignment of assets and liabilities to reporting units, assignment of goodwill to reporting units, and determination of the fair value of each reporting unit. The Company tests goodwill and long-lived assets annually as of June 30, the last day of its fiscal year, unless an event occurs that would cause the Company to believe the value is impaired at an interim date. The Company concluded as of June 30, 2021 and 2020, there was no impairment of goodwill or indefinite lived intangible assets. The Company follows the provisions of ASC No. 360, “Property, Plant and Equipment - Impairment or Disposal of Long-Lived Assets (“ASC 360"). ASC 360 which requires evaluation of the need for an impairment charge relating to long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If an evaluation for impairment is required, the estimated future undiscounted cash flows associated with the asset would be compared to the asset’s carrying amount to determine if a write down to a new depreciable basis is required. If required, an impairment charge is recorded based on an estimate of future discounted cash flows. The Company concluded as of June 30, 2021 and 2020, there was no impairment of long-lived assets. The Company and its subsidiaries file a consolidated U.S. federal income tax return. Income taxes are accounted for under the asset and liability method. The Company provides for federal, and state income taxes currently payable, as well as for those deferred due to timing differences between reporting income and expenses for financial statement purposes versus tax purposes. Deferred tax assets and liabilities are recognized for the future tax consequences attributed to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted income tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect of a change in income tax rates is recognized as income or expense in the period that includes the enactment date. The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. Advertising costs are expensed as incurred. Advertising expense amounted to $399,700 and $218,700 for the years ended June 30, 2021 and 2020, respectively. 399700 218700 The Company has a ten-year stock option plan (the “2012 Plan”) which provides for the grant of options to purchase up to 1,193,000 shares of the Company’s Common Stock, par value $.05 per share (“Common Stock”), plus up to 57,000 shares under options previously granted under the 2002 Stock Option Plan of the Company (the “Prior Plan”). The 2012 Plan provides for the granting of incentive or non-incentive stock options as defined in the 2012 Plan through 2022. Incentive stock options may be granted to employees at an exercise price equal to 100% (or 110% if the optionee owns directly or indirectly more than 10% of the outstanding voting stock) of the fair market value of the shares of Common Stock on the date of the grant. Non-incentive stock options shall be granted at the fair market value of the shares of Common Stock on the date of grant. At June 30, 2021 and 2020, 5,243 and 147,414 shares respectively, of Common Stock were available for grant of options under the 2012 Plan. Stock-based compensation is accounted for in accordance with ASC No. 718 “Compensation-Stock Compensation” (“ASC No. 718”) which requires compensation costs related to stock-based payment transactions to be recognized. The amount of compensation cost is measured based on the grant-date fair value of the equity issued and expensed ratably over the requisite service period. 5243 147414 The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission requires management to make estimates and judgments that affect the amounts reported in the financial statements and accompanying notes. Estimates are used for, but not limited to, the allowance for doubtful accounts, slow-moving inventory reserves, depreciation and amortization, assumptions made in valuing equity instruments, fair value of stock options, the fair values of intangibles and goodwill, and provision or benefit for income taxes. The actual results experienced by the Company may differ materially from management’s estimates. Basic earnings or loss per common share is computed by dividing net income (loss) by the weighted-average number of shares outstanding. Diluted earnings per common share includes the dilutive effect of stock options, if any. Since the Company was in a loss position during the years ended June 30, 2021 and 2020, respectively, basic net loss per share is the same as dilutive net loss per share as the inclusion of the weighted-average number of all potential dilutive common shares which consists of stock options and warrants are anti-dilutive. In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes, which is designed to simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. ASU No. 2020-12 is effective for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years; this ASU allows for early adoption in any interim period after issuance of the update. The Company is currently evaluating the impact of adopting this guidance. In August 2018, the FASB issued Accounting Standards Update ("ASU") 2018-13, "Fair Value Measurement (Topic 820): Disclosure Framework Changes to the Disclosure Requirements for Fair Value Measurement", which is part of the FASB disclosure framework project to improve the effectiveness of disclosures in the notes to the financial statements. The amendments in the new guidance remove, modify, and add certain disclosure requirements related to fair value measurements covered in Topic 820, "Fair Value Measurement." The new standard is effective for fiscal years beginning after December 15, 2019. Early adoption is permitted for either the entire standard or only the requirements that modify or eliminate the disclosure requirements, with certain requirements applied prospectively, and all other requirements applied retrospectively to all periods presented. In February 2016, the FASB issued ASU No. 2016-02, Leases, which replaces previous lease guidance in its entirety with ASC 842 and requires lessees to recognize lease assets and lease liabilities for those arrangements classified as operating leases under previous guidance, with the exception of leases with a term of twelve months or less. The Company adopted ASU No. 2016-02 on July 1, 2019 using the additional transition method, which allows prior periods to be presented under previous lease accounting guidance. Refer to Note 11, "Leases", for related disclosures. 2. Segment Information The Company views its operations as two segments: the manufacture and marketing of standard benchtop laboratory equipment for research in university, hospital and industrial laboratories sold primarily through laboratory equipment distributors and laboratory and pharmacy balances and scales (“Benchtop Laboratory Equipment Operations”), and the design and marketing of bioprocessing systems and products and related royalty income (“Bioprocessing Systems”). Segment information is reported as follows: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Benchtop Laboratory Equipment</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Bioprocessing Systems</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Corporate and Other</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Consolidated</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:bottom;">June 30, 2021:</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Revenues</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,043,600</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">731,600</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,775,200</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Foreign Sales</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,483,700</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">684,600</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">_</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,168,300</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Income (Loss) From Operations</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,461,300</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(4,828,600</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,341,400</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(4,708,800</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Assets</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">14,783,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8,735,100</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,488,300</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">29,006,400</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Long-Lived Asset Expenditures</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">60,500</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">196,900</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">257,400</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Depreciation and Amortization</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">103,100</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">148,400</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">251,500</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Benchtop Laboratory Equipment</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Bioprocessing Systems</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Corporate and Other</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Consolidated</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:bottom;">June 30, 2020:</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Revenues</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,783,600</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,000,800</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,784,400</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Foreign Sales</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,589,800</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,000,400</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,590,200</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Income (Loss) From Operations</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">449,700</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(727,500</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(385,700</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(663,500</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Assets</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12,232,600</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">546,100</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,018,700</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">14,797,400</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Long-Lived Asset Expenditures</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">36,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">40,700</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">76,700</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Depreciation and Amortization</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">116,900</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">42,700</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">159,600</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Benchtop Laboratory Equipment</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Bioprocessing Systems</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Corporate and Other</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Consolidated</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:bottom;">June 30, 2021:</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Revenues</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,043,600</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">731,600</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,775,200</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Foreign Sales</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,483,700</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">684,600</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">_</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,168,300</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Income (Loss) From Operations</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,461,300</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(4,828,600</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,341,400</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(4,708,800</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Assets</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">14,783,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8,735,100</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,488,300</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">29,006,400</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Long-Lived Asset Expenditures</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">60,500</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">196,900</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">257,400</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Depreciation and Amortization</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">103,100</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">148,400</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">251,500</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Benchtop Laboratory Equipment</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Bioprocessing Systems</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Corporate and Other</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Consolidated</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:bottom;">June 30, 2020:</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Revenues</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,783,600</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,000,800</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,784,400</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Foreign Sales</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,589,800</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,000,400</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,590,200</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Income (Loss) From Operations</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">449,700</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(727,500</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(385,700</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(663,500</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Assets</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12,232,600</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">546,100</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,018,700</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">14,797,400</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Long-Lived Asset Expenditures</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">36,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">40,700</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">76,700</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Depreciation and Amortization</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">116,900</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">42,700</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">159,600</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table> 9043600 731600 0 9775200 3483700 684600 4168300 1461300 -4828600 -1341400 -4708800 14783000 8735100 5488300 29006400 60500 196900 0 257400 103100 148400 0 251500 6783600 1000800 0 7784400 2589800 1000400 0 3590200 449700 -727500 -385700 -663500 12232600 546100 2018700 14797400 36000 40700 0 76700 116900 42700 0 159600 3. Fair Value of Financial Instruments The FASB defines the fair value of financial instruments as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value measurements do not include transaction costs. The accounting guidance also expands the disclosure requirements around fair value and establishes a fair value hierarchy for valuation inputs. The hierarchy prioritizes the inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market. Each fair value measurement is reported in one of the three levels, which is determined by the lowest level input that is significant to the fair value measurement in its entirety. These levels are described below: Level 1 Inputs that are based upon unadjusted quoted prices for identical instruments traded in active markets. Level 2 Quoted prices in markets that are not considered to be active or financial instruments for which all significant inputs are observable, either directly or indirectly. Level 3 Prices or valuation that require inputs that are both significant to the fair value measurement and unobservable. In valuing assets and liabilities, the Company is required to maximize the use of quoted market prices and minimize the use of unobservable inputs. The Company calculated the fair value of its Level 1 and 2 instruments based on the exchange traded price of similar or identical instruments where available or based on other observable instruments. These calculations take into consideration the credit risk of both the Company and its counterparties. The Company has not changed its valuation techniques in measuring the fair value of any financial assets and liabilities during the period. The fair value of the contingent consideration obligations is based on a probability weighted approach derived from the estimates of earn-out criteria and the probability assessment with respect to the likelihood of achieving those criteria. The measurement is based on significant inputs that are not observable in the market, therefore, the Company classifies this liability as Level 3 in the following table. The following tables set forth by level within the fair value hierarchy the Company’s financial assets that were accounted for at fair value on a recurring basis at June 30, 2021 and 2020 according to the valuation techniques the Company used to determine their fair values: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;">Fair Value at June 30,</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="10" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Fair Value Measurements Using Inputs Considered as</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">2021</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Level 1</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Level 2</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Level 3</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:bottom;">Assets:</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Cash and cash equivalents</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,675,200</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,675,200</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Investment securities</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,744,600</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,920,600</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">824,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Total</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,419,800</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12,595,800</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">824,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Liabilities:</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Contingent consideration</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">160,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">$ 160,000 </td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="10" style="width:9%;vertical-align:bottom;text-align:center;">Fair Value Measurements Using Inputs Considered as</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Fair Value at June 30, 2020</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Level 1</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Level 2</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Level 3</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:bottom;">Assets:</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Cash and cash equivalents</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,559,700</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,559,700</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Investment securities</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">331,800</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">331,800</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Total</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,891,500</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,891,500</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Liabilities:</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Contingent consideration</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">358,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">$ 358,000 </td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table>The following table sets forth an analysis of changes during the years ended June 30, 2021 and 2020, respectively, in Level 3 financial liabilities of the Company: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">2021</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">2020</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Beginning balance</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">358,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">618,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Increase (decrease) in contingent consideration liability</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(30,000</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">112,600</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Payments</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(168,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(372,600</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Ending balance</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">160,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">358,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> The Company’s contingent obligations require cash payments to the sellers of certain acquired operations based on royalty payments received or operating results achieved. These contingent considerations are classified as liabilities and the liabilities are remeasured to an estimated fair value at each reporting date. During the years ended June 30, 2021 and 2020, the Company recorded an increase (decrease) in the estimated fair value of contingent liabilities of approximately ($30,000) and $112,600, respectively related to its Bioprocessing Systems Operations segment. Investments in marketable securities by security type at June 30, 2021 and 2020 consisted of the following: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Cost</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Fair Value</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Unrealized Holding Gain (Loss)</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">At June 30, 2021:</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Equity securities</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">102,200</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">154,100</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">51,900</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Mutual funds</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,752,400</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,766,500</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">14,100</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Debt securities</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">832,700</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">824,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(8,700</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,687,300</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,744,600</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">57,300</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Cost</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Fair Value</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Unrealized Holding Gain (Loss)</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:bottom;">At June 30, 2020:</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Equity securities</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">77,600</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">101,900</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">24,300</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Mutual funds</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">250,300</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">229,900</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(20,400</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">327,900</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">331,800</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,900</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;">Fair Value at June 30,</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="10" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Fair Value Measurements Using Inputs Considered as</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">2021</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Level 1</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Level 2</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Level 3</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:bottom;">Assets:</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Cash and cash equivalents</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,675,200</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,675,200</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Investment securities</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,744,600</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,920,600</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">824,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Total</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,419,800</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12,595,800</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">824,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Liabilities:</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Contingent consideration</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">160,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">$ 160,000 </td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="10" style="width:9%;vertical-align:bottom;text-align:center;">Fair Value Measurements Using Inputs Considered as</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Fair Value at June 30, 2020</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Level 1</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Level 2</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Level 3</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:bottom;">Assets:</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Cash and cash equivalents</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,559,700</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,559,700</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Investment securities</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">331,800</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">331,800</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Total</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,891,500</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,891,500</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Liabilities:</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Contingent consideration</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">358,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">$ 358,000 </td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table> 9675200 9675200 0 0 3744600 2920600 824000 0 13419800 12595800 824000 0 160000 0 7559700 7559700 0 0 331800 331800 0 0 7891500 7891500 0 0 358000 0 358000 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">2021</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">2020</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Beginning balance</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">358,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">618,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Increase (decrease) in contingent consideration liability</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(30,000</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">112,600</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Payments</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(168,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(372,600</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Ending balance</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">160,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">358,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> 358000 618000 -30000 112600 -168000 -372600 160000 358000 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Cost</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Fair Value</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Unrealized Holding Gain (Loss)</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">At June 30, 2021:</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Equity securities</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">102,200</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">154,100</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">51,900</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Mutual funds</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,752,400</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,766,500</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">14,100</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Debt securities</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">832,700</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">824,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(8,700</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,687,300</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,744,600</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">57,300</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Cost</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Fair Value</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Unrealized Holding Gain (Loss)</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:bottom;">At June 30, 2020:</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Equity securities</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">77,600</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">101,900</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">24,300</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Mutual funds</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">250,300</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">229,900</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(20,400</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">327,900</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">331,800</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,900</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> 102200 154100 51900 2752400 2766500 14100 832700 824000 3687300 3744600 -57300 77600 101900 24300 250300 229900 -20400 327900 331800 3900 4. Inventories <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">2021</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">2020</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Raw materials</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,170,400</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,726,400</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Work-in-process</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">39,600</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">35,700</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Finished goods</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">767,100</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">778,900</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,977,100</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,541,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">2021</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">2020</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Raw materials</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,170,400</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,726,400</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Work-in-process</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">39,600</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">35,700</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Finished goods</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">767,100</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">778,900</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,977,100</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,541,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> 2170400 1726400 39600 35700 767100 778900 2977100 2541000 5. Property and Equipment <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">Useful Lives</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">(Years)</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">2021</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">2020</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Automobiles</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">22,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">22,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Computer equipment</td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2"> 3-5</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">233,500</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">215,300</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Machinery and equipment</td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2"> 3-7</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,047,600</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">847,500</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Furniture and fixtures</td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2"> 4-10</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">148,800</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">142,300</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Leasehold improvements</td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td colspan="2" style="BORDER-BOTTOM: black 1px solid;"> 3-10 </td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">64,400</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">50,300</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,516,300</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,277,400</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Less accumulated depreciation and amortization</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,103,700</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">999,100</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">412,600</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">278,300</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> Depreciation expense was $104,600 and $88,700 for the years ended June 30, 2021 and 2020, respectively. <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">Useful Lives</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">(Years)</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">2021</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">2020</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Automobiles</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">22,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">22,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Computer equipment</td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2"> 3-5</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">233,500</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">215,300</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Machinery and equipment</td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2"> 3-7</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,047,600</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">847,500</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Furniture and fixtures</td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2"> 4-10</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">148,800</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">142,300</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Leasehold improvements</td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td colspan="2" style="BORDER-BOTTOM: black 1px solid;"> 3-10 </td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">64,400</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">50,300</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,516,300</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,277,400</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Less accumulated depreciation and amortization</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,103,700</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">999,100</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">412,600</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">278,300</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> P5Y 22000 22000 P3Y P5Y 233500 215300 P3Y P7Y 1047600 847500 P4Y P10Y 148800 142300 P3Y P10Y 64400 50300 1516300 1277400 1103700 999100 412600 278300 104600 88700 6. Goodwill and Finite Lived Intangible Assets Goodwill represents the excess of the purchase price over the fair value of the net assets acquired in connection with the Company’s acquisitions. Goodwill amounted to $4,395,400 at June 30, 2021 and 257,300 at June 30, 2020, all of which is expected to be deductible for tax purposes. The components of finite lived intangible assets are as follows: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" style="width:9%;vertical-align:bottom;text-align:center;">UsefulLives</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">Cost</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">Accumulated Amortization</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">Net</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">At June 30, 2021:</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Technology, trademarks</td><td style="width:1%;white-space: nowrap;"> </td><td>5-10 yrs.</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">364,700</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">362,200</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,500</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Trade names</td><td style="width:1%;white-space: nowrap;"> </td><td>3-6 yrs.</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">592,300</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">152,600</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">439,700</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Websites</td><td style="width:1%;white-space: nowrap;"> </td><td>3-7 yrs.</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">210,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">210,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Customer relationships</td><td style="width:1%;white-space: nowrap;"> </td><td>4-10 yrs.</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">372,200</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">102,400</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">269,800</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Sublicense agreements</td><td style="width:1%;white-space: nowrap;"> </td><td>10 yrs.</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">294,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">283,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Non-compete agreements</td><td style="width:1%;white-space: nowrap;"> </td><td>4-5 yrs.</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,060,500</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">308,600</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">751,900</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">IPR&D</td><td style="width:1%;white-space: nowrap;"> </td><td>3-5 yrs.</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">852,100</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">134,800</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">717,300</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Patents</td><td style="width:1%;white-space: nowrap;"> </td><td>5-7 yrs.</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">591,500</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">225,900</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">365,600</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">4,337,300</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,779,500</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,557,800</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">UsefulLives</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">Cost</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">Accumulated Amortization</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">Net</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">At June 30, 2020:</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Technology, trademarks</td><td style="width:1%;white-space: nowrap;"> </td><td>5/10 yrs.</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">664,700</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">662,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,700</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Trade names</td><td style="width:1%;white-space: nowrap;"> </td><td>6 yrs.</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">140,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">140,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Websites</td><td style="width:1%;white-space: nowrap;"> </td><td>5 yrs.</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">210,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">210,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Customer relationships</td><td style="width:1%;white-space: nowrap;"> </td><td>9/10 yrs.</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">357,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">321,400</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">35,600</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Sublicense agreements</td><td style="width:1%;white-space: nowrap;"> </td><td>10 yrs.</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">294,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">253,600</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">40,400</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Non-compete agreements</td><td style="width:1%;white-space: nowrap;"> </td><td>5 yrs.</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">384,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">384,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">IPR&D</td><td style="width:1%;white-space: nowrap;"> </td><td>3 yrs.</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">110,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">110,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Patents</td><td style="width:1%;white-space: nowrap;"> </td><td>5 yrs.</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">246,600</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">196,600</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">50,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,406,300</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,277,600</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">128,700</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> Total amortization expense was $146,900 and $72,000 in 2021 and 2020, respectively. Estimated future amortization expense of intangible assets as of June 30, 2021 is as follows: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:bottom;">Year Ended June 30,</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2022</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">525,700</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">2023</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">520,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2024</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">508,800</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">2025</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">473,100</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2026</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">530,200</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Total</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,557,800</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> 4395400 257300 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" style="width:9%;vertical-align:bottom;text-align:center;">UsefulLives</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">Cost</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">Accumulated Amortization</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">Net</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">At June 30, 2021:</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Technology, trademarks</td><td style="width:1%;white-space: nowrap;"> </td><td>5-10 yrs.</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">364,700</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">362,200</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,500</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Trade names</td><td style="width:1%;white-space: nowrap;"> </td><td>3-6 yrs.</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">592,300</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">152,600</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">439,700</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Websites</td><td style="width:1%;white-space: nowrap;"> </td><td>3-7 yrs.</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">210,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">210,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Customer relationships</td><td style="width:1%;white-space: nowrap;"> </td><td>4-10 yrs.</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">372,200</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">102,400</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">269,800</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Sublicense agreements</td><td style="width:1%;white-space: nowrap;"> </td><td>10 yrs.</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">294,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">283,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Non-compete agreements</td><td style="width:1%;white-space: nowrap;"> </td><td>4-5 yrs.</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,060,500</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">308,600</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">751,900</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">IPR&D</td><td style="width:1%;white-space: nowrap;"> </td><td>3-5 yrs.</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">852,100</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">134,800</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">717,300</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Patents</td><td style="width:1%;white-space: nowrap;"> </td><td>5-7 yrs.</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">591,500</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">225,900</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">365,600</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">4,337,300</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,779,500</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,557,800</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">UsefulLives</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">Cost</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">Accumulated Amortization</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">Net</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">At June 30, 2020:</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Technology, trademarks</td><td style="width:1%;white-space: nowrap;"> </td><td>5/10 yrs.</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">664,700</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">662,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,700</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Trade names</td><td style="width:1%;white-space: nowrap;"> </td><td>6 yrs.</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">140,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">140,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Websites</td><td style="width:1%;white-space: nowrap;"> </td><td>5 yrs.</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">210,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">210,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Customer relationships</td><td style="width:1%;white-space: nowrap;"> </td><td>9/10 yrs.</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">357,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">321,400</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">35,600</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Sublicense agreements</td><td style="width:1%;white-space: nowrap;"> </td><td>10 yrs.</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">294,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">253,600</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">40,400</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Non-compete agreements</td><td style="width:1%;white-space: nowrap;"> </td><td>5 yrs.</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">384,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">384,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">IPR&D</td><td style="width:1%;white-space: nowrap;"> </td><td>3 yrs.</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">110,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">110,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Patents</td><td style="width:1%;white-space: nowrap;"> </td><td>5 yrs.</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">246,600</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">196,600</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">50,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,406,300</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,277,600</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">128,700</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> 364700 362200 2500 592300 152600 439700 210000 210000 0 372200 102400 269800 294000 283000 11000 1060500 308600 751900 852100 134800 717300 591500 225900 365600 4337300 1779500 2557800 P5Y P10Y 664700 662000 2700 P6Y 140000 140000 0 P5Y 210000 210000 0 P9Y P10Y 357000 321400 35600 P10Y 294000 253600 40400 P5Y 384000 384000 0 P3Y 110000 110000 0 P5Y 246600 196600 50000 2406300 2277600 128700 146900 72000 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:bottom;">Year Ended June 30,</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2022</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">525,700</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">2023</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">520,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2024</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">508,800</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">2025</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">473,100</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2026</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">530,200</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Total</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,557,800</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> 525700 520000 508800 473100 530200 2557800 7. Line of Credit The Company has a Demand Line of Credit through December 2021 with First National Bank of Pennsylvania which provides for borrowings of up to $300,000 for regular working capital needs, bearing interest at prime, currently 3.25%. The agreement does not contain financial covenants and borrowings are secured by a pledge of substantially all of the assets of the Company. As of June 30, 2021 and 2020, there were no borrowings outstanding under the line. 8. Payroll Protection Program Loan The Company received $563,800 and $433,800 in Payroll Protection Program loans in April 2020 and March 2021, respectively, pursuant to the Paycheck Protection Program loan (“PPP”) administered by the U.S. Small Business Administration through its bank. The first loan was forgiven in June 2021, and reflected as other income in the accompanying statements of comprehensive loss , except for $32,700 which was repaid by the Company. The remaining loan bears interest at 1% per annum and matures in March 2026 and contains no collateral or guarantee requirements. The Company expects to apply and receive forgiveness for the second loan. 9. Employee Benefit Plans The Company has a 401(k) profit sharing plan covering all its employees, which provides for voluntary employee salary contributions not to exceed the statutory limitations provided by the Internal Revenue Code. The plan provides for Company matching contribution equal to 100% of employee’s deferral up to 3% of pay, plus 50% of employee’s deferral over 3% of pay up to 5%. Total matching contributions amounted to $90,700 and $84,100 for the years ended June 30, 2021 and 2020, respectively. 10. Commitments and Contingencies The Company has a three-year employment contract with its President, effective July 1, 2017, which was extended by mutual agreement for each one year periods ending June 30, 2021 and 2022. The agreement provided for an annual base salary of $175,000 for the year ended June 30, 2018, with subsequent annual increases of 3% or the percentage increase in Consumer Price Index (“CPI”), whichever is higher, plus $25,000 cash bonus for the year ended June 30, 2018, and a discretionary bonus for subsequent years. Bonuses totaling $100,000 and $50,000 were awarded for the years ended June 30, 2021 and 2020, respectively. The agreement also provided for a grant of options to purchase 25,000 shares of the Company’s stock, which were granted during the year ended June 30, 2018. No shares were granted during the year ended June 30, 2021, and 215,366 shares were authorized to be granted by the Board of Directors during the year ended June 30, 2020, which shares were not available and subject to amendment to the Company’s 2012 Stock Option Plan which was approved in February 2021. The agreement also contains a provision that within one year of a change of control, if either the Company terminates the employment for any reason other than for "cause" or the Presidents terminates her employment for "good reason", the President will have the right to receive a lump sum payment equal to three times the average of her total annual compensation paid for the last five years preceding such termination. The Company has a three-year employment contract with its President of the Genie Products Division of the Benchtop Laboratory Equipment Operations and Corporate Secretary effective July 1, 2017, which was extended by mutual agreement for each one year period ending June 30, 2021 and 2022. The agreement provides for an annual base salary of $153,000 for the year ended June 30, 2018, with subsequent annual increases of 3% or percentage increase in the CPI, whichever is higher, plus $10,000 cash bonus for the year ended June 30, 2018, and a discretionary bonus for subsequent years. No bonus was awarded for the year ended June 30, 2021 and a $5,000 bonus was awarded in 2020. The agreement also provides for a grant of options to purchase 7,500 shares of the Company’s stock, which were granted during the year ended June 30, 2018. No options were granted during the year ended June 30, 2021 or 2020. The Company has a three-year employment contract with its President and Director of Marketing of Torbal Products Division of the Benchtop Laboratory Equipment Operations and Director of Marketing effective July 1, 2017, which was extended by mutual agreement for each one year periods ending June 30, 2021 and 2022. The agreement provides for an annual base salary of $157,000 for the year ended June 30, 2018, with subsequent annual increases of 4% or percentage increase in the CPI, whichever is higher, plus $10,000 cash bonus for the year ended June 30, 2018 and subsequent years, subject to a minimum increase of 5% in the divisions’ EBITDA for the related year. The agreement also provides for a grant of options to purchase 7,500 shares of the Company’s stock, which were granted during the year ended June 30, 2018. No options were granted during the year ended June 30, 2021 or 2020. A performance-based bonus of $10,000 was awarded during the years ended June 30, 2020. No bonus was awarded for the year ended June 30, 2021.The Company has a three-year employment contract with its President of Scientific Bioprocessing, Inc., effective July 1, 2020. The agreement provides for an annual base salary of $175,000, with subsequent annual increases of 3% or percentage increase in Consumer Price Index (“CPI”), whichever is higher, plus discretionary bonuses. The agreement also provides for a grant of options to purchase 215,366 shares which were authorized to be granted by the Board of Directors during the year ended June 30, 2020, which shares were not available and subject to amendment to the Company’s 2012 Stock Option Plan which was approved in February 2021. Prior to July 1, 2020, the officer had a consulting agreement, which terminated upon becoming an employee of the Company. Consulting fees paid under this agreement amounted to $145,000 for the year ended June 30, 2020, respectively plus stock options valued at $36,000 were granted as part of the total compensation under the consulting agreement, for the year ended June 30, 2020. Bonuses amounting to $100,000 were awarded during the year ended June 30, 2021 and $50,000 in 2020. The employment agreement contains termination provisions stipulating that if the Company terminates the employment other than for death, disability, or cause (as such term is defined therein), or if employee resigns for “good reason”(as such term is defined in the agreement) , the Company shall pay severance payments equal to either one year’s salary at the rate of the compensation at the time of termination is employee is terminated within 12 months of the date of the agreement or six months’ salary is the employee is terminated after 12 months of the date of the agreement, continue to pay the regular benefits provided by the Company for the period equal to the length of the severance payments and pay a pro rata portion of any bonus achieved prior to such termination of employment. On April 30, 2021, the Company entered into an employment agreement with each of the four managing directors and sellers of Aquila for an indefinite term, which can be terminated by either party upon six months’ written notice in accordance with German law. The agreements, which are identical, stipulate that in calendar year 2021, the employees will receive a salary of 105,000 euros, and a guaranteed bonus of 45,000 euros for a total of 150,000 euros per year on a pro-rata basis, and in calendar year 2022, they will receive a salary of 105,000 euros and a bonus of 45,000 euros, subject to the achievement by Aquila of certain targets. In addition, the employment agreements included a one time retention bonus of 10,000 euros upon closing of the acquisition which was paid in May 2021 by Aquila, and a retention bonus of 25,000 euros if the employee does not terminate his employment with the Company within two years after the agreement date or the Company does not terminate his employment for good cause. The Company has a consulting agreement, which expires on December 31, 2021, with a Director of the Company and his affiliate for product development consulting services. The agreement provides that the consultant be paid a monthly retainer fee of $9,000, plus a grant of 20,000 options which were awarded during the year ended June 30, 2020. Consulting expense related to this agreement amounted to $108,000 and $76,200 for the years ended June 30, 2021 and 2020, respectively. On July 20, 2020, the Company entered into a two-year consulting agreement with a Director and Chairman of the Board of SBI for consulting on strategic matters of the Company’s Bioprocessing Systems Operations. The agreement provided that the consultant be paid a monthly retainer of 5,000 euros which was increased to 12,500 euros effective March 2021 plus the issuance of 125,000 stock options of the Company which were awarded during the year ended June 30, 2021. Consulting expense related to this agreement amounted to $207,900 for the year ended June 30, 2021 and none in 2020, respectively. The Company is required to make payments of 30% of the net royalties received from the license and sublicense acquired in the SBI acquisition in fiscal 2014 through December 2023, at which time the related patents will expire. Total contingent consideration payments made for this acquisition amounted to $168,000 and $372,600 for the years ended June 30, 2021 and 2020, respectively.The fair value of contingent consideration estimated to be paid as of June 30, 2021 is as follows: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:bottom;">Year ended June 30,</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Amount</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2022</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">136,600</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">2023</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2024</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">11,400</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">160,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:bottom;">Year ended June 30,</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Amount</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2022</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">136,600</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">2023</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2024</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">11,400</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">160,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> 136600 12000 11400 160000 11. Leases On July 1, 2019, the Company adopted the new accounting pronouncement as it relates to its leases which requires a lessee to recognize all long-term leases on its balance sheet as a liability for its lease obligation, measured at the present value of lease payments not yet paid, and a corresponding asset representing its right to use the underlying asset over the lease term and expands disclosure of key information about leasing arrangements. The Company leases certain properties consisting principally of a facility in Bohemia, New York (headquarters) through January 2025 which was amended in September 2021 to increase the space by approximately 25% and lease term through approximately October 2028, a facility in Pittsburgh, Pennsylvania for its Bioprocessing Systems Operations through May 2023, and a facility for sales and administration in Orangeburg, New York through October 2022. The Company had a lease for its discontinued operations through November 2020. There are no renewal options with any of the leases, no residual values or significant restrictions or covenants other than those customary in such arrangements, and no non-cash activities, and any rent escalations incorporated within the leases are included in the calculation of the future minimum lease payments, as further described below. All of the Company’s leases are deemed operating leases. The Company determines whether an agreement contains a lease at inception based on the Company’s right to obtain substantially all of the economic benefits from the use of the identified asset and its right to direct the use of the identified asset. Lease liabilities represent the present value of future lease payments and the Right-Of-Use (“ROU”) assets represent the Company’s right to use the underlying assets for the respective lease terms. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term. The ROU asset is further adjusted to account for previously recorded lease expenses such as deferred rent and other lease liabilities. As the Company’s leases do not provide an implicit rate, the Company used its incremental borrowing rate of 5.0% as the discount rate to calculate the present value of future lease payments, which was the interest rate that its bank would charge for a similar loan.The Company elected not to recognize a ROU asset and a lease liability for leases with an initial term of twelve months or less. In addition to minimum lease payments, certain leases require payment of a proportionate share of real estate taxes and certain building operating expenses or payments based on an excess of a specified base. These variable lease costs are not included in the measurement of the ROU asset or lease liability due to unpredictability of the payment amount and are recorded as lease expenses in the period incurred. The Company’s lease agreements do not contain residual value guarantees. The Company elected available practical expedients for existing or expired contracts of lessees wherein the Company is not required to reassess whether such contracts contain leases, the lease classification or the initial direct costs. The Company is not utilizing the practical expedient which allows the use of hindsight by lessees and lessors in determining the lease term and in assessing impairment of its ROU assets. The Company utilized the transition method allowing entities to only apply the new lease standard in the year of adoption. As of June 30, 2021, the weighted-average remaining lease term for operating lease liabilities was approximately 2.68 years and the weighted-average discount rate was 5.0%. Total cash payments under these leases were $289,100 for the year ended June 30, 2021, of which $277,300 was recorded as lease expense. The Company’s approximate future minimum rental payments under all leases existing at June 30, 2021, through January 2025 are as follows: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:bottom;">Year ended June 30,</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Amount</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2022</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">260,300</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">2023</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">245,300</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2024</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">195,900</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">2025</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">91,600</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Total future minimum payments</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">793,100</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Less: Imputed interest</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(62,100</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Total Present Value of Operating Lease Liabilities</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">731,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> P2Y8M4D 0.050 289100 277300 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:bottom;">Year ended June 30,</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Amount</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2022</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">260,300</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">2023</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">245,300</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2024</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">195,900</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">2025</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">91,600</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Total future minimum payments</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">793,100</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Less: Imputed interest</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(62,100</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Total Present Value of Operating Lease Liabilities</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">731,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> 260300 245300 195900 91600 793100 62100 731000 12. Income Taxes The reconciliation of the provision for income taxes at the federal statutory rate of 21% to the actual tax benefit for the applicable fiscal year was as follows: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">2021</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">2020</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Computed “expected” income tax benefit</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,014,300</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(239,400</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Research and development credits</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(93,900</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(89,400</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Rate changes and NOL carrybacks</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(122,600</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Incentive Stock Option Expense</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">59,500</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">13,800</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">PPP Loan Forgiveness</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(111,700</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">0</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Other, net</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(7,900</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Income tax benefit</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1,152,500</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(436,600</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table>Deferred tax assets and liabilities consist of the following: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">2021</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">2020</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:bottom;">Deferred tax assets:</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Amortization of intangible assets, including goodwill</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">374,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">329,700</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Research and development credits</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">164,600</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">89,400</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Various accruals</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">64,600</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">150,700</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Stock options expense</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">383,200</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Net operating loss</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,515,800</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Other</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">24,900</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">19,400</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,527,100</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">589,200</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Deferred tax liability:</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Depreciation of property and amortization of goodwill</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(37,200</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(52,100</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Net deferred tax assets</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,489,900</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">537,100</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> The Company has incurred cumulatively $715,800 of US net operating losses and $800,300 of German net operating losses as of June 30, 2021. These will be carried forward indefinitely without expiration, until fully utilized. The company expects to fully utilize these losses to offset taxable income in future years. ASC No. 740 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC No. 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. As of June 30, 2021 and 2020, the Company did not have any unrecognized tax benefits related to various federal and state income tax matters. The Company’s policy is to recognize interest and penalties on any unrecognized tax benefits as a component of income tax expense. The Company does not have any accrued interest or penalties associated with any unrecognized tax benefits. The Company is subject to U.S. federal income tax, as well as various state jurisdictions. The Company is currently open to audit under the statute of limitations by the federal and state jurisdictions for the years ended June 30, 2018 and after. The Company does not anticipate any material amount of unrecognized tax benefits within the next 12 months. <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">2021</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">2020</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Computed “expected” income tax benefit</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,014,300</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(239,400</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Research and development credits</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(93,900</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(89,400</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Rate changes and NOL carrybacks</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(122,600</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Incentive Stock Option Expense</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">59,500</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">13,800</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">PPP Loan Forgiveness</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(111,700</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">0</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Other, net</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(7,900</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Income tax benefit</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1,152,500</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(436,600</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table> -1014300 -239400 93900 89400 -122600 59500 13800 -111700 0 -7900 1000 -1152500 -436600 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">2021</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">2020</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:bottom;">Deferred tax assets:</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Amortization of intangible assets, including goodwill</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">374,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">329,700</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Research and development credits</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">164,600</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">89,400</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Various accruals</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">64,600</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">150,700</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Stock options expense</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">383,200</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Net operating loss</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,515,800</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Other</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">24,900</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">19,400</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,527,100</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">589,200</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Deferred tax liability:</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Depreciation of property and amortization of goodwill</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(37,200</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(52,100</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Net deferred tax assets</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,489,900</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">537,100</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> 374000 329700 164600 89400 64600 150700 383200 1515800 24900 19400 2527100 589200 37200 52100 2489900 537100 13. Stock Options Equity awards are measured at each reporting period. Compensation costs are recognized over the period that an employee provides service in exchange for the award. During the years ended June 30, 2021 and 2020, the Company granted 1,094,171 and 25,881 options, respectively, to employees that had a fair value of $7,929,600 and $144,500, respectively. The fair value of the options granted during the years ended June 30, 2021 and 2020, were determined using the Black-Scholes-Merton option-pricing model. The weighted average assumptions used for the years ended June 30, 2021 and 2020, was an expected life of 10 years; risk free interest rate of 1.40% and .89%; volatility of 66% and 74%, and dividend yield of 0% and .08%, respectively. The Company declared no dividends for the years ending June 30, 2021 or 2020. The weighted-average fair value per share of the options granted during the years ended June 30, 2021 and 2020, was $7.25 and $5.58, respectively, and total stock-based compensation costs were $2,108,000 and $65,800 for the years ended June 30, 2021 and 2020, respectively. Stock-based compensation costs related to nonvested awards expected to be recognized in the future are $5,935,000 and $113,400 as of June 30, 2021 and 2020, respectively. The stockholders approved an amendment to the Company’s 2012 Stock Option Plan (“Plan”) to increase the number of shares available under the Plan by 943,000 shares, from 307,000 to 1,250,000 shares, which, together with 150,000 shares that were added to the Plan in 2020, were registered by the Company on a Form S-8 Registration Statement with the Securities and Exchange Commission on March 15, 2021. The Company’s Board of Directors authorized and approved the grant of Stock Options in June 2020 and July 2020 to three key officers, subject to availability of option shares. In February 2021, upon availability, the Company issued these stock options to the Company’s Chairman of the Board, its Chief Executive Officer and President, and the Vice President of Sales-Americas of Company’s Bioprocessing Systems.Option activity is summarized as follows: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">June 30, 2021</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">June 30, 2020</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">Weighted-</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">Weighted-</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">Average</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">Average</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">Exercise</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">Exercise</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Shares</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Price</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Shares</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Price</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:bottom;">Shares under option:</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Outstanding, beginning of year</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">96,586</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.35</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">97,205</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.24</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Granted</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,094,171</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9.07</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">25,881</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7.47</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Exercised</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,000</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.05</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(24,000</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.35</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Forfeited</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(9,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">3.11</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2,500</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">3.08</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Outstanding, end of year</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,180,757</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">8.73</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">96,586</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">4.35</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Options exercisable at year-end</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">296,821</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">7.69</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">49,236</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">3.29</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Weighted average fair value per share of options granted during the fiscal year</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">7.25</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">5.58</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td colspan="2"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="10" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:center;">As of June 30, 2021 Options Outstanding</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:center;">As of June 30, 2021 Exercisable</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td colspan="2"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;">Weighted-</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2"> </td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td colspan="2"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;">Average</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;">Weighted-</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;">Weighted-</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td colspan="2" style="vertical-align:bottom;">Range</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;">Remaining</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;">Average</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;">Average</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td colspan="2" style="vertical-align:bottom;">Exercise</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;">Number</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;">Contractual</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;">Exercise</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;">Number</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;">Exercise</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td colspan="2" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;">Prices</td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:center;">Outstanding</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:center;">Life (Years)</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:center;">Price</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:center;">Outstanding</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:center;">Price</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td colspan="2"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" colspan="2"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" colspan="2"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" colspan="2"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" colspan="2"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" colspan="2"> </td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:1%;white-space: nowrap;"/><td style="width:13%;">$5.35 - $ 11.30</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:14%;vertical-align:bottom;text-align:right;">1,120,052</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:14%;vertical-align:bottom;text-align:right;">9.35</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:14%;vertical-align:bottom;text-align:right;">9.03</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:14%;vertical-align:bottom;text-align:right;">238,351</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:14%;vertical-align:bottom;text-align:right;">8.76</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="white-space: nowrap;"> </td><td> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="white-space: nowrap;"/><td style="BORDER-BOTTOM: #000000 1px solid;">$2.91 - $ 4.65</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;">60,705</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;">5.28</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;">3.36</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;">58,470</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;">3.32</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="white-space: nowrap;"> </td><td> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="white-space: nowrap;"> </td><td> </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;">1,180,757</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;">296,821</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td colspan="2"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="10" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:center;">As of June 30, 2020 Options Outstanding</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:center;">As of June 30, 2020 Exercisable</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td colspan="2"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;">Weighted-</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2"> </td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td colspan="2"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;">Average</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;">Weighted-</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;">Weighted-</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td colspan="2" style="vertical-align:bottom;">Range</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;">Remaining</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;">Average</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;">Average</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td colspan="2" style="vertical-align:bottom;">Exercise</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;">Number</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;">Contractual</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;">Exercise</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;">Number</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;">Exercise</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td colspan="2" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;">Prices</td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:center;">Outstanding</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:center;">Life (Years)</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:center;">Price</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:center;">Outstanding</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:center;">Price</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td colspan="2"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" colspan="2"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" colspan="2"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" colspan="2"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" colspan="2"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" colspan="2"> </td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:1%;"/><td style="width:13%;vertical-align:top;">$5.35- $ 11.30 </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:14%;vertical-align:bottom;text-align:right;">25,881</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:14%;vertical-align:bottom;text-align:right;">9.87</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:14%;vertical-align:bottom;text-align:right;">7.47</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:14%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:14%;vertical-align:bottom;text-align:right;">0.00</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="2"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="white-space: nowrap;"/><td style="BORDER-BOTTOM: #000000 1px solid;">$2.91- $ 4.65 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;">70,705</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;">6.46</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;">3.33</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;">49,236</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;">3.29</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="white-space: nowrap;"> </td><td> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="white-space: nowrap;"> </td><td> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;">96,586</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;">49,236</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">June 30, 2021</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">June 30, 2020</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">Weighted-</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">Weighted-</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">Average</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">Average</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">Exercise</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">Exercise</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Shares</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Price</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Shares</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Price</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:bottom;">Shares under option:</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Outstanding, beginning of year</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">96,586</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.35</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">97,205</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.24</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Granted</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,094,171</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9.07</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">25,881</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7.47</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Exercised</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,000</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.05</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(24,000</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.35</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Forfeited</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(9,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">3.11</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2,500</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">3.08</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Outstanding, end of year</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,180,757</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">8.73</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">96,586</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">4.35</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Options exercisable at year-end</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">296,821</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">7.69</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">49,236</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">3.29</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Weighted average fair value per share of options granted during the fiscal year</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">7.25</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">5.58</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> 96586 4.35 97205 3.24 1094171 9.07 25881 7.47 3.05 3.35 -9000 3.11 -2500 3.08 1180757 8.73 96586 4.35 296821 7.69 49236 3.29 7.25 5.58 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td colspan="2"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="10" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:center;">As of June 30, 2021 Options Outstanding</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:center;">As of June 30, 2021 Exercisable</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td colspan="2"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;">Weighted-</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2"> </td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td colspan="2"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;">Average</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;">Weighted-</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;">Weighted-</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td colspan="2" style="vertical-align:bottom;">Range</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;">Remaining</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;">Average</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;">Average</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td colspan="2" style="vertical-align:bottom;">Exercise</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;">Number</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;">Contractual</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;">Exercise</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;">Number</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;">Exercise</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td colspan="2" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;">Prices</td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:center;">Outstanding</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:center;">Life (Years)</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:center;">Price</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:center;">Outstanding</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:center;">Price</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td colspan="2"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" colspan="2"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" colspan="2"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" colspan="2"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" colspan="2"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" colspan="2"> </td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:1%;white-space: nowrap;"/><td style="width:13%;">$5.35 - $ 11.30</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:14%;vertical-align:bottom;text-align:right;">1,120,052</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:14%;vertical-align:bottom;text-align:right;">9.35</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:14%;vertical-align:bottom;text-align:right;">9.03</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:14%;vertical-align:bottom;text-align:right;">238,351</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:14%;vertical-align:bottom;text-align:right;">8.76</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="white-space: nowrap;"> </td><td> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="white-space: nowrap;"/><td style="BORDER-BOTTOM: #000000 1px solid;">$2.91 - $ 4.65</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;">60,705</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;">5.28</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;">3.36</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;">58,470</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;">3.32</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="white-space: nowrap;"> </td><td> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="white-space: nowrap;"> </td><td> </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;">1,180,757</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;">296,821</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td colspan="2"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="10" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:center;">As of June 30, 2020 Options Outstanding</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:center;">As of June 30, 2020 Exercisable</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td colspan="2"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;">Weighted-</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2"> </td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td colspan="2"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;">Average</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;">Weighted-</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;">Weighted-</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td colspan="2" style="vertical-align:bottom;">Range</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;">Remaining</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;">Average</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;">Average</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td colspan="2" style="vertical-align:bottom;">Exercise</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;">Number</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;">Contractual</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;">Exercise</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;">Number</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;">Exercise</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td colspan="2" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;">Prices</td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:center;">Outstanding</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:center;">Life (Years)</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:center;">Price</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:center;">Outstanding</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:center;">Price</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td colspan="2"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" colspan="2"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" colspan="2"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" colspan="2"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" colspan="2"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" colspan="2"> </td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:1%;"/><td style="width:13%;vertical-align:top;">$5.35- $ 11.30 </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:14%;vertical-align:bottom;text-align:right;">25,881</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:14%;vertical-align:bottom;text-align:right;">9.87</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:14%;vertical-align:bottom;text-align:right;">7.47</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:14%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:14%;vertical-align:bottom;text-align:right;">0.00</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="2"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="white-space: nowrap;"/><td style="BORDER-BOTTOM: #000000 1px solid;">$2.91- $ 4.65 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;">70,705</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;">6.46</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;">3.33</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;">49,236</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;">3.29</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="white-space: nowrap;"> </td><td> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="white-space: nowrap;"> </td><td> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;">96,586</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;">49,236</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td></tr></tbody></table> 1120052 P9Y4M6D 9.03 238351 8.76 60705 P5Y3M10D 3.36 58470 3.32 1180757 296821 25881 P9Y10M13D 7.47 70705 P6Y5M15D 3.33 49236 3.29 96586 49236 14. Earnings (Loss) Per Common Share The Company presents the computation of earnings per share (“EPS”) on a basic basis. Basic EPS is computed by dividing net income or loss by the weighted average number of shares outstanding during the reported period. Diluted EPS is computed similarly to basic EPS, except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential additional common shares that were dilutive had been issued. Common shares are excluded from the calculation if they are determined to be anti-dilutive. The following table sets forth the weighted average number of common shares outstanding for each period presented. <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">2021</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">2020</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Weighted average number of common shares outstanding</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,189,602</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,515,103</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Effect of dilutive securities:</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Weighted average number of dilutive common shares outstanding</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,189,602</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,515,103</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Basic and Diluted loss per common share:</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Continuing operations</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(0.97</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(0.30</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Discontinued operations</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(0.18</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(0.16</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Consolidated operations</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">(1.15</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.46</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table> Approximately 88,691 and 2,481,783 shares of the Company's common stock issuable upon the exercise of stock options and warrants, respectively, were excluded from the calculation because the effect would be anti-dilutive due to the loss for the year ended June 30, 2021. Approximately 54,513 and 1,349,850 shares of the Company's common stock issuable upon the exercise of stock options and warrants, respectively, were excluded from the calculation because the effect would be anti-dilutive due to the loss for the year ended June 30, 2020. <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">2021</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;">2020</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Weighted average number of common shares outstanding</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,189,602</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,515,103</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Effect of dilutive securities:</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Weighted average number of dilutive common shares outstanding</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,189,602</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,515,103</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Basic and Diluted loss per common share:</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Continuing operations</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(0.97</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(0.30</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Discontinued operations</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(0.18</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(0.16</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Consolidated operations</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">(1.15</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.46</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table> 3189602 1515103 3189602 1515103 -0.97 -0.30 -0.18 -0.16 -1.15 -0.46 88691 2481783 54513 1349850 15. Equity At the 2020 Annual Meeting of Stockholders, the stockholders of the Company approved an amendment to the Certificate of Incorporation of the Company to increase the number of authorized shares of the Company’s Common stock by 3,000,000 shares from 7,000,000 to 10,000,000 shares, and a further amendment was approved by a majority of the Company’s shareholders on June 17, 2021 increasing the authorized shares to 15,000,000. On June 18, 2020, the Company entered into a securities purchase agreement in the amount of $6,074,400 with several accredited investors for the sale and issuance of 1,349,850 shares of the Company’s Common Stock at an offering price of $4.50 per share and warrants to purchase up to 1,349,850 shares of the Company’s Common Stock exercisable at $9.0 0 per share. The issuance cost realated to this stock issuance amounted to approximately $70,000. The proceeds were used to fund the operations of the Company’s Bioprocessing Systems Operations. The warrants were immediately exercisable and expire five years from the date of issuance. If at any time commencing twelve months from the date of the agreement, but before the expiration of the warrant, the volume weighted average price of the Company’s Common Stock exceeds $18 per share for each of thirty consecutive days, the Company may at any time in its sole discretion, call for the exercise of the Warrants, in their entirety. On April 29, 2021, the Company received proceeds of approximately $7,580,400 from the sale of its securities to private investors upon the issuance of 1,595,880 shares of the Company’s Common Stock at an offering price of $4.75 per share which included warrants to purchase up to 797,940 shares of the Company’s Common Stock exercisable at $9.50 per share. The issuance costs related to this stock issuance amounted to approximately $581,000. In June 2021, the Company received an additional $9.5 million through the sale of an additional 2,000,000 shares of the Company’s Common Stock at $4.75 per share which also included warrants to purchase up to 999,993 of the Company's Common Stock exercisable at $9.50 per share. The issuance costs related to this stock issuance amounted to approximately $425,400. These warrants are exercisable immediately and expire five years from date of issuance. The Company utilized the services of brokers for both transactions and incurred a total of approximately $1.0 million in issuance related costs for broker and legal fees. The Company was required under a registration rights agreement to register the shares, which it did through an S-1 Registration Statement filed with the Securities and Exchange Commission, which became effective on August 13, 2021. The proceeds were used for the Aquila acquisition with the remainder being used to fund the Bioprocessing Systems Operations. 16. Acquisition of Aquila Biolabs GmbH Effective April 29, 2021, pursuant to a Stock Purchase Agreement ("SPA") the Company acquired all the outstanding capital stock of Aquila biolabs GmbH, a German start-up company engaged from its facility in Baesweiler, Germany in the design, production, and sale of bioprocessing systems and products which focus on the control and analysis of bioprocesses in bioreactors and incubation shakers for an aggregate purchase price of $7,880,100 in cash upon closing. Aquila’s principal customers are universities, pharmaceutical companies, and industrial companies. The products are sold primarily on a direct basis and to a lesser extent, through distributors. The acquisition was accounted for under the acquisition method of accounting in accordance with Accounting Standards Codification (“ASC”) 805, Business Combinations (“ASC 805”) in which the Company is treated as the accounting acquirer. In accordance with ASC 805, the assets acquired and liabilities assumed have been measured at fair value. For purposes of measuring the estimated fair value, where applicable, of the assets acquired and liabilities assumed, as reflected in the unaudited pro forma condensed consolidated financial information, the guidance in ASC 820, Fair Value Measurements and Disclosures (“ASC 820”) has been applied, which establishes a framework for measuring fair value. In accordance with ASC 820, fair value is an exit price and is defined as “the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.” Under ASC 805, acquisition-related transaction costs and acquisition-related restructuring charges are not included as components of consideration transferred but are accounted for as expenses in the period in which the costs are incurred. Management of the Company allocated the purchase price based on its valuation of the assets acquired and liabilities assumed as follows: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">Amount</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" style="width:9%;vertical-align:bottom;text-align:center;">Useful life</td><td style="width:1%;"> </td></tr><tr style="height:15px"><td style="vertical-align:bottom;">Fair value of assets acquired</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" style="width:9%;"/><td> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" style="width:9%;"/><td> </td></tr><tr style="height:15px"><td style="vertical-align:bottom;">Current assets:</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" style="width:9%;"/><td> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" style="width:9%;"/><td> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Cash and cash equivalents</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">201,100</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Accounts receivable</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">159,200</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Inventory</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">187,500</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Prepaid expenses and other current assets</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">25,400</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Property, plant and equipment</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">40,200</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Deferred tax asset</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">800,300</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Tradename</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">452,300</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td> 6 years</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Non-compete agreements</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">784,500</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>4 years</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">IPR&D</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">742,100</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>5 years</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Customer relationships</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">252,200</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>9 years</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Patents and other intangibles</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">286,200</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>7 years</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Total assets acquired</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,931,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Fair value of liabilities assumed:</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Accounts payable</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(39,300</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Accrued expenses</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(90,300</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Other current liabilities</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(59,400</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Total liabilities assumed</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(189,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Total identifiable net assets</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,742,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Fair value of consideration transferred</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">7,880,100</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Goodwill</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">4,138,100</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr></tbody></table>Accounting Periods Presented Aquila’s fiscal year ended on December 31. Its historical results have been aligned to more closely conform to the Company’s June 30 fiscal year end by taking Aquila’s interim financial results for six months ended December 31, 2019 and for the six months ended June 30, 2020. In addition, certain historical Aquila balances have been reclassified to conform to the pro forma consolidated presentation. There were no transactions between the two companies during the period presented. No pro forma adjustments were made to conform Aquila’s accounting policies which follow Germany’s generally accepted accounting principles (“German GAAP”) to the Company’s accounting principles, as any differences were deemed immaterial. Unaudited Pro forma information is as follows: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;"/><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:bottom;">(In $000’s)</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">6/30/2020</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Revenues</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">9,346</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Net loss</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1,650</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Earnings per share</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;"> </td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Diluted</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(0.37</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Basic</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(0.37</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table> These pro forma results do not represent financial results that would have been realized had the acquisition actually occurred on July 1, 2019, nor are they intended to be a projection of future results. For additional information, please refer to the Company’s current report on Form 8-KA, filed on July12, 2021. <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">Amount</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" style="width:9%;vertical-align:bottom;text-align:center;">Useful life</td><td style="width:1%;"> </td></tr><tr style="height:15px"><td style="vertical-align:bottom;">Fair value of assets acquired</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" style="width:9%;"/><td> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" style="width:9%;"/><td> </td></tr><tr style="height:15px"><td style="vertical-align:bottom;">Current assets:</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" style="width:9%;"/><td> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" style="width:9%;"/><td> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Cash and cash equivalents</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">201,100</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Accounts receivable</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">159,200</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Inventory</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">187,500</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Prepaid expenses and other current assets</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">25,400</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Property, plant and equipment</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">40,200</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Deferred tax asset</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">800,300</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Tradename</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">452,300</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td> 6 years</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Non-compete agreements</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">784,500</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>4 years</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">IPR&D</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">742,100</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>5 years</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Customer relationships</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">252,200</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>9 years</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Patents and other intangibles</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">286,200</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>7 years</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Total assets acquired</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,931,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Fair value of liabilities assumed:</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Accounts payable</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(39,300</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Accrued expenses</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(90,300</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Other current liabilities</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(59,400</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Total liabilities assumed</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(189,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Total identifiable net assets</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,742,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Fair value of consideration transferred</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">7,880,100</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Goodwill</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">4,138,100</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr></tbody></table> 201100 159200 187500 25400 40200 800300 452300 P6Y 784500 P4Y 742100 P5Y 252200 P9Y 286200 P7Y 3931000 39300 90300 59400 189000 3742000 7880100 4138100 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;"/><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:bottom;">(In $000’s)</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">6/30/2020</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Revenues</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">9,346</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Net loss</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1,650</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Earnings per share</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;"> </td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Diluted</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(0.37</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Basic</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(0.37</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table> 9346 -1650 -0.37 -0.37 17. Discontinued Operations Effective November 30, 2020, the Company, as part of its strategic shift to becoming a life sciences tool provider, sold its Catalyst Research Instruments Operations reporting segment through the sale by Altamira of substantially all of its assets, which comprised of fixed assets, and inventory to Beijing JWGB Sci. & Tech. Co. Ltd., a corporation formed under the laws of the People’s Republic of China (“JWGB”) for $440,000 payable in cash through January 2021, resulting in a $405,400 pre-tax loss. In order to preserve business continuity for the buyer, Altamira agreed to purchase certain components on behalf of JWGB for which JWGB agreed to reimburse Altamira. At March 31, 2021, JWGB paid the full $440,000 purchase price and $28,500 for component purchases made on its behalf. The Company retained all its receivables and payables related to sales made prior to November 30, 2020, certain inventory related to two work-in-process orders which will be shipped by the end of the fiscal year ending June 30, 2021, product warranty and other miscellaneous liabilities related to certain employee benefits, and expenses related to the closure of the Altamira facility, which was substantially completed at the end of December 2020. As a result of the disposal described above, the operating results of the former Catalyst Research Instruments Operations segment have been presented as discontinued operations in the balance sheets, the statements of operations, and the statements of cash flows, as detailed below. <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:bottom;">Assets:</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">June 30, 2021</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">June 30, 2020</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Accounts receivable</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">52,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Inventories</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,300</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">343,700</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Property and equipment, net</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,400</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Goodwill</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">447,900</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Discontinued operations</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">55,300</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">793,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:bottom;">Liabilities:</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">June 30, 2021</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">June 30, 2020</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Accounts payable</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20,100</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Accrued expenses and taxes</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20,700</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">120,700</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Contract liabilities</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">16,500</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">69,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Operating lease liabilities, current portion</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">31,100</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">37,200</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">240,900</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Years Ended</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">June 30, 2021</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">June 30, 2020</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Revenues</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">387,700</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">785,900</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Cost of goods sold</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">471,800</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">869,900</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Gross profit</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(84,100</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(84,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Selling, general and administrative expenses</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">280,400</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">388,500</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Loss from operations</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(364,500</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(472,500</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Loss on disposal</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(405,400</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">--</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Loss before income tax benefit</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(769,900</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(472,500</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Income tax benefit, all deferred</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(207,400</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(222,600</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Net income (loss) attributable to discontinued operations</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">(562,500</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">(249,900</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table> In our Consolidated Statements of Cash Flows, the cash flows from discontinued operations are not separately classified. Cash (used) and provided by operating activities from discontinued operations for year ended June 30, 2021 and June 30, 2020 was ($75,000) and $66,100, respectively. Cash provided by investing activities from discontinued operations for the year ended June 30, 2021 was $440,000 and $2,200 for the year ended June 30, 2020. There was no cash provided or used by the discontinued operations for financing activities for both the current and prior year periods. <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:bottom;">Assets:</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">June 30, 2021</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">June 30, 2020</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Accounts receivable</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">52,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Inventories</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,300</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">343,700</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Property and equipment, net</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,400</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Goodwill</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">447,900</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Discontinued operations</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">55,300</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">793,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:bottom;">Liabilities:</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">June 30, 2021</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">June 30, 2020</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Accounts payable</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20,100</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Accrued expenses and taxes</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20,700</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">120,700</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Contract liabilities</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">16,500</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">69,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Operating lease liabilities, current portion</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">31,100</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">37,200</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">240,900</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Years Ended</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">June 30, 2021</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">June 30, 2020</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Revenues</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">387,700</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">785,900</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Cost of goods sold</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">471,800</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">869,900</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Gross profit</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(84,100</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(84,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Selling, general and administrative expenses</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">280,400</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">388,500</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Loss from operations</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(364,500</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(472,500</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Loss on disposal</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(405,400</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">--</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Loss before income tax benefit</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(769,900</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(472,500</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Income tax benefit, all deferred</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(207,400</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(222,600</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Net income (loss) attributable to discontinued operations</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">(562,500</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">(249,900</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table> 52000 3300 343700 0 1400 447900 55300 793000 20100 20700 120700 16500 69000 0 31100 37200 240900 387700 785900 471800 869900 -84100 -84000 280400 388500 -364500 -472500 -405400 -769900 -472500 -207400 -222600 -562500 -249900 -75000 66100 440000 2200 4068000 9675200 7768600 3744600 15600 1712900 1294700 4367900 2977100 161100 333300 312800 350900 600 55300 18391900 18431100 566900 412600 4395400 4395400 2216300 2557800 3445300 2489900 1448600 665300 62400 54300 30526800 29006400 1051100 453500 661100 633500 117500 136600 40600 321700 124300 270500 0 433800 7900 37200 2002500 2286800 0 23400 1388100 460500 0 10900 3390600 2781600 0.05 20000000 15000000 7023401 6477945 7003599 6458143 351200 324000 31233600 26613500 -104800 -9200 -4291400 -651100 27188600 26277200 19802 52400 52400 27136200 26224800 30526800 29006400 2864900 2508600 8623500 7245100 1318300 1145700 4154600 3419400 1546600 1362900 4468900 3825700 1610400 1385600 4442300 2441700 1054000 1386100 2996800 2658900 624500 450000 2141300 1024000 3288900 3221700 9580400 6124600 -1742300 -1858800 -5111500 -2298900 -102700 6100 363500 22300 400 22500 49800 71400 -102300 28600 413300 93700 -1844600 -1830200 -4698200 -2205200 -95100 0 -95100 0 -222100 -378200 -959400 -472300 -317200 -378200 -1054500 -472300 -1527400 -1452000 -3643700 -1732900 -7600 16400 3400 -578500 -1535000 -1435600 -3640300 -2311400 -4700 0 -5100 0 -194500 0 -90500 0 -199200 0 -95600 0 -1734200 -1435600 -3735900 -2311400 -0.23 -0.51 -0.56 -0.61 -0.00 0.01 0.00 -0.20 -0.23 -0.50 -0.56 -0.81 6477945 324000 26613500 -9200 -651100 19802 52400 26224800 0 0 0 -1208800 0 -1208800 0 0 34100 0 0 34100 0 0 2200 0 0 2200 0 675400 0 0 0 675400 6477945 324000 27288900 27100 -1859900 19802 52400 25727700 0 0 0 -896500 0 -896500 0 0 69900 0 0 69900 0 0 -2600 0 0 -2600 0 591000 0 0 0 591000 6477945 324000 27879900 94400 -2756400 19802 52400 25489500 0 0 0 -1535000 0 -1535000 545456 27200 2700000 0 0 0 2727200 0 -194500 0 0 -194500 0 0 -4700 0 0 -4700 0 653700 0 0 0 653700 7023401 351200 31233600 -104800 -4291400 19802 52400 27136200 2881065 144100 8608300 3021400 19802 52400 11721400 0 0 -263300 0 -263300 0 61300 0 0 61300 2881065 144100 8669600 2758100 19802 52400 11519400 0 0 -612500 0 -612500 0 76100 0 0 76100 2881065 144100 8745700 2145600 19802 52400 10983000 0 0 -1435600 0 -1435600 0 1292000 0 0 1292000 1000 100 2900 0 0 3000 2882065 144200 10040600 710000 19802 52400 10842400 -3640300 -2311400 11100 -34600 102800 18900 433800 0 581800 126700 -955400 -652300 0 405400 1920100 1429400 -42500 -118500 -328700 -758500 -1383900 -697700 783300 87700 172200 -1500 -127700 57400 585500 142600 796100 -20000 0 -51000 -281100 7500 107100 0 25400 0 -20700 -222600 -55000 -281100 -3695300 -2592500 1278500 1631000 5422700 6609200 0 440000 337400 183700 67000 41200 -4548600 -4763100 3000000 0 272800 0 -13400 0 433800 0 3000 2727200 423400 -90500 0 -5607200 -6932200 9675200 7559700 4068000 627500 0 2500 941300 0 941300 0 1. Significant Accounting Policies Principles of Consolidation The accompanying consolidated financial statements include the accounts of Scientific Industries, Inc., its wholly- owned subsidiary, Scientific Bioprocessing Holdings, Inc. (“SBHI”), SBHI’s wholly-owned subsidiaries, Scientific Bioprocessing, Inc. (“SBI”), and aquila biolabs GmbH (“Aquila”), a German corporation, which was acquired on April 29, 2021, Scientific Packaging Industries, Inc., an inactive wholly-owned subsidiary, and Altamira Instruments, Inc. (“Altamira”), and wholly-owned subsidiary (accounted for as a discontinued operation as of November 30, 2020) (all collectively referred to as the “Company”). All material intercompany balances and transactions have been eliminated in consolidation. COVID-19 Pandemic The challenges posed by the COVID-19 pandemic on the global economy began to take effect and adversely affected the Company’s operations at the end of the third quarter of the fiscal year ended June 30, 2020. At that time, the Company took appropriate action and put plans in place to diminish the adverse effects of COVID-19 on its operations, enabling the Company to continue to operate with minor or temporary disruptions to its operations. The Company took immediate action pertaining to COVID-19 preparedness by implementing the US Center for Disease Control’s guidelines for employers in order to protect the Company’s employees’ health and safety, with actions such as implementing work from home, social distancing in the workplace, requiring self-quarantine for any employee showing symptoms, wearing face coverings, and training employees on maintaining a healthy work environment. The Company experienced supply chain disruptions which had an impact on its operations causing delayed delivery of some products to its customers, and production inefficiencies. SBI’s facility was shut down temporarily due to state mandates, however, the impact on operations was minimal, and the Company was able to retain its employees without furloughs or layoffs, in part, due to the Company’s receipt of two loans under the Federal Government’s Small Business Administration Paycheck Protection Program (“PPP”). The Company received $563,800 and $433,800 in PPP loans in April 2020 and March 2021, respectively. The first loan was forgiven in June 2021 except for $32,700 which was repaid by the Company and the second loan was forgiven in full in December 2021. The Company elected to account for its PPP Loans in accordance with Accounting Standards Codification (“ASC”), Topic 470 Debt, with interest, if any, accrued in accordance with the interest method under ASC 835-30, Imputation of Interest. Initially, the Company recognized the entire loan amounts as liabilities on its balance sheets and remained as liabilities until either the Company was legally released from its obligations or paid the lender. Once the loans were forgiven, the amounts forgiven were recorded in the Company’s statement of operations as “Other Income.” Adopted Accounting Pronouncements In December 2019, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2019-12, “Simplifying the Accounting for Income Taxes”, which is designed to simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. ASU No. 2019-12 is effective for fiscal years beginning after December 15, 2020. The adoption of this standard as of July 1, 2021 did not have a material impact on the Company’s financial statements. Recently Issued Accounting Pronouncements The Company has implemented all new accounting pronouncements that are in effect and is evaluating any that may impact its financial statements. The Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations. The accompanying consolidated financial statements include the accounts of Scientific Industries, Inc., its wholly- owned subsidiary, Scientific Bioprocessing Holdings, Inc. (“SBHI”), SBHI’s wholly-owned subsidiaries, Scientific Bioprocessing, Inc. (“SBI”), and aquila biolabs GmbH (“Aquila”), a German corporation, which was acquired on April 29, 2021, Scientific Packaging Industries, Inc., an inactive wholly-owned subsidiary, and Altamira Instruments, Inc. (“Altamira”), and wholly-owned subsidiary (accounted for as a discontinued operation as of November 30, 2020) (all collectively referred to as the “Company”). All material intercompany balances and transactions have been eliminated in consolidation. The challenges posed by the COVID-19 pandemic on the global economy began to take effect and adversely affected the Company’s operations at the end of the third quarter of the fiscal year ended June 30, 2020. At that time, the Company took appropriate action and put plans in place to diminish the adverse effects of COVID-19 on its operations, enabling the Company to continue to operate with minor or temporary disruptions to its operations. The Company took immediate action pertaining to COVID-19 preparedness by implementing the US Center for Disease Control’s guidelines for employers in order to protect the Company’s employees’ health and safety, with actions such as implementing work from home, social distancing in the workplace, requiring self-quarantine for any employee showing symptoms, wearing face coverings, and training employees on maintaining a healthy work environment. The Company experienced supply chain disruptions which had an impact on its operations causing delayed delivery of some products to its customers, and production inefficiencies. SBI’s facility was shut down temporarily due to state mandates, however, the impact on operations was minimal, and the Company was able to retain its employees without furloughs or layoffs, in part, due to the Company’s receipt of two loans under the Federal Government’s Small Business Administration Paycheck Protection Program (“PPP”). The Company received $563,800 and $433,800 in PPP loans in April 2020 and March 2021, respectively. The first loan was forgiven in June 2021 except for $32,700 which was repaid by the Company and the second loan was forgiven in full in December 2021. The Company elected to account for its PPP Loans in accordance with Accounting Standards Codification (“ASC”), Topic 470 Debt, with interest, if any, accrued in accordance with the interest method under ASC 835-30, Imputation of Interest. Initially, the Company recognized the entire loan amounts as liabilities on its balance sheets and remained as liabilities until either the Company was legally released from its obligations or paid the lender. Once the loans were forgiven, the amounts forgiven were recorded in the Company’s statement of operations as “Other Income.” 563800 433800 32700 In December 2019, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2019-12, “Simplifying the Accounting for Income Taxes”, which is designed to simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. ASU No. 2019-12 is effective for fiscal years beginning after December 15, 2020. The adoption of this standard as of July 1, 2021 did not have a material impact on the Company’s financial statements. The Company has implemented all new accounting pronouncements that are in effect and is evaluating any that may impact its financial statements. The Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations. 2. Revenue The Company generates revenues from the following sources: (1) Benchtop Laboratory Equipment, and (2) Bioprocessing Systems. The following table summarizes the Company’s disaggregation of revenues for the three and nine months ended March 31, 2022 and 2021. <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Benchtop Laboratory Equipment </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Bioprocessing Systems </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Consolidated </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">Three Months Ended March 31, 2022:</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Revenues</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,434,600</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">430,300</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,864,900</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Foreign Sales</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">783,600</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">269,700</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,053,300</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Benchtop Laboratory Equipment </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Bioprocessing Systems </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Consolidated </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">Three Months Ended March 31, 2021:</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Revenues</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,365,700</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">142,900</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,508,600</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Foreign Sales</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">942,200</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">102,600</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,044,800</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Benchtop Laboratory Equipment </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Bioprocessing Systems </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Consolidated </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">Nine Months Ended March 31, 2022:</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Revenues</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,465,700</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,157,800</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8,623,500</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Foreign Sales</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,814,700</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">791,200</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,605,900</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Benchtop Laboratory Equipment </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Bioprocessing Systems </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Consolidated </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">Nine Months Ended March 31, 2021:</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Revenues</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,803,300</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">441,800</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,245,100</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Foreign Sales</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,724,800</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">395,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,119,800</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table> Benchtop Laboratory Equipment sales are comprised primarily of standard benchtop laboratory equipment sold to laboratory equipment distributors, or directly to end users primarily online via the Company’s website. The sales cycle from time of receipt of order to shipment ranges from a day to a few weeks. Customers either pay by credit card (online sales) or Net 30-90 days, depending on the customer. Once the item is shipped under the terms specified in the order, which is primarily “FOB Factory”, other than a standard warranty, there are no other obligations to the customer. The standard warranty is typically one or two years, covering parts and labor, and is deemed immaterial. Revenue is recognized at the point in time when the risks and rewards of ownership have transferred to the customer, which is generally upon shipment. Bioprocessing Systems revenues consist of royalty revenues generated through SBI and product revenues generated primarily through Aquila. Royalty revenues are earned by the Company under a licensing agreement from a single licensee and its sublicenses. The license agreement included two United States patents, which expired in August 2021. The Company is obligated to pay 50% of all royalties earned to the entity that licensed the intellectual property to the Company. <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Benchtop Laboratory Equipment </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Bioprocessing Systems </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Consolidated </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">Three Months Ended March 31, 2022:</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Revenues</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,434,600</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">430,300</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,864,900</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Foreign Sales</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">783,600</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">269,700</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,053,300</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Benchtop Laboratory Equipment </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Bioprocessing Systems </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Consolidated </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">Three Months Ended March 31, 2021:</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Revenues</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,365,700</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">142,900</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,508,600</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Foreign Sales</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">942,200</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">102,600</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,044,800</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Benchtop Laboratory Equipment </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Bioprocessing Systems </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Consolidated </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">Nine Months Ended March 31, 2022:</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Revenues</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,465,700</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,157,800</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8,623,500</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Foreign Sales</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,814,700</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">791,200</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,605,900</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Benchtop Laboratory Equipment </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Bioprocessing Systems </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Consolidated </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">Nine Months Ended March 31, 2021:</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Revenues</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,803,300</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">441,800</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,245,100</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Foreign Sales</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,724,800</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">395,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,119,800</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table> 2434600 430300 2864900 783600 269700 1053300 2365700 142900 2508600 942200 102600 1044800 7465700 1157800 8623500 2814700 791200 3605900 6803300 441800 7245100 2724800 395000 3119800 3. Segment Information and Concentrations The Company views its operations as two segments: the manufacture and marketing of standard benchtop laboratory equipment for research in university, hospital and industrial laboratories sold primarily through laboratory equipment distributors and laboratory and pharmacy balances and scales (“Benchtop Laboratory Equipment Operations”); and the design, manufacture, and marketing of bioprocessing systems and products (“Bioprocessing Systems”) and related royalty income. Segment information is reported as follows: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Benchtop Laboratory Equipment</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Bioprocessing Systems</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Corporate And Other</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Consolidated</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">Three Months Ended March 31, 2022:</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Revenues</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,434,600</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">430,300</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,864,900</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Foreign Sales</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">783,600</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">269,700</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,053,300</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Income (Loss) From Operations</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">247,300</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,651,700</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(337,900</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,742,300</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Assets</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,231,100</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,024,261</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,271,439</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">30,526,800</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Long-Lived Asset Expenditures</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">16,500</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">158,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">174,500</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Depreciation and Amortization</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">24,600</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">229,900</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">254,500</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td/><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Benchtop Laboratory Equipment </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Bioprocessing Systems </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Corporate And Other </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Consolidated </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">Three Months Ended March 31, 2021:</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Revenues</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,365,700</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">142,900</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,508,600</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Foreign Sales</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">942,200</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">102,600</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,044,800</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Income (Loss) From Operations</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">394,700</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,323,900</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(929,600</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,858,800</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Assets</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,979,400</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,281,200</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,639,700</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,900,300</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Long-Lived Asset Expenditures</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">18,600</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">92,100</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">110,700</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Depreciation and Amortization</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">30,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">16,700</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">46,700</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table>Approximately 50% and 55% of net sales from Benchtop Laboratory Equipment Operations (42% and 52% of total revenues) for the three months ended March 31, 2022 and 2021, respectively, were derived from sales of the Company’s main product, the Vortex-Genie 2 mixer, excluding accessories. Approximately 24% and 20% of total Benchtop Laboratory Equipment Operations sales (20% and 19% of total revenues) were derived from the Torbal Scales Division for the three months ended March 31, 2022 and 2021, respectively. For the three months ended March 31, 2022 and 2021, respectively, three customers accounted for approximately 19% and 26% of net sales of the Benchtop Laboratory Equipment Operations (16% and 25% of the Company’s total revenues), respectively. <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Benchtop Laboratory Equipment </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Bioprocessing Systems </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Corporate And Other </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Consolidated </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">Nine Months Ended March 31, 2022:</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Revenues</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,465,700</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,157,800</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8,623,500</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Foreign Sales</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,814,700</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">791,200</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,605,900</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Income (Loss) From Operations</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,107,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(5,091,300</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,127,200</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(5,111,500</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Assets</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,231,100</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,024,261</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,271,439</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">30,526,800</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Long-Lived Asset Expenditures</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">83,100</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">321,300</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">404,400</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Depreciation and Amortization</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">71,200</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">510,600</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">581,800</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td/><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Benchtop Laboratory Equipment </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Bioprocessing Systems </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Corporate And Other </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Consolidated </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">Nine Months Ended March 31, 2021:</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Revenues</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,803,300</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">441,800</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,245,100</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Foreign Sales</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,724,800</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">395,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,119,800</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Income (Loss) From Operations</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,347,100</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(2,598,000</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,048,000</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(2,298,900</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Assets</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,979,400</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,281,200</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,639,700</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,900,300</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Long-Lived Asset Expenditures</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">54,100</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">170,800</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">224,900</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Depreciation and Amortization</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">79,700</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">46,500</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">500</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">126,700</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table>Approximately 49% and 51% of total Benchtop Laboratory Equipment Operations sales (42% and 47% of total revenues) for the nine months ended March 31, 2022 and 2021, respectively, were derived from sales of the Company’s main product, the Vortex-Genie 2 mixer, excluding accessories. Approximately 24% and 23% for both periods of total Benchtop Laboratory Equipment Operations sales (21% and 21% of total revenues) were derived from the Torbal Scales Division for the nine months ended March 31, 2022 and 2021, respectively. For each of the nine-month periods ended March 31, 2022 and 2021, three customers accounted for approximately 20% and 23% of net sales of the Benchtop Laboratory Equipment Operations (17% and 21% of the Company’s total revenues), respectively. <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Benchtop Laboratory Equipment</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Bioprocessing Systems</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Corporate And Other</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Consolidated</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">Three Months Ended March 31, 2022:</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Revenues</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,434,600</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">430,300</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,864,900</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Foreign Sales</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">783,600</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">269,700</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,053,300</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Income (Loss) From Operations</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">247,300</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,651,700</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(337,900</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,742,300</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Assets</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,231,100</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,024,261</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,271,439</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">30,526,800</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Long-Lived Asset Expenditures</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">16,500</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">158,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">174,500</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Depreciation and Amortization</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">24,600</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">229,900</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">254,500</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td/><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Benchtop Laboratory Equipment </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Bioprocessing Systems </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Corporate And Other </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Consolidated </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">Three Months Ended March 31, 2021:</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Revenues</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,365,700</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">142,900</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,508,600</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Foreign Sales</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">942,200</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">102,600</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,044,800</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Income (Loss) From Operations</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">394,700</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,323,900</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(929,600</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,858,800</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Assets</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,979,400</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,281,200</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,639,700</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,900,300</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Long-Lived Asset Expenditures</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">18,600</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">92,100</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">110,700</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Depreciation and Amortization</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">30,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">16,700</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">46,700</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Benchtop Laboratory Equipment </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Bioprocessing Systems </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Corporate And Other </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Consolidated </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">Nine Months Ended March 31, 2022:</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Revenues</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,465,700</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,157,800</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8,623,500</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Foreign Sales</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,814,700</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">791,200</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,605,900</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Income (Loss) From Operations</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,107,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(5,091,300</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,127,200</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(5,111,500</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Assets</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,231,100</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,024,261</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,271,439</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">30,526,800</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Long-Lived Asset Expenditures</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">83,100</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">321,300</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">404,400</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Depreciation and Amortization</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">71,200</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">510,600</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">581,800</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td/><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Benchtop Laboratory Equipment </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Bioprocessing Systems </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Corporate And Other </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Consolidated </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">Nine Months Ended March 31, 2021:</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Revenues</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,803,300</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">441,800</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,245,100</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Foreign Sales</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,724,800</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">395,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,119,800</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Income (Loss) From Operations</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,347,100</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(2,598,000</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,048,000</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(2,298,900</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Assets</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,979,400</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,281,200</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,639,700</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,900,300</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Long-Lived Asset Expenditures</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">54,100</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">170,800</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">224,900</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Depreciation and Amortization</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">79,700</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">46,500</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">500</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">126,700</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table> 2434600 430300 2864900 783600 269700 1053300 247300 -1651700 -337900 -1742300 10231100 10024261 10271439 30526800 16500 158000 174500 24600 229900 254500 2365700 142900 2508600 942200 102600 1044800 394700 -1323900 -929600 -1858800 5979400 1281200 6639700 13900300 18600 92100 110700 30000 16700 46700 0.50 0.55 0.42 0.52 0.24 0.20 0.20 0.19 0.19 0.26 0.16 0.25 7465700 1157800 8623500 2814700 791200 3605900 1107000 -5091300 -1127200 -5111500 10231100 10024261 10271439 30526800 83100 321300 404400 71200 510600 581800 6803300 441800 7245100 2724800 395000 3119800 1347100 -2598000 -1048000 -2298900 5979400 1281200 6639700 13900300 54100 170800 224900 79700 46500 500 126700 0.49 0.51 0.42 0.47 0.24 0.23 0.21 0.21 0.20 0.23 0.17 0.21 4. Fair Value of Financial Instruments In valuing assets and liabilities, the Company is required to maximize the use of quoted market prices and minimize the use of unobservable inputs. The Company calculated the fair value of its Level 1 and 2 instruments based on the exchange traded price of similar or identical instruments where available or based on other observable instruments. These calculations take into consideration the credit risk of both the Company and its counterparties. The Company has not changed its valuation techniques in measuring the fair value of any financial assets or liabilities during the period. The fair value of the contingent consideration obligations are based on a probability-weighted approach derived from the estimates of earn-out criteria and the probability assessment with respect to the likelihood of achieving those criteria. The measurement is based on significant inputs that are not observable in the market, therefore, the Company classifies this liability as Level 3 in the following table.The following tables set forth by level within the fair value hierarchy the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis at March 31, 2022 and June 30, 2021 according to the valuation techniques the Company used to estimate their fair values: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">Fair Value at</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="10" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Fair Value Measurements Using Inputs Considered as</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">March 31, 2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Level 1</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Level 2</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Level 3</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">Assets:</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Cash and cash equivalents</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,068,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,068,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Investment securities</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">7,768,600</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">6,796,500</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">972,100</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Total</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">11,836,600</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">10,864,500</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">972,100</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Liabilities:</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Contingent consideration</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">117,500</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">117,500</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">Fair Value at</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="10" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Fair Value Measurements Using Inputs Considered as</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">June 30, 2021</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Level 1</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Level 2</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Level 3</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">Assets:</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Cash and cash equivalents</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,675,200</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,675,200</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Investment securities</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,744,600</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,920,600</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">824,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Total</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">13,419,800</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">12,595,800</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">824,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Liabilities:</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Contingent consideration</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">160,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">160,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> Investments in marketable securities by security type at March 31, 2022 and June 30, 2021 consisted of the following: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Cost</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Fair Value</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">UnrealizedHolding Gain (Loss)</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">At March 31, 2022:</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Equity securities</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">118,900</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">176,900</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">58,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Mutual funds</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,708,300</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,619,600</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(88,700</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> Debt securities</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">977,200</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">972,100</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(5,100</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">7,804,400</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">7,768,600</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(35,800</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Cost</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Fair Value</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">UnrealizedHolding Gain (Loss)</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">At June 30, 2021:</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Equity securities</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">102,200</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">154,100</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">51,900</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Mutual funds</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,752,400</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,766,500</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">14,100</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Debt securities</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">832,700</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">824,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(8,700 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">3,687,300</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">3,744,600</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">57,300</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">Fair Value at</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="10" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Fair Value Measurements Using Inputs Considered as</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">March 31, 2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Level 1</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Level 2</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Level 3</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">Assets:</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Cash and cash equivalents</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,068,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,068,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Investment securities</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">7,768,600</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">6,796,500</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">972,100</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Total</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">11,836,600</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">10,864,500</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">972,100</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Liabilities:</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Contingent consideration</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">117,500</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">117,500</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">Fair Value at</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="10" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Fair Value Measurements Using Inputs Considered as</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">June 30, 2021</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Level 1</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Level 2</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Level 3</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">Assets:</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Cash and cash equivalents</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,675,200</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,675,200</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Investment securities</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,744,600</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,920,600</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">824,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Total</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">13,419,800</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">12,595,800</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">824,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Liabilities:</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Contingent consideration</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">160,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">160,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> 4068000 4068000 0 0 7768600 6796500 972100 0 11836600 10864500 972100 0 117500 0 0 117500 9675200 9675200 0 0 3744600 2920600 824000 0 13419800 12595800 824000 0 160000 0 0 160000 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Cost</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Fair Value</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">UnrealizedHolding Gain (Loss)</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">At March 31, 2022:</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Equity securities</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">118,900</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">176,900</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">58,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Mutual funds</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,708,300</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,619,600</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(88,700</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> Debt securities</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">977,200</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">972,100</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(5,100</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">7,804,400</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">7,768,600</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(35,800</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Cost</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Fair Value</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">UnrealizedHolding Gain (Loss)</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">At June 30, 2021:</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Equity securities</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">102,200</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">154,100</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">51,900</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Mutual funds</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,752,400</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,766,500</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">14,100</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Debt securities</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">832,700</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">824,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(8,700 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">3,687,300</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">3,744,600</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">57,300</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> 118900 176900 58000 6708300 6619600 -88700 977200 972100 5100 7804400 7768600 35800 102200 154100 51900 2752400 2766500 14100 832700 824000 -8700 3687300 3744600 -57300 5. Inventories <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">March 31, 2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">June 30, 2021</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Raw materials</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,058,100</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,170,400</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Work-in-process</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">106,400</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">39,600</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Finished goods</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,203,400</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">767,100</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">4,367,900</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2,977,100</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">March 31, 2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">June 30, 2021</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Raw materials</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,058,100</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,170,400</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Work-in-process</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">106,400</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">39,600</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Finished goods</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,203,400</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">767,100</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">4,367,900</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2,977,100</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> 3058100 2170400 106400 39600 1203400 767100 4367900 2977100 6. Goodwill and Finite Lived Intangible Assets Goodwill amounted to $4,395,400 at March 31, 2022 and June 30, 2021, all of which is expected to be deductible for tax purposes. The components of finite-lived intangible assets are as follows: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Useful Lives</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Cost</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Accumulated Amortization</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Net</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">At March 31, 2022:</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Technology, trademarks</td><td style="width:1%;white-space: nowrap;"> </td><td>5-10 yrs.</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">817,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">431,800</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">385,200</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Trade names</td><td style="width:1%;white-space: nowrap;"> </td><td>3-6 yrs.</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">140,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">140,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Websites</td><td style="width:1%;white-space: nowrap;"> </td><td>3-7 yrs.</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">210,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">210,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Customer relationships</td><td style="width:1%;white-space: nowrap;"> </td><td>4-10 yrs.</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">372,200</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">133,100</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">239,100</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Sublicense agreements</td><td style="width:1%;white-space: nowrap;"> </td><td>10 yrs.</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">294,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">294,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Non-compete agreements</td><td style="width:1%;white-space: nowrap;"> </td><td>4-5 yrs.</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,060,500</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">455,300</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">605,200</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">In-process research and development</td><td style="width:1%;white-space: nowrap;"> </td><td>3-5 yrs.</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">917,600</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">249,600</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">668,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Patents</td><td style="width:1%;white-space: nowrap;"> </td><td>5-7 yrs.</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">593,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">274,200</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">318,800</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">4,404,300</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2,188,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2,216,300</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td> </td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Useful Lives</td><td> </td><td colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Cost</td><td style="PADDING-BOTTOM: 1px;"> </td><td> </td><td colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Accumulated Amortization</td><td style="PADDING-BOTTOM: 1px;"> </td><td> </td><td colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Net</td><td style="PADDING-BOTTOM: 1px;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">At June 30, 2021:</td><td style="width:1%;"> </td><td style="width:9%;"> </td><td style="width:1%;"> </td><td colspan="2" style="width:9%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td colspan="2" style="width:9%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td colspan="2" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Technology, trademarks</td><td style="width:1%;"> </td><td>5-10 yrs.</td><td style="width:1%;"> </td><td style="width:1%;vertical-align:bottom;">$</td><td style="width:9%;vertical-align:bottom;text-align:right;">364,700</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;vertical-align:bottom;">$</td><td style="width:9%;vertical-align:bottom;text-align:right;">362,200</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;vertical-align:bottom;">$</td><td style="width:9%;vertical-align:bottom;text-align:right;">2,500</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Trade names</td><td style="width:1%;"> </td><td>3-6 yrs.</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">592,300</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">152,600</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">439,700</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Websites</td><td style="width:1%;"> </td><td>3-7 yrs.</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">210,000</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">210,000</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Customer relationships</td><td style="width:1%;"> </td><td>4-10 yrs.</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">372,200</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">102,400</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">269,800</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Sublicense agreements</td><td style="width:1%;"> </td><td>10 yrs.</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">294,000</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">283,000</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">11,000</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Non-compete agreements</td><td style="width:1%;"> </td><td>4-5 yrs.</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">1,060,500</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">308,600</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">751,900</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">In-process research and development</td><td style="width:1%;"> </td><td>3-5 yrs.</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">852,100</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">134,800</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">717,300</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Patents</td><td style="width:1%;"> </td><td>5-7 yrs.</td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">591,500</td><td style="PADDING-BOTTOM: 1px;width:1%;"> </td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">225,900</td><td style="PADDING-BOTTOM: 1px;width:1%;"> </td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">365,600</td><td style="PADDING-BOTTOM: 1px;width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;"> </td><td style="width:9%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;"> </td><td style="width:9%;"> </td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;">$</td><td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">4,337,300</td><td style="PADDING-BOTTOM: 3px;width:1%;"> </td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;">$</td><td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,779,500</td><td style="PADDING-BOTTOM: 3px;width:1%;"> </td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;">$</td><td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2,557,800</td><td style="PADDING-BOTTOM: 3px;width:1%;"> </td></tr></tbody></table> Total amortization expense was $134,600 and $16,000 for the three months ended March 31, 2022 and 2021, respectively, and $408,500 and $48,500 for the nine months ended March 31, 2022 and 2021, respectively. As of March 31, 2022, estimated future amortization expense related to intangible assets is $134,300 for the remainder of the fiscal year ending June 30, 2022, $520,900 for fiscal 2023, $518,900 for fiscal 2024, $485,100 for fiscal 2025, $284,600 for fiscal 2026 and $137,500 thereafter. 4395400 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Useful Lives</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Cost</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Accumulated Amortization</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Net</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">At March 31, 2022:</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Technology, trademarks</td><td style="width:1%;white-space: nowrap;"> </td><td>5-10 yrs.</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">817,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">431,800</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">385,200</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Trade names</td><td style="width:1%;white-space: nowrap;"> </td><td>3-6 yrs.</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">140,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">140,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Websites</td><td style="width:1%;white-space: nowrap;"> </td><td>3-7 yrs.</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">210,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">210,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Customer relationships</td><td style="width:1%;white-space: nowrap;"> </td><td>4-10 yrs.</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">372,200</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">133,100</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">239,100</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Sublicense agreements</td><td style="width:1%;white-space: nowrap;"> </td><td>10 yrs.</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">294,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">294,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Non-compete agreements</td><td style="width:1%;white-space: nowrap;"> </td><td>4-5 yrs.</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,060,500</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">455,300</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">605,200</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">In-process research and development</td><td style="width:1%;white-space: nowrap;"> </td><td>3-5 yrs.</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">917,600</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">249,600</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">668,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Patents</td><td style="width:1%;white-space: nowrap;"> </td><td>5-7 yrs.</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">593,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">274,200</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">318,800</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">4,404,300</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2,188,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2,216,300</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td> </td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Useful Lives</td><td> </td><td colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Cost</td><td style="PADDING-BOTTOM: 1px;"> </td><td> </td><td colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Accumulated Amortization</td><td style="PADDING-BOTTOM: 1px;"> </td><td> </td><td colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Net</td><td style="PADDING-BOTTOM: 1px;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">At June 30, 2021:</td><td style="width:1%;"> </td><td style="width:9%;"> </td><td style="width:1%;"> </td><td colspan="2" style="width:9%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td colspan="2" style="width:9%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td colspan="2" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Technology, trademarks</td><td style="width:1%;"> </td><td>5-10 yrs.</td><td style="width:1%;"> </td><td style="width:1%;vertical-align:bottom;">$</td><td style="width:9%;vertical-align:bottom;text-align:right;">364,700</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;vertical-align:bottom;">$</td><td style="width:9%;vertical-align:bottom;text-align:right;">362,200</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;vertical-align:bottom;">$</td><td style="width:9%;vertical-align:bottom;text-align:right;">2,500</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Trade names</td><td style="width:1%;"> </td><td>3-6 yrs.</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">592,300</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">152,600</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">439,700</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Websites</td><td style="width:1%;"> </td><td>3-7 yrs.</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">210,000</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">210,000</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Customer relationships</td><td style="width:1%;"> </td><td>4-10 yrs.</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">372,200</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">102,400</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">269,800</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Sublicense agreements</td><td style="width:1%;"> </td><td>10 yrs.</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">294,000</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">283,000</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">11,000</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Non-compete agreements</td><td style="width:1%;"> </td><td>4-5 yrs.</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">1,060,500</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">308,600</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">751,900</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">In-process research and development</td><td style="width:1%;"> </td><td>3-5 yrs.</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">852,100</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">134,800</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">717,300</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Patents</td><td style="width:1%;"> </td><td>5-7 yrs.</td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">591,500</td><td style="PADDING-BOTTOM: 1px;width:1%;"> </td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">225,900</td><td style="PADDING-BOTTOM: 1px;width:1%;"> </td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">365,600</td><td style="PADDING-BOTTOM: 1px;width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;"> </td><td style="width:9%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;"> </td><td style="width:9%;"> </td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;">$</td><td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">4,337,300</td><td style="PADDING-BOTTOM: 3px;width:1%;"> </td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;">$</td><td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,779,500</td><td style="PADDING-BOTTOM: 3px;width:1%;"> </td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;">$</td><td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2,557,800</td><td style="PADDING-BOTTOM: 3px;width:1%;"> </td></tr></tbody></table> P5Y P10Y 817000 431800 385200 P3Y P6Y 140000 140000 0 P3Y P7Y 210000 210000 0 P4Y P10Y 372200 133100 239100 P10Y 294000 294000 0 P4Y P5Y 1060500 455300 605200 P3Y P5Y 917600 249600 668000 P5Y P7Y 593000 274200 318800 4404300 2188000 2216300 P5Y P10Y 364700 362200 2500 P3Y P6Y 592300 152600 439700 P3Y P7Y 210000 210000 0 P4Y P10Y 372200 102400 269800 P10Y 294000 283000 11000 P4Y P5Y 1060500 308600 751900 P3Y P5Y 852100 134800 717300 P5Y P7Y 591500 225900 365600 4337300 1779500 2557800 134600 16000 408500 48500 134300 520900 518900 485100 284600 137500 7. Loss Per Common Share The Company presents the computation of earnings per share (“EPS”) on a basic basis. Basic EPS is computed by dividing net income, if any, by the weighted average number of shares outstanding during the reported period. Diluted EPS is computed similarly to basic EPS, except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential additional common shares that were dilutive had been issued. Common shares are excluded from the calculation if they are determined to be anti-dilutive; accordingly, no dilution is shown for loss periods. The following table sets forth the weighted average number of common shares outstanding for each period presented. <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">For the Three Month Period Ended March 31, 2022 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">For the Three Month Period Ended March 31, 2021 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">For the Nine Month Period Ended March 31, 2022 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"> For the Nine Month Period Ended March 31, 2021</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Weighted average number of common shares outstanding</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,633,901</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,861,607</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,544,112</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,861,376</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Effect of dilutive securities</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Weighted average number of dilutive common shares outstanding</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,633,901</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,861,607</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,544,112</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,861,376</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Basic and diluted loss per common share:</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Continuing operations</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.23</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.51</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.56</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.61</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Discontinued operations</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">0.01</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.20</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Consolidated operations</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.23</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.50</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.56</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.81</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table> Approximately 3,452,542 and 3,451,461 shares of the Company’s common stock issuable upon the exercise of options and warrants, respectively, were excluded from the calculation because the effect would be anti-dilutive due to the loss for the three and nine months ended March 31, 2022. Approximately 259,357 and 1,349,850 shares of the Company’s common stock issuable upon the exercise of options and warrants, respectively, were excluded from the calculation because the effect would be anti-dilutive due to the loss for the three and nine months ended March 31, 2021. <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">For the Three Month Period Ended March 31, 2022 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">For the Three Month Period Ended March 31, 2021 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">For the Nine Month Period Ended March 31, 2022 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"> For the Nine Month Period Ended March 31, 2021</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Weighted average number of common shares outstanding</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,633,901</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,861,607</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,544,112</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,861,376</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Effect of dilutive securities</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Weighted average number of dilutive common shares outstanding</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,633,901</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,861,607</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,544,112</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,861,376</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Basic and diluted loss per common share:</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Continuing operations</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.23</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.51</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.56</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.61</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Discontinued operations</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">0.01</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.20</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Consolidated operations</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.23</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.50</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.56</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.81</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table> 6633901 2861607 6544112 2861376 6633901 2861607 6544112 2861376 -0.23 -0.51 -0.56 -0.61 0.01 -0.20 -0.23 -0.50 -0.56 -0.81 3452542 3451461 259357 1349850 8. Leases The Company leases certain properties consisting principally of (i) a facility in Bohemia, New York (headquarters) through October 2028, (ii) a facility in Pittsburgh, Pennsylvania for SBI’s Bioprocessing Systems Operations through May 2023, and (iii) a facility for sales and administration in Orangeburg, New York through October 2022. There are no renewal options with any of the leases, no residual values or significant restrictions or covenants other than those customary in such arrangements, and no non-cash activities; and any rent escalations incorporated within the leases are included in the calculation of the future minimum lease payments, as further described below. The Company determines whether an agreement contains a lease at inception based on the Company’s right to obtain substantially all of the economic benefits from the use of the identified asset and its right to direct the use of the identified asset. Lease liabilities represent the present value of future lease payments and the Right-Of-Use (“ROU”) assets represent the Company’s right to use the underlying assets for the respective lease terms. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term. Each ROU asset is further adjusted to account for previously recorded lease expenses such as deferred rent and other lease liabilities. As the Company’s leases do not provide an implicit rate, the Company used its incremental borrowing rate of 5.0% as the discount rate to calculate the present value of future lease payments, which was the interest rate that its bank would charge for a similar loan.The Company elected not to recognize a ROU asset or a lease liability for leases with an initial term of twelve months or less. In addition to minimum lease payments, certain leases require payment of a proportionate share of real estate taxes and certain building operating expenses or payments based on an excess of a specified base. These variable lease costs are not included in the measurement of the ROU asset or lease liability due to unpredictability of the payment amount and are recorded as lease expenses in the period incurred. The Company’s lease agreements do not contain residual value guarantees. The Company elected available practical expedients for existing or expired contracts of lessees whereby the Company is not required to reassess whether such contracts contain leases, the lease classification or the initial direct costs. The Company is not utilizing the practical expedient which allows the use of hindsight by lessees and lessors in determining the lease term and in assessing impairment of its ROU assets. The Company utilized the transition method allowing entities to only apply the new lease standard in the year of adoption. As of March 31, 2022, the weighted-average remaining lease term for operating lease liabilities was approximately 5.32 years and the weighted-average discount rate was 5.0%. Total cash payments under these leases were approximately $82,000 and $240,200, for the three and nine months ended March 31, 2022 of which $81,800 and $226,300 was recorded as leases expense, respectively. The Company’s approximate future minimum rental payments under all leases existing at March 31, 2022 through October 2028 are as follows: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Fiscal year ending June 30,</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Amount</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Remainder of 2022</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">82,200</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">2023</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">311,400</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2024</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">247,600</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">2025</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">255,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2026</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">262,700</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Thereafter </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">609,600</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Total future minimum payments</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,768,500</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Less imputed interest</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(256,100 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Total Present Value of Operating Lease Liabilities</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,512,400</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> 0.050 P5Y3M25D 0.050 82000 240200 81800 226300 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Fiscal year ending June 30,</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Amount</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Remainder of 2022</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">82,200</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">2023</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">311,400</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2024</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">247,600</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">2025</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">255,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2026</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">262,700</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Thereafter </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">609,600</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Total future minimum payments</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,768,500</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Less imputed interest</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(256,100 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Total Present Value of Operating Lease Liabilities</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,512,400</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> 82200 311400 247600 255000 262700 609600 1768500 256100 1512400 9. Discontinued Operations Effective November 30, 2020, as part of its strategic shift to becoming a life sciences tool provider, the Company sold its operations relating to the manufacture and marketing of custom-made catalyst research instruments for universities, government laboratories, and chemical petrochemical companies sold on direct basis (the “Catalyst Research Instruments Operations”) through the sale by Altamira of substantially all of its assets and inventory to Beijing JWGB Sci. & Tech. Co. Ltd., a corporation formed under the laws of the People’s Republic of China (“JWGB”) for $440,000 which was fully paid in cash by January 2021, resulting in a $405,400 pre-tax loss. To preserve business continuity for the buyer, Altamira agreed to purchase certain components on behalf of JWGB for which JWGB agreed to reimburse Altamira. The Company retained all its receivables and payables related to sales made prior to November 30, 2020, certain inventory related to two work-in-process orders which have been shipped, product warranty and other miscellaneous liabilities related to certain employee benefits, and expenses related to the closure of the Altamira facility, which was completed at the end of December 2020.As a result of the disposal described above, the operating results of the former Catalyst Research Instruments Operations segment have been presented as discontinued operations in the balance sheets, the statements of operations, and the statements of cash flows, as detailed below. <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:bottom;">Assets:</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">March 31,2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">June 30,2021</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Cash</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">600</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Accounts receivable</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">52,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Inventories</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,300</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">600</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">55,300</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:bottom;">Liabilities:</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">March 31,2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">June 30,2021</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Accrued expenses and taxes</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20,700</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Contract liabilities</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">7,900</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">16,500</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">7,900</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">37,200</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td> </td><td colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Three Months Ended </td><td> </td><td> </td><td colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Nine Months Ended </td><td> </td></tr><tr style="height:15px"><td> </td><td> </td><td colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">March 31,2022 </td><td style="PADDING-BOTTOM: 1px;"> </td><td> </td><td colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">March 31,2021</td><td style="PADDING-BOTTOM: 1px;"> </td><td> </td><td colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">March 31,2022 </td><td style="PADDING-BOTTOM: 1px;"> </td><td> </td><td colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">March 31,2021 </td><td style="PADDING-BOTTOM: 1px;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Revenues</td><td style="width:1%;"> </td><td style="width:1%;vertical-align:bottom;">$</td><td style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;vertical-align:bottom;">$</td><td style="width:9%;vertical-align:bottom;text-align:right;">107,800</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;vertical-align:bottom;">$</td><td style="width:9%;vertical-align:bottom;text-align:right;">20,600</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;vertical-align:bottom;">$</td><td style="width:9%;vertical-align:bottom;text-align:right;">387,700</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Cost of goods sold</td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">6,900</td><td style="PADDING-BOTTOM: 1px;width:1%;"> </td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">78,800</td><td style="PADDING-BOTTOM: 1px;width:1%;"> </td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">10,300</td><td style="PADDING-BOTTOM: 1px;width:1%;"> </td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">458,500</td><td style="PADDING-BOTTOM: 1px;width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Gross profit (loss)</td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(6,900</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;">)</td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">29,000</td><td style="PADDING-BOTTOM: 1px;width:1%;"> </td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">10,300</td><td style="PADDING-BOTTOM: 1px;width:1%;"> </td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(70,800</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Selling, general and administrative expenses</td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">700</td><td style="PADDING-BOTTOM: 1px;width:1%;"> </td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">12,600</td><td style="PADDING-BOTTOM: 1px;width:1%;"> </td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,900</td><td style="PADDING-BOTTOM: 1px;width:1%;"> </td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">282,200</td><td style="PADDING-BOTTOM: 1px;width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Income (loss) from operations</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">(7,600</td><td style="width:1%;vertical-align:bottom;">)</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">16,400</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">7,400</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">(353,000</td><td style="width:1%;vertical-align:bottom;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Loss on disposal</td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;"> </td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;"> </td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;"> </td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(405,400</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Income (loss) before income tax benefit</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">(7,600</td><td style="width:1%;vertical-align:bottom;">)</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">16,400</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">7,400</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">(758,400</td><td style="width:1%;vertical-align:bottom;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Income tax expense (benefit)</td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;"> </td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;"> </td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4,000</td><td style="PADDING-BOTTOM: 1px;width:1%;"> </td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(179,900</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Net income (loss) attributable to discontinued operations</td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;">$</td><td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(7,600</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;">)</td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;">$</td><td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">16,400</td><td style="PADDING-BOTTOM: 3px;width:1%;"> </td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;">$</td><td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">3,400</td><td style="PADDING-BOTTOM: 3px;width:1%;"> </td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;">$</td><td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(578,500</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;">)</td></tr></tbody></table> In our Consolidated Statements of Cash Flows, the cash flows from discontinued operations are not separately classified. Cash provided by (used in) operating activities from discontinued operations for nine months ended March 31, 2022 and March 31, 2021 was $25,400 and $(502,900), respectively. Cash provided by investing activities from discontinued operations for the nine months ended March 31, 2022 was none and $440,000 for the nine months ended March 31, 2021. There was no cash provided by or used in financing activities for either period. 440000 405400 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:bottom;">Assets:</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">March 31,2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">June 30,2021</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Cash</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">600</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Accounts receivable</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">52,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Inventories</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,300</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">600</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">55,300</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:bottom;">Liabilities:</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">March 31,2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">June 30,2021</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Accrued expenses and taxes</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20,700</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Contract liabilities</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">7,900</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">16,500</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">7,900</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">37,200</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td> </td><td colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Three Months Ended </td><td> </td><td> </td><td colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Nine Months Ended </td><td> </td></tr><tr style="height:15px"><td> </td><td> </td><td colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">March 31,2022 </td><td style="PADDING-BOTTOM: 1px;"> </td><td> </td><td colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">March 31,2021</td><td style="PADDING-BOTTOM: 1px;"> </td><td> </td><td colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">March 31,2022 </td><td style="PADDING-BOTTOM: 1px;"> </td><td> </td><td colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">March 31,2021 </td><td style="PADDING-BOTTOM: 1px;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Revenues</td><td style="width:1%;"> </td><td style="width:1%;vertical-align:bottom;">$</td><td style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;vertical-align:bottom;">$</td><td style="width:9%;vertical-align:bottom;text-align:right;">107,800</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;vertical-align:bottom;">$</td><td style="width:9%;vertical-align:bottom;text-align:right;">20,600</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;vertical-align:bottom;">$</td><td style="width:9%;vertical-align:bottom;text-align:right;">387,700</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Cost of goods sold</td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">6,900</td><td style="PADDING-BOTTOM: 1px;width:1%;"> </td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">78,800</td><td style="PADDING-BOTTOM: 1px;width:1%;"> </td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">10,300</td><td style="PADDING-BOTTOM: 1px;width:1%;"> </td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">458,500</td><td style="PADDING-BOTTOM: 1px;width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Gross profit (loss)</td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(6,900</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;">)</td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">29,000</td><td style="PADDING-BOTTOM: 1px;width:1%;"> </td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">10,300</td><td style="PADDING-BOTTOM: 1px;width:1%;"> </td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(70,800</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Selling, general and administrative expenses</td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">700</td><td style="PADDING-BOTTOM: 1px;width:1%;"> </td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">12,600</td><td style="PADDING-BOTTOM: 1px;width:1%;"> </td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,900</td><td style="PADDING-BOTTOM: 1px;width:1%;"> </td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">282,200</td><td style="PADDING-BOTTOM: 1px;width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Income (loss) from operations</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">(7,600</td><td style="width:1%;vertical-align:bottom;">)</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">16,400</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">7,400</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">(353,000</td><td style="width:1%;vertical-align:bottom;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Loss on disposal</td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;"> </td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;"> </td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;"> </td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(405,400</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Income (loss) before income tax benefit</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">(7,600</td><td style="width:1%;vertical-align:bottom;">)</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">16,400</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">7,400</td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:1%;"> </td><td style="width:9%;vertical-align:bottom;text-align:right;">(758,400</td><td style="width:1%;vertical-align:bottom;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Income tax expense (benefit)</td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;"> </td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;"> </td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4,000</td><td style="PADDING-BOTTOM: 1px;width:1%;"> </td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(179,900</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Net income (loss) attributable to discontinued operations</td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;">$</td><td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(7,600</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;">)</td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;">$</td><td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">16,400</td><td style="PADDING-BOTTOM: 3px;width:1%;"> </td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;">$</td><td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">3,400</td><td style="PADDING-BOTTOM: 3px;width:1%;"> </td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;">$</td><td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(578,500</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;">)</td></tr></tbody></table> 600 52000 3300 600 55300 20700 7900 16500 7900 37200 107800 20600 387700 6900 78800 10300 458500 -6900 29000 10300 -70800 700 12600 2900 282200 -7600 16400 7400 -353000 -405400 -7600 16400 7400 -758400 4000 -179900 -7600 16400 3400 -578500 25400 -502900 440000 10. Acquisition of Aquila Biolabs GmbH Effective April 29, 2021, the Company acquired all the outstanding capital stock of Aquila, a German start-up company engaged from its facility in Baesweiler, Germany in the design, production, and sale of bioprocessing systems and products which focus on the control and analysis of bioprocesses in bioreactors and incubation shakers for an aggregate purchase price of $7,880,100 in cash upon closing. Aquila’s principal customers are universities, pharmaceutical companies, and industrial companies. Aquila’s products are sold primarily on a direct basis and to a lesser extent, through distributors. The acquisition was accounted for in accordance with ASC 805, Business Combinations (“ASC 805”) in which the Company is treated as the accounting acquirer. Accordingly, the assets acquired and liabilities assumed were measured at estimated fair value.For purposes of measuring the estimated fair value, where applicable, of the assets acquired and liabilities assumed, as reflected in the unaudited pro forma condensed consolidated financial information, the guidance in ASC 820, Fair Value Measurements and Disclosures (“ASC 820”) has been applied, which establishes a framework for measuring fair value. In accordance with ASC 820, fair value is an exit price and is defined as “the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.” Under ASC 805, acquisition-related transaction costs and acquisition-related restructuring charges are not included as components of consideration transferred but are accounted for as expenses in the period in which the costs are incurred. Management of the Company allocated the purchase price based on its estimated valuation of the assets acquired and liabilities assumed as follows: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Amount</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Useful life</td><td style="width:1%;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">Fair value of assets acquired:</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">Current assets:</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Cash and cash equivalents</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">201,100</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Accounts receivable</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">159,200</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Inventory</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">187,500</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Prepaid expenses and other current assets</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">25,400</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Property, plant and equipment</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">40,200</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Deferred tax asset</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">800,300</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Tradename</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">452,300</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>6 years</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Non-compete agreements</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">784,500</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>4 years</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">In-process research and development</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">742,100</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>5 years</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Customer relationships</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">252,200</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>9 years</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Patents and other intangibles</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">286,200</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>7 years</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Total assets acquired</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,931,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Fair value of liabilities assumed:</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Accounts payable</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(39,300 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Accrued expenses</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(90,300 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Other current liabilities</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(59,400 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Total liabilities assumed</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(189,000 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Total identifiable net assets</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,742,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Fair value of consideration transferred</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">7,880,100</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Goodwill</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4,138,100</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr></tbody></table> 7880100 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Amount</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Useful life</td><td style="width:1%;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">Fair value of assets acquired:</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">Current assets:</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Cash and cash equivalents</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">201,100</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Accounts receivable</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">159,200</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Inventory</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">187,500</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Prepaid expenses and other current assets</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">25,400</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Property, plant and equipment</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">40,200</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Deferred tax asset</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">800,300</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Tradename</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">452,300</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>6 years</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Non-compete agreements</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">784,500</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>4 years</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">In-process research and development</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">742,100</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>5 years</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Customer relationships</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">252,200</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>9 years</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Patents and other intangibles</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">286,200</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>7 years</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Total assets acquired</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,931,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Fair value of liabilities assumed:</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Accounts payable</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(39,300 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Accrued expenses</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(90,300 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Other current liabilities</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(59,400 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Total liabilities assumed</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(189,000 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Total identifiable net assets</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,742,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Fair value of consideration transferred</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">7,880,100</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Goodwill</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4,138,100</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;"> </td></tr></tbody></table> 201100 159200 187500 25400 40200 800300 452300 P6Y 784500 P4Y 742100 P5Y 252200 P9Y 286200 P7Y 3931000 39300 90300 59400 189000 3742000 7880100 4138100 11. Paycheck Protection Program Loan The Company received a second $433,800 PPP loan in March 2021, pursuant to the PPP loan administered by the U.S. Small Business Administration through its bank. The full amount of this loan was forgiven in December 2021, and is reflected as other income (extinguishment of debt) in the accompanying statements of operations and comprehensive loss. 433800 12. Equity Authorized Shares On February 25, 2022, at the Company’s Annual Stockholders Meeting, the stockholders of the Company approved an amendment to its Certificate of Incorporation to increase the number of authorized shares of the Company’s common stock by 5,000,000 shares from 15,000,000 to 20,000,000 shares. In addition, the stockholders also approved the adoption of the Company’s 2022 Equity Incentive Plan (“Plan”) providing for the issuance of up to 1,750,000 shares plus outstanding options granted under the Company’s 2012 Stock Option Plan that expire or are forfeited. The Plan provides various stock awards including incentive and nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, and other stock awards, which can be awarded to employees and directors of the Company and its subsidiaries. Issuance and Sale of Common Stock On March 2, 2022, the Company entered into a Securities Purchase Agreement with certain private investors pursuant to which the Company issued and sold an aggregate of 545,456 shares of common stock and warrants to purchase up to an additional 274,727 shares of common stock, at an offering price of $5.50 per share, for a gross consideration of $3,000,000. The issuance cost related to this private placement stock issuance amounted to approximately $272,800. Under the terms of Securities Purchase Agreement between the Company and the investors, the Company must use commercially reasonable efforts to file a registration statement with the SEC within 90 days of the closing date to register for resale the shares of common stock sold in the private offering, including the shares of common stock issuable upon the exercise of the warrants. As of March 31, 2022, the Company had not yet filed a registration statement with respect to the offering. 5000000 15000000 20000000 1750000 545456 274727 5.50 3000000 272800 EXCEL 82 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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�?K#='HPLA11MZ\C$R^:LJ__ MD ?,[0T](A-W,K&1B:_(N'9_PTP,4Y\(+\LXFB5QH-)[Z:_J1%PQ$?=@X\(D MBWJP_V6:=)DFHYG^R212U:P9E^0_9(X1_*H.1(%=N3>QTIX'&,7II=5U8EF% M"G19(#M8'.3))>S>#A;;J,+A+$YG5A'M8%D8#-4P[6J8CM9PX,%N\9]>\1R[OF4,ML.JYF08KG+#!NN>=]_R:]]CE/;?58&Y[ MGP8K'+ @SX>\SSKOLVO>$Y?WF?U0Y FTO$^#%0Y8%L$A[S#XWET$U]RGSLX@ ML 3#W'Y!;";BBA;7?UZ32)TD0PGTVB,X_MI3)P<&:"9[TZ0+L&4G*IM3J9OM/@3N3/M[,;^"MVOHF-_ VWO7?*$_*$Q' M^5VV^1I1?<&>4 $JO%,6@IM,)<&;!K\92'8T_>4SDZI;-9<']5&$N0:H^SO& MY-M "W2?6&PO=V]R M:W-H965TFX^_=[2"FJ(]&*@]J 35(SA757(U M\79:[V]]7ZUWM")J)/:4PY6-D!71T)5;7^TE)84E5:4?!D'J5X1Q;SJV8_=R M.A8'73).[R52AZHB\K\[6HKCQ,/>\\ 7MMUI,^!/QWNRI0]4?]O?2^CYK4K! M*LH5$QQ)NIEX[_'M*C=X"_C.Z%&=M)&YDTWDDBLY$^8,5>C?Q<@\5=$,.I?XBCO_0 MYGX2H[<6I;*_Z%ACD]!#ZX/2HFK(,(.*\?J?_&I\."& CIL0-H2P2XC/$**& M$%T:(6X(\:41DH:0= GI&4+:$-)+(V0-(;.+5;MKEV9.-)F.I3@B:="@9AIV M?2T;5H1QDXD/6L)5!CP]_2240O=4HIFH*DB-AQV1%%W-J2:L5-?H'?H+^4B9 M437V-40T/'_=J-_5ZN$9]0A]%ESO%%KP@A8._GR8?_,:?SG,Q^& @ ]6M7Z% MSW[=A8.*GXDC"P M%%&;NI'5B\[H+8CDC&\5NC))?.W(XJ_DL:3J>B!6W,:*;:SX3*P?=DNC!2)/ M5,(.C=9UH/K!0+#%*TUX =-Q/22U=FJUS:OA:9JF4703@(E/I[G3QX5YBM,@ M>XF;._22.,8X?(E;N/6B+'V)6_9Q$&\+X,[X';Z=8OC")0-6\85*ND&IA",,MBA9%WBUQTM]K;"?!0:ZE7;W,&IB$H#@.L; M(?1SQP1HSUG3_P%02P,$% @ +H&[5'4?BSV^ @ D !D !X;"]W M;W)K&ULK59;;YLP%/XK%D^;M)4[N2A!:F[=JG6+ M&FU]=N$DH!H[LTW3_?O9AK T(312]P(^Q^?[CL\%'T8[QI]$!B#12T&H&%N9 ME-NA;8LD@P*+*[8%JG;6C!=8*I%O;+'E@%,#*HCM.4YD%SBG5CPRNB6/1ZR4 M)*>PY$B418'YGPD0MAM;KK57W.>;3&J%'8^V> ,KD#^W2ZXDNV%)\P*HR!E% M'-9CZ]H=WD3:WAC\RF$G#M9(1_+(V),6OJ9CR]$' @*)U Q8O9YA"H1H(G6, MWS6GU;C4P,/UGGUA8E>Q/&(!4T8>\E1F8ZMOH136N"3RGNV^0!U/J/D21H1Y MHEUE&RJ/22DD*VJPDHN<5F_\4N?A *!XV@%>#?". <$9@%\#_$L]!#4@N-1# M6 /"8T!T!A#5@.A2#[T:T#/%JK)K2C/#$LFO@:M*I)3W8DK MR=5NKG R_L:$0$O@:,J*0K7&*L,8TA;0%/^O&#]["+[KQKM=!8*N$-5GS]EF;>)V, M=YA?(=_]A#S'\UH.-+T<[K;EXWW>Y^_SONB&WY94P9VS\)O+X4Y'*?RF@7W# M%YSA6TF6/*$?6WVQB0Z^H.$+.OEF.2EUP]?=CN E(65[VTTJIL@PZ2O_.?:# MT L#593GPW*VVKE!Y+ZV6YS:]?O1X,CJYM0J5&Q^8_4J[+ ).^P,^T%_Z%1V M93!JJ*+_E<%I=!*+%P[\L/L'@W[H'"6PA2[HN[V^?Y3"M_FJR.V# MB[4 OC$S4Z"$E516+=5HF[%\;:;1D7[B#J=NBW[F#N=M^H4:[]4T_N>V^C=0 M7^\FIP(16*LC.%<]55=>S=M*D&QKKOM')M7P,,M,_:( UP9J?\V8W O:0?/3 M$_\%4$L#!!0 ( "Z!NU3IH%&;W ( /4( 9 >&PO=V]R:W-H965T MJ@>]8\R@IU)4>A[LC*DOPE"O M=ZRD^ES6K(([A50E-;!5VU#7BM&-$Y4B)%&4AB7E5;"8N6LW:C&3C1&\8C<* MZ:8LJ7J^9$+NYP$.7B[<\NW.V OA8E;3+;MCYKZ^4; +.Y<-+UFEN:R08L4\ M^((OEM@)7,1OSO:ZMT:VE)64#W;S?3,/(DO$!%L;:T'A[Y$MF1#6"3C^'DR# M+J<5]M&05W.>C,XIK!&6AT%3CZ=SD(# M_C8J7!^\+ELO,N+UDZIS%.//B$2$#,B7Q^4_F@KDD9/CU_(0JNI*(UUIQ/G% M1TL[8A1W1K$SFHP8W3+[/FR80K(8J^VRM4B6<>CG3*!^M,.]RYL=S2D,%*AK3*&:;&"^;$M7T&<:!T4,8 MN?_PLW2:>,_#C\OR&(_AXNA_4XR. E\SK2\0+^O&L WB%9P6TV:P(T8>PAE) M4NRA#@6F9)RUU\#Q!PX79KB&TT2/5#3,]BD8](H:7FV1L'T0"4Y77'##W[;$ M0QW8ZTPXP<1O%@.!F3WRMW6$O9ED/PA@.&QYI8&F &%TGH&#:F=LNS&R=F-J M)0T,/;?-G7S=E\[B'U!+ P04 " N@;M492<6+]\" M !#"0 &0 'AL+W=O:G*6DZ<7*GEI>O*-(>*R0%?0HU?YEQ43&%7+%RY%, R0ZI* MEWK>R*U843O3V(S=BFG,5ZHL:K@51*ZJBHGM#$J^F3A#9S=P5RQRI0?<:;QD M"[@'];"\%=AS.Y6LJ*"6!:^)@/G$N1I>)I'&&\"O C9RKTVTDR?.GW7G:S9Q M/+T@*"%56H'A:PW74)9:")?QN]5TNBDU<;^]4_]LO*.7)R;AFI>/1:;RB1,Y M)(,Y6Y7JCF^^0.LGU'HI+Z5YDDV#]1& ;(C0:U73#!-.PT7Y1ZVV_ M5P*_%LA3T^^ 09/D+ '%BE*2'TP(IK?B SDG#_<).7OW(785SJ3Q;MJJSAI5 M>D+5)S>\5KDDG^H,LA[^M9U_\2]^8NX9^M#BQN]VW3=ZOG77+4)!)Q08H>"$T$^N6$E2)G.R M9%M,!TJ2%89[*[WXWF,HH%'7\.2'EAT,=R# M'=@*.UNAU=:C21>0G;,U",Q^F.!T"BWJ1>.+*!!5WU]@EPW)%IB0Q"=5\W?2 MD&1LVQ>EQ*Y$6Z5HIQ3T"!U8'W761V^SGA4RY:M:$?=KUPX'GO^T+U M9MJ!G7%G9VS52?973[#0F/WK6X]=YY2-Y,VT QM19R.RZI@#2^ %JWWOZF?1 M\:$:1D>'ZAA%Z<@_.E0]L/'8/SI4[E[9J4 L3/F6Q,2[J4#=:'=#N#*%T?T+ M;ZX7F!\712UQ=^9(]09CG%PT);OI*+XT1>R)*RR)IIGC+0>$!N#W.>=JU]$3 M=/>FZ1]02P,$% @ +H&[5/=&KW+2!0 [1H !D !X;"]W;W)K&ULI5EM;^(X$/XK%KH/7:E=8N>5JD5J@7 ][=Y56^W= MYP &HDUBSC:E^^_/>6D"G8GAM%]:8IYY\3/CF3&Y.PCY0VTYU^0MSPIU/]AJ MO;L=#M5RR_-$?18[7IAOUD+FB3:/:%241#)U_>#!WH[9UXI4"'^3OE!'7TFY5860OPH'YY6]P.G](AG?*E+ M%8GY]\HG/,M*3<:/?QNE@]9F*7C\^5U[7&W>;&:1*#X1V3_I2F_O!]& K/@Z MV6?ZFSC\SIL-^:6^I)JJI2AT6NSYBORUXS(I,T21 MJRG729JI3^2&?'^9DJO?/MT-M3%8B@V7C?+'6CGK4>Z2KT;W5I%9L>(K1'YJ MEQ^=DX_M\I19% P-4RU=[)VN1V;5^#61GXE+KPES&$,L MQW;Q/_:%$7=ZQ>>7BSN64+AMYKJ5/K='WX-27*M;BR:OU>15FKP>39-$;;'D MKJ7\2JHLZ:_CP#&>OQX'[ ),##$=XL1AOW78MSK\L%R*?:&5Z05+GKXFBXQC M_M=* M1N[?U91 P1ONER/?X'K?^!U?^GXI476LB4*\SOX*S?9Q$Q1+CNQ\#, M Q 8UW/#OMV%[>Y"Z^Z>I1D4I/Y)DF)%^+_[=&=:M[XF!=?8J0F!I]3KYX6C/HNCUN+(:O&DCXBVCV#A'0$'X+&Z !-#C._# M&$-4.')[,Y@Z7=]TK.7G2YHLTBS5)H=M-8@>-6)Z[E#+DCS^9L9,Q565/CIY MP\](H\QV2,Y#8@3"G!!PB,#H*>YTSZS;,[NLD.V2GSU5;-ZH./61]MKNV@=U M[57?I*LTDS#)NDBB3+M(!H&$O0@5(R@:^)!O" M&_3G;]3EJ;W3-?%=L2,;- M^'Z\\VLS;$IIZA39"5D>7304'JRJM#\473NC]GYV=):(6)/5Y;6$POZ$!><2 M5(R@W)#!X$ 8\YS> DJ[IDCM7?$;-UUQWY.$9SO>A,)N1ITP@F1 58(+HS\?MJZ;DOM[78BE"ZS9F-ZGB)*9-A%X9'"-AN %)@@ MJ#!"*$1ZM@-:SPR!>7X$CGN,X4(*S,X17!2,^BGLI@5Z9ER00ID:+,4ZU>0J M,P_X90^.#C<8B1#&3JI70R*$H20B1D,'D!-CN,BCD$04UU]@%YZ9 MI=GDA9-7I*U%'G7%# B&V6G&0,XFB P&H!- M31%8"% SS*;KNR#K8Q08>' &P(!>R/K9[ 9-9A\TOY2'711EF]T)E6"7A$=V M=G:DI9-ZU$V42CJ]H-D(8FHT0AF4C9M./$%)1YT:@5,PQH#4;NS&QZ8?(S(0" M X;4403(/&1J&A[]B)YSN:G>CRA275#KWQ+;U?8=S$/UYN'#^B.]G5!D?4IO M9]AZ3&_G]9N7SFS](NAK(C=IHR?K=2/VBQJW[:7PBM15Y] MW/)DQ64),-^OA=#O#Z6!]@W7^#]02P,$% @ +H&[5#8S3M_; @ O@@ M !D !X;"]W;W)K&ULE59M;]HP$/XK5K0/K;0U M+R1AK0)2>9FV2=U0JVZ?#3F(U<3.; ?:?S^_A(R%)*)\(/;YGN?N'@Y?D@/C M+R(#D.BUR*F8.)F4Y9WKBDT&!18WK 2J3K:,%UBJ+=^YHN2 4P,JP1/(YW+% MU].9;.G$\G1#DL)&: M :O''N:0YYI(I?&GYG2:D!IXNCZR?S&UJUK66," MP*@&C-J N <0UH#PT@A1#3"EN[9V(]P"2SQ-.#L@KKT5FUX8]0U:Z46H[I,G MR=4I43@Y71"Q85026D&*?I; L?[]!+I:@,0D%^@'YMJVAVOT"3T_+=#5A^O$ ME2JT)G W=9B9#1/TA+E%#RI*)M"2II!VX!?#>#\8('!5S4WAP;'P63#(^(#Y M#1KY'U'@!4%'0O/+X7Y7/KH:PTE[DMS]V"X$P9]^1" M+H#OS"04:,,J*NV_LK$VP_;>S)B6?>;?S?T.^T(-9SM+_]';R:XNIAU1%W@. M6Q7*NQFK5+F=EG8C66G&P9I)-5S,,E,O&,"U@SK?,B:/&QV@>669_@502P,$ M% @ +H&[5/EL 116!0 0AD !D !X;"]W;W)K&ULM9E;;^,H%,>_"HKV84::U#:.$V>41NIEY[+2[%9SV7TF-DG0V,8# MI&F__8*=&K,0Z%;J2VLGYQQ^<,SY'YS5D;*??(^Q ]UU?#+R5Z(]GT4\6*/ M:\0O:(L;^Z1NSQ&E?T>#E))D\??"6[O5 ?1.M5BW;X&Q8_VCLF[Z(A2DEJW'!"&\#P M]G)RE;R_27/ET%G\3?"1CZZ!FLJ&TI_JYG-Y.8D5$:YP(50()/_=XQM<52J2 MY/AU"CH9QE2.X^NGZ!^ZR""UB=G25"3IO^/'DX+,7)(SCG DP/\K\/\C$-Z83>'.+!2(5?PNFX,>W6_#FM[>K2,BQ582H.(USW8\# MSXR3@"^T$7L.?F]*7#K\;P+^T!,@DI,>9@Z?9GX-O1&O6G8!X/(=@#%,7$!^ M]S\.S05(8Y>[@9,.B4B[>.F9>#<'QG C .(<"_[>$W$V1)QU$6?G(B*^!Z@I M0:$NL,SL/:KD$-R5O3Y4UH526_]^#>,DB>-5=#]>DZ"909H-I)F7]*HHZ$&" MR;I08$FYJ;"+L0\R'PV>9$MH,0;-#,;YP#CW,GYN[N7:4?;H(IO;0^:+S"(+ MFAEDBX%LX26[8[A%I 3X0=9VCGF7UEN\Q7(I2R#0 M@V1RG%F+0S&!,8EW+8R_E=X9*W*#:N7M.OL;"9-"&"]N9=".E2;QT M?])F6M"ZQ0(#M&,8U^>*T2G0&&&1S^S]%+8S4:%&A8'-/FT9+3!7)8ECQ(J^ MDI;X7C8^9Q_04U2#9P;M*AJV,[FUAB2IO^1W#8/<^ Q72&DZWY/6O<2I8TM# M>S>%[4Q4+4Z)7YWND%#I'Q4KT@C4[(@L_F[BF4V2SQW$03N36(M4XE>I[U2@ MZK3Y9?LI*Q5S=C+7B:U Z3*5Z;50PX8FJQ:K9.[M)CX@PH"4^P-675U%T(94 MLLE3XL!EQXY+7X.1:.5)_-(S"'>+'L^I=F*+QU3.TEZ,H)T)J64F\>N,A&0' MK/71"6FKQG3IJ-QA.Q-2ZTOB%YB_#+T>)"H8;W'8F3WJ$O>1[;0O0,0Y->*Q'T*]%' M2LLCJ2HG7FJ=(F9)FCOPPH8FGE8?&#@;/4,HS=!:)F#V>J47Z@H/_>>1'QQO M#VH/;IU5-^"]!(^RJW$]^C/9SB$9OJ:7T[KJ7]QQT)XC^ MA?7PZ? #P57W6CS2YOVO"U\0VY&&@PIOI6M\L9!/".M?V/U<" #W M!0 &0 'AL+W=O3',2J8Z>V ZVT'S^_0,8T8"]?$I]]S\O9NLNV M0CZI"E'#2\VXF@25ULTX#%5184U43S3(SY)G;NY=Y)EK-*,=[":JM:R)?9\C$=A+T@_W&@JXK;3?"/&O(&A]0/S;W MTD1AQU+2&KFB@H/$U228]L>SU.:[A*\4M^I@#;:2I1!/-OA43H+(&D*&A;8, MQ/PV>(V,62)CXWG'&722%GBXWK-_<+6;6I9$X;5@WVBIJTGP+H 25Z1E>B&V MM[BK9VCY"L&4^\+6YP[2 (I6:5'OP,9!3;G_DY?=/1P DOX)0+P#Q,ZW%W(N MYT23/)-B"])F&S:[<*4ZM#%'N7V4!RW-*34XG4^+YY8JZFY(K&!J(D9@1@4C M2P4?Z^4M7,Y1$\H4]*^R4!M-BPR+'?_,\\6]R")WD NC0MK$V^?MD,,K"S1'-8:,#+1K7VDNAS:!PR\I,9I0VP9ROA-#[P ITLS[_ M 5!+ P04 " N@;M4=8?KD T" !N! &0 'AL+W=O<23NE7TR-:.%-<&F646UM(R6L4U-RH M!J4[*946U+I05\0T&FD10(*3)(X_$4&9C+(T[&UUEJK6XU< M=[0/C=;[2(RLA1,H#1,2=!8+J/5Y&X]\_DAX2?# MSIRLP5>R5^K%!]^+911[0\@QMYZ!NM<*AG[OERQ4UX0M?GSN<1Y*VQ2@Q@YT P MV;_IV]"'$T R.0-(!D 2?/="P>6&6IJE6G6@?;9C\XM0:D [:1Z8 M_ T[9+>+13R)XY0<3BV0DQD0J*LPZ09RU4K;C\.X.UZF53]#?]+[F^A:6S%I M@&/IH/'-K5/7_73W@55-F*B]LFX^P[)V/P34/L&=ETK98^ %QE],]@Y02P,$ M% @ +H&[5+,%YGCG 0 Z0, !D !X;"]W;W)K&ULG5/=:]LP$/]7A-E#!R5R[&8KQ3$L#6.#=82&;@]C#XISCD7TX4GG MN/WO>Y)=$\;:A[W8=]+]/NXD%;UU1]\ ('O4ROAETB"V-YS[J@$M_,RV8&BG MMDX+I-0=N&\=B'T$:<6S-/W M9 F*8NXMG%E83M4TL#&,=]I+=S3"I3ME\D\ M>5FXEX<&PP(OBU8<8 OXT&X<97QBV4L-QDMKF(-ZF7R:WZSR4!\+?DCH_5G, M0B<[:X\A^;I?)FDP! HJ# R"?B>X!:4"$=GX,W(FDV0 GLJGW&.S3*X3MH=:= KO;?\%QGX6@:^RRL MQSF< ;+Y*X!L!&31]R 47:X%BK)PMF5Z/*:E#)7E&Y M$V[&\ODER])L_K!=LXMW?[%P\CV9SR;S6:2]^E_SO^Y [\#]?D,KG[3R-[76 ML$,F#;J.KB1>LEI4P(2VG<%_S6,@6T2R\#!.Y56>7Z=IP4_G)OC9R85'0(,Z M2..9@IJ Z>PC,;CA8@T)VC8>YLXB78T8-O06P84"VJ\M36),POV87G?Y#%!+ M P04 " N@;M41A"0RAL# #\"@ &0 'AL+W=O.V# *F!J MFZ;=IY]M*".*82R1$@SW^]_Y[HP]/Q+ZS%*$.'C+LX(MC)3S\MHT69BB'+() M*5$AGL2$YI"+(4U,5E($(P7EF>E8EF_F$!?&ER3BJ>X0+M*6!5GD/Z MOD(9.2X,V_BX\8"3E,L;YG)>P@0](OY4[JD8F:U*A'-4,$P*0%&\,&[LZYUM M24!9_,3HR#K70$[E0,BS'-Q'"\.2$:$,A5Q*0/'WBM8HRZ22B..E$35:GQ+L M7G^H;]7DQ60.D*$UR7[AB*<+8V: ",6PRO@#.>Y0,R%/ZH4D8^H7'&M;WS5 M6#%.\@86$>2XJ/_A6Y.(#F#W 4X#.&.!:0-,QP)N [AC :\!O+& WP#^6"!H M@& L,&N F:IN70Y5RPWD<#FGY BHM!9J\D(UA*)%"7$A>_>14_$4"XXO;U\J MS-_!Q09QB#,&OD-*H6RG2_ %/#UNP,6GR[G)A2=I;X:-ZJI6=7I4OT$Z 9;S M&3B6XVCP]3"^18<)<+Q>?#/"^]3NQ6_'X[8&WXX)WNWU?C>,?ZT*X=WJ];X; MCUNGN"E:H^T/I^T/1^E-_[L_!L2GK?A4B;L]XFN2Y^+]Q5)($8 53PG%OU&D M:YA:R%="\GW\NA1O9_69FZ_=UAAKN#TWM#V=X=U8P]T(PY,TN6V:W,$TW1>A MV)88 KCH9*E.FRY7[ED<@V%X;1C>8!@_XAA17"2@I#C4.5[5?-!U//'T3OW6 MJ3_H=$])B%#$0$Q)#L*F83@)GW4!U%I>)X"IMDE&VMV>V_7D,&BG$PR7DK$* M%:'H]D(4D&01@$E"40(YJNO) (E/IJDLCW+5%9SIYAR<5]L57U\?Z*P-=#88 MZ$T487FX@-EI-&5%PU3THFZ1KF;G:R]P R?0AW+5AG+USYQ!F;.0,*YS>W56 M)2=P9GWM;EM_MT9KG&-1DKHXVJW,.E_V@:=9;F9GEY;G0K'/)+A@($.Q(*U) M(&9 ZZ-6/>"D5!OW@7!Q#%"7J3B>(BH-Q/.8$/XQD&>!]L"[_ -02P,$% M @ +H&[5$6_.8W_ 0 @4 !D !X;"]W;W)K&ULG53;BMLP$/T58?JPA1+Y%F]9'$.34-I"(6RZ[;-B3V*QNKC2)-G^?279 M,:%)=J$OED::H]"JY@98C=2\G,GSD(?9Q%271:>.2[ M%OT"K")GX_? &8V2'G@^/[%_#K6[6C;,PD*+7[S! M=A9]C$@#6[87^*B/7V"H9^KY:BUL^))CGYO'$:GW%K4 M-+D!2 = &GSW0L'EDB&K2J./Q/ALQ^8GH=2 =N:X\C]EC<;M$Z2QFGR MM%Z2NW?_L%!G=?2;CG[30)O]C]]7^+.1/PO\^0U^YS:]5FR/F@:4O^B'*LF* M(HY+>KBBEH]J^5MJV36U'E69#N&"_DZ-F5]J_#=V9V7%DB8.N \>3>,9B^X_H =1=N^4:CZYDP M;=TC!<8GN/VMUG@*?..,SU[U%U!+ P04 " N@;M45_RMJ',# #_"P M&0 'AL+W=O'@[DP/C MKR(%D.A8Y%1,K53*\MZV19Q"0<0=*X&J+QO&"R)5EV]M47(@244JLT\)QM4ZD'[-FD)%MX ?F] M7''5LUN5)"N BHQ1Q&$SM3[@^X_8T80*\2.#@SAK(SV5-6.ONO,IF5J.=@0Y MQ%)+$/6WASGDN592/OYK1*TVIB:>MT_JRVKR:C)K(F#.\G^S1*93:V2A!#9D ME\MG=O@;F@D%6B]FN:A^T:'&^BIBO!.2%0U9]8N,UO_DV"3BC*!TS 2W(;B7 M!+^'X#4$[]H(?D/PKXT0-(3@DA#V$,*&$%X;(6H(4;58=7:KI5D02683S@Z( M:[12TXUJ?2NV6I&,ZJWX(KGZFBF>G'VB,2L ?2-'$.AF 9)DN7B';M'WEP6Z M^>O=Q)8JBL;:<:/X4"NZ/8H>^L*H3 5ZI DD!OYBF#_^'7\YS,?N@("MTM/F MR#WEZ,$=5/Q"^!WR\'OD.JYK,#2_GHY-^?BSZ(]_%GTY3/^\HXKN]-(_7D]W M!I;":[>K5^EY5VS7 3F_E?,K.;]';LZ*^_,,&8"N-_;/<+]X#UKOP:#W9Q! >)PB M0A-U^>[5JU*J-T*BF$.226'R7"N&YU;&WKCCV ;]1L.6\/AL&$B <4IH5MU MU6C37Y_^03'A_.>:Q*]&OV''R*75+N(6NV[8YS5JO4:#7M4^4ZE4CR12-W#\ MBEA9/9QZEU !)JM1QT@P#CJ9[:*P-^HS.VK-C@;-KE8KE#-"D:I,MMF>@C F M7O\G-\M M\^FL-T?=^-XYW1/LX,R5-'!VAK_MG_4$L#!!0 ( "Z!NU1>V0AJ' , .$) 9 >&PO M=V]R:W-H965T,]%\]R Z#0H6"E MG#@;I:HKUY79!@HB+WD%I?ZRXJ(@2D_%VI65 )+73@5SL>>-W(+0TIF.ZW=W M8CKF6\5H"7<"R6U1$/%R XSO)X[OO+ZXI^N-,B_JSNA)ZYC4I. M"R@EY242L)HXU_[5S,?&H;9XHK"7K3$RH2PY?S:3VWSB>(8(&&3*2!#]V,$, M&#-*FN/W2=1IUC2.[?&K^I!W,DDB8+DK D*6AZ?Y'!*1,O![W/ )P?\48?@Y!#4@1[) MZK#F1)'I6/ ]$L9:JYE!G9O:6T=#2_,W+I307ZGV4]/;,N,%H =R (G.YJ ( M91+YY^@"/2[FZ.S3^=A5>AUC[68GS9NC)N[1_+8M+U'@?4;8PWZ'^^SC[MY[ M=U='UX2(FQ!QK1?TZ,UA!4) CA0Y("(E*'DU(!LTLD$M&_;(7A=<*/J'U-7( M5XB6BI1KNF0@NU)V%(MJ,;.W=M,@#CU/![AKIZ;##*=QR^P=:]BPAH.L]R"! MB&R#2)GK(M_IW5OIO:A0IO-"52?P47'4(O%'X<@"MLV2-.SCC1K>:)#WB0C* MMU)O\DQL">ODBZR%N_!L*S_R>O,Y:OA&@WP+Q;-GQ"OSWTL$!]U4)71!CJSE M@R3 %J5MU@,8-X#Q(. /?0#H5B]T=99KQ+CL3&'A%N:WNK\_&/0<].&?T::)5<)4C7JI&P7YI\.M.<_WE'4F MZ;1.._J+(+8KOD[6;'59'&8I':==1A&06S#NJWS MUUQ^OA.QIKHQ,%AI1^\RU@KB>)\X3A2OZB-YR94^X.OA1M_!0!@#_7W%N7J= MF%.^N=5-_P)02P,$% @ +H&[5#G] WV5 P G T !D !X;"]W;W)K M&ULI9=MCYLX$,>_BH7N14]JP3;/51)IL]WV>M)> M5UVU?>V DZ %G+--LO?MSS8L(3QITWT3C#/SYS?#,+87)\:?Q)Y2"9Z+O!1+ M:R_EX:/CB&1/"R)L=J"E^F?+>$&DNN4[1QPX):EQ*G('0Q@X!)[MMM+/>&L%@>RHX]4_C@\<'7GM"II M5M!29*P$G&Z7U@WZ>(L"[6 L?F;T)#ICH$/9,/:D;[ZF2PMJ(IK31&H)HBY' M>DOS7"LICG\;4:M]IG;LCE_4/YO@53 ;(N@MRW]EJ=POK<@"*=V2*I??V>DO MV@3D:[V$Y<+\@E-MZX<62"HA6=$X*X(B*^LK>6X2T7%0@8X[X,8!]QV\"0>W M<7!-H#69">L3D62UX.P$N+96:GI@I)VMY)&M5UK8HG5!$&]ZR4>P'NRI2F MEP*.0FPY\0OG&L\J_EV5-G#A>X A1B- MZ]WAS,X;ILVU^BYKTG;C)[7ZGE& MSYO0^Z<_H# @1C#X6H1SJTPWX4H7'2H"4- MKB2]>Z8\R<0X:S!@^( @A#W2$2OL=(AZH@5 M]J=(HY8T>DO5WIGK&',T+ 44P= />]1#N\O2OJ".6^KX]TJ!;'(Z1AL/"S(. M(MROVZ&9%V-W A;!>)?2*1M$\*.P2VJ[? M"V/$RK6Q-Q%&9YU!;PICIG$TRE&W#&S8KY41J]#VP@EN?.;&;^*>;2.-=G21 M2SC(^)B5.]&:T7F)0NZ;R&>[2J-]R83Z)3]J!:,)\O-BB.97PZM*?KK+-$_I MTD5VZ/9C&%IYT]D_KXQH?FE\9=U,]9Q&_;*:@[C//K12WVH\P7Y>*]'\8MFR MDX9]2S(.CB2O*#BHUFFVA;J!LJ:![F8^WF#03D(;#SZ!H95O^_U"ISRSWAJH,*D-.MDH1VJ#+, MZZ- ?2/9P>RF-TRJO;D9[M7QB7)MH/[?,B9?;O0#V@/9ZG]02P,$% @ M+H&[5*[U/>3O P 1Q !D !X;"]W;W)K&UL MO5C;;N,V$/T50NA#"VPEDA)U"6P#L;U%6W2[08+N/M,6;0N11)>DX^3O2TJR M;$N4-D%VZP=;EYG#Y8XQ!9Z+O)139Z?4_L;SY'K'"BI=OF>E MOK/AHJ!*GXJM)_>"T;1R*G(/0QAZ!2@**E[F M+.?'J8.6Z0-(]_&U"G7=,X M7AZ?T'^KQ&LQ*RK9@N=?LU3MID[L@)1MZ"%7]_SX.VL$$8.WYKFLOL&QMB7$ M >N#5+QHG#6#(BOK7_K_XH&5'CMW'W*[Q@ ._O0[%B M O!-&_O/!R45+=.LW'X <[;-RE(?VB)?(X<5LLGKIQE",8Q(-/&>+@/2MTM" M$H?75DN+580A::VNY 6MO&!4WM7,)H?THHV3,#8/])6@ MOEF08#^TDPU;LN&[-N4;U,->_"(W3#K$^T8ZR(F==]3RCD9Y=VC>TU)S)WJ# M=8U"R/7A2#[&[1KQ#\O'V)*/NN\2W(E-WPZ3.$;VX"0M\>1_RK2DMW6)"W%R M^>D(ZGM$;A#9]2!X[DCP^^94@W<56#_V23>I+'9P@.Q%^T0_,J<:]$YY"[O$ M:ROR"N+X3!R_C?@],Z^)^MD "]VXA7XA.] <_)5M[,3'T1/PPJB0( !%_180 M@I2^V-XC%J]$0O $A7P+UG44SET8C;=A:VG!;H)T:0GV M--"7SVP((TBZ3TC?++HRNZ9^;F]HO+]]O^K2+'3=&?S>DVZU\@=DG!L?&N]\ M;R\I82^>) XBV*7;-QOIT^C<\-!XQWMO58EL4>RV(ZO54*]&YT:*QCOI>PO+ M.#IIRH'?5@,X7%G&H<(&BK109+"P>!<35L'$MII4)5CS0ZGJ$::]VD[#M]4, MV+D^1S>+>J8]P]0C]BG$[- ^]_![#]02P,$% @ +H&[5/+O>ZL& P +1 T M !X;"]S='EL97,N>&ULW5AM;YLP$/XKB$Y3*TTEA)6%-43:D"I-6J=*[8=] MJYQ@B"5C,^-TI+]^/DS(2WU5UP];-J($^Q[NGN?.!T:9-GK-Z>V24NVU%1=- MZB^UKC\&0;-8THHTY[*FPB"%5!719JK*H*D5)7D#3A4/QJ-1'%2$"7\V%:OJ MJM*-MY KH5-_/)@\>_J2IWX8O_<]&RZ3.4W]^].W/U927[[Q[/GDWO&"H./D[%A%0=MV6PO_/^\@-@,P.! MC/.]6H-A-JV)UE2)*S/I+NZ,3R"O']^M:Z.P5&0=CB_\K4-W,B1SJ7*J!IK0 MWYAF4TX+D*-8N82SEG4 H-:R,H./0#$W9!.;^%WOM>[,5NBYU5 M'<&:BF%H!/5#&\9.(/YN-!M[)VSRJK!>S1ZD_KPRV8AN#KU";Q0M6-O-VV+@ MQZ*'>'12UWS]B;-25-3F_F+"V91L_+RE5.S1L$&G+(R!*M][H$JSQ:[EIR+U M'6WUIIO: M<\_@& _O!8:+ MB9RV-,_ZJ2KGW= S \/:'^!PB%QUAQO!?"SF1@##># %F(_UPGC^IWPF:#X6 MP[1-G,@$]9F@/M;+A63=!^-Q^R3F<&>:)%$4QUA%L\RI(,/J%L?P=4?#M($' MQ@-,OU=K?+7Q#GF^#[ U?:Y#L$SQ3L0RQ6L-B+MNX)$D[M7&>, #6P6L=X#? MS0,]Y?:)(EA53!MV!^-(DF (]**[1^,8J4X,'_?Z8'=)%"6)&P',K2"*, 3N M1AS!%( &#(FB;A\\V(^"S3X5;/\@F/T"4$L#!!0 ( "Z!NU27BKL
-8?20$3;8T.P6BP^0"X99K>]9!:G-7OF^+ 2FK^4$6R=W-]N=9:]_T-95EAN9)N9[7CD;-7\^MXM4E>N.%/7'![ M'O7J[X+U2,DE+_D/MAWU!CUB#NKU3Z7Y#R4M%9M"*R%&O:@Y\,BTY<5ONS<5 MY -],O4>2Y^^40*7_3QC5;L<+-E7%J632-G'43%2 TASXT?2(I"4; M]2;JA>GJ?MP?S+?-O5D'Y45*7W%W0,^W-1XBRFHYG2TWLREQWS:KQ7PZ?G ; MM^/%>#F9$0\R!B#C#B'_CCW(!(!,.H'3!? M )@OR!%C^^H,,I?-S]UQ#^PK /85%^R.
J3BQJC7ON*2RX%0X4&/UJ?0[ MZ@'44P]P,>?2-:9UOF3&1P+E@6P/EPDF'9-:JG<5QQD[&-"WHB0Q;'@DIGJR9MHMN5!]"!31,BJ6--S ME7F17]E>]76O:4D6BOJO;@2Y(D*6Q4(90]:N:2>J+!WCYD"UW^%%D",B9$G, MRJ-09\;(+9-LQRU9"RJ#MQ>20X1LAP6C)NQ+(#M$R'J8/%;762J?N32N##:]?5M>AC-V6 MH.26*^$J)G+O8T+:B+&U0<_N*L7S.WV+CPE6'!OZJ844DR*K!@0,XPFI)@463$_#%D\(&883<@]&;)[ M8$R_M\S B?V!,?]%*!KDG^Y#YE?;P0;+)D&7SAJL]5*P7H:R#@YLG%@3#]5RR'C MY,C&@3']5"V'C)/C3]^_/\<6/IN0<7)DXS131__1%^7@.B]DV8 #IF$@(=GD MR+()A_Q:E)-#RLF1E=-*1Z* #Q).CBR<-V.2+>$;0J(98@^CM>*%\1M"BADV MJYSKD\W-]9;MN&3;I;NXA)Q1JA 7'XQ^(2 QY=\:,=]=RJ[?5\6G\?#J:RJW3CV MO^JZK'?YV):[KL^G\Y%--QS;\;PSER\?O7Y M?R9VF\U^G7]WZS_'?!K_,;C^Z(;WLLMYK!:O[;#-XZJJ/P_7W:6^;-+=>7*U M>'Y;5I@_*"U1QB5!T@1K JT3@WD*@MZ#>0J"W MH-Y"H+>@WD*@MZ#>0J"WH-Y"H+>BWDJ@MZ+>2J"WHMY*H+=.7I80Z*VHMQ+H MK:BW$NBMJ+<2Z*VHMQ+HK:BW$NBMJ+<2Z&VHMQ'H;:BW$>AMJ+<1Z&VHMQ'H M;9.7W01Z&^IM!'H;ZFT$>AOJ;01Z&^IM!'H;ZFT$>COJ[01Z.^KM!'H[ZNT$ M>COJ[01Z.^KM!'K[Y&,E@=Z.>CN!WHYZ.X'>CGH[@=Z.>CN!WH%Z!X'>@7H' M@=Z!>@>!WH%Z!X'>@7H'@=Z!>@>!WC'YV81 [T"]@T#O0+V#0.] O8- [P;U M;@CT;E#OYB?U+N/7(9=KS_<:K_^35(_G<_/U\I?E]\[)3;C@7-]6E*>_4$L# M!!0 ( "Z!NU3ART;(_0$ #TI 3 6T-O;G1E;G1?5'EP97-=+GAM M;,W:34[#,! %X*M4V:+&]6\!43; %EAP 9-,VZA);-D&RNUQ4D "004J$F_3 MJ+4];^*1OE7/[IX]Q>KSRM*%SJ;\-:R8M]7& MKHB)V6NZ)'^Y-3OF':??*# M\\1#*>G/A>BD)K]K_B>F$L?_'XT3+NF^H?9^7J? M7-B,\XAL?!Q^QQ]G_%[_EWT(D#XD2!\*I \-TH?_*>N];_BV?C?^:/'\!4$L! A0#% @ +H&[5 =!36*! L0 ! M ( ! &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4 " N M@;M4BY?.:NX K @ $0 @ &O 9&]C4')O<',O8V]R M92YX;6Q02P$"% ,4 " N@;M4F5R<(Q & "<)P $P M@ ', 0 >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0 ( "Z!NU0=2G$L MH@, "0- 8 " @0T( !X;"]W;W)K&PO=V]R:W-H965T&UL4$L! A0#% @ +H&[ M5 1=.H\) P E0D !@ ("!,10 'AL+W=O&PO=V]R:W-H M965T&UL4$L! A0#% @ +H&[5 ]X;2(+"P _C0 !@ M ("!4BL 'AL+W=O&PO=V]R:W-H965T&UL M4$L! A0#% @ +H&[5 J+\U1E!P ]1D !@ ("!YU\ M 'AL+W=O&UL4$L! A0#% @ +H&[5&_EHT)^ @ ; 8 !D M ("!&W$ 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ +H&[5');I[S+ @ !@8 !D ("!^7P 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ +H&[5!)4 M ^O, @ 5@8 !D ("!P(@ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ +H&[5"XEN4>7"@ /"0 !D M ("!OIX 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ +H&[5 HY!PDC!@ "0X !D ("! M_[0 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ +H&[5-@]"2:Q) /WH !D ("!T,H 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ +H&[5,12+;*] @ P@4 !D M ("!O0,! 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ +H&[5.:OFW0N P 9PD !D ("!P T! M 'AL+W=O4" D!P &0 @($E$0$ >&PO=V]R:W-H965T&UL4$L! A0#% @ M+H&[5-%&P#ZY P O D !D ("!"1@! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ +H&[5$P/.0K/ P MZ X !D ("!!R4! 'AL+W=O&PO=V]R:W-H965T M+"S&XP, !D0 9 " @7&UL4$L! A0#% @ +H&[5 CB@3(W @ R@0 !D M ("!D3 ! 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ +H&[5+G\Z_ W! Q10 !D ("!+CX! 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ +H&[ M5## PR)M @ (@< !D ("!'$D! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ +H&[5$\Z'2Z#!P R3 M !D ("!A5(! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ +H&[5%GR0CI\ P &PO=V]R:W-H965T M&UL4$L! A0# M% @ +H&[5&4G%B_? @ 0PD !D ("!8FH! 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ +H&[5/EL M 116!0 0AD !D ("!DW8! 'AL+W=OU<" #W!0 &0 M @($@? $ >&PO=V]R:W-H965T&UL4$L! A0#% @ +H&[5+,%YGCG 0 Z0, !D M ("!\H ! 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ +H&[5%?\K:AS P _PL !D ("! MF(@! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ +H&[5*[U/>3O P 1Q !D ("!89,! 'AL+W=O&PO&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$" M% ,4 " N@;M4X XML 83 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 84 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 85 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 275 336 1 false 45 0 false 4 false false R1.htm 000001 - Document - Cover Sheet http://scnd.com/role/Cover Cover Cover 1 false false R2.htm 000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://scnd.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://scnd.com/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Sheet http://scnd.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Statements 4 false false R5.htm 000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS EQUITY Sheet http://scnd.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS EQUITY Statements 5 false false R6.htm 000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 6 false false R7.htm 000007 - Disclosure - Summary of Significant Accounting Policies Sheet http://scnd.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 7 false false R8.htm 000008 - Disclosure - Revenue Sheet http://scnd.com/role/Revenue Revenue Notes 8 false false R9.htm 000009 - Disclosure - Segment Information Sheet http://scnd.com/role/SegmentInformation Segment Information Notes 9 false false R10.htm 000010 - Disclosure - Fair Value of Financial Instruments Sheet http://scnd.com/role/FairValueOfFinancialInstruments Fair Value of Financial Instruments Notes 10 false false R11.htm 000011 - Disclosure - Inventories Sheet http://scnd.com/role/Inventories Inventories Notes 11 false false R12.htm 000012 - Disclosure - Property and Equipment Sheet http://scnd.com/role/PropertyAndEquipment Property and Equipment Notes 12 false false R13.htm 000013 - Disclosure - Goodwill and Other Intangible Assets Sheet http://scnd.com/role/GoodwillAndOtherIntangibleAssets Goodwill and Other Intangible Assets Notes 13 false false R14.htm 000014 - Disclosure - Lines of Credit Sheet http://scnd.com/role/LinesOfCredit Lines of Credit Notes 14 false false R15.htm 000015 - Disclosure - Payroll Protection Program Loan Sheet http://scnd.com/role/PayrollProtectionProgramLoan Payroll Protection Program Loan Notes 15 false false R16.htm 000016 - Disclosure - Loss Per Common Share Sheet http://scnd.com/role/LossPerCommonShare Loss Per Common Share Notes 16 false false R17.htm 000017 - Disclosure - Employee Benefit Plans Sheet http://scnd.com/role/EmployeeBenefitPlans Employee Benefit Plans Notes 17 false false R18.htm 000018 - Disclosure - Leases Sheet http://scnd.com/role/Leases Leases Notes 18 false false R19.htm 000019 - Disclosure - Discontinued Operations Sheet http://scnd.com/role/DiscontinuedOperations Discontinued Operations Notes 19 false false R20.htm 000020 - Disclosure - Commitments and Contingencies Sheet http://scnd.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 20 false false R21.htm 000021 - Disclosure - Acquisition of Aquila Biolabs GmbH Sheet http://scnd.com/role/AcquisitionOfAquilaBiolabsGmbh Acquisition of Aquila Biolabs GmbH Notes 21 false false R22.htm 000022 - Disclosure - Paycheck Protection Program Loan Sheet http://scnd.com/role/PaycheckProtectionProgramLoan Paycheck Protection Program Loan Notes 22 false false R23.htm 000023 - Disclosure - Income Taxes Sheet http://scnd.com/role/IncomeTaxes Income Taxes Notes 23 false false R24.htm 000024 - Disclosure - Stock Options Sheet http://scnd.com/role/StockOptions Stock Options Notes 24 false false R25.htm 000025 - Disclosure - Equity Sheet http://scnd.com/role/Equity Equity Notes 25 false false R26.htm 000026 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://scnd.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://scnd.com/role/SummaryOfSignificantAccountingPolicies 26 false false R27.htm 000027 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://scnd.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://scnd.com/role/SummaryOfSignificantAccountingPolicies 27 false false R28.htm 000028 - Disclosure - Revenue (Tables) Sheet http://scnd.com/role/RevenueTables Revenue (Tables) Tables http://scnd.com/role/Revenue 28 false false R29.htm 000029 - Disclosure - Segment Information and Concentrations (Tables) Sheet http://scnd.com/role/SegmentInformationAndConcentrationsTables Segment Information and Concentrations (Tables) Tables 29 false false R30.htm 000030 - Disclosure - Fair Value of Financial Instruments (Tables) Sheet http://scnd.com/role/FairValueOfFinancialInstrumentsTables Fair Value of Financial Instruments (Tables) Tables http://scnd.com/role/FairValueOfFinancialInstruments 30 false false R31.htm 000031 - Disclosure - Inventories (Tables) Sheet http://scnd.com/role/InventoriesTables Inventories (Tables) Tables http://scnd.com/role/Inventories 31 false false R32.htm 000032 - Disclosure - Property and Equipment (Tables) Sheet http://scnd.com/role/PropertyAndEquipmentTables Property and Equipment (Tables) Tables http://scnd.com/role/PropertyAndEquipment 32 false false R33.htm 000033 - Disclosure - Goodwill and Other Intangible Assets (Tables) Sheet http://scnd.com/role/GoodwillAndOtherIntangibleAssetsTables Goodwill and Other Intangible Assets (Tables) Tables http://scnd.com/role/GoodwillAndOtherIntangibleAssets 33 false false R34.htm 000034 - Disclosure - Commitments and Contingencies (Tables) Sheet http://scnd.com/role/CommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://scnd.com/role/CommitmentsAndContingencies 34 false false R35.htm 000035 - Disclosure - Earnings (Loss) Per Common Share (Tables) Sheet http://scnd.com/role/EarningsLossPerCommonShareTables Earnings (Loss) Per Common Share (Tables) Tables 35 false false R36.htm 000036 - Disclosure - Leases (Tables) Sheet http://scnd.com/role/LeasesTables Leases (Tables) Tables http://scnd.com/role/Leases 36 false false R37.htm 000037 - Disclosure - Income Taxes (Tables) Sheet http://scnd.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://scnd.com/role/IncomeTaxes 37 false false R38.htm 000038 - Disclosure - Stock Options (Tables) Sheet http://scnd.com/role/StockOptionsTables Stock Options (Tables) Tables http://scnd.com/role/StockOptions 38 false false R39.htm 000039 - Disclosure - Discontinued Operations (Tables) Sheet http://scnd.com/role/DiscontinuedOperationsTables Discontinued Operations (Tables) Tables http://scnd.com/role/DiscontinuedOperations 39 false false R40.htm 000040 - Disclosure - Acquisition of Aquila Biolabs GmbH (Tables) Sheet http://scnd.com/role/AcquisitionOfAquilaBiolabsGmbhTables Acquisition of Aquila Biolabs GmbH (Tables) Tables http://scnd.com/role/AcquisitionOfAquilaBiolabsGmbh 40 false false R41.htm 000041 - Disclosure - Significant Accounting Policies (Details) Sheet http://scnd.com/role/SignificantAccountingPoliciesDetails Significant Accounting Policies (Details) Details 41 false false R42.htm 000042 - Disclosure - Significant Accounting Policies (Details Narrative) Sheet http://scnd.com/role/SignificantAccountingPoliciesDetailsNarrative Significant Accounting Policies (Details Narrative) Details 42 false false R43.htm 000043 - Disclosure - Revenues (Details) Sheet http://scnd.com/role/RevenuesDetails Revenues (Details) Details http://scnd.com/role/RevenueTables 43 false false R44.htm 000044 - Disclosure - Revenues (Details Narrative) Sheet http://scnd.com/role/RevenuesDetailsNarrative Revenues (Details Narrative) Details http://scnd.com/role/RevenueTables 44 false false R45.htm 000045 - Disclosure - Segment Information and Concentrations (Details) Sheet http://scnd.com/role/SegmentInformationAndConcentrationsDetails Segment Information and Concentrations (Details) Details http://scnd.com/role/SegmentInformationAndConcentrationsTables 45 false false R46.htm 000046 - Disclosure - Segment Information and Concentrations (Details Narrative) Sheet http://scnd.com/role/SegmentInformationAndConcentrationsDetailsNarrative Segment Information and Concentrations (Details Narrative) Details http://scnd.com/role/SegmentInformationAndConcentrationsTables 46 false false R47.htm 000047 - Disclosure - Fair Value of Financial Instruments (Details) Sheet http://scnd.com/role/FairValueOfFinancialInstrumentsDetails Fair Value of Financial Instruments (Details) Details http://scnd.com/role/FairValueOfFinancialInstrumentsTables 47 false false R48.htm 000048 - Disclosure - Fair Value of Financial Instruments (Details 1) Sheet http://scnd.com/role/FairValueOfFinancialInstrumentsDetails1 Fair Value of Financial Instruments (Details 1) Details http://scnd.com/role/FairValueOfFinancialInstrumentsTables 48 false false R49.htm 000049 - Disclosure - Fair Value of Financial Instruments (Details 2) Sheet http://scnd.com/role/FairValueOfFinancialInstrumentsDetails2 Fair Value of Financial Instruments (Details 2) Details http://scnd.com/role/FairValueOfFinancialInstrumentsTables 49 false false R50.htm 000050 - Disclosure - Inventories (Details) Sheet http://scnd.com/role/InventoriesDetails Inventories (Details) Details http://scnd.com/role/InventoriesTables 50 false false R51.htm 000051 - Disclosure - Property and Equipment (Details) Sheet http://scnd.com/role/PropertyAndEquipmentDetails Property and Equipment (Details) Details http://scnd.com/role/PropertyAndEquipmentTables 51 false false R52.htm 000052 - Disclosure - Property and Equipment (Details Narrative) Sheet http://scnd.com/role/PropertyAndEquipmentDetailsNarrative Property and Equipment (Details Narrative) Details http://scnd.com/role/PropertyAndEquipmentTables 52 false false R53.htm 000053 - Disclosure - Goodwill and Finite Lived Intangible Assets (Details) Sheet http://scnd.com/role/GoodwillAndFiniteLivedIntangibleAssetsDetails Goodwill and Finite Lived Intangible Assets (Details) Details 53 false false R54.htm 000054 - Disclosure - Goodwill and Finite Lived Intangible Assets (Details 1) Sheet http://scnd.com/role/GoodwillAndFiniteLivedIntangibleAssetsDetails1 Goodwill and Finite Lived Intangible Assets (Details 1) Details 54 false false R55.htm 000055 - Disclosure - Goodwill and Finite Lived Intangible Assets (Details Narrative) Sheet http://scnd.com/role/GoodwillAndFiniteLivedIntangibleAssetsDetailsNarrative Goodwill and Finite Lived Intangible Assets (Details Narrative) Details 55 false false R56.htm 000056 - Disclosure - Loss Per Common Share (Details) Sheet http://scnd.com/role/LossPerCommonShareDetails Loss Per Common Share (Details) Details http://scnd.com/role/LossPerCommonShare 56 false false R57.htm 000057 - Disclosure - Loss Per Common Share (Details Narrative) Sheet http://scnd.com/role/LossPerCommonShareDetailsNarrative Loss Per Common Share (Details Narrative) Details http://scnd.com/role/LossPerCommonShare 57 false false R58.htm 000058 - Disclosure - Leases (Details) Sheet http://scnd.com/role/LeasesDetails Leases (Details) Details http://scnd.com/role/LeasesTables 58 false false R59.htm 000059 - Disclosure - Leases (Details Narrative) Sheet http://scnd.com/role/LeasesDetailsNarrative Leases (Details Narrative) Details http://scnd.com/role/LeasesTables 59 false false R60.htm 000060 - Disclosure - Discontinued Operations (Details) Sheet http://scnd.com/role/DiscontinuedOperationsDetails Discontinued Operations (Details) Details http://scnd.com/role/DiscontinuedOperationsTables 60 false false R61.htm 000061 - Disclosure - Discontinued Operations (Details Narrative) Sheet http://scnd.com/role/DiscontinuedOperationsDetailsNarrative Discontinued Operations (Details Narrative) Details http://scnd.com/role/DiscontinuedOperationsTables 61 false false R62.htm 000062 - Disclosure - Acquisition of Aquila Biolabs GmbH (Details) Sheet http://scnd.com/role/AcquisitionOfAquilaBiolabsGmbhDetails Acquisition of Aquila Biolabs GmbH (Details) Details http://scnd.com/role/AcquisitionOfAquilaBiolabsGmbhTables 62 false false R63.htm 000063 - Disclosure - Acquisition of Aquila Biolabs GmbH (Details 1) Sheet http://scnd.com/role/AcquisitionOfAquilaBiolabsGmbhDetails1 Acquisition of Aquila Biolabs GmbH (Details 1) Details http://scnd.com/role/AcquisitionOfAquilaBiolabsGmbhTables 63 false false R64.htm 000064 - Disclosure - Acquisition of Aquila Biolabs GmbH (Details Narrative) Sheet http://scnd.com/role/AcquisitionOfAquilaBiolabsGmbhDetailsNarrative Acquisition of Aquila Biolabs GmbH (Details Narrative) Details http://scnd.com/role/AcquisitionOfAquilaBiolabsGmbhTables 64 false false R65.htm 000065 - Disclosure - Paycheck Protection Program Loan (Details Narrative) Sheet http://scnd.com/role/PaycheckProtectionProgramLoanDetailsNarrative Paycheck Protection Program Loan (Details Narrative) Details http://scnd.com/role/PaycheckProtectionProgramLoan 65 false false R66.htm 000066 - Disclosure - Equity (Details Narrative) Sheet http://scnd.com/role/EquityDetailsNarrative Equity (Details Narrative) Details http://scnd.com/role/Equity 66 false false R67.htm 000067 - Disclosure - Commitments and Contingencies (Details) Sheet http://scnd.com/role/CommitmentsAndContingenciesDetails Commitments and Contingencies (Details) Details http://scnd.com/role/CommitmentsAndContingenciesTables 67 false false R68.htm 000068 - Disclosure - Income Taxes (Details) Sheet http://scnd.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://scnd.com/role/IncomeTaxesTables 68 false false R69.htm 000069 - Disclosure - Income Taxes (Details 1) Sheet http://scnd.com/role/IncomeTaxesDetails1 Income Taxes (Details 1) Details http://scnd.com/role/IncomeTaxesTables 69 false false R70.htm 000070 - Disclosure - Stock Options (Details) Sheet http://scnd.com/role/StockOptionsDetails Stock Options (Details) Details http://scnd.com/role/StockOptionsTables 70 false false R71.htm 000071 - Disclosure - Stock Options (Details 1) Sheet http://scnd.com/role/StockOptionsDetails1 Stock Options (Details 1) Details http://scnd.com/role/StockOptionsTables 71 false false All Reports Book All Reports scnd_s1.htm scnd-20220331.xsd scnd-20220331_cal.xml scnd-20220331_def.xml scnd-20220331_lab.xml scnd-20220331_pre.xml scnd_ex107.htm scnd_ex231.htm scnd_s1img1.jpg http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021q4 true true JSON 88 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "scnd_s1.htm": { "axisCustom": 0, "axisStandard": 11, "contextCount": 275, "dts": { "calculationLink": { "local": [ "scnd-20220331_cal.xml" ] }, "definitionLink": { "local": [ "scnd-20220331_def.xml" ] }, "inline": { "local": [ "scnd_s1.htm" ] }, "labelLink": { "local": [ "scnd-20220331_lab.xml" ] }, "presentationLink": { "local": [ "scnd-20220331_pre.xml" ] }, "schema": { "local": [ "scnd-20220331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 455, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 47, "http://scnd.com/20220331": 17, "http://xbrl.sec.gov/dei/2021q4": 3, "total": 67 }, "keyCustom": 48, "keyStandard": 288, "memberCustom": 29, "memberStandard": 16, "nsprefix": "scnd", "nsuri": "http://scnd.com/20220331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2021-07-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000001 - Document - Cover", "role": "http://scnd.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2021-07-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2021-07-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000010 - Disclosure - Fair Value of Financial Instruments", "role": "http://scnd.com/role/FairValueOfFinancialInstruments", "shortName": "Fair Value of Financial Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2021-07-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2021-07-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000011 - Disclosure - Inventories", "role": "http://scnd.com/role/Inventories", "shortName": "Inventories", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2021-07-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2020-07-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000012 - Disclosure - Property and Equipment", "role": "http://scnd.com/role/PropertyAndEquipment", "shortName": "Property and Equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2020-07-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2021-07-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000013 - Disclosure - Goodwill and Other Intangible Assets", "role": "http://scnd.com/role/GoodwillAndOtherIntangibleAssets", "shortName": "Goodwill and Other Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2021-07-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2020-07-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000014 - Disclosure - Lines of Credit", "role": "http://scnd.com/role/LinesOfCredit", "shortName": "Lines of Credit", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2020-07-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2020-07-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShortTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000015 - Disclosure - Payroll Protection Program Loan", "role": "http://scnd.com/role/PayrollProtectionProgramLoan", "shortName": "Payroll Protection Program Loan", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2020-07-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShortTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2021-07-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000016 - Disclosure - Loss Per Common Share", "role": "http://scnd.com/role/LossPerCommonShare", "shortName": "Loss Per Common Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2021-07-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2020-07-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000017 - Disclosure - Employee Benefit Plans", "role": "http://scnd.com/role/EmployeeBenefitPlans", "shortName": "Employee Benefit Plans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2020-07-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2021-07-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000018 - Disclosure - Leases", "role": "http://scnd.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2021-07-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2021-07-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000019 - Disclosure - Discontinued Operations", "role": "http://scnd.com/role/DiscontinuedOperations", "shortName": "Discontinued Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2021-07-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "role": "http://scnd.com/role/CondensedConsolidatedBalanceSheets", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "lang": null, "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2020-07-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000020 - Disclosure - Commitments and Contingencies", "role": "http://scnd.com/role/CommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2020-07-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2021-07-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000021 - Disclosure - Acquisition of Aquila Biolabs GmbH", "role": "http://scnd.com/role/AcquisitionOfAquilaBiolabsGmbh", "shortName": "Acquisition of Aquila Biolabs GmbH", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2021-07-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2021-07-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "scnd:PaycheckProtectionProgramLoantextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000022 - Disclosure - Paycheck Protection Program Loan", "role": "http://scnd.com/role/PaycheckProtectionProgramLoan", "shortName": "Paycheck Protection Program Loan", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2021-07-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "scnd:PaycheckProtectionProgramLoantextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2020-07-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000023 - Disclosure - Income Taxes", "role": "http://scnd.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2020-07-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2020-07-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000024 - Disclosure - Stock Options", "role": "http://scnd.com/role/StockOptions", "shortName": "Stock Options", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2020-07-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2021-07-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000025 - Disclosure - Equity", "role": "http://scnd.com/role/Equity", "shortName": "Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2021-07-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2021-07-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000026 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://scnd.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2021-07-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "scnd:Revenue", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2021-07-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000027 - Disclosure - Summary of Significant Accounting Policies (Tables)", "role": "http://scnd.com/role/SummaryOfSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R28": { "firstAnchor": { "ancestors": [ "scnd:Revenue", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2021-07-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000028 - Disclosure - Revenue (Tables)", "role": "http://scnd.com/role/RevenueTables", "shortName": "Revenue (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2021-07-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000029 - Disclosure - Segment Information and Concentrations (Tables)", "role": "http://scnd.com/role/SegmentInformationAndConcentrationsTables", "shortName": "Segment Information and Concentrations (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2021-07-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "role": "http://scnd.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2021-07-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000030 - Disclosure - Fair Value of Financial Instruments (Tables)", "role": "http://scnd.com/role/FairValueOfFinancialInstrumentsTables", "shortName": "Fair Value of Financial Instruments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2021-07-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2021-07-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000031 - Disclosure - Inventories (Tables)", "role": "http://scnd.com/role/InventoriesTables", "shortName": "Inventories (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2021-07-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2020-07-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000032 - Disclosure - Property and Equipment (Tables)", "role": "http://scnd.com/role/PropertyAndEquipmentTables", "shortName": "Property and Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2020-07-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "us-gaap:GoodwillDisclosureTextBlock", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2021-07-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000033 - Disclosure - Goodwill and Other Intangible Assets (Tables)", "role": "http://scnd.com/role/GoodwillAndOtherIntangibleAssetsTables", "shortName": "Goodwill and Other Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:GoodwillDisclosureTextBlock", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2021-07-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2020-07-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "scnd:FairValueOfContingentConsiderationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000034 - Disclosure - Commitments and Contingencies (Tables)", "role": "http://scnd.com/role/CommitmentsAndContingenciesTables", "shortName": "Commitments and Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2020-07-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "scnd:FairValueOfContingentConsiderationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2021-07-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000035 - Disclosure - Earnings (Loss) Per Common Share (Tables)", "role": "http://scnd.com/role/EarningsLossPerCommonShareTables", "shortName": "Earnings (Loss) Per Common Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2021-07-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2021-07-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000036 - Disclosure - Leases (Tables)", "role": "http://scnd.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2021-07-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2020-07-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000037 - Disclosure - Income Taxes (Tables)", "role": "http://scnd.com/role/IncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2020-07-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2020-07-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000038 - Disclosure - Stock Options (Tables)", "role": "http://scnd.com/role/StockOptionsTables", "shortName": "Stock Options (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2020-07-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2021-07-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000039 - Disclosure - Discontinued Operations (Tables)", "role": "http://scnd.com/role/DiscontinuedOperationsTables", "shortName": "Discontinued Operations (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2021-07-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS", "role": "http://scnd.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "lang": null, "name": "us-gaap:CostOfRevenue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2021-07-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000040 - Disclosure - Acquisition of Aquila Biolabs GmbH (Tables)", "role": "http://scnd.com/role/AcquisitionOfAquilaBiolabsGmbhTables", "shortName": "Acquisition of Aquila Biolabs GmbH (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2021-07-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000041 - Disclosure - Significant Accounting Policies (Details)", "role": "http://scnd.com/role/SignificantAccountingPoliciesDetails", "shortName": "Significant Accounting Policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueRecognitionPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2020-07-01to2021-06-30_scnd_ConsolidatedMember", "decimals": "0", "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashUninsuredAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000042 - Disclosure - Significant Accounting Policies (Details Narrative)", "role": "http://scnd.com/role/SignificantAccountingPoliciesDetailsNarrative", "shortName": "Significant Accounting Policies (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashUninsuredAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000043 - Disclosure - Revenues (Details)", "role": "http://scnd.com/role/RevenuesDetails", "shortName": "Revenues (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R44": { "firstAnchor": null, "groupType": "disclosure", "isDefault": "false", "longName": "000044 - Disclosure - Revenues (Details Narrative)", "role": "http://scnd.com/role/RevenuesDetailsNarrative", "shortName": "Revenues (Details Narrative)", "subGroupType": "details", "uniqueAnchor": null }, "R45": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000045 - Disclosure - Segment Information and Concentrations (Details)", "role": "http://scnd.com/role/SegmentInformationAndConcentrationsDetails", "shortName": "Segment Information and Concentrations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2022-01-01to2022-03-31_scnd_BenchtopLaboratoryEquipmentMember", "decimals": "0", "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2022-01-01to2022-03-31_scnd_TorbalScalesDivisionsMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000046 - Disclosure - Segment Information and Concentrations (Details Narrative)", "role": "http://scnd.com/role/SegmentInformationAndConcentrationsDetailsNarrative", "shortName": "Segment Information and Concentrations (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2022-01-01to2022-03-31_scnd_TorbalScalesDivisionsMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000047 - Disclosure - Fair Value of Financial Instruments (Details)", "role": "http://scnd.com/role/FairValueOfFinancialInstrumentsDetails", "shortName": "Fair Value of Financial Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:MarketableSecuritiesTextBlock", "ix:continuation", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000048 - Disclosure - Fair Value of Financial Instruments (Details 1)", "role": "http://scnd.com/role/FairValueOfFinancialInstrumentsDetails1", "shortName": "Fair Value of Financial Instruments (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:MarketableSecuritiesTextBlock", "ix:continuation", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "AsOf2020-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000049 - Disclosure - Fair Value of Financial Instruments (Details 2)", "role": "http://scnd.com/role/FairValueOfFinancialInstrumentsDetails2", "shortName": "Fair Value of Financial Instruments (Details 2)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "AsOf2019-06-30", "decimals": "0", "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "AsOf2019-06-30_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS EQUITY", "role": "http://scnd.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "AsOf2019-06-30_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000050 - Disclosure - Inventories (Details)", "role": "http://scnd.com/role/InventoriesDetails", "shortName": "Inventories (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000051 - Disclosure - Property and Equipment (Details)", "role": "http://scnd.com/role/PropertyAndEquipmentDetails", "shortName": "Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2020-07-01to2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000052 - Disclosure - Property and Equipment (Details Narrative)", "role": "http://scnd.com/role/PropertyAndEquipmentDetailsNarrative", "shortName": "Property and Equipment (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2020-07-01to2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:GoodwillDisclosureTextBlock", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000053 - Disclosure - Goodwill and Finite Lived Intangible Assets (Details)", "role": "http://scnd.com/role/GoodwillAndFiniteLivedIntangibleAssetsDetails", "shortName": "Goodwill and Finite Lived Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:GoodwillDisclosureTextBlock", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "p", "us-gaap:GoodwillDisclosureTextBlock", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000054 - Disclosure - Goodwill and Finite Lived Intangible Assets (Details 1)", "role": "http://scnd.com/role/GoodwillAndFiniteLivedIntangibleAssetsDetails1", "shortName": "Goodwill and Finite Lived Intangible Assets (Details 1)", "subGroupType": "details", "uniqueAnchor": null }, "R55": { "firstAnchor": { "ancestors": [ "p", "us-gaap:GoodwillDisclosureTextBlock", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000055 - Disclosure - Goodwill and Finite Lived Intangible Assets (Details Narrative)", "role": "http://scnd.com/role/GoodwillAndFiniteLivedIntangibleAssetsDetailsNarrative", "shortName": "Goodwill and Finite Lived Intangible Assets (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:GoodwillDisclosureTextBlock", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "lang": null, "name": "us-gaap:AdjustmentForAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "scnd:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000056 - Disclosure - Loss Per Common Share (Details)", "role": "http://scnd.com/role/LossPerCommonShareDetails", "shortName": "Loss Per Common Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "scnd:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "p", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2022-01-01to2022-03-31_scnd_StockOptionsMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000057 - Disclosure - Loss Per Common Share (Details Narrative)", "role": "http://scnd.com/role/LossPerCommonShareDetailsNarrative", "shortName": "Loss Per Common Share (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2022-01-01to2022-03-31_scnd_StockOptionsMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000058 - Disclosure - Leases (Details)", "role": "http://scnd.com/role/LeasesDetails", "shortName": "Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PaymentsForRent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000059 - Disclosure - Leases (Details Narrative)", "role": "http://scnd.com/role/LeasesDetailsNarrative", "shortName": "Leases (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PaymentsForRent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2021-07-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "role": "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2021-07-01to2022-03-31", "decimals": "0", "lang": null, "name": "us-gaap:GainLossOnSaleOfInvestments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "ix:continuation", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000060 - Disclosure - Discontinued Operations (Details)", "role": "http://scnd.com/role/DiscontinuedOperationsDetails", "shortName": "Discontinued Operations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "ix:continuation", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "lang": null, "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "p", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DueToRelatedPartiesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000061 - Disclosure - Discontinued Operations (Details Narrative)", "role": "http://scnd.com/role/DiscontinuedOperationsDetailsNarrative", "shortName": "Discontinued Operations (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DueToRelatedPartiesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "AsOf2021-04-29", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000062 - Disclosure - Acquisition of Aquila Biolabs GmbH (Details)", "role": "http://scnd.com/role/AcquisitionOfAquilaBiolabsGmbhDetails", "shortName": "Acquisition of Aquila Biolabs GmbH (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "AsOf2021-04-29", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2019-07-01to2020-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000063 - Disclosure - Acquisition of Aquila Biolabs GmbH (Details 1)", "role": "http://scnd.com/role/AcquisitionOfAquilaBiolabsGmbhDetails1", "shortName": "Acquisition of Aquila Biolabs GmbH (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2019-07-01to2020-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "p", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2021-07-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PaymentsForProceedsFromPreviousAcquisition", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000064 - Disclosure - Acquisition of Aquila Biolabs GmbH (Details Narrative)", "role": "http://scnd.com/role/AcquisitionOfAquilaBiolabsGmbhDetailsNarrative", "shortName": "Acquisition of Aquila Biolabs GmbH (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2021-07-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PaymentsForProceedsFromPreviousAcquisition", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "p", "scnd:PaycheckProtectionProgramLoantextblock", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "AsOf2021-03-31_scnd_PaycheckProtectionProgramLoanMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000065 - Disclosure - Paycheck Protection Program Loan (Details Narrative)", "role": "http://scnd.com/role/PaycheckProtectionProgramLoanDetailsNarrative", "shortName": "Paycheck Protection Program Loan (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "scnd:PaycheckProtectionProgramLoantextblock", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "AsOf2021-03-31_scnd_PaycheckProtectionProgramLoanMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "AsOf2022-02-25", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000066 - Disclosure - Equity (Details Narrative)", "role": "http://scnd.com/role/EquityDetailsNarrative", "shortName": "Equity (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "AsOf2022-02-25", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "scnd:FairValueOfContingentConsiderationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "scnd:FairValueContingentConsiderationDueCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000067 - Disclosure - Commitments and Contingencies (Details)", "role": "http://scnd.com/role/CommitmentsAndContingenciesDetails", "shortName": "Commitments and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "scnd:FairValueOfContingentConsiderationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "scnd:FairValueContingentConsiderationDueCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2020-07-01to2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000068 - Disclosure - Income Taxes (Details)", "role": "http://scnd.com/role/IncomeTaxesDetails", "shortName": "Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2020-07-01to2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000069 - Disclosure - Income Taxes (Details 1)", "role": "http://scnd.com/role/IncomeTaxesDetails1", "shortName": "Income Taxes (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2021-07-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000007 - Disclosure - Summary of Significant Accounting Policies", "role": "http://scnd.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2021-07-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "AsOf2020-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000070 - Disclosure - Stock Options (Details)", "role": "http://scnd.com/role/StockOptionsDetails", "shortName": "Stock Options (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2020-07-01to2021-06-30", "decimals": "0", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "ix:continuation", "p", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000071 - Disclosure - Stock Options (Details 1)", "role": "http://scnd.com/role/StockOptionsDetails1", "shortName": "Stock Options (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "ix:continuation", "p", "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "AsOf2021-06-30_scnd_ExercisePriceRange9Member", "decimals": "0", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2021-07-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "scnd:Revenue", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000008 - Disclosure - Revenue", "role": "http://scnd.com/role/Revenue", "shortName": "Revenue", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2021-07-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "scnd:Revenue", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2021-07-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000009 - Disclosure - Segment Information", "role": "http://scnd.com/role/SegmentInformation", "shortName": "Segment Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "scnd_s1.htm", "contextRef": "From2021-07-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 45, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://scnd.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://scnd.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://scnd.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line 1" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://scnd.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line 2" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://scnd.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://scnd.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://scnd.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://scnd.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r514" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://scnd.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r514" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://scnd.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r514" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://scnd.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://scnd.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r514" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://scnd.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r514" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://scnd.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r514" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://scnd.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://scnd.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "scnd_AdditionalCommonStockPurchasedShare": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Additional common stock purchased" } } }, "localname": "AdditionalCommonStockPurchasedShare", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/EquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "scnd_AssetsNet1": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Assets" } } }, "localname": "AssetsNet1", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/SegmentInformationAndConcentrationsDetails" ], "xbrltype": "monetaryItemType" }, "scnd_AutomobileMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Automobiles" } } }, "localname": "AutomobileMember", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "scnd_BenchtopLaboratoryEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Benchtop Laboratory Equipment" } } }, "localname": "BenchtopLaboratoryEquipmentMember", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/RevenuesDetails", "http://scnd.com/role/SegmentInformationAndConcentrationsDetails", "http://scnd.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "scnd_BenchtopLaboratoryEquipmentOperationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Benchtop Laboratory Operations Equipment [Member]" } } }, "localname": "BenchtopLaboratoryEquipmentOperationsMember", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/SegmentInformationAndConcentrationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "scnd_BioprocessingSystemsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Bioprocessing Systems" } } }, "localname": "BioprocessingSystemsMember", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/RevenuesDetails", "http://scnd.com/role/SegmentInformationAndConcentrationsDetails", "http://scnd.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "scnd_BusinessCombinationIPRDMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "In-process research and development" } } }, "localname": "BusinessCombinationIPRDMember", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/AcquisitionOfAquilaBiolabsGmbhDetails" ], "xbrltype": "domainItemType" }, "scnd_BusinessCombinationPatentsAndOtherIntangiblesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Patents and Other Intangibles" } } }, "localname": "BusinessCombinationPatentsAndOtherIntangiblesMember", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/AcquisitionOfAquilaBiolabsGmbhDetails" ], "xbrltype": "domainItemType" }, "scnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredCustomerRelationships": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "[Customer relationships]", "verboseLabel": "Customer relationships" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredCustomerRelationships", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/AcquisitionOfAquilaBiolabsGmbhDetails" ], "xbrltype": "monetaryItemType" }, "scnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredIPRandD": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "[In-process research and development]", "verboseLabel": "In-process research and development" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredIPRandD", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/AcquisitionOfAquilaBiolabsGmbhDetails" ], "xbrltype": "monetaryItemType" }, "scnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredNonCompeteAgreements": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "[Non-compete agreements 1]", "verboseLabel": "Non-compete agreements" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredNonCompeteAgreements", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/AcquisitionOfAquilaBiolabsGmbhDetails" ], "xbrltype": "monetaryItemType" }, "scnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTradeName": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "[Tradename]", "verboseLabel": "Tradename" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTradeName", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/AcquisitionOfAquilaBiolabsGmbhDetails" ], "xbrltype": "monetaryItemType" }, "scnd_BusinessCombinationTradeNameMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Tradename" } } }, "localname": "BusinessCombinationTradeNameMember", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/AcquisitionOfAquilaBiolabsGmbhDetails" ], "xbrltype": "domainItemType" }, "scnd_ComprehensiveGain": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Comprehensive loss" } } }, "localname": "ComprehensiveGain", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "scnd_ConsolidatedEntityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Consolidated]", "verboseLabel": "Consolidated" } } }, "localname": "ConsolidatedEntityMember", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/RevenuesDetails", "http://scnd.com/role/SegmentInformationAndConcentrationsDetails" ], "xbrltype": "domainItemType" }, "scnd_ConsolidatedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consolidated" } } }, "localname": "ConsolidatedMember", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "scnd_ContingentConsideration1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Custom Element.", "label": "[Contingent consideration]", "verboseLabel": "Contingent consideration" } } }, "localname": "ContingentConsideration1", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "scnd_ContingentConsiderationPayableCurrent": { "auth_ref": [], "calculation": { "http://scnd.com/role/CondensedConsolidatedBalanceSheets": { "order": 21.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Contingent consideration" } } }, "localname": "ContingentConsiderationPayableCurrent", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "scnd_ContingentConsiderationPayableLessCurrentPortion": { "auth_ref": [], "calculation": { "http://scnd.com/role/CondensedConsolidatedBalanceSheets": { "order": 27.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Contingent consideration payable, less current portion" } } }, "localname": "ContingentConsiderationPayableLessCurrentPortion", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "scnd_ContractualRightMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-compete agreements", "verboseLabel": "Non-compete agreements" } } }, "localname": "ContractualRightMember", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/AcquisitionOfAquilaBiolabsGmbhDetails", "http://scnd.com/role/GoodwillAndFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "scnd_ContractualsRightsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Non-compete agreements]", "verboseLabel": "Non-compete agreements" } } }, "localname": "ContractualsRightsMember", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/GoodwillAndFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "scnd_CovidPandemicPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "COVID-19 Pandemic" } } }, "localname": "CovidPandemicPolicyTextBlock", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "scnd_DebtsSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Securities" } } }, "localname": "DebtsSecuritiesMember", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/FairValueOfFinancialInstrumentsDetails1" ], "xbrltype": "domainItemType" }, "scnd_DeferredIncomeTaxExpenseBenefit1": { "auth_ref": [], "calculation": { "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Deferred income tax benefit" } } }, "localname": "DeferredIncomeTaxExpenseBenefit1", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "scnd_DeferredTaxAssetNetNoncurrent": { "auth_ref": [], "calculation": { "http://scnd.com/role/CondensedConsolidatedBalanceSheets": { "order": 15.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Deferred taxes" } } }, "localname": "DeferredTaxAssetNetNoncurrent", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "scnd_DescriptionOfNewAccountingPronouncementNotYetAdopted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Recent Accounting Pronouncements" } } }, "localname": "DescriptionOfNewAccountingPronouncementNotYetAdopted", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "scnd_DescriptionOfObligation": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Description of obligation" } } }, "localname": "DescriptionOfObligation", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/RevenuesDetailsNarrative" ], "xbrltype": "stringItemType" }, "scnd_DilutiveSecurities1": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Effect of dilutive securities" } } }, "localname": "DilutiveSecurities1", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/LossPerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "scnd_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Discontinued operations]", "verboseLabel": "Discontinued operations" } } }, "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShares", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/LossPerCommonShareDetails" ], "xbrltype": "perShareItemType" }, "scnd_EarningPerShareBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consolidated operations", "verboseLabel": "Consolidated operations" } } }, "localname": "EarningPerShareBasicAndDiluted", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://scnd.com/role/LossPerCommonShareDetails" ], "xbrltype": "perShareItemType" }, "scnd_EquitySecuritieMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity Securities" } } }, "localname": "EquitySecuritieMember", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/FairValueOfFinancialInstrumentsDetails1" ], "xbrltype": "domainItemType" }, "scnd_ExercisePriceRange10Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Exercise Price Range 2.91 - 4.65" } } }, "localname": "ExercisePriceRange10Member", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/StockOptionsDetails1" ], "xbrltype": "domainItemType" }, "scnd_ExercisePriceRange9Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Exercise Price Range 5.35 - 11.30" } } }, "localname": "ExercisePriceRange9Member", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/StockOptionsDetails1" ], "xbrltype": "domainItemType" }, "scnd_FairValueContingentConsiderationDueCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "[2022]", "verboseLabel": "2022" } } }, "localname": "FairValueContingentConsiderationDueCurrent", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "scnd_FairValueContingentConsiderationDueInThreeYears": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "[2024]", "verboseLabel": "2024" } } }, "localname": "FairValueContingentConsiderationDueInThreeYears", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "scnd_FairValueContingentConsiderationDueInTwoYears": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "[2023]", "verboseLabel": "2023" } } }, "localname": "FairValueContingentConsiderationDueInTwoYears", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "scnd_FairValueContingentConsiderationMinimumPaymentsDue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "[Total]", "verboseLabel": "Total" } } }, "localname": "FairValueContingentConsiderationMinimumPaymentsDue", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "scnd_FairValueOfContingentConsiderationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair value of contingent consideration" } } }, "localname": "FairValueOfContingentConsiderationTableTextBlock", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/CommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "scnd_FairValueOfLiabilitiesAssumedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair value of liabilities assumed:" } } }, "localname": "FairValueOfLiabilitiesAssumedAbstract", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/AcquisitionOfAquilaBiolabsGmbhDetails" ], "xbrltype": "stringItemType" }, "scnd_ForeignSales": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Custom Element.", "label": "Foreign sales", "terseLabel": "Foreign Sales", "verboseLabel": "Foreign Sales" } } }, "localname": "ForeignSales", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/RevenuesDetails", "http://scnd.com/role/SegmentInformationAndConcentrationsDetails", "http://scnd.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "scnd_IPRandDMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "IPR and D" } } }, "localname": "IPRandDMember", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/GoodwillAndFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "scnd_IncomeLossFromContinuingOperationPerBasicAndDilutedShare": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Continuing operations]", "verboseLabel": "Continuing operations" } } }, "localname": "IncomeLossFromContinuingOperationPerBasicAndDilutedShare", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/LossPerCommonShareDetails" ], "xbrltype": "perShareItemType" }, "scnd_IncreaseDecreaseInContingentLiabilities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Increase (decrease) in contingent consideration liability" } } }, "localname": "IncreaseDecreaseInContingentLiabilities", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/FairValueOfFinancialInstrumentsDetails2" ], "xbrltype": "monetaryItemType" }, "scnd_IncreaseDecreaseInLeaseLiabilities": { "auth_ref": [], "calculation": { "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Lease liabilities" } } }, "localname": "IncreaseDecreaseInLeaseLiabilities", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "scnd_IncreaseDecreaseInOtherAssets": { "auth_ref": [], "calculation": { "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "[Other assets]", "verboseLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInOtherAssets", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "scnd_IncreaseDecreaseInRightOfUseAssets": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Right-of-use assets" } } }, "localname": "IncreaseDecreaseInRightOfUseAssets", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "scnd_IssuanceCostsOfCommonStockAndWarrants": { "auth_ref": [], "calculation": { "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 32.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "lang": { "en-us": { "role": { "label": "[Issuance costs of common stock and warrants]", "negatedLabel": "Issuance costs of common stock and warrants" } } }, "localname": "IssuanceCostsOfCommonStockAndWarrants", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "sharesItemType" }, "scnd_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Issuance of common stock and warrants, net of issuance costs" } } }, "localname": "IssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "scnd_LicensingAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Sublicense agreements" } } }, "localname": "LicensingAgreementMember", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/GoodwillAndFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "scnd_LonglivedAssetExpenditures": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Long-lived Asset Expenditures" } } }, "localname": "LonglivedAssetExpenditures", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/SegmentInformationAndConcentrationsDetails" ], "xbrltype": "monetaryItemType" }, "scnd_LossPerCommonShareabstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Loss Per Common Share" } } }, "localname": "LossPerCommonShareabstract", "nsuri": "http://scnd.com/20220331", "xbrltype": "stringItemType" }, "scnd_MutualFundsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Mutual Funds" } } }, "localname": "MutualFundsMember", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/FairValueOfFinancialInstrumentsDetails1" ], "xbrltype": "domainItemType" }, "scnd_NonoperatingIncomeExpensenet": { "auth_ref": [], "calculation": { "http://scnd.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 11.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "[Total other income (expense), net]", "totalLabel": "Total other income (expense), net" } } }, "localname": "NonoperatingIncomeExpensenet", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "scnd_NumberOfOptionsExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Custom Element.", "label": "[Number of Options Exercised]", "negatedLabel": "Number of Options Exercised" } } }, "localname": "NumberOfOptionsExercised", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/StockOptionsDetails" ], "xbrltype": "sharesItemType" }, "scnd_NumberOfOptionsForfeited": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Number of Options Forfeited" } } }, "localname": "NumberOfOptionsForfeited", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/StockOptionsDetails" ], "xbrltype": "sharesItemType" }, "scnd_OperatingLeaseWeightedAverageRemainingLeaseTerms": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted-average remaining lease term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerms", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/LeasesDetailsNarrative" ], "xbrltype": "durationItemType" }, "scnd_OtherIntangiblesAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other intangible assets" } } }, "localname": "OtherIntangiblesAssetsMember", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/GoodwillAndFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "scnd_PaycheckProtectionProgramLoan": { "auth_ref": [], "calculation": { "http://scnd.com/role/CondensedConsolidatedBalanceSheets": { "order": 18.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Paycheck Protection Program loan" } } }, "localname": "PaycheckProtectionProgramLoan", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "scnd_PaycheckProtectionProgramLoanAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Paycheck Protection Program Loan (Details Narrative)" } } }, "localname": "PaycheckProtectionProgramLoanAbstract", "nsuri": "http://scnd.com/20220331", "xbrltype": "stringItemType" }, "scnd_PaycheckProtectionProgramLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Paycheck Protection Program Loan [Member]" } } }, "localname": "PaycheckProtectionProgramLoanMember", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/PaycheckProtectionProgramLoanDetailsNarrative" ], "xbrltype": "domainItemType" }, "scnd_PaycheckProtectionProgramLoantextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Paycheck Protection Program Loan]", "verboseLabel": "Paycheck Protection Program Loan" } } }, "localname": "PaycheckProtectionProgramLoantextblock", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/PaycheckProtectionProgramLoan" ], "xbrltype": "textBlockItemType" }, "scnd_PaymentsForContingentLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Payments" } } }, "localname": "PaymentsForContingentLiabilities", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/FairValueOfFinancialInstrumentsDetails2" ], "xbrltype": "monetaryItemType" }, "scnd_PaymentsOfContingentConsideration": { "auth_ref": [], "calculation": { "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 29.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Custom Element.", "label": "Payments of contingent consideration" } } }, "localname": "PaymentsOfContingentConsideration", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "scnd_PayrollProtectionProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payroll Protection Program [Member]" } } }, "localname": "PayrollProtectionProgramMember", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "scnd_ProceedsFromSaleOfAssetsOfDiscontinuedOperations": { "auth_ref": [], "calculation": { "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 31.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Proceeds from sale of assets of discontinued operations" } } }, "localname": "ProceedsFromSaleOfAssetsOfDiscontinuedOperations", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "scnd_RecordLeaseLiabilitiesNonCashFinacingActivities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Record lease liabilities" } } }, "localname": "RecordLeaseLiabilitiesNonCashFinacingActivities", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "scnd_RecordRightOfUseAssetsNonCashFinacingActivities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Record right-of-use assets" } } }, "localname": "RecordRightOfUseAssetsNonCashFinacingActivities", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "scnd_RedemptionOfInvestmentSecuritiesAvailableForSale": { "auth_ref": [], "calculation": { "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 27.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Custom Element.", "label": "Redemption of investment securities" } } }, "localname": "RedemptionOfInvestmentSecuritiesAvailableForSale", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "scnd_Revenue": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Revenue]", "verboseLabel": "Revenue" } } }, "localname": "Revenue", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/Revenue" ], "xbrltype": "textBlockItemType" }, "scnd_RevenueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue" } } }, "localname": "RevenueAbstract", "nsuri": "http://scnd.com/20220331", "xbrltype": "stringItemType" }, "scnd_RevenueTablesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue (Tables)" } } }, "localname": "RevenueTablesAbstract", "nsuri": "http://scnd.com/20220331", "xbrltype": "stringItemType" }, "scnd_StockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Stock Options]", "verboseLabel": "Stock Options" } } }, "localname": "StockOptionsMember", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/LossPerCommonShareDetailsNarrative" ], "xbrltype": "domainItemType" }, "scnd_SupplementalDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUPPLEMENTAL DISCLOSURES" } } }, "localname": "SupplementalDisclosureAbstract", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "scnd_Thereafter": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Thereafter" } } }, "localname": "Thereafter", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "scnd_ThreeCustomerstMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Three Customerst [Member]" } } }, "localname": "ThreeCustomerstMember", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/SegmentInformationAndConcentrationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "scnd_TorbalScalesDivisionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Torbal Scales Division" } } }, "localname": "TorbalScalesDivisionsMember", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/SegmentInformationAndConcentrationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "scnd_TradeNameMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Trade names" } } }, "localname": "TradeNameMember", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/GoodwillAndFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "scnd_TrademarkMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Technology, trademarks" } } }, "localname": "TrademarkMember", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/GoodwillAndFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "scnd_TradesNamesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Trade names]", "verboseLabel": "Trade names" } } }, "localname": "TradesNamesMember", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/GoodwillAndFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "scnd_UnrealizedHoldingGainLoss": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "[Unrealized holding gain (loss)]", "negatedLabel": "Unrealized holding gain (loss)" } } }, "localname": "UnrealizedHoldingGainLoss", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/FairValueOfFinancialInstrumentsDetails1" ], "xbrltype": "monetaryItemType" }, "scnd_UnrealizedHoldingLossOnInvestmentSecuritiesNetOfTax": { "auth_ref": [], "calculation": { "http://scnd.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 20.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Unrealized holding loss on investment securities, net of tax" } } }, "localname": "UnrealizedHoldingLossOnInvestmentSecuritiesNetOfTax", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "scnd_WarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants" } } }, "localname": "WarrantsMember", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/LossPerCommonShareDetailsNarrative" ], "xbrltype": "domainItemType" }, "scnd_WebsitesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Websites" } } }, "localname": "WebsitesMember", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/GoodwillAndFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "scnd_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average common shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasicAndDiluted", "nsuri": "http://scnd.com/20220331", "presentation": [ "http://scnd.com/role/LossPerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "srt_MaximumMember": { "auth_ref": [ "r270", "r300", "r329", "r330", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r497", "r498", "r511", "r512" ], "lang": { "en-us": { "role": { "label": "Maximum", "verboseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://scnd.com/role/GoodwillAndFiniteLivedIntangibleAssetsDetails", "http://scnd.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r270", "r300", "r329", "r330", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r497", "r498", "r511", "r512" ], "lang": { "en-us": { "role": { "label": "Minimum", "verboseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://scnd.com/role/GoodwillAndFiniteLivedIntangibleAssetsDetails", "http://scnd.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r270", "r300", "r320", "r329", "r330", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r497", "r498", "r511", "r512" ], "lang": { "en-us": { "role": { "label": "Range Axis" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://scnd.com/role/GoodwillAndFiniteLivedIntangibleAssetsDetails", "http://scnd.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r270", "r300", "r320", "r329", "r330", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r497", "r498", "r511", "r512" ], "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://scnd.com/role/GoodwillAndFiniteLivedIntangibleAssetsDetails", "http://scnd.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r62", "r449" ], "calculation": { "http://scnd.com/role/CondensedConsolidatedBalanceSheets": { "order": 23.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r29", "r41", "r204", "r205" ], "calculation": { "http://scnd.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Trade accounts receivable, less allowance for doubtful accounts of $15,600 at March 31, 2022 and June 30, 2021" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r64" ], "calculation": { "http://scnd.com/role/CondensedConsolidatedBalanceSheets": { "order": 22.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r60", "r238" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Less accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r44", "r74", "r75", "r76", "r485", "r503", "r504" ], "calculation": { "http://scnd.com/role/CondensedConsolidatedBalanceSheets": { "order": 31.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r73", "r76", "r80", "r81", "r82", "r133", "r134", "r135", "r414", "r499", "r500", "r515" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "auth_ref": [ "r226" ], "lang": { "en-us": { "role": { "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "[Acquired Finite-lived Intangible Assets, Weighted Average Useful Life]", "verboseLabel": "Useful life" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/AcquisitionOfAquilaBiolabsGmbhDetails" ], "xbrltype": "durationItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r42" ], "calculation": { "http://scnd.com/role/CondensedConsolidatedBalanceSheets": { "order": 32.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r133", "r134", "r135", "r350", "r351", "r352", "r420" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentForAmortization": { "auth_ref": [ "r111", "r230" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.", "label": "Total amortization expense" } } }, "localname": "AdjustmentForAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/GoodwillAndFiniteLivedIntangibleAssetsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r332", "r333", "r354", "r355" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r112" ], "calculation": { "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The sum of adjustments which are added to or deducted from net income or loss, including the portion attributable to noncontrolling interest, to reflect cash provided by or used in operating activities, in accordance with the indirect cash flow method.", "label": "Total adjustments" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "auth_ref": [ "r358" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for advertising cost.", "label": "Advertising" } } }, "localname": "AdvertisingCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_AdvertisingExpense": { "auth_ref": [ "r359" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.", "label": "Advertising expense" } } }, "localname": "AdvertisingExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r48", "r208", "r217" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Allowance doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r152" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Dilutive shares excluded" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/LossPerCommonShareDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r152" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities Axis" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/LossPerCommonShareDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r152" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/LossPerCommonShareDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r126", "r181", "r188", "r195", "r215", "r254", "r255", "r256", "r258", "r259", "r260", "r261", "r262", "r263", "r265", "r266", "r409", "r415", "r428", "r447", "r449", "r469", "r484" ], "calculation": { "http://scnd.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "[Assets]", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r30", "r31", "r71", "r126", "r215", "r254", "r255", "r256", "r258", "r259", "r260", "r261", "r262", "r263", "r265", "r266", "r409", "r415", "r428", "r447", "r449" ], "calculation": { "http://scnd.com/role/CondensedConsolidatedBalanceSheets": { "order": 14.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "[Assets, Current]", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r422" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "[Assets, Fair Value Disclosure]", "verboseLabel": "Total" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets:" } } }, "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/DiscontinuedOperationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "auth_ref": [ "r1", "r2", "r18", "r20", "r24", "r235", "r240" ], "calculation": { "http://scnd.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Assets of discontinued operations", "verboseLabel": "Discontinued operations" } } }, "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedBalanceSheets", "http://scnd.com/role/DiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecurities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.", "label": "Fair value" } } }, "localname": "AvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/FairValueOfFinancialInstrumentsDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAmortizedCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.", "label": "Cost" } } }, "localname": "AvailableForSaleSecuritiesAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/FairValueOfFinancialInstrumentsDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesCurrent": { "auth_ref": [], "calculation": { "http://scnd.com/role/CondensedConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt and equity securities categorized neither as trading securities nor held-to-maturity securities and intended be sold or mature one year or operating cycle, if longer.", "label": "Investment securities", "verboseLabel": "Investment securities" } } }, "localname": "AvailableForSaleSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedBalanceSheets", "http://scnd.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BankOverdrafts": { "auth_ref": [ "r64", "r253" ], "calculation": { "http://scnd.com/role/CondensedConsolidatedBalanceSheets": { "order": 20.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of payments made in excess of existing cash balances, which will be honored by the bank but reflected as a loan to the entity. Overdrafts generally have a very short time frame for correction or repayment and are therefore more similar to short-term bank financing than trade financing.", "label": "Bank overdraft" } } }, "localname": "BankOverdrafts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic": { "auth_ref": [ "r394", "r395" ], "lang": { "en-us": { "role": { "documentation": "The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.", "label": "Earnings per share: Basic" } } }, "localname": "BusinessAcquisitionProFormaEarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/AcquisitionOfAquilaBiolabsGmbhDetails1" ], "xbrltype": "perShareItemType" }, "us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted": { "auth_ref": [ "r394", "r395" ], "lang": { "en-us": { "role": { "documentation": "The pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.", "label": "Earnings per share: Diluted" } } }, "localname": "BusinessAcquisitionProFormaEarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/AcquisitionOfAquilaBiolabsGmbhDetails1" ], "xbrltype": "perShareItemType" }, "us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTableTextBlock": { "auth_ref": [ "r396" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the nature and amount of any material, nonrecurring adjustments directly attributable to the business combination(s) included in the reported pro forma revenue and earnings (supplemental pro forma information).", "label": "Pro forma information" } } }, "localname": "BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/AcquisitionOfAquilaBiolabsGmbhTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": { "auth_ref": [ "r394", "r395" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.", "label": "[Business Acquisition, Pro Forma Net Income (Loss)]", "verboseLabel": "Net loss" } } }, "localname": "BusinessAcquisitionsProFormaNetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/AcquisitionOfAquilaBiolabsGmbhDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionsProFormaRevenue": { "auth_ref": [ "r394", "r395" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.", "label": "[Business Acquisition, Pro Forma Revenue]", "verboseLabel": "Revenues" } } }, "localname": "BusinessAcquisitionsProFormaRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/AcquisitionOfAquilaBiolabsGmbhDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r403", "r404", "r406" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Fair value of consideration transferred" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/AcquisitionOfAquilaBiolabsGmbhDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": { "auth_ref": [ "r402", "r405" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.", "label": "[Business Combination, Contingent Consideration, Liability, Current]", "negatedLabel": "Accrued expenses" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/AcquisitionOfAquilaBiolabsGmbhDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": { "auth_ref": [ "r400" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets acquired at the acquisition date.", "label": "Total assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/AcquisitionOfAquilaBiolabsGmbhDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "auth_ref": [ "r400" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "[Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents]", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/AcquisitionOfAquilaBiolabsGmbhDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets [Abstract]", "verboseLabel": "Current assets:" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/AcquisitionOfAquilaBiolabsGmbhDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": { "auth_ref": [ "r400" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "[Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets]", "verboseLabel": "Prepaid expenses and other current assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/AcquisitionOfAquilaBiolabsGmbhDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": { "auth_ref": [ "r400" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "[Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables]", "verboseLabel": "Accounts receivable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/AcquisitionOfAquilaBiolabsGmbhDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": { "auth_ref": [ "r400" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.", "label": "[Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable]", "negatedLabel": "Accounts payable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/AcquisitionOfAquilaBiolabsGmbhDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther": { "auth_ref": [ "r400" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.", "label": "[Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other]", "negatedLabel": "Other current liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/AcquisitionOfAquilaBiolabsGmbhDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets": { "auth_ref": [ "r400" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax asset attributable to deductible temporary differences and carryforwards acquired at the acquisition date.", "label": "Deferred tax assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/AcquisitionOfAquilaBiolabsGmbhDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": { "auth_ref": [ "r400" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.", "label": "Patents and other intangibles" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/AcquisitionOfAquilaBiolabsGmbhDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": { "auth_ref": [ "r399", "r400" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of inventory recognized as of the acquisition date.", "label": "[Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory]", "verboseLabel": "Inventory" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/AcquisitionOfAquilaBiolabsGmbhDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": { "auth_ref": [ "r400" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities assumed at the acquisition date.", "label": "[Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities]", "negatedLabel": "Total liabilities assumed" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/AcquisitionOfAquilaBiolabsGmbhDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "auth_ref": [ "r399", "r400" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.", "label": "Total identifiable net assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/AcquisitionOfAquilaBiolabsGmbhDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "auth_ref": [ "r399", "r400" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.", "label": "Property, plant and equipment" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/AcquisitionOfAquilaBiolabsGmbhDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock": { "auth_ref": [ "r393" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination.", "label": "Purchase price allocation" } } }, "localname": "BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/AcquisitionOfAquilaBiolabsGmbhTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Acquisition of Aquila Biolabs GmbH" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_Cash": { "auth_ref": [ "r57", "r449", "r505", "r506" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash", "verboseLabel": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/DiscontinuedOperationsDetails", "http://scnd.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r27", "r57", "r113" ], "calculation": { "http://scnd.com/role/CondensedConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents", "periodEndLabel": "Cash and cash equivalents, end of period", "periodStartLabel": "Cash and cash equivalents, beginning of year", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedBalanceSheets", "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://scnd.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r33", "r115" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r106", "r429" ], "calculation": { "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "[Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect]", "totalLabel": "Net decrease in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations": { "auth_ref": [ "r17", "r106" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Cash provided by investing activities from discontinued operations" } } }, "localname": "CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/DiscontinuedOperationsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": { "auth_ref": [ "r17", "r106" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Cash provided by (used in) operating activities" } } }, "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/DiscontinuedOperationsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashUninsuredAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.", "label": "FDIC excess cash balance" } } }, "localname": "CashUninsuredAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r249", "r250", "r251", "r252", "r507" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "verboseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r133", "r134", "r420" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r40" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock,par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r40" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, authorized shares", "verboseLabel": "Common share authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://scnd.com/role/EquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r40" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, issued shares" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r40", "r312" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, outstanding shares" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r40", "r449" ], "calculation": { "http://scnd.com/role/CondensedConsolidatedBalanceSheets": { "order": 33.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, $.05 par value; 20,000,000 and 15,000,000 shares authorized; 7,023,401 and 6,477,945 shares issued; 7,003,599 and 6,458,143 shares outstanding at March 31, 2022 and June 30, 2021" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": { "auth_ref": [ "r318", "r319", "r331", "r357" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.", "label": "Compensation and Employee Benefit Plans [Text Block]", "verboseLabel": "Employee Benefit Plans" } } }, "localname": "CompensationAndEmployeeBenefitPlansTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/EmployeeBenefitPlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Employee Benefit Plans" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer equipment" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r163", "r164", "r202", "r426", "r427" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Total revenue" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/SegmentInformationAndConcentrationsDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r119", "r411" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Principles of consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CorporateAndOtherMember": { "auth_ref": [ "r169" ], "lang": { "en-us": { "role": { "documentation": "Component of an entity that provides financial and operational oversight and administrative support for other segments and other segments not separately reported due to size or nature of business activities. Excludes intersegment elimination and reconciling items.", "label": "Corporate and Other [Member]" } } }, "localname": "CorporateAndOtherMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/SegmentInformationAndConcentrationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r92", "r126", "r215", "r254", "r255", "r256", "r259", "r260", "r261", "r262", "r263", "r265", "r266", "r428" ], "calculation": { "http://scnd.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of revenues" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerAdvancesCurrent": { "auth_ref": [ "r64" ], "calculation": { "http://scnd.com/role/CondensedConsolidatedBalanceSheets": { "order": 24.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The current portion of prepayments received from customers for goods or services to be provided in the future.", "label": "Contract liabilities" } } }, "localname": "CustomerAdvancesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r401" ], "lang": { "en-us": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer relationships", "verboseLabel": "Customer relationships" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/AcquisitionOfAquilaBiolabsGmbhDetails", "http://scnd.com/role/GoodwillAndFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r123", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r284", "r291", "r292", "r293", "r298" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Lines of credit" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/LinesOfCredit" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r36", "r37", "r38", "r125", "r131", "r267", "r268", "r269", "r270", "r271", "r272", "r274", "r280", "r281", "r282", "r283", "r285", "r286", "r287", "r288", "r289", "r290", "r294", "r295", "r296", "r297", "r437", "r470", "r471", "r483" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument Axis" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/PaycheckProtectionProgramLoanDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r267", "r294", "r295", "r436", "r437", "r438" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt intrument, face amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/PaycheckProtectionProgramLoanDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r66", "r125", "r131", "r267", "r268", "r269", "r270", "r271", "r272", "r274", "r280", "r281", "r282", "r283", "r285", "r286", "r287", "r288", "r289", "r290", "r294", "r295", "r296", "r297", "r437" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/PaycheckProtectionProgramLoanDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r111", "r127", "r376", "r383", "r384", "r385" ], "calculation": { "http://scnd.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 13.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Income tax benefit, deferred" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredOtherTaxExpenseBenefit": { "auth_ref": [ "r127", "r377", "r382" ], "calculation": { "http://scnd.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 14.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other deferred income tax expense (benefit) pertaining to income (loss) from continuing operations. For example, but not limited to, acquisition-date income tax benefits or expenses recognized from changes in the acquirer's valuation allowance for its previously existing deferred tax assets resulting from a business combination and adjustments to beginning-of-year balance of a valuation allowance because of a change in circumstance causing a change in judgment about the realizability of the related deferred tax asset in future periods.", "label": "Income tax benefit, current" } } }, "localname": "DeferredOtherTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueDisclosureTextBlock": { "auth_ref": [ "r248" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for deferred revenues at the end of the reporting period, and description and amounts of significant changes that occurred during the reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.", "label": "Contract Liabilities" } } }, "localname": "DeferredRevenueDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.", "label": "Amortization of intangibles" } } }, "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/IncomeTaxesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r369" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "[Deferred Tax Assets, Gross]", "verboseLabel": "Total" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/IncomeTaxesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGrossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred tax assets:" } } }, "localname": "DeferredTaxAssetsGrossAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/IncomeTaxesDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r370" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Net deferred tax assets" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/IncomeTaxesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred tax liability:" } } }, "localname": "DeferredTaxAssetsNetAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/IncomeTaxesDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r374", "r375" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Net operating loss" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/IncomeTaxesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOther": { "auth_ref": [ "r374", "r375" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.", "label": "Other" } } }, "localname": "DeferredTaxAssetsOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/IncomeTaxesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": { "auth_ref": [ "r373", "r374", "r375" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.", "label": "[Deferred Tax Assets, Tax Credit Carryforwards, Research]", "verboseLabel": "Research and development credits" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/IncomeTaxesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther": { "auth_ref": [ "r374", "r375" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from compensation and benefits, classified as other.", "label": "Stock options expense" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/IncomeTaxesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": { "auth_ref": [ "r374", "r375" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.", "label": "Various accruals" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/IncomeTaxesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "auth_ref": [ "r374", "r375" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.", "label": "[Deferred Tax Liabilities, Property, Plant and Equipment]", "negatedLabel": "Depreciation of property and amortization of goodwill" } } }, "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/IncomeTaxesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r111", "r236" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r111", "r176" ], "calculation": { "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation and amortization", "verboseLabel": "Depreciation and Amortization and Impairment" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://scnd.com/role/SegmentInformationAndConcentrationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "auth_ref": [ "r419" ], "calculation": { "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.", "label": "Change in fair value of contingent consideration" } } }, "localname": "DerivativeGainLossOnDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of revenues", "verboseLabel": "Schedule Of Revenue" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/RevenueTables", "http://scnd.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r357" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "verboseLabel": "Stock Options" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/StockOptions" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Options" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax": { "auth_ref": [ "r3", "r5", "r7" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation.", "label": "Loss on disposal" } } }, "localname": "DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/DiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax": { "auth_ref": [ "r3", "r4", "r5", "r6", "r7", "r15", "r87", "r490" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.", "label": "Income (loss) before income tax benefit" } } }, "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/DiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax": { "auth_ref": [ "r3", "r5", "r7", "r21" ], "calculation": { "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a discontinued operation.", "label": "[Discontinued Operation, Provision for Loss (Gain) on Disposal, Net of Tax]", "verboseLabel": "Discontinued operations" } } }, "localname": "DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation": { "auth_ref": [ "r4", "r5", "r6", "r7", "r15", "r21", "r364", "r382", "r388" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.", "label": "Income tax expense (benefit)" } } }, "localname": "DiscontinuedOperationTaxEffectOfDiscontinuedOperation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/DiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Discontinued Operations" } } }, "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet": { "auth_ref": [ "r1", "r2", "r18", "r240" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of.", "label": "Accounts receivable" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/DiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable": { "auth_ref": [ "r1", "r2", "r18", "r240" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as accounts payable attributable to disposal group held for sale or disposed of.", "label": "[Disposal Group, Including Discontinued Operation, Accounts Payable]", "verboseLabel": "Accounts payable" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/DiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities": { "auth_ref": [ "r1", "r2", "r18", "r240" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of.", "label": "Accrued expenses and taxes" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/DiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold": { "auth_ref": [ "r16", "r24" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Cost of goods sold" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/DiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense": { "auth_ref": [ "r16" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Selling, general and administrative expenses" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/DiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1": { "auth_ref": [ "r1", "r2", "r18", "r240" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as goodwill attributable to disposal group held for sale or disposed of.", "label": "[Disposal Group, Including Discontinued Operation, Goodwill]", "verboseLabel": "Goodwill" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationGoodwill1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/DiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss": { "auth_ref": [ "r16", "r24" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gross profit attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Gross profit (loss)" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/DiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1": { "auth_ref": [ "r1", "r2", "r18", "r240" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as inventory attributable to disposal group held for sale or disposed of.", "label": "[Disposal Group, Including Discontinued Operation, Inventory]", "verboseLabel": "Inventories" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationInventory1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/DiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss": { "auth_ref": [ "r16" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Gain (loss) from operation" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/DiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities": { "auth_ref": [ "r1", "r2", "r18", "r240" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of.", "label": "[Disposal Group, Including Discontinued Operation, Other Liabilities]", "verboseLabel": "Contract liabilities" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOtherLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/DiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities": { "auth_ref": [ "r1", "r2", "r18", "r234", "r240" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.", "label": "Operating lease liabilities, current portion" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/DiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment": { "auth_ref": [ "r1", "r2", "r18", "r240" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of.", "label": "[Disposal Group, Including Discontinued Operation, Property, Plant and Equipment]", "verboseLabel": "Property and equipment, net" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/DiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": { "auth_ref": [ "r16", "r24" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.", "label": "[Disposal Group, Including Discontinued Operation, Revenue]", "verboseLabel": "Revenues" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/DiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "auth_ref": [ "r25", "r245" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]", "verboseLabel": "Discontinued Operations" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/DiscontinuedOperations" ], "xbrltype": "textBlockItemType" }, "us-gaap_DueToRelatedPartiesCurrent": { "auth_ref": [ "r62", "r130", "r257", "r259", "r260", "r264", "r265", "r266", "r446" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).", "label": "Cash paid to the related party" } } }, "localname": "DueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/DiscontinuedOperationsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings (Loss) Per Common Share (Tables)" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Basic loss per common share:" } } }, "localname": "EarningsPerShareBasicAndDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r152", "r153" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings (Loss) Per Common Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r152", "r153", "r154", "r156" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "verboseLabel": "Loss Per Common Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/LossPerCommonShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r429" ], "calculation": { "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 34.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of changes in foreign currency exchange rates" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": { "auth_ref": [ "r356", "r365" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.", "label": "Incentive stock option expense" } } }, "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity (Details Narrative)" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r80", "r81", "r82", "r133", "r134", "r135", "r137", "r142", "r144", "r157", "r216", "r312", "r313", "r350", "r351", "r352", "r379", "r380", "r420", "r430", "r431", "r432", "r433", "r434", "r435", "r499", "r500", "r501", "r515" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_ExtinguishmentOfDebtAmount": { "auth_ref": [], "calculation": { "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 20.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross amount of debt extinguished.", "label": "[Extinguishment of Debt, Amount]", "negatedLabel": "Extinguishment of debt" } } }, "localname": "ExtinguishmentOfDebtAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "auth_ref": [ "r422", "r423" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.", "label": "Fair value inputs" } } }, "localname": "FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/FairValueOfFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r282", "r294", "r295", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r423", "r450", "r451", "r452" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value By Fair Value Hierarchy Level Axis" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value of Financial Instruments" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r425" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "verboseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/FairValueOfFinancialInstruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r282", "r321", "r322", "r327", "r328", "r423", "r450" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r282", "r294", "r295", "r321", "r322", "r327", "r328", "r423", "r451" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r282", "r294", "r295", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r423", "r452" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r424" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "[Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value]", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/FairValueOfFinancialInstrumentsDetails2" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r282", "r294", "r295", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r450", "r451", "r452" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Useful life" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/GoodwillAndFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r229" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/GoodwillAndFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "There after" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/GoodwillAndFiniteLivedIntangibleAssetsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r231" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2022", "verboseLabel": "2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/GoodwillAndFiniteLivedIntangibleAssetsDetails1", "http://scnd.com/role/GoodwillAndFiniteLivedIntangibleAssetsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.", "label": "Estimated future amortization expense of intangible assets" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/GoodwillAndOtherIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r231" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2026", "verboseLabel": "2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/GoodwillAndFiniteLivedIntangibleAssetsDetails1", "http://scnd.com/role/GoodwillAndFiniteLivedIntangibleAssetsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r231" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2025", "verboseLabel": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/GoodwillAndFiniteLivedIntangibleAssetsDetails1", "http://scnd.com/role/GoodwillAndFiniteLivedIntangibleAssetsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r231" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2024", "verboseLabel": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/GoodwillAndFiniteLivedIntangibleAssetsDetails1", "http://scnd.com/role/GoodwillAndFiniteLivedIntangibleAssetsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r231" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2023", "verboseLabel": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/GoodwillAndFiniteLivedIntangibleAssetsDetails1", "http://scnd.com/role/GoodwillAndFiniteLivedIntangibleAssetsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r225", "r227", "r229", "r232", "r465", "r466" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite Lived Intangible Assets By Major Class Axis" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/AcquisitionOfAquilaBiolabsGmbhDetails", "http://scnd.com/role/GoodwillAndFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r229", "r466" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "[Finite-Lived Intangible Assets, Gross]", "verboseLabel": "Cost" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/GoodwillAndFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r225", "r228" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/AcquisitionOfAquilaBiolabsGmbhDetails", "http://scnd.com/role/GoodwillAndFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r229", "r465" ], "calculation": { "http://scnd.com/role/CondensedConsolidatedBalanceSheets": { "order": 16.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Intangible assets, net", "terseLabel": "Total", "verboseLabel": "Net" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedBalanceSheets", "http://scnd.com/role/GoodwillAndFiniteLivedIntangibleAssetsDetails", "http://scnd.com/role/GoodwillAndFiniteLivedIntangibleAssetsDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnSaleOfInvestments": { "auth_ref": [ "r111" ], "calculation": { "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 22.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.", "label": "Loss/(Gain) on sale of investments" } } }, "localname": "GainLossOnSaleOfInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "auth_ref": [ "r111" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.", "label": "Gain on sale of fixed assets" } } }, "localname": "GainLossOnSaleOfPropertyPlantEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnSalesOfAssets": { "auth_ref": [], "calculation": { "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of assets utilized in financial service operations.", "label": "Loss on disposal of subsidiary" } } }, "localname": "GainsLossesOnSalesOfAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r93" ], "calculation": { "http://scnd.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 6.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r220", "r221", "r449", "r468" ], "calculation": { "http://scnd.com/role/CondensedConsolidatedBalanceSheets": { "order": 12.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "verboseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedBalanceSheets", "http://scnd.com/role/GoodwillAndFiniteLivedIntangibleAssetsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAcquiredDuringPeriod": { "auth_ref": [ "r222" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.", "label": "[Goodwill, Acquired During Period]", "verboseLabel": "Goodwill" } } }, "localname": "GoodwillAcquiredDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/AcquisitionOfAquilaBiolabsGmbhDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Other Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": { "auth_ref": [ "r223" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.", "label": "Goodwill and Indefinite Lived Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillDisclosureTextBlock": { "auth_ref": [ "r224" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill.", "label": "Goodwill Disclosure [Text Block]", "verboseLabel": "Goodwill and Other Intangible Assets" } } }, "localname": "GoodwillDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/GoodwillAndOtherIntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r90", "r126", "r181", "r187", "r191", "r194", "r197", "r215", "r254", "r255", "r256", "r259", "r260", "r261", "r262", "r263", "r265", "r266", "r428" ], "calculation": { "http://scnd.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 8.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "[Gross Profit]", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r233", "r244" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment of Long-Lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperations": { "auth_ref": [ "r91", "r112", "r138", "r139", "r140", "r141", "r148", "r151", "r407" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent.", "label": "Loss from continuing operations" } } }, "localname": "IncomeLossFromContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r86", "r181", "r187", "r191", "r194", "r197", "r467", "r474", "r479", "r494" ], "calculation": { "http://scnd.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 17.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "[Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest]", "totalLabel": "Loss from continuing operations before income tax benefit" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": { "auth_ref": [ "r84", "r89", "r136", "r138", "r139", "r140", "r141", "r146", "r149", "r150", "r421", "r473", "r475", "r477", "r489" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.", "label": "Continuing operations" } } }, "localname": "IncomeLossFromContinuingOperationsPerBasicShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": { "auth_ref": [ "r3", "r4", "r5", "r6", "r7", "r21", "r24", "r389", "r490" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.", "label": "Net income (loss) from attributable to discontinued operations" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/DiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Discontinued operations (Note 9):" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": { "auth_ref": [ "r3", "r4", "r5", "r6", "r7", "r15", "r21", "r408" ], "calculation": { "http://scnd.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 15.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.", "label": "Gain (loss) from discontinued operations, net of tax" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": { "auth_ref": [ "r87", "r89", "r147", "r149", "r150", "r477", "r490", "r492", "r493" ], "lang": { "en-us": { "role": { "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.", "label": "Discontinued operations" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r128", "r366", "r367", "r372", "r381", "r386", "r390", "r391", "r392" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "verboseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r129", "r143", "r144", "r179", "r364", "r382", "r387", "r495" ], "calculation": { "http://scnd.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 16.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "[Income Tax Expense (Benefit)]", "totalLabel": "Total Income tax benefit", "verboseLabel": "Income tax benefit" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://scnd.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r79", "r362", "r363", "r367", "r368", "r371", "r378" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "verboseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReceivable": { "auth_ref": [ "r56", "r482" ], "calculation": { "http://scnd.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of income taxes previously overpaid to tax authorities (such as U.S. Federal, state and local tax authorities) representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes. Also called income tax refund receivable.", "label": "Income tax receivable" } } }, "localname": "IncomeTaxReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": { "auth_ref": [ "r361", "r365" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.", "label": "Rate changes and NOL carrybacks" } } }, "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r365" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Computed \"expected\" income tax (benefit)" } } }, "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationOtherAdjustments": { "auth_ref": [ "r365" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Other, net" } } }, "localname": "IncomeTaxReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationOtherReconcilingItems": { "auth_ref": [ "r365" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority noncontrolling interest income (loss), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, increase (decrease) in enacted tax rate, prior year income taxes, increase (decrease) in deferred tax asset valuation allowance, and other adjustments.", "label": "PPP loan forgivness" } } }, "localname": "IncomeTaxReconciliationOtherReconcilingItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": { "auth_ref": [ "r365" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.", "label": "[Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount]", "negatedLabel": "Research and development credits" } } }, "localname": "IncomeTaxReconciliationTaxCreditsResearch", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r107", "r116" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Income taxes" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r110" ], "calculation": { "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "[Increase (Decrease) in Accounts Payable]", "verboseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r110" ], "calculation": { "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Trade accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r110" ], "calculation": { "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "[Increase (Decrease) in Accrued Liabilities]", "verboseLabel": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInCustomerAdvances": { "auth_ref": [ "r110" ], "calculation": { "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of prepayments by customers for goods or services to be provided at a later date.", "label": "[Increase (Decrease) in Customer Advances]", "verboseLabel": "Contract liabilities" } } }, "localname": "IncreaseDecreaseInCustomerAdvances", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInIncomeTaxesReceivable": { "auth_ref": [ "r110" ], "calculation": { "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.", "label": "[Increase (Decrease) in Income Taxes Receivable]", "verboseLabel": "Income tax receivable" } } }, "localname": "IncreaseDecreaseInIncomeTaxesReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r110" ], "calculation": { "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "[Increase (Decrease) in Inventories]", "verboseLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.", "label": "[Increase (Decrease) in Other Noncurrent Liabilities]", "verboseLabel": "Other long-term liabilities" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r110" ], "calculation": { "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "Prepaid and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InformationByCategoryOfDebtSecurityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by category of debt security, either available-for-sale or held-to-maturity.", "label": "Information By Category Of Debt Security Axis" } } }, "localname": "InformationByCategoryOfDebtSecurityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/FairValueOfFinancialInstrumentsDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_IntangibleAssetsFiniteLivedPolicy": { "auth_ref": [ "r120", "r228", "r461", "r462", "r463", "r465" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.", "label": "Intangible Assets" } } }, "localname": "IntangibleAssetsFiniteLivedPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InterestAndOtherIncome": { "auth_ref": [], "calculation": { "http://scnd.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 9.0, "parentTag": "scnd_NonoperatingIncomeExpensenet", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).", "label": "Interest income" } } }, "localname": "InterestAndOtherIncome", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryCashFlowPolicy": { "auth_ref": [ "r117" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining where the cash flows related to the sale of inventory are classified in the statements of cash flows and explain the nature of the receivables, notes, and loans.", "label": "Inventory, Cash Flow Policy [Policy Text Block]", "verboseLabel": "Inventories" } } }, "localname": "InventoryCashFlowPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventories" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r219" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "verboseLabel": "Inventories" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/Inventories" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r49", "r218" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Finished goods" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r28", "r70", "r449" ], "calculation": { "http://scnd.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "[Inventory, Net]", "terseLabel": "Inventory", "verboseLabel": "Inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedBalanceSheets", "http://scnd.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r51", "r218" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Raw materials" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r50", "r218" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Work-in-process" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r237" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_LeasesOfLesseeDisclosureTextBlock": { "auth_ref": [ "r439" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.", "label": "Leases of Lessee Disclosure [Text Block]", "verboseLabel": "Leases" } } }, "localname": "LeasesOfLesseeDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r444" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Future minimum rental payments" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r444" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Total future minimum payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r444" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Remainder of 2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r444" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "[Lessee, Operating Lease, Liability, to be Paid, Year Five]", "verboseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r444" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "[Lessee, Operating Lease, Liability, to be Paid, Year Four]", "verboseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r444" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "[Lessee, Operating Lease, Liability, to be Paid, Year Three]", "verboseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r444" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "[Lessee, Operating Lease, Liability, to be Paid, Year Two]", "verboseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r444" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "[Lessee, Operating Lease, Liability, Undiscounted Excess Amount]", "negatedLabel": "Less: imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r63", "r126", "r189", "r215", "r254", "r255", "r256", "r259", "r260", "r261", "r262", "r263", "r265", "r266", "r410", "r415", "r416", "r428", "r447", "r448" ], "calculation": { "http://scnd.com/role/CondensedConsolidatedBalanceSheets": { "order": 35.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "[Liabilities]", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities:" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r47", "r126", "r215", "r428", "r449", "r472", "r487" ], "calculation": { "http://scnd.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "[Liabilities and Equity]", "totalLabel": "Total liabilities and shareholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shareholders' equity:" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r65", "r126", "r215", "r254", "r255", "r256", "r259", "r260", "r261", "r262", "r263", "r265", "r266", "r410", "r415", "r416", "r428", "r447", "r448", "r449" ], "calculation": { "http://scnd.com/role/CondensedConsolidatedBalanceSheets": { "order": 28.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "[Liabilities, Current]", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Liabilities [Abstract]", "verboseLabel": "Liabilities:" } } }, "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/DiscontinuedOperationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "auth_ref": [ "r1", "r2", "r18", "r20", "r24", "r235", "r240" ], "calculation": { "http://scnd.com/role/CondensedConsolidatedBalanceSheets": { "order": 17.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Liabilities of discontinued operations", "verboseLabel": "Liabilities of discontinued operations" } } }, "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedBalanceSheets", "http://scnd.com/role/DiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lines of Credit" } } }, "localname": "LineOfCreditFacilityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_LoansPayableAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payroll Protection Program Loan" } } }, "localname": "LoansPayableAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_MachineryAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery and equipment" } } }, "localname": "MachineryAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MarketableSecuritiesPolicy": { "auth_ref": [ "r480" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment classified as marketable security.", "label": "Investment Securities" } } }, "localname": "MarketableSecuritiesPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_MarketableSecuritiesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.", "label": "Investments in marketable securitites" } } }, "localname": "MarketableSecuritiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/FairValueOfFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r158", "r168" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature of Operations" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r106" ], "calculation": { "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 37.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "[Net Cash Provided by (Used in) Financing Activities]", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r106" ], "calculation": { "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 36.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "[Net Cash Provided by (Used in) Investing Activities]", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r106", "r109", "r112" ], "calculation": { "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 35.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "[Net Cash Provided by (Used in) Operating Activities]", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r24", "r77", "r78", "r82", "r88", "r112", "r126", "r136", "r138", "r139", "r140", "r141", "r143", "r144", "r148", "r181", "r187", "r191", "r194", "r197", "r215", "r254", "r255", "r256", "r259", "r260", "r261", "r262", "r263", "r265", "r266", "r421", "r428", "r476", "r491" ], "calculation": { "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 23.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://scnd.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 19.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "[Net Income (Loss) Attributable to Parent]", "terseLabel": "Net loss", "totalLabel": "Net loss", "verboseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://scnd.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity", "http://scnd.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Adopted Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://scnd.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 7.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "[Operating Expenses]", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r181", "r187", "r191", "r194", "r197" ], "calculation": { "http://scnd.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 12.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "[Operating Income (Loss)]", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r442" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Lease expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/LeasesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r441" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Total present value of operating lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r441" ], "calculation": { "http://scnd.com/role/CondensedConsolidatedBalanceSheets": { "order": 19.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Lease liabilities, current portion" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r441" ], "calculation": { "http://scnd.com/role/CondensedConsolidatedBalanceSheets": { "order": 26.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Lease liabilities, less current portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r440" ], "calculation": { "http://scnd.com/role/CondensedConsolidatedBalanceSheets": { "order": 10.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "auth_ref": [ "r111" ], "calculation": { "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for right-of-use asset from operating lease.", "label": "Carrying value of right of use assets" } } }, "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r443", "r445" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Weighted-average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/LeasesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r61" ], "calculation": { "http://scnd.com/role/CondensedConsolidatedBalanceSheets": { "order": 9.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": { "auth_ref": [ "r76", "r80", "r81", "r83", "r430", "r432", "r435" ], "calculation": { "http://scnd.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).", "label": "[Other Comprehensive Income (Loss), before Reclassifications, Net of Tax]", "totalLabel": "Total comprehensive loss" } } }, "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax": { "auth_ref": [ "r72", "r74" ], "calculation": { "http://scnd.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 18.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Foreign currency translation adjustment", "verboseLabel": "Foreign currency translation adjustment" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity", "http://scnd.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Comprehensive loss:" } } }, "localname": "OtherComprehensiveIncomeLossTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherIntangibleAssetsNet": { "auth_ref": [], "calculation": { "http://scnd.com/role/CondensedConsolidatedBalanceSheets": { "order": 11.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other.", "label": "Other intangible assets, net" } } }, "localname": "OtherIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r67" ], "calculation": { "http://scnd.com/role/CondensedConsolidatedBalanceSheets": { "order": 25.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other income (expense):" } } }, "localname": "OtherNonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherOperatingIncomeExpenseNet": { "auth_ref": [], "calculation": { "http://scnd.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 10.0, "parentTag": "scnd_NonoperatingIncomeExpensenet", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.", "label": "Other income (expense), net" } } }, "localname": "OtherOperatingIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain": { "auth_ref": [ "r214" ], "lang": { "en-us": { "role": { "documentation": "Provides the categories of debt securities, available-for-sale or held-to-maturity, on which an entity may recognize other than temporary impairments (OTTI) for which a portion related to credit losses has been recognized in earnings and a portion related to all other factors has been recognized in other comprehensive income." } } }, "localname": "OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/FairValueOfFinancialInstrumentsDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsForProceedsFromPreviousAcquisition": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net cash inflow or outflow associated with the aggregate amount of adjustment to the purchase price of a previous acquisition.", "label": "Aggregate purchase price" } } }, "localname": "PaymentsForProceedsFromPreviousAcquisition", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/AcquisitionOfAquilaBiolabsGmbhDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRent": { "auth_ref": [ "r108" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash payments to lessor's for use of assets under operating leases.", "label": "Total cash payments under leases" } } }, "localname": "PaymentsForRent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/LeasesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r104" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Issuance cost" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/EquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireAvailableForSaleSecurities": { "auth_ref": [ "r97", "r213" ], "calculation": { "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 26.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to acquire debt and equity securities not classified as either held-to-maturity securities or trading securities which would be classified as available-for-sale securities and reported at fair value, with unrealized gains and losses excluded from earnings and reported in a separate component of shareholders' equity.", "label": "[Payments to Acquire Available-for-sale Securities]", "negatedLabel": "Purchase of investment securities" } } }, "localname": "PaymentsToAcquireAvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r98" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Purchase of Aquila, net of cash acquired" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r99" ], "calculation": { "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 24.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "[Payments to Acquire Intangible Assets]", "negatedLabel": "Purchase of other intangible assets" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r99" ], "calculation": { "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 25.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "[Payments to Acquire Property, Plant, and Equipment]", "negatedLabel": "Capital expenditures" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r334", "r348" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name Axis" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r30", "r55", "r56" ], "calculation": { "http://scnd.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromCollectionOfNotesReceivable": { "auth_ref": [ "r94" ], "calculation": { "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 28.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with principal collections from a borrowing supported by a written promise to pay an obligation.", "label": "Proceeds from Payroll Protection Program" } } }, "localname": "ProceedsFromCollectionOfNotesReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromDivestitureOfBusinesses": { "auth_ref": [ "r95" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.", "label": "Proceeds from sale Altamaria" } } }, "localname": "ProceedsFromDivestitureOfBusinesses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r100" ], "calculation": { "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 30.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from issuance of common stock", "verboseLabel": "Proceeds from common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://scnd.com/role/EquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfBankOverdrafts": { "auth_ref": [ "r101", "r102", "r114" ], "calculation": { "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The net cash inflow or outflow from the excess drawing from an existing cash balance, which will be honored by the bank but reflected as a loan to the drawer.", "label": "[Proceeds from (Repayments of) Bank Overdrafts]", "verboseLabel": "Bank overdraft" } } }, "localname": "ProceedsFromRepaymentsOfBankOverdrafts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "auth_ref": [ "r96" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.", "label": "Proceeds from sale of fixed assets" } } }, "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r100", "r349" ], "calculation": { "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 33.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from stock options exercised" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r24", "r77", "r78", "r82", "r105", "r126", "r136", "r143", "r144", "r181", "r187", "r191", "r194", "r197", "r215", "r254", "r255", "r256", "r259", "r260", "r261", "r262", "r263", "r265", "r266", "r408", "r412", "r413", "r417", "r418", "r421", "r428", "r479" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Income (Loss) from Operations", "verboseLabel": "Pre tax loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/DiscontinuedOperationsDetailsNarrative", "http://scnd.com/role/SegmentInformationAndConcentrationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r60", "r239" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property Plant And Equipment By Type Axis" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r245", "r508", "r509", "r510" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "verboseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/PropertyAndEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r59", "r237" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r34", "r35", "r239", "r449", "r481", "r488" ], "calculation": { "http://scnd.com/role/CondensedConsolidatedBalanceSheets": { "order": 13.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, net", "verboseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedBalanceSheets", "http://scnd.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r58", "r239", "r508", "r509" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "verboseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r34", "r239" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Schedule of property and equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/PropertyAndEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r34", "r237" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Useful lives" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ProvisionForLoanAndLeaseLosses": { "auth_ref": [ "r110", "r206", "r478" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense related to estimated loss from loan and lease transactions.", "label": "Provision for bad debt" } } }, "localname": "ProvisionForLoanAndLeaseLosses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReceivablesPolicyTextBlock": { "auth_ref": [ "r207", "r210", "r211", "r212" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.", "label": "Accounts Receivable" } } }, "localname": "ReceivablesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Reclassifications": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for classifying current financial statements, which may be different from classifications in the prior year's financial statements. Disclose any material changes in classification including an explanation of the reason for the change and the areas impacted.", "label": "Reclasses" } } }, "localname": "Reclassifications", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfLongtermLoansFromVendors": { "auth_ref": [ "r103" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash outflows under financing arrangements with vendors (seller-financed debt), which had a maturity date at inception of more than one year (or more than one operating cycle, if longer); such debt may have arisen from purchases of property, plant and equipment or other productive assets.", "label": "Repayment of loan" } } }, "localname": "RepaymentsOfLongtermLoansFromVendors", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfNotesPayable": { "auth_ref": [ "r102" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.", "label": "[Repayments of Notes Payable]", "negatedLabel": "Repayment of 1st Payroll Protection Plan loan" } } }, "localname": "RepaymentsOfNotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r360", "r460", "r513" ], "calculation": { "http://scnd.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r360" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expenses" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r43", "r313", "r353", "r449", "r486", "r502", "r504" ], "calculation": { "http://scnd.com/role/CondensedConsolidatedBalanceSheets": { "order": 30.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r133", "r134", "r135", "r137", "r142", "r144", "r216", "r350", "r351", "r352", "r379", "r380", "r420", "r499", "r501" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated Deficit Retained Earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r121", "r122" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue Recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r85", "r126", "r172", "r173", "r186", "r192", "r193", "r199", "r200", "r202", "r215", "r254", "r255", "r256", "r259", "r260", "r261", "r262", "r263", "r265", "r266", "r428", "r479" ], "calculation": { "http://scnd.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 3.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Revenues", "verboseLabel": "Revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://scnd.com/role/RevenuesDetails", "http://scnd.com/role/SegmentInformationAndConcentrationsDetails", "http://scnd.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Issuence and sold aggregate shares of common stock and warrants" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/EquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction.", "label": "Net sales percentage" } } }, "localname": "SaleOfStockPercentageOfOwnershipAfterTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/SegmentInformationAndConcentrationsDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": { "auth_ref": [ "r397", "r398" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.", "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]", "verboseLabel": "Acquisition of Aquila Biolabs GmbH" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/AcquisitionOfAquilaBiolabsGmbh" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r370" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Deferred tax assets and liabilities" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "auth_ref": [ "r2", "r9", "r10", "r11", "r12", "r13", "r14", "r19", "r22", "r23", "r24", "r242", "r243" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]", "verboseLabel": "Discontinued operations" } } }, "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/DiscontinuedOperationsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock": { "auth_ref": [ "r147", "r151", "r155" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the effect of income (loss) on an entity's diluted earnings per share.", "label": "Loss per common share" } } }, "localname": "ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/EarningsLossPerCommonShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r365" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Income tax reconciliation" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r422", "r423" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Analysis of changes in Level 3 financial liabilities" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/FairValueOfFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r225", "r228" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Intangible assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/GoodwillAndOtherIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r32", "r52", "r53", "r54" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "verboseLabel": "Inventories" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/InventoriesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r181", "r184", "r190", "r223" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Segment information" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/SegmentInformationAndConcentrationsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": { "auth_ref": [ "r348" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.", "label": "Options outstanding" } } }, "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/StockOptionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r336", "r341", "r343" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Option activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/StockOptionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r169", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r186", "r187", "r188", "r189", "r191", "r192", "r193", "r194", "r195", "r197", "r202", "r246", "r247", "r496" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/RevenuesDetails", "http://scnd.com/role/SegmentInformationAndConcentrationsDetails", "http://scnd.com/role/SegmentInformationAndConcentrationsDetailsNarrative", "http://scnd.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Information" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r169", "r170", "r171", "r181", "r185", "r191", "r195", "r196", "r197", "r198", "r199", "r201", "r202", "r203" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "verboseLabel": "Segment Information" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/SegmentInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingExpense": { "auth_ref": [ "r93" ], "calculation": { "http://scnd.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 5.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expenses recognized in the period that are directly related to the selling and distribution of products or services.", "label": "Selling" } } }, "localname": "SellingExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r110" ], "calculation": { "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "[Share-based Payment Arrangement, Noncash Expense]", "verboseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions": { "auth_ref": [ "r346" ], "lang": { "en-us": { "role": { "documentation": "Restrictions on equity-based instruments during the vesting period, such as the inability to transfer unvested awards, are not taken into account in estimating the fair value of the award. However, restrictions that remain in effect after an award is vested, such as the inability to transfer or hedge vested options or a prohibition on the sale of outstanding vested shares (or other type of equity) for a period of time, affect the estimate of an award's fair value.", "label": "Discount rate on lease" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/LeasesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r348" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Common stock available for grant" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r339" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "[Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number]", "periodEndLabel": "Number of Options Exercisable", "verboseLabel": "Number of Options Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/StockOptionsDetails", "http://scnd.com/role/StockOptionsDetails1" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r339" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "[Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price]", "periodEndLabel": "Weighted Average Exercise Price Exercisable", "verboseLabel": "Weighted Average Exercise Price Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/StockOptionsDetails", "http://scnd.com/role/StockOptionsDetails1" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Number of Options Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/StockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r342" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Weighted average fair value per share of options granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/StockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r338", "r348" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "[Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number]", "periodEndLabel": "Number of Options Outstanding, Ending", "periodStartLabel": "Number of Options Outstanding, Beginning", "verboseLabel": "Number of Options Outstanding, Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/StockOptionsDetails", "http://scnd.com/role/StockOptionsDetails1" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r337" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "[Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price]", "periodEndLabel": "Weighted Average Exercise Price Outstanding, Ending", "periodStartLabel": "Weighted Average Exercise Price Outstanding, Beginning", "verboseLabel": "Weighted Average Exercise Price Outstanding, Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/StockOptionsDetails", "http://scnd.com/role/StockOptionsDetails1" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Weighted Average Exercise Price Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/StockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Weighted Average Exercise Price Forfeited" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/StockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Weighted Average Exercise Price Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/StockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r334", "r335" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Stock Compensation Plan" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": { "auth_ref": [ "r345" ], "lang": { "en-us": { "role": { "documentation": "Information by range of option prices pertaining to options granted.", "label": "Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range Axis" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/StockOptionsDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": { "auth_ref": [ "r347" ], "lang": { "en-us": { "role": { "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices." } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/StockOptionsDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Offering price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/EquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r344" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted Average Remaining Contractual Life" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/StockOptionsDetails1" ], "xbrltype": "durationItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r312" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "[Shares, Issued]", "periodEndLabel": "Balance, shares", "periodStartLabel": "Balance, shares" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermDebtTextBlock": { "auth_ref": [ "r298" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for short-term debt.", "label": "Short-term Debt [Text Block]", "verboseLabel": "Payroll Protection Program Loan" } } }, "localname": "ShortTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/PayrollProtectionProgramLoan" ], "xbrltype": "textBlockItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r118", "r132" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "verboseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r8", "r169", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r186", "r187", "r188", "r189", "r191", "r192", "r193", "r194", "r195", "r197", "r202", "r223", "r241", "r246", "r247", "r496" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Statement Business Segments Axis" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/RevenuesDetails", "http://scnd.com/role/SegmentInformationAndConcentrationsDetails", "http://scnd.com/role/SegmentInformationAndConcentrationsDetailsNarrative", "http://scnd.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r69", "r80", "r81", "r82", "r133", "r134", "r135", "r137", "r142", "r144", "r157", "r216", "r312", "r313", "r350", "r351", "r352", "r379", "r380", "r420", "r430", "r431", "r432", "r433", "r434", "r435", "r499", "r500", "r501", "r515" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/AcquisitionOfAquilaBiolabsGmbhDetails", "http://scnd.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity", "http://scnd.com/role/FairValueOfFinancialInstrumentsDetails", "http://scnd.com/role/FairValueOfFinancialInstrumentsDetails1", "http://scnd.com/role/GoodwillAndFiniteLivedIntangibleAssetsDetails", "http://scnd.com/role/LossPerCommonShareDetailsNarrative", "http://scnd.com/role/PaycheckProtectionProgramLoanDetailsNarrative", "http://scnd.com/role/PropertyAndEquipmentDetails", "http://scnd.com/role/RevenuesDetails", "http://scnd.com/role/SegmentInformationAndConcentrationsDetails", "http://scnd.com/role/SegmentInformationAndConcentrationsDetailsNarrative", "http://scnd.com/role/SignificantAccountingPoliciesDetails", "http://scnd.com/role/SignificantAccountingPoliciesDetailsNarrative", "http://scnd.com/role/StockOptionsDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED BALANCE SHEETS" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS EQUITY" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r133", "r134", "r135", "r157", "r464" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/AcquisitionOfAquilaBiolabsGmbhDetails", "http://scnd.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity", "http://scnd.com/role/FairValueOfFinancialInstrumentsDetails", "http://scnd.com/role/FairValueOfFinancialInstrumentsDetails1", "http://scnd.com/role/GoodwillAndFiniteLivedIntangibleAssetsDetails", "http://scnd.com/role/LossPerCommonShareDetailsNarrative", "http://scnd.com/role/PaycheckProtectionProgramLoanDetailsNarrative", "http://scnd.com/role/PropertyAndEquipmentDetails", "http://scnd.com/role/RevenuesDetails", "http://scnd.com/role/SegmentInformationAndConcentrationsDetails", "http://scnd.com/role/SegmentInformationAndConcentrationsDetailsNarrative", "http://scnd.com/role/SignificantAccountingPoliciesDetails", "http://scnd.com/role/SignificantAccountingPoliciesDetailsNarrative", "http://scnd.com/role/StockOptionsDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r39", "r40", "r312", "r313" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Issuance of Common Stock and Warrants, net of issuance costs, shares", "verboseLabel": "Issuance of shares" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity", "http://scnd.com/role/EquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease": { "auth_ref": [ "r312" ], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the number of shares issued.", "label": "Increase in authorized share" } } }, "localname": "StockIssuedDuringPeriodSharesPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/EquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r39", "r40", "r312", "r313", "r340" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Stock options exercised, shares" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r39", "r40", "r312", "r313" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Issuance of Common Stock and Warrants, net of issuance costs, amount" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r69", "r312", "r313" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock options exercised, amount" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r40", "r45", "r46", "r126", "r209", "r215", "r428", "r449" ], "calculation": { "http://scnd.com/role/CondensedConsolidatedBalanceSheets": { "order": 34.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "[Stockholders' Equity Attributable to Parent]", "periodEndLabel": "Balance, amount", "periodStartLabel": "Balance, amount", "totalLabel": "Total shareholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedBalanceSheets", "http://scnd.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "verboseLabel": "Shareholders' equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityBeforeTreasuryStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total amount of stockholders' equity (deficit) items including stock value, paid in capital, retained earnings and including equity attributable to noncontrolling interests and before deducting the carrying value of treasury stock.", "label": "[Stockholders' Equity before Treasury Stock]", "verboseLabel": "Total" } } }, "localname": "StockholdersEquityBeforeTreasuryStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r124", "r299", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r313", "r316" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "verboseLabel": "Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/Equity" ], "xbrltype": "textBlockItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r68", "r314" ], "lang": { "en-us": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r68", "r314" ], "lang": { "en-us": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Stock held in treasury, shares" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r68", "r314", "r315" ], "calculation": { "http://scnd.com/role/CondensedConsolidatedBalanceSheets": { "order": 29.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Less common stock held in treasury at cost, 19,802 shares" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrealizedGainLossOnInvestments": { "auth_ref": [ "r111" ], "calculation": { "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 21.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment.", "label": "Unrealized holding gain on investment securities, net of tax", "verboseLabel": "Unrealized holding loss on investments" } } }, "localname": "UnrealizedGainLossOnInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://scnd.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r159", "r160", "r161", "r162", "r165", "r166", "r167" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r145", "r151" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted average dilutive common shares outstanding" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://scnd.com/role/LossPerCommonShareDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3098-108585" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431969&loc=d3e4458-108587" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r132": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r156": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r168": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r203": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27340-111563" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r219": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r224": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/subtopic&trid=2144439" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2510-110228" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2473-110228" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742" }, "r245": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r248": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "430", "URI": "http://asc.fasb.org/topic&trid=2122452" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r25": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/subtopic&trid=2122178" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r251": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r252": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=d3e1243-112600" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r26": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r298": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r316": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r318": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "710", "URI": "http://asc.fasb.org/topic&trid=2127225" }, "r319": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "712", "URI": "http://asc.fasb.org/topic&trid=2197446" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r331": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "http://asc.fasb.org/topic&trid=2235017" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "740", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120384911&loc=d3e23163-113944" }, "r357": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(a)", "Topic": "720", "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(b)", "Topic": "720", "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32059-109318" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109227538&loc=d3e44648-109337" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r392": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(4)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "b", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4613673-111683" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r439": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "840", "URI": "http://asc.fasb.org/topic&trid=2208923" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(a)", "Topic": "920", "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(b)", "Topic": "920", "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(a)", "Topic": "920", "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(20))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.11)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62652-112803" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(11))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "3B", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r514": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(13))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868656-224227" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(14))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.13)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" } }, "version": "2.1" } ZIP 89 0001654954-22-007636-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001654954-22-007636-xbrl.zip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�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ȶ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

		As of June 30, 2021 Options Outstanding						As of June 30, 2021 Exercisable
				Weighted-
				Average		Weighted-				Weighted-
Range				Remaining		Average				Average
Exercise		Number		Contractual		Exercise		Number		Exercise
Prices		Outstanding		Life (Years)		Price		Outstanding		Price

	$5.35 - $ 11.30		1,120,052		9.35	$	9.03		238,351	$	8.76

	$2.91 - $ 4.65		60,705		5.28	$	3.36		58,470	$	3.32

			1,180,757						296,821

Cover	9 Months Ended
Cover	Mar. 31, 2022
Cover [Abstract]
Entity Registrant Name	SCIENTIFIC INDUSTRIES, INC.
Entity Central Index Key	0000087802
Document Type	S-1
Amendment Flag	false
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Filer Category	Non-accelerated Filer
Entity Incorporation State Country Code	DE
Entity Tax Identification Number	04-2217279
Entity Address Address Line 1	80 Orville Drive
Entity Address Address Line 2	Suite 102
Entity Address City Or Town	Bohemia
Entity Address State Or Province	NY
Entity Address Postal Zip Code	11716
City Area Code	631
Local Phone Number	567-4700

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Mar. 31, 2022	Jun. 30, 2021	Jun. 30, 2020
Current assets:
Cash and cash equivalents	$ 4,068,000	$ 9,675,200	$ 7,559,700
Investment securities	7,768,600	3,744,600	331,800
Trade accounts receivable, less allowance for doubtful accounts of $15,600 at March 31, 2022 and June 30, 2021	1,712,900	1,294,700	1,064,000
Inventories	4,367,900	2,977,100	2,541,000
Income tax receivable	161,100	333,300	334,800
Prepaid expenses and other current assets	312,800	350,900	112,400
Assets of discontinued operations	600	55,300	793,000
Total current assets	18,391,900	18,431,100	12,736,700
Property and equipment, net	566,900	412,600	278,300
Goodwill	4,395,400	4,395,400	257,300
Intangible assets, net	2,216,300	2,557,800	128,700
Other intangible assets, net	2,216,300	2,557,800
Deferred taxes	3,445,300	2,489,900	537,100
Operating lease right-of-use assets	1,448,600	665,300	803,300
Other assets	62,400	54,300	56,000
Total assets	30,526,800	29,006,400	14,797,400
Current liabilities:
Accounts payable	1,051,100	453,500	334,600
Accrued expenses	661,100	633,500	679,000
Contract liabilities		0	20,000
Contingent consideration	117,500	136,600	111,000
Bank overdraft	40,600	321,700	43,100
Lease liabilities, current portion	124,300	270,500	195,800
Paycheck Protection Program loan	0	433,800	563,800
Liabilities of discontinued operations	7,900	37,200	240,900
Total current liabilities	2,002,500	2,286,800	2,188,200
Contingent consideration payable, less current portion	0	23,400	247,000
Lease liabilities, less current portion	1,388,100	460,500	640,800
Other long-term liabilities	0	10,900	0
Total liabilities	3,390,600	2,781,600	3,076,000
Shareholders' equity:
Common stock, $.05 par value; 20,000,000 and 15,000,000 shares authorized; 7,023,401 and 6,477,945 shares issued; 7,003,599 and 6,458,143 shares outstanding at March 31, 2022 and June 30, 2021	351,200	324,000	144,100
Additional paid-in capital	31,233,600	26,613,500	8,608,300
Accumulated comprehensive loss	(104,800)	(9,200)	0
Accumulated deficit	(4,291,400)	(651,100)	3,021,400
Total	27,188,600	26,277,200	11,773,800
Less common stock held in treasury at cost, 19,802 shares	52,400	52,400	52,400
Total shareholders' equity	27,136,200	26,224,800	11,721,400
Total liabilities and shareholders' equity	$ 30,526,800	$ 29,006,400	$ 14,797,400

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	Mar. 31, 2022	Jun. 30, 2021	Jun. 30, 2020
CONDENSED CONSOLIDATED BALANCE SHEETS
Allowance doubtful accounts	$ 15,600	$ 15,600	$ 11,600
Shareholders' equity:
Common stock,par value	$ 0.05	$ 0.05	$ 0.05
Common stock, authorized shares	20,000,000	15,000,000	15,000,000
Common stock, issued shares	7,023,401	6,477,945	2,881,065
Common stock, outstanding shares	7,003,599	6,458,143	2,861,263
Stock held in treasury, shares	19,802	19,802	19,802

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021	Jun. 30, 2021	Jun. 30, 2020
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
Revenues	$ 2,864,900	$ 2,508,600	$ 8,623,500	$ 7,245,100	$ 9,775,200	$ 7,784,400
Cost of revenues	1,318,300	1,145,700	4,154,600	3,419,400	4,799,800	3,847,000
Gross profit	1,546,600	1,362,900	4,468,900	3,825,700	4,975,400	3,937,400
Operating expenses:
General and administrative	1,610,400	1,385,600	4,442,300	2,441,700	4,028,500	2,275,400
Selling	1,054,000	1,386,100	2,996,800	2,658,900	4,031,900	1,185,800
Research and development	624,500	450,000	2,141,300	1,024,000	1,623,800	1,139,700
Total operating expenses	3,288,900	3,221,700	9,580,400	6,124,600	9,684,200	4,600,900
Loss from operations	(1,742,300)	(1,858,800)	(5,111,500)	(2,298,900)	(4,708,800)	(663,500)
Other income (expense):
Other income (expense), net	(102,700)	6,100	363,500	22,300	571,600	12,600
Interest income	400	22,500	49,800	71,400	82,200	16,500
Total other income (expense), net	(102,300)	28,600	413,300	93,700	653,800	(3,900)
Loss from continuing operations before income tax benefit	(1,844,600)	(1,830,200)	(4,698,200)	(2,205,200)	(4,055,000)	(667,400)
Income tax benefit, current	(95,100)	0	(95,100)	0
Income tax benefit, deferred	(222,100)	(378,200)	(959,400)	(472,300)	(945,000)	(214,000)
Total Income tax benefit	(317,200)	(378,200)	(1,054,500)	(472,300)	(1,152,500)	(436,600)
Loss from continuing operations	(1,527,400)	(1,452,000)	(3,643,700)	(1,732,900)	(3,110,000)	(453,400)
Discontinued operations (Note 9):
Gain (loss) from discontinued operations, net of tax	(7,600)	16,400	3,400	(578,500)	(562,500)	(249,900)
Net loss	(1,535,000)	(1,435,600)	(3,640,300)	(2,311,400)	(3,672,500)	(703,300)
Comprehensive loss:
Unrealized holding loss on investment securities, net of tax	(4,700)	0	(5,100)	0
Foreign currency translation adjustment	(194,500)	0	(90,500)	0	(9,200)
Comprehensive loss	(199,200)	0	(95,600)	0
Total comprehensive loss	$ (1,734,200)	$ (1,435,600)	$ (3,735,900)	$ (2,311,400)	$ (3,681,700)	$ (703,300)
Basic loss per common share:
Continuing operations	$ (0.23)	$ (0.51)	$ (0.56)	$ (0.61)	$ (0.97)	$ (0.30)
Discontinued operations	(0.00)	0.01	0.00	(0.20)	(0.18)	(0.16)
Consolidated operations	$ (0.23)	$ (0.50)	$ (0.56)	$ (0.81)	$ (1.15)	$ (0.46)

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS EQUITY - USD ($)	Total	Common Stock	Treasury Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit Retained Earnings
Balance, shares at Jun. 30, 2019		1,513,914	19,802
Balance, amount at Jun. 30, 2019	$ 6,340,700	$ 75,700	$ 52,400	$ 2,592,700		$ 3,724,700
Net loss	(703,300)					(703,300)
Issuance of Common Stock and Warrants, net of issuance costs, shares		1,349,850
Issuance of Common Stock and Warrants, net of issuance costs, amount	6,004,400	$ 67,500		5,936,900
Stock options exercised, shares		17,301
Stock options exercised, amount	13,800	$ 900		12,900
Stock-based compensation	65,800			65,800
Unrealized holding gain on investment securities, net of tax	12,400
Balance, shares at Jun. 30, 2020		2,881,065	19,802
Balance, amount at Jun. 30, 2020	11,721,400	$ 144,100	$ 52,400	8,608,300		3,021,400
Net loss	(2,311,400)
Foreign currency translation adjustment	0
Unrealized holding gain on investment securities, net of tax	18,900
Balance, shares at Mar. 31, 2021		2,882,065	19,802
Balance, amount at Mar. 31, 2021	10,842,400	$ 144,200	$ 52,400	10,040,600		710,000
Balance, shares at Jun. 30, 2020		2,881,065	19,802
Balance, amount at Jun. 30, 2020	11,721,400	$ 144,100	$ 52,400	8,608,300		3,021,400
Net loss	(3,672,500)		0		$ 0	(3,672,500)
Issuance of Common Stock and Warrants, net of issuance costs, shares		3,595,880
Issuance of Common Stock and Warrants, net of issuance costs, amount	16,074,000	$ 179,800	0	15,894,200		0
Stock options exercised, shares		1,000
Stock options exercised, amount	3,100	$ 100	0	3,000		0
Stock-based compensation	2,108,000	0	0	2,108,000		0
Foreign currency translation adjustment	(9,200)	$ 0	$ 0	0	(9,200)	0
Unrealized holding gain on investment securities, net of tax	10,400
Balance, shares at Jun. 30, 2021		6,477,945	19,802
Balance, amount at Jun. 30, 2021	26,224,800	$ 324,000	$ 52,400	26,613,500	(9,200)	(651,100)
Balance, shares at Jul. 01, 2020		2,881,065	19,802
Balance, amount at Jul. 01, 2020	11,721,400	$ 144,100	$ 52,400	8,608,300		3,021,400
Net loss	(263,300)					(263,300)
Stock-based compensation	61,300			61,300
Balance, shares at Sep. 30, 2020		2,881,065	19,802
Balance, amount at Sep. 30, 2020	11,519,400	$ 144,100	$ 52,400	8,669,600		2,758,100
Net loss	(612,500)					(612,500)
Stock-based compensation	76,100			76,100
Balance, shares at Dec. 31, 2020		2,881,065	19,802
Balance, amount at Dec. 31, 2020	10,983,000	$ 144,100	$ 52,400	8,745,700		2,145,600
Net loss	(1,435,600)					(1,435,600)
Stock options exercised, shares		1,000
Stock options exercised, amount	3,000	$ 100		2,900
Stock-based compensation	1,292,000			1,292,000
Foreign currency translation adjustment	0
Balance, shares at Mar. 31, 2021		2,882,065	19,802
Balance, amount at Mar. 31, 2021	10,842,400	$ 144,200	$ 52,400	10,040,600		710,000
Balance, shares at Jun. 30, 2021		6,477,945	19,802
Balance, amount at Jun. 30, 2021	26,224,800	$ 324,000	$ 52,400	26,613,500	(9,200)	(651,100)
Net loss	(3,640,300)
Foreign currency translation adjustment	(90,500)
Unrealized holding gain on investment securities, net of tax	102,800
Balance, shares at Mar. 31, 2022		7,023,401	19,802
Balance, amount at Mar. 31, 2022	27,136,200	$ 351,200	$ 52,400	31,233,600	(104,800)	(4,291,400)
Balance, shares at Jul. 01, 2021		6,477,945	19,802
Balance, amount at Jul. 01, 2021	26,224,800	$ 324,000	$ 52,400	26,613,500	(9,200)	(651,100)
Net loss	(1,208,800)	0	0	0	0	(1,208,800)
Stock-based compensation	675,400	0	0	675,400	0	0
Foreign currency translation adjustment	34,100	0	0	0	34,100	0
Unrealized holding gain on investment securities, net of tax	2,200	$ 0	$ 0	0	2,200	0
Balance, shares at Sep. 30, 2021		6,477,945	19,802
Balance, amount at Sep. 30, 2021	25,727,700	$ 324,000	$ 52,400	27,288,900	27,100	(1,859,900)
Net loss	(896,500)	0	0	0	0	(896,500)
Stock-based compensation	591,000	0	0	591,000	0	0
Foreign currency translation adjustment	69,900	0	0	0	69,900	0
Unrealized holding gain on investment securities, net of tax	(2,600)	$ 0	$ 0	0	(2,600)	0
Balance, shares at Dec. 31, 2021		6,477,945	19,802
Balance, amount at Dec. 31, 2021	25,489,500	$ 324,000	$ 52,400	27,879,900	94,400	(2,756,400)
Net loss	(1,535,000)	$ 0	0	0	0	(1,535,000)
Issuance of Common Stock and Warrants, net of issuance costs, shares		545,456
Issuance of Common Stock and Warrants, net of issuance costs, amount	2,727,200	$ 27,200	0	2,700,000	0	0
Stock-based compensation	653,700	0	0	653,700	0	0
Foreign currency translation adjustment	(194,500)	0	0		(194,500)	0
Unrealized holding gain on investment securities, net of tax	(4,700)	$ 0	$ 0	0	(4,700)	0
Balance, shares at Mar. 31, 2022		7,023,401	19,802
Balance, amount at Mar. 31, 2022	$ 27,136,200	$ 351,200	$ 52,400	$ 31,233,600	$ (104,800)	$ (4,291,400)

Significant Accounting Policies (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
Significant Accounting Policies (Details) - USD ($)	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021	Jun. 30, 2021	Jun. 30, 2020
Revenues	$ 2,864,900	$ 2,508,600	$ 8,623,500	$ 7,245,100	$ 9,775,200	$ 7,784,400
Benchtop Laboratory Equipment
Revenues	2,434,600	2,365,700	7,465,700	6,803,300	9,043,600	6,783,600
Foreign sales	783,600	942,200	2,814,700	2,724,800	3,483,700	2,589,800
Bioprocessing Systems
Revenues	430,300	142,900	1,157,800	441,800	731,600	1,000,800
Foreign sales	$ 269,700	$ 102,600	$ 791,200	$ 395,000	684,600	1,000,400
Consolidated
Revenues					9,775,200	7,784,400
Foreign sales					$ 4,168,300	$ 3,590,200

Significant Accounting Policies (Details Narrative) - USD ($)	6 Months Ended	12 Months Ended
	Dec. 31, 2021	Jun. 30, 2021	Jun. 30, 2020	Mar. 31, 2022	Mar. 31, 2021	Apr. 30, 2020
FDIC excess cash balance		$ 8,922,800	$ 6,729,300
Advertising expense		$ 399,700	$ 218,700
Common stock available for grant		5,243	147,414
Cash		$ 0		$ 600
Payroll Protection Program [Member]
Repayment of loan	$ 32,700
Cash					$ 433,800	$ 563,800

Revenues (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
Revenues (Details) - USD ($)	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021	Jun. 30, 2021	Jun. 30, 2020
Revenues	$ 2,864,900	$ 2,508,600	$ 8,623,500	$ 7,245,100	$ 9,775,200	$ 7,784,400
Benchtop Laboratory Equipment
Revenues	2,434,600	2,365,700	7,465,700	6,803,300	9,043,600	6,783,600
Foreign Sales	783,600	942,200	2,814,700	2,724,800	3,483,700	2,589,800
Bioprocessing Systems
Revenues	430,300	142,900	1,157,800	441,800	731,600	1,000,800
Foreign Sales	269,700	102,600	791,200	395,000	684,600	1,000,400
Consolidated
Revenues	2,864,900	2,508,600	8,623,500	7,245,100	9,775,200	7,784,400
Foreign Sales	$ 1,053,300	$ 1,044,800	$ 3,605,900	$ 3,119,800	$ 4,168,300	$ 3,590,200

Revenues (Details Narrative)	9 Months Ended
Revenues (Details Narrative)	Mar. 31, 2022
Segment Information
Description of obligation	The Company is obligated to pay 50% of all royalties earned to the entity that licensed the intellectual property to the Company.

Fair Value of Financial Instruments (Details 1) - USD ($)	Mar. 31, 2022	Jun. 30, 2021	Jun. 30, 2020
Cost	$ 7,804,400	$ 3,687,300	$ 327,900
Fair value	7,768,600	3,744,600	331,800
Unrealized holding gain (loss)	(35,800)	57,300	(3,900)
Equity Securities
Cost	118,900	102,200	77,600
Fair value	176,900	154,100	101,900
Unrealized holding gain (loss)	(58,000)	(51,900)	(24,300)
Mutual Funds
Cost	6,708,300	2,752,400	250,300
Fair value	6,619,600	2,766,500	229,900
Unrealized holding gain (loss)	88,700	(14,100)	$ 20,400
Debt Securities
Cost	977,200	832,700
Fair value	972,100	824,000
Unrealized holding gain (loss)	$ (5,100)	$ 8,700

Fair Value of Financial Instruments (Details 2) - USD ($)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Fair Value of Financial Instruments
Beginning balance	$ 358,000	$ 618,000
Increase (decrease) in contingent consideration liability	(30,000)	112,600
Payments	(168,000)	(372,600)
Ending balance	$ 160,000	$ 358,000

Inventories (Details) - USD ($)	Mar. 31, 2022	Jun. 30, 2021	Jun. 30, 2020
Inventories
Raw materials	$ 3,058,100	$ 2,170,400	$ 1,726,400
Work-in-process	106,400	39,600	35,700
Finished goods	1,203,400	767,100	778,900
Inventory	$ 4,367,900	$ 2,977,100	$ 2,541,000

Property and Equipment (Details) - USD ($)	12 Months Ended
Property and Equipment (Details) - USD ($)	Jun. 30, 2021	Mar. 31, 2022	Jun. 30, 2020
Property and equipment, gross	$ 1,516,300		$ 1,277,400
Less accumulated depreciation and amortization	1,103,700		999,100
Property and equipment, net	412,600	$ 566,900	278,300
Automobiles
Property and equipment, gross	$ 22,000		22,000
Useful lives	5 years
Computer equipment
Property and equipment, gross	$ 233,500		215,300
Computer equipment \| Minimum
Useful lives	3 years
Computer equipment \| Maximum
Useful lives	5 years
Machinery and equipment
Property and equipment, gross	$ 1,047,600		847,500
Machinery and equipment \| Minimum
Useful lives	3 years
Machinery and equipment \| Maximum
Useful lives	7 years
Furniture and fixtures
Property and equipment, gross	$ 148,800		142,300
Furniture and fixtures \| Minimum
Useful lives	4 years
Furniture and fixtures \| Maximum
Useful lives	10 years
Leasehold improvements
Property and equipment, gross	$ 64,400		$ 50,300
Leasehold improvements \| Minimum
Useful lives	3 years
Leasehold improvements \| Maximum
Useful lives	10 years

Property and Equipment (Details Narrative) - USD ($)	12 Months Ended
Property and Equipment (Details Narrative) - USD ($)	Jun. 30, 2021	Jun. 30, 2020
Property and Equipment
Depreciation expense	$ 104,600	$ 88,700

Goodwill and Finite Lived Intangible Assets (Details 1) - USD ($)	Mar. 31, 2022	Jun. 30, 2021	Jun. 30, 2020
Goodwill and Other Intangible Assets
2022	$ 134,300	$ 525,700
2023	520,900	520,000
2024	518,900	508,800
2025	485,100	473,100
2026	284,600	530,200
Total	$ 2,216,300	$ 2,557,800	$ 128,700

Loss Per Common Share (Details) - $ / shares	3 Months Ended		9 Months Ended		12 Months Ended
Loss Per Common Share (Details) - $ / shares	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021	Jun. 30, 2021	Jun. 30, 2020
Earnings (Loss) Per Common Share (Tables)
Weighted average common shares outstanding	6,633,901	2,861,607	6,544,112	2,861,376	3,189,602	1,515,103
Weighted average dilutive common shares outstanding	6,633,901	2,861,607	6,544,112	2,861,376	3,189,602	1,515,103
Continuing operations	$ (0.23)	$ (0.51)	$ (0.56)	$ (0.61)	$ (0.97)	$ (0.30)
Discontinued operations	0	0.01	0.00	(0.20)	(0.18)	(0.16)
Consolidated operations	$ (0.23)	$ (0.50)	$ (0.56)	$ (0.81)	$ (1.15)	$ (0.46)

Loss Per Common Share (Details Narrative) - shares	3 Months Ended		9 Months Ended		12 Months Ended
Loss Per Common Share (Details Narrative) - shares	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021	Jun. 30, 2021	Jun. 30, 2020
Stock Options
Dilutive shares excluded	3,452,542		3,451,461		88,691	54,513
Warrants
Dilutive shares excluded		259,357		1,349,850	2,481,783	1,349,850

Leases (Details) - USD ($)	Mar. 31, 2022	Jun. 30, 2021
Leases
Remainder of 2022	$ 82,200	$ 260,300
2023	311,400	245,300
2024	247,600	195,900
2025	255,000	91,600
2026	262,700
Thereafter	609,600
Total future minimum payments	1,768,500	793,100
Less: imputed interest	(256,100)	(62,100)
Total present value of operating lease liabilities	$ 1,512,400	$ 731,000

Leases (Details Narrative) - USD ($)	3 Months Ended	9 Months Ended	12 Months Ended
Leases (Details Narrative) - USD ($)	Mar. 31, 2022	Mar. 31, 2022	Jun. 30, 2021
Leases
Total cash payments under leases	$ 82,000	$ 240,200	$ 289,100
Weighted-average remaining lease term		5 years 3 months 25 days	2 years 8 months 4 days
Weighted-average discount rate	5.00%	5.00%
Discount rate on lease		5.00%	5.00%
Lease expense	$ 81,800	$ 226,300	$ 277,300

Discontinued Operations (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
Discontinued Operations (Details) - USD ($)	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021	Jun. 30, 2021	Jun. 30, 2020
Assets:
Cash	$ 600		$ 600		$ 0
Accounts receivable	0		0		52,000
Inventories	0		0		3,300	$ 343,700
Property and equipment, net						1,400
Goodwill						447,900
Discontinued operations	600		600		55,300	793,000
Liabilities:
Accrued expenses and taxes	0		0		20,700	120,700
Accounts payable						20,100
Contract liabilities	7,900		7,900		16,500	69,000
Operating lease liabilities, current portion						31,100
Liabilities of discontinued operations	7,900		7,900		37,200	240,900
Revenues	0	$ 107,800	20,600	$ 387,700	387,700	785,900
Cost of goods sold	6,900	78,800	10,300	458,500	471,800	869,900
Gross profit (loss)	(6,900)	29,000	10,300	(70,800)	(84,100)	(84,000)
Selling, general and administrative expenses	700	12,600	2,900	282,200	280,400	388,500
Gain (loss) from operation	(7,600)	16,400	7,400	(353,000)	(364,500)	(472,500)
Loss on disposal	0	0	0	(405,400)	(405,400)	0
Income (loss) before income tax benefit	(7,600)	16,400	7,400	(758,400)	(769,900)	(472,500)
Income tax expense (benefit)	0	0	4,000	(179,900)	(207,400)	(222,600)
Net income (loss) from attributable to discontinued operations	$ (7,600)	$ 16,400	$ 3,400	$ (578,500)	$ (562,500)	$ (249,900)

Discontinued Operations (Details Narrative) - USD ($)	9 Months Ended		12 Months Ended
Discontinued Operations (Details Narrative) - USD ($)	Mar. 31, 2022	Mar. 31, 2021	Jun. 30, 2021	Jun. 30, 2020
Discontinued Operations
Cash paid to the related party	$ 440,000
Pre tax loss	405,400
Cash provided by (used in) operating activities	25,400	$ (502,900)	$ (75,000)	$ 66,100
Cash provided by investing activities from discontinued operations	$ 0	$ 440,000	$ 440,000	$ 2,200

Acquisition of Aquila Biolabs GmbH (Details) - USD ($)	1 Months Ended	12 Months Ended
Acquisition of Aquila Biolabs GmbH (Details) - USD ($)	Apr. 29, 2021	Jun. 30, 2021
Current assets:
Cash and cash equivalents	$ 201,100	$ 201,100
Accounts receivable	159,200	159,200
Inventory	187,500	187,500
Prepaid expenses and other current assets	25,400	25,400
Property, plant and equipment	40,200	40,200
Deferred tax assets	800,300	800,300
Tradename	452,300	452,300
Non-compete agreements	784,500	784,500
In-process research and development	742,100	742,100
Customer relationships	252,200	252,200
Patents and other intangibles	286,200	286,200
Total assets acquired	3,931,000	3,931,000
Fair value of liabilities assumed:
Accounts payable	(39,300)	(39,300)
Accrued expenses	(90,300)	(90,300)
Other current liabilities	(59,400)	(59,400)
Total liabilities assumed	(189,000)	(189,000)
Total identifiable net assets	3,742,000	3,742,000
Fair value of consideration transferred	7,880,100	7,880,100
Goodwill	$ 4,138,100	$ 4,138,100
Customer relationships
Fair value of liabilities assumed:
Useful life	9 years	9 years
Non-compete agreements
Fair value of liabilities assumed:
Useful life	4 years	4 years
Tradename
Fair value of liabilities assumed:
Useful life	6 years	6 years
In-process research and development
Fair value of liabilities assumed:
Useful life	5 years	5 years
Patents and Other Intangibles
Fair value of liabilities assumed:
Useful life	7 years	7 years

Acquisition of Aquila Biolabs GmbH (Details 1)	12 Months Ended
Acquisition of Aquila Biolabs GmbH (Details 1)	Jun. 30, 2020 USD ($) $ / shares
Acquisition of Aquila Biolabs GmbH
Revenues \| $	$ 9,346
Net loss \| $	$ (1,650)
Earnings per share: Diluted \| $ / shares	$ (0.37)
Earnings per share: Basic \| $ / shares	$ (0.37)

Acquisition of Aquila Biolabs GmbH (Details Narrative)	9 Months Ended
Acquisition of Aquila Biolabs GmbH (Details Narrative)	Mar. 31, 2022 USD ($)
Acquisition of Aquila Biolabs GmbH
Aggregate purchase price	$ 7,880,100

Paycheck Protection Program Loan (Details Narrative)	Mar. 31, 2021 USD ($)
Paycheck Protection Program Loan [Member]
Debt intrument, face amount	$ 433,800

Equity (Details Narrative) - USD ($)		1 Months Ended	9 Months Ended
Equity (Details Narrative) - USD ($)	Mar. 02, 2022	Feb. 25, 2022	Mar. 31, 2022	Mar. 31, 2021	Feb. 24, 2022	Jun. 30, 2021	Jun. 30, 2020
Equity (Details Narrative)
Common share authorized		20,000,000	20,000,000		15,000,000	15,000,000	15,000,000
Increase in authorized share		5,000,000
Offering price	$ 5.50
Proceeds from common stock	$ 3,000,000		$ 3,000,000	$ 0
Issuence and sold aggregate shares of common stock and warrants	545,456
Additional common stock purchased	274,727
Issuance cost	$ 272,800
Issuance of shares		1,750,000

Commitments and Contingencies (Details)	Jun. 30, 2021 USD ($)
Commitments and Contingencies
2022	$ 136,600
2023	12,000
2024	11,400
Total	$ 160,000

Income Taxes (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
Income Taxes (Details) - USD ($)	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021	Jun. 30, 2021	Jun. 30, 2020
Income Taxes
Computed "expected" income tax (benefit)					$ (1,014,300)	$ (239,400)
Research and development credits					(93,900)	(89,400)
Rate changes and NOL carrybacks					0	(122,600)
Incentive stock option expense					59,500	13,800
PPP loan forgivness					(111,700)	0
Other, net					(7,900)	1,000
Income tax benefit	$ (317,200)	$ (378,200)	$ (1,054,500)	$ (472,300)	$ (1,152,500)	$ (436,600)

Income Taxes (Details 1) - USD ($)	Jun. 30, 2021	Jun. 30, 2020
Deferred tax assets:
Amortization of intangibles	$ 374,000	$ 329,700
Research and development credits	164,600	89,400
Various accruals	64,600	150,700
Stock options expense	383,200	0
Net operating loss	1,515,800	0
Other	24,900	19,400
Total	2,527,100	589,200
Deferred tax liability:
Depreciation of property and amortization of goodwill	(37,200)	(52,100)
Net deferred tax assets	$ 2,489,900	$ 537,100